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Abstract 
Prostate cancer (PCa) progression is dependent on transcriptional activation of 
the androgen receptor (AR) in the majority of cases. Therefore, therapies include 
anti-androgens, which decrease levels of circulating androgens and inhibit AR 
activity. However, resistance inevitably develops, resulting in more aggressive, 
incurable late-stage disease with intact or constitutively active AR signalling. There 
is currently no cure for castration-resistant metastatic PCa and novel therapies are 
needed. In this work I aimed to develop a non-replicating adenovirus for delivery of 
a potent prodrug-converting enzyme expressed at high levels to specifically target 
and kill PCa cells.  
TMPRSS2 is a major AR-regulated gene, commonly expressed at higher levels in 
cancer than normal prostate. In 40-70% of PCa cases the AR-regulated 
TMPRSS2 promoter is fused to oncogenic ERG. Based on this, we generated 
TMPRSS2 promoter and enhancer constructs, utilising promoter regions upstream 
of Exon1 and Exon2 of TMPRSS2 to drive the prodrug-converting chimeric 
enzyme cytosine deaminase uracil phosphoribosyl transferase (CD/UPRT) to 
investigate the therapeutic efficacy in various PCa models.  
Prior work in the lab evaluated the selectivity and transcriptional efficiency of the 
various promoter and enhancer regions upstream of Exon1 and Exon2 in 
TMPRSS2 were investigated by Luciferase (Luc) expression. To further improve 
on promoter activity and transcription, the TMPRSS2 constructs were inserted into 
an expression cassette derived from the versatile expression vector VISA (VP16-
GAL4-WPRE integrated systemic amplifier). When the Luc-gene was replaced 
with CD/UPRT in the VISA vector, specific and dose-dependent cell killing was 
observed in 22RV1 (AR+) cells when the non-toxic prodrug 5-flourocytosine (5-
FC) was administered.  
To increase transfection efficiency, I inserted the TMPRSS2-VISA-CD/UPRT 
expression cassette into a non-replicating adenovirus (Ad5-TV-CU) replacing the 
E1-genes. Ad5-TV-CU was characterized and protein expression of the CD/UPRT 
gene was detected at high levels post infection in AR-expressing 22RV1, LNCaP 
sublines, and VCaP cells, whilst remaining inactive in DU145 and HEK293 cells 
(AR-negative). Dose-dependent decreases in EC50-values were observed upon 
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infection with Ad5-TV-CU in combination with low doses of 5-FC in a number of 
cell lines, including 22RV1, LNCaP-104-S, LNCaP-CDXR3 and LNCaP-104R1 
cells, whilst demonstrating no cell killing at any concentration in PC3, PNT1a, 
PNT2 and PrEC cells (AR-). 
To determine efficacy of the viral vector in vivo, I explored various AR-expressing 
PCa cell lines grown as xenografts in immunodeficient murine models, including 
22RV1 and the LNCaP sublines LNCaP-104-S and LNCaP-CDXR3. However, 
establishment of the in vivo models was unsuccessful due to variable tumour take 
and growth (LNCaP) or tumours grew fast and studies had to be terminated prior 
to efficacy determination (22RV1).  
Further comparison of the Exon1 TMPRSS2 promoter with the traditional PSA 
promoter and the chimeric PSA promoter/enhancer demonstrated the Exon1 
TMPRSS2 construct to be superior by inducing 3.5-fold and 2.3-fold higher levels 
of luciferase expression than the PSA constructs, respectively. Investigation of 
both Exon1 and Exon2 TMPRSS2 promoters revealed that fusion of the two 
regions to form the chimeric Exon1/Exon2 promoter, drove higher levels of 
prostate specific expression, that have the potential to drive higher level 
expression than the SV40 promoter, this higher expression could improve efficacy 
of the current non-replicating Ad5-TV-CU.  
In summary, Ad5-TV-CU has demonstrated efficacy in a number of AR expressing 
cell lines, with limited results in vivo. Further studies that incorporate the optimal 
LW chimeric promoter into a replicating adenoviral vector could dramatically 
improve the efficacy of this virus for future studies. Additionally the discovery of a 
more suitable in vivo model will help to establish the true therapeutic potential of 
the new optimal Ad5-TV-CU virus. 
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DNTP: deoxyribonucleotide triphosphate 
DRE: digital rectal exam 
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gDNA: genomic DNA 
GFP: green fluorescence protein 
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GDEPT: Gene Directed Enzyme Prodrug Therapy 
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GMP: good manufacturing practice  
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HSP: heat shock protein 
HSPG: heparin sulphate proteoglycans 
HSV: herpes simplex virus 
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lats: large tumour suppressor 2 
LB: lysogeny broth bacteria media 
LBD: ligand-binding domain 
LH: luteinizing hormone 
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MAPK: mitogen-activated protein kinase 
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Mab: monoclonal antibody 
MHC: major histocompatibility complex 
min: minutes 
mRNA: messenger RNA 
miRNA: micro RNA 
MLP: major late promoter 
MOI: multiplicity of infection 
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n: number of times an experiment was repeated 
NEB: new England biolabs 
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ns: not significant 
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ppc: particles per cell 
pRB: retinoblastoma tumour suppressor protein 
PolyQ: polyglutamine 
PSA: prostate specific antigen 
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RLU: raw light units 
RNA: ribonucleic acid 
RPMI: Roswell Park Memorial Institute medium 
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RT: room temperature  
SCID-X1: X-linked severe combined immunodeficiency 
SDS: sodium dodecyl sulphate 
SDS-PAGE: sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM: standard error of the mean 
SMRT: silencing mediator of retinoic acid 
SNP: single nucleotide polymorphism 
SRC: steroid-receptor-coactivator 
SSC: right angle side scatter 
STR: short tandem repeat 
TARP: T-cell receptor gamma-chain alternate reading frame 
TAU: transactivation domain 
TBE- Tris Borate EDTA 
TBP: TATA-binding protein 
TCID50: tissue culture infectious dose 50% 
TGF-β: transforming growth factor-β 
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TSG: tumour suppressor gene  
TSP: tissue specific promoter 
TSS: transcription start site 
TSTA: Two Step Transcriptional Amplification 
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1.1 The normal prostate, PCa 
aetiology and PCa diagnosis 
1.1.1 Anatomy of the Prostate. 
The prostate is the size of a walnut and is located around the neck of the bladder 
and urethra, just in front of the rectum in men (Shen and Abate-Shen 2010). 
During fetal development, at around 10 weeks, the budding of the prostate 
epithelium is stimulated from the urogenital sinus, composed of urogenital sinus 
epithelium and urogenital sinus mesenchyme, by fetal androgens that are 
essential for normal prostate development (Cronauer et al. 2003). As a bi-product 
of this action, growth factors are released to activate the mesenchyme cells which 
express high levels of androgen receptor (AR). The development of the normal 
prostate is dependent on the interaction between the urogenital sinus epithelial 
cells and the urogenital sinus mesenchyme cells. Expression of AR from the 
mesenchyme cells results in induction of epithelial bud formation, bud growth and 
ductal branching, promotion of epithelial differentiation into secretory epithelial 
cells, which are AR-positive,  and release of paracrine growth factors from the 
mesenchyme cells that stimulate glandular morphogenesis and epithelial cell 
growth (Cunha et al. 2003). As a reciprocal result of epithelial cell differentiation, 
the developing prostatic epithelium induces smooth muscle differentiation in the 
urogenital sinus mesenchyme, resulting in development of the mesenchyme into a 
mature prostatic stroma, consisting mainly of smooth muscle cells and the 
epithelium displaying a highly differentiated phenotype. 
The adult prostate is partly muscular, partly glandular, composing of a glandular 
epithelial and a fibromuscular stroma compartment. It has a zonal architecture 
which includes central and large peripheral zones contained within the glandular 
portion of the prostate, constituting 95% of the gland. The remaining 5% is 
composed of the transition zone and periurethral glands that share a similar acinar 
structure due to their common origin, the urogenital sinus (Figure 1). In contrast, 
the glands of the central zone, both originating from the Wolffian duct are 
morphologically distinct. 
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Figure 1 Two-dimensional schematic showing the zonal architecture of the prostate 
95% of the prostate is composed of the central and peripheral zones, with the remaining 5 
% consisting of the transitional zone and the periurethral gland region. 
The outermost peripheral zone harbours the majority of prostate carcinomas 
(about 60-70%) and occupies the largest volume (Shen and Abate-Shen 2010, 
Cronauer et al. 2003). The primary function of the prostate is to secrete a slightly 
alkaline fluid (~pH 7.2-8) that constitutes the majority of the seminal fluid, the fluid 
that carries sperm and protects it from the acidic environment of the vagina, as 
well as protecting the male urinary and reproductive system from pathogens. 
There is a medium-high prevalence of cancers that occur in the peripheral gland, 
fewer in the transition zone and a very low number in the central zone. Large 
areas of inflammation can be found around the transition zone, where most benign 
prostate hyperplasia (BPH) cases develop, most often in combination with focal 
atrophy. Acute inflammation is also apparent in the transition zone as well as the 
peripheral zone. Most cases of high-grade prostatic intraepithelial neoplasia 
(HGPIN) occur in both the peripheral and transition zones as seen with 
Carcinomas (Table 1) 
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Table 1 Table showing the prevelance of PCa in the different areas of the prostate. 
Zone/ 
condition 
Focal 
atrophy 
Acute 
inflammation 
Chronic 
inflammation 
BPH HGPIN Carcinoma 
Peripheral       
Transition       
Central       
= high prevalence, =medium-high prevalence, = low prevalence. Blank boxes = 
no cases. BPH= benign prostate hyperplasia, HGPIN= high grade prostatic intraepithelial 
neoplasia. 
The human prostate contains a pseudostratified epithelium consisting of three 
differentiated epithelial cell types: Luminal, basal and neuroendocrine cells (Shen 
and Abate-Shen 2010) (Figure 2). The luminal cells produce protein secretions 
and express cytokeratins 8 and 18 among other markers including high levels of 
AR. The basal cells are located below the luminal epithelium and express AR at 
very low levels along with p63 and cytokeratins 5 and 14. The neuroendocrine 
cells are morphologically undistinguishable from basal cells and are thought to 
regulate the growth, differentiation and secretory function of the prostate gland 
(Abate-Shen and Shen 2000a, Sun, Niu, and Huang 2009). Neuroendocrine cells 
are very rare and express no AR but do express chromogranin A and 
synaptophysin (Shen and Abate-Shen 2010). 
 
Figure 2 Schematic illustration of the different cell types in the human prostatic duct  
The human prostate comprises three differentiated epithelial cell types, luminal, basal and 
endocrine. These cell types differ in their protein secretions, each of which has a different 
function in driving prostate cell growth (Abate-Shen and Shen 2000). 
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1.1.2 Aetiology of PCa 
In 1863 Virchow proposed a causal link between chronic inflammation and 
carcinogenesis that is now widely accepted (Balkwill and Mantovani 2001). It is 
estimated that 25% of all malignancies are connected to chronic inflammation 
(Woenckhaus and Fenic 2008). This has been confirmed in patients who suffer 
from Crohn’s disease or ulcerative colitis, who have a 10-fold increased risk of 
developing colon cancer (Itzkowitz and Yio 2004, Seril et al. 2003). Similarly, 
inflammation of the prostate has been proposed as a potential precursor to 
prostate cancer (PCa). 
Regions of prostatic inflammatory atrophy (PIA) are associated with inflammatory 
cell infiltrates and develop at high frequencies to include large regions of the 
prostate in some men (De Marzo et al. 1999). This often includes a reduction in 
the volume of pre-existing glands and stroma (McNeal 1988). This process occurs 
in response to unknown stimuli and features atrophic epithelial cells that 
regenerate in response to cellular damage. These cells have been shown to 
merge with high grade prostatic intraepithelial neoplasia (HGPIN) and contain 
some of the well recognised genetic mutations that are found in PCa (De Marzo et 
al. 2007). PIA has been found in 30% of prostate biopsies, has a lower association 
to PCa than HGPIN and is associated with low grade tumours (Celma et al. 2014). 
Despite evidence suggestive of a role for PIA in prostate carcinogenesis, the 
mechanisms that would permit its neoplastic transformation are still unknown. 
However, evidence suggests a model in which PIA may progress into prostate 
intraepithelial neoplasia (PIN) and/or invasive PCa (Putzi and De Marzo 2000). 
Further evidence needs to be gathered to fully elucidate the role of PIA in the 
development of PCa.  
PIN is widely believed to be the precursor of PCa (Figure 3), although this is yet to 
be conclusively proven (Shen and Abate-Shen 2010). PIN is described as the 
abnormal proliferation of the secretory epithelium within prostatic ducts and acini, 
without the invasion of the basement membrane (Godoy and Taneja 2008). 
HGPIN has been recognised as a risk factor for PCa and is found in 85-100% of 
radical prostatectomy specimens, and tissue adherent to PCa tumours (Godoy 
and Taneja 2008). Characteristics typical of PIN include appearance of luminal 
epithelial hyperplasia, reduction in basal cells, enlargement of nuclei and nucleoli, 
cytoplasmic hyperchromasia, and nuclear atypia (Godoy and Taneja 2008). PIN 
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displays a reduced number of basal cells, which are entirely absent in PCa. The 
difference between HGPIN and PIN is defined by the presence of prominent 
nucleoli. HGPIN can be identified due to an increase in cellular proliferation 
markers and the incidence and severity of HGPIN has been shown to increase 
with age, similar to the development of PCa (Qian, Wollan, and Bostwick 1997). 
HGPIN also has similar patterns of prevalence to PCa, with increased incidence in 
African- American men compared with Caucasian men (Sakr et al. 1995). 
PCa is frequently multifocal, resulting in huge heterogeneity. As a result of this 
cellular dysplasia, tissue disorganization and genetic alterations vary massively 
within these distinct foci. It is widely accepted that PCa can arise from multiple 
independent foci and is therefore polyclonal in origin. However, some studies have 
suggested a monoclonal origin for PCa, as identical genomic copy number 
changes were detected through analysis of genome-wide DNA copy number, in a 
high resolution SNP array study, in isolated individual cancer and precursor 
legions (Boyd, Mao, and Lu 2012). This study also recorded extensive subclonal 
genomic alterations for all tumours, suggestive of interfocal heterogeneity.  
PCas are largely indolent with respect to growth and only one third become locally 
invasive, spreading beyond the tissue capsule or metastasizing to local lymph 
nodes and distal organs, including bone, liver and lung (Schulz, Burchardt, and 
Cronauer 2003). In contrast to the normal prostate, the luminal cells express high 
levels of AR, resulting in enhanced cell growth in the early stages of PCa 
development. Consequently, androgen withdrawal (androgen deprivation therapy, 
ADT) is the mainstay therapy for the treatment of PCa, but will only induce 
apoptosis in androgen-dependent cells. Due to the heterogeneous nature of PCa 
(Bastus et al. 2010), where not all cells are reliant on androgen stimulation for 
growth, ADT will select for those cells that are androgen-independent, leading to 
the occurrence of a castration resistant PCa phenotype (discussed later in more 
detail) (Litvinov, De Marzo, and Isaacs 2003). 
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Figure 3  Progression pathway to PCa 
The progression from normal prostate tissue to metastasis. Normal cells progress to 
atrophy or proliferative inflammatory atrophy (PIA). From this stage they progress to 
prostatic intraepithelial neoplasia (PIN) and then on to invasive carcinoma and, eventually, 
metastasis. Adapted from (De Marzo et al. 2007). 
1.1.3 PCa Statistics. 
PCa is the second biggest cause of cancer-related death in men in the western 
world, accounting for 12% of deaths (statistics 2014). In the UK, 37,000 men are 
diagnosed with PCa every year and 9,698 male PCa deaths were recorded in 
England and Wales in 2012, accounting for 4% of total deaths (Statistics 2012). 
Estimates suggest that the incidence of PCa is set to rise to >61,000 cases per 
year by 2030 (Mistry et al. 2011).  PCa is the second most frequently diagnosed 
cancer worldwide and the sixth leading cause of cancer death, accounting for 6% 
of total cancer deaths in 2008 (Jemal et al. 2011). Incidence rates of PCa vary by 
more than 25-fold worldwide (Jemal et al. 2011). More developed countries have a 
higher incidence of the disease, thought to be due to a number of reasons 
including the frequency of Prostate Specific Antigen (PSA) testing, diet, lifestyle 
and genetic background.  
PCa is a slow growing, progressive disease and as a result has become known as 
a ‘disease of the elderly’. Autopsy studies showed that a large number of men die 
of different illnesses before the cancer is detected and 73% of PCa deaths occur 
in men over the age of 75. Despite the lack of a cure for PCa, the 5-year survival 
rates post diagnosis are still at 81.4% 
(http://www.ons.gov.uk/ons/rel/vsob1/mortality-statistics--deaths-registered-in-
england-and-wales--series-dr-/2012/stb-deaths-registered-in-england-and-wales-
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in-2012-by-cause.html). This is most probably due to the detection of early stage 
non-life threatening PCa by regular testing for PSA. The majority of PCas are 
indolent, unlike many other cancers, which even when detected at an early stage 
will kill without an effective treatment, discussed further in section 1.1.4.1. 
1.1.4 PCa diagnosis, grading and staging 
Traditionally, detection of PCa relied on a digital rectal examination (DRE) 
(Damber and Aus). Approximately 18% of PCa cases were detected by a PCa 
suggestive finding via DRE alone, regardless of PSA level (Carvalhal et al. 1999). 
However, over recent years the application of PSA serum concentration as a 
biomarker and transrectal ultrasound (TRUS)- guided biopsy have revolutionised 
the diagnosis and treatment of PCa, facilitating screening programs to diagnose 
larger numbers of men at earlier stages of the disease (Nash and Melezinek 
2000). This allows for disease detection when the cancer is indolent and would 
otherwise be left undetected, most probably accounting for the increase in survival 
rates due to the combination of earlier treatment and the detection of many 
indolent cancers that would never have killed the patients, even without treatment.  
1.1.4.1 Prostate Specific Antigen (PSA)  
PSA was first investigated as a serum biomarker for adenocarcinoma of the 
prostate in 1987 (Stamey et al. 1987). It has since become standard practice to 
measure serum testosterone levels in men over the age of 50 if they present with 
symptoms of PCa, but there is currently no organised screening program in the 
UK for PCa, and screening differs between countries. Until recently, yearly PSA 
screening was recommended in the United States for men over 50, however some 
advisory groups are now advising against regular testing due to the potential 
harms outweighing benefits, although yearly testing is still carried out through 
Medicare insurance.  
PSA is specific to the prostate as it is produced in normal prostate secretions. 
Increases in the levels of PSA are a hallmark of prostate cancer, however raised 
PSA levels do not necessarily indicate cancer. High PSA levels can also be due to 
benign prostatic hypertrophy (BPH), prostatitis or urinary infection (Nadler et al. 
1995). Normal PSA levels are 0-4 ng/ml for men aged up to 70 years and can rise 
to 5 ng/ml for men aged over 70 (Nash and Melezinek 2000). The age specific cut-
offs in normal PSA measurement recommended by the PCa risk management 
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program in the UK are: 50-59 years ≥ 3 ng/ml: 60-69 years ≥ 4 ng/ml: 70 years 
and above ≥ 5  ng/ml. Studies have shown that approximately 80% of patients with 
PCa and 20% of patients with BPH have PSA levels exceeding 4 ng/ml (Catalona, 
Richie, Ahmann, Hudson, et al. 1994). Thus, elevated levels of PSA antigen in the 
blood indicate that further investigation is necessary to identify the cause. 
Conflicting with this evidence, 2% of men that present with fast growing PCa have 
a normal PSA level, suggesting that PSA is not a totally reliable biomarker for the 
detection of PCa. Men who present with high PSA levels will have a biopsy to 
confirm if cancer is present and approximately 25% of biopsy cases return with a 
positive diagnosis (Smith, Humphrey, and Catalona 1997). In order to establish 
the stage and grade of the cancer, the patient may be given a ‘TNM’ assessment 
(although this is not currently as popular) and a Gleason score (described more 
fully below). This score will determine the intensity of any resulting treatment.  
1.1.4.2 Gleason score. 
The Gleason score has been established as being one of the most informative 
grading systems to determine the stage and prognosis for PCa. It was developed 
in 1974 by Dr Donald Gleason, who based the score on biopsies from almost 
3,000 patients with PCa (Gleason and Mellinger 1974), and it is currently used to 
grade PCa based on core biopsies. It is calculated by the addition of the two most 
common patterns (grades 1-5) of tumour that are found and so ranges between 2 
and 10. However, more recently, individual Gleason scores of 1 or 2 are not 
defined as cancer, therefore a combined score of 6 is regarded as showing the 
least aggressive form of disease and a score of 10 showing the most aggressive 
(see Table 2) (Gleason and Mellinger 1974).  
Table 2 Gleason score 
Gleason score What does it mean? 
3+3 All cancer cells proliferate slowly  
3+4 Most cancer cells proliferate slowly, however some cells grow at a 
moderate rate  
4+3 Most cancer cells proliferate at a moderate rate, but some 
proliferate more slowly  
4+4 All cancer cells proliferate at a moderate rate  
4+5 Most cancer cells proliferate at a moderate rate, however some 
cells rapidly proliferate  
5+4 Most cancer cells proliferate quickly  
5+5 All cancer cells proliferate quickly  
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1.1.4.3 Tumour, lymph node, metastasis (TNM) 
classification of malignant tumours 
PCa is also staged using the TNM system (Figure 4, Table 3), which separately 
assesses tumour (T), lymph nodes (N) and secondary cancer (metastases-M). 
Together with PSA levels and Gleason score to categorize PCa into 5 stages 
(Sobin, Gospodarowicz, and Wittekind 2010) (Figure 4). TNM was devised by 
Pierre Denoix between 1943 and 1952 and is a globally recognised standard for 
classifying the extent and spread of cancer. 
 
Figure 4 Diagrammatic illustrating tumour grades 1-4 
T1- localised to the prostate. T2 tumours are restricted to the prostate but occupy a larger 
area of the prostate that can extend to both lobes. T3 tumours are locally advanced and 
have spread outside the prostate but not yet invaded other organs. T4 tumours have 
spread to nearby organs such as the bladder. 
T (tumour staging) is subdivided into T1-T4. T1 tumours are most often discovered 
by needle biopsy that has been performed as a result of raised PSA levels. T1 
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stage tumours cannot be seen on scans or felt during examination. T2 tumours 
are restricted to the prostate gland and can be subdivided into 3 smaller groups; 
T2a- present in only half of one of the prostate gland lobes, T2b- present in more 
than half of one of the lobes and T2c- present in both lobes but still restricted to 
the prostate gland. T3 tumours are locally advanced cancers that have spread 
outside the prostate gland, but have not yet infiltrated other organs. T3 tumours 
are subdivided into 2 further groups; T3a- the tumour has broken through the 
prostate gland and T3b- the tumour has spread into the seminal vesicles. T4 
tumours are also locally advanced, but have spread into nearby organs, such as 
the bladder. 
N (lymph node) staging- Metastatic PCa can spread to the lymph nodes, causing 
inflammation. Lymph node staging can be divided into 3 groups; NX- lymph nodes 
cannot be checked, N0- no cancer cells can be detected in lymph nodes close to 
the prostate or N1- there are cancer cells present in lymph nodes. 
Table 3 PCa overall staging 
Stage  T score  N score  M score  Gleason score  PSA levels (ng/ml)  
I  1  0  0  ≤6  <10  
2a  0  0  ≤6  <10  
IIA  1  0  0  <7  <20  
1  0  0  ≤6  ≥10<20  
2a/2b  0  0  ≤7  <20  
IIB  2c  0  0  Any  Any  
1/2  0  0  Any  ≥20  
1/2  0  0  ≥8  Any  
III  3  0  0  Any  Any  
IV  4  0  0  Any  Any  
Any  1  0  Any  Any  
Any  Any  1  Any  Any  
 
M staging- metastases (Metastatic cancer is cancer that has spread to other parts 
of the body, most commonly the bone and lymph nodes), sub-categorized into 5 
groups (M0, M1, M1a, M1b and M1c). M0- cancer has not spread outside the 
pelvis, M1- cancer has spread outside the pelvis, M1a- cancer cells can be found 
in the lymph nodes outside the pelvis, M1b, cancer cells can be found in the bone 
and finally M1c, cancer cells can be found in other parts of the body. 
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1.2 Genomic alterations in PCa. 
Cancer is recognised as a genetic disease and PCa is both very heterogeneous 
and characterised by somatic copy number alterations, point mutations and 
structural rearrangements that cause loss of function of tumour suppressor genes 
(TSGs) or overexpression of oncogenes. Genetic alterations can be inherited 
(germline mutations), or induced by endogenous or exogenous carcinogenic 
factors (somatic alterations). Epigenetic modifications to the DNA including DNA 
methylation and histone accetylation have also been shown to contribute towards 
prostate carcinogenesis. As well as pathological heterogeneity, PCa is also highly 
heterogeneous when presented clinically. Many same stage tumours can lead to 
different clinical outcomes ranging from latent to highly aggressive disease states 
despite tumours being considered as histologically identical (Boyd, Mao, and Lu 
2012). 
1.2.1 Hereditary PCa 
A familial history of PCa is an important risk factor in PCa development. 
Individuals who have a first degree relative with a history of PCa have a two-fold 
risk of developing cancer compared with the general population (Carter et al. 
1992, Edwards and Eeles 2004). In some cases hereditary cancers are a result of 
an inherited mutation in one allele of a tumour suppressor gene, requiring one 
further somatic mutation in the second allele for the development of cancer 
(Schulz, Burchardt, and Cronauer 2003). 40% of hereditary PCa is diagnosed by 
the age of 55 and accounts for 9% of total PCas (Carter et al. 1992). Due to the 
age at which hereditary cancer presents, genotype data are often unavailable for 
older relatives of the patient. Despite this, several regions of the genome have 
been identified as containing PCa predisposition genes through linkage studies, 
including; 1q24-1q25 (HPC1) containing the RNASEL gene which is susceptible to 
both nonsense and frameshift mutations (Xu 2000), 1q42-q43 (PCAP) (Berthon et 
al. 1998), 8p22-23 (PANX1) (Xu et al. 2001), Xq27-q28 (HPCX), 1p36 (CAPB) 
(Gibbs et al. 1999), 20q13 (HPC20), 17p11 (ELAC2) that suffers nonsense or 
missense mutations (Tavtigian et al. 2001) and 16q23 (Nwosu et al. 2001, Bratt 
2002, Simard et al. 2002). The results of several linkage studies were later 
reanalysed as a combined dataset. This new dataset represented 426 families 
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with hereditary PCa and allowed for identification of a new susceptibility loci at 
17q21-22 (BRCA1) (Gillanders et al. 2004). 
In 2006 the application of a new analysis technology, genome wide association 
studies (GWAS), identified a 3.8Mb region on the 8q24 chromosome band, 
containing the MYC oncogene (Amundadottir et al. 2006). Subsequently, 29 SNP 
loci on various chromosomes have been identified in addition to 9 SNP loci on 
8q24. The latter of which were shown to be independently associated with PCa 
risk. A later study identified a further seven susceptibility loci (Boyd, Mao, and Lu 
2012, Kote-Jarai et al. 2011). 
Germline mutations in the AR are rarely identified in patients with PCa. However, 
prevalent polymorphisms have also been described as contributing towards the 
genetic susceptibility of PCa. Polymorphisms in the steroid hormone receptor AR, 
include differences in CAG and GGN repeats encoding glutamine and glycine 
repeats respectively, in the N terminal transcriptional activation domain of AR. 
Studies have suggested that shorter CAG repeats are associated with a small 
increased risk of PCa (Wang et al. 2014), although the true association between 
CAG and GGN repeat length and PCa risk remains unclear (Zeegers et al. 2004, 
Gu et al. 2012). A population disparity exists between CAG repeat lengths in white 
men, Asian men and black men. CAG repeat length is shortest in black men and 
longest in Asian men, with white men in the middle (Hsing et al. 2000). 
Interestingly this disparity also correlates with ethnicity based variation in PCa 
incidence and mortality (Buchanan et al. 2001). Despite extensive investigation 
into the association of CAG repeat length and PCa incidence a true causal link 
has not yet been conclusively proven.  
Polymorphisms in genes associate with androgen biosynthesis are also frequently 
observed. The SRD5A2 gene contains a V89L polymorphism associated with 
decreased DHT production in vitro and in vivo (Hsing et al. 2001). SRD5A2 
encodes part of 5-α-reductase and the V89L polymorphism is more common in 
Chinese and Japanese men, contradicting PCa ethnical disparity studies in which 
PCa is less prevalent in the Asian population. A number of other common 
polymorphisms in the androgen biosynthesis pathway occur in CYP17A1, a gene 
which encodes the cytochrome P450 (CYP) subfamily 17A enzyme. This enzyme 
mediates 17 α-hydroxylase and 17, 20 lyase activities. Other genes required for 
androgen biosynthesis and susceptible to polymorphisms include; CYP19A, 
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CYP3A HSD3B and HSD17B (Mononen and Schleutker 2009, Li et al. 2013). 
Polymorphisms have also been detected in the vitamin D receptor (VDR), where 
different lengths of a polyA-repeat in the 3’ region confer susceptibility to PCa 
(Ingles et al. 1997). 
1.2.2 Somatic DNA alterations in PCa 
Somatic copy number alterations are present in 90% of primary prostate tumours 
and more commonly occur as deletions rather than amplifications (Schoenborn, 
Nelson, and Fang 2013). In localised cancer these somatic alterations occur in 
only a small portion of the genome, progressing to large proportions of the 
genome in metastatic disease, suggesting increased genomic instability. Several 
gains and losses of chromosomal regions have been identified by comparative 
genomic hybridization (CGH), including gain at 8q and losses at 3p, 8p, 10q, 13q, 
and 17p (Dong 2001, Lapointe, Li, et al. 2007). Frequent deletions of 8p, 10q and 
13q encompass genes such as NKX3-1, PTEN, BRCA2 and RB1. Frequent 
amplifications are seen in chromosomes X, 7, 8q and 9q in Castration resistant 
metastatic tumours and include AR at Xq12 and MYC oncogenes at 8q24. 
Unlike copy number alterations, point mutations are uncommon in PCa and result 
in both missense and nonsense mutations (Barbieri et al. 2013). Point mutations 
are more common in CRPC cases that harbour genomic alterations of the AR, 
occurring in 20% of cases (Beltran et al. 2013). Primary PCa has a somatic 
mutation rate of 1-2x10-6 (Schoenborn, Nelson, and Fang 2013). Of the thousands 
of mutations that can exist within one tumour only ~20 are likely to impact on 
protein stability and function (Schoenborn, Nelson, and Fang 2013). However, 
mutations in essential genes such as MSH6, a DNA mismatch repair enzyme, 
have been associated with hypermutator phenotypes. These hypermutators result 
in 25-fold more mutations than are seen in normal PCa (Taylor et al. 2010, Kumar 
et al. 2011). Point mutations also occur in the tumour suppressor genes TP53, 
PTEN, RB1 and the PIK3CA oncogene in a very small proportion of PCas, as well 
as mutations in other genes including KRAS and BRAF, resulting in an oncogenic 
phenotype. 
Other genetic alterations in cancer include chromosomal rearrangements, caused 
by double strand breaks that occur during replication or transcription as a 
consequence of DNA unwinding. Inefficient repair of these breaks can result in 
intra and inter chromosome rearrangement, sometimes resulting in the production 
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of  fusion genes (Schoenborn, Nelson, and Fang 2013). Understanding how these 
genes contribute to cancer is important, as they can act at the molecular level, 
either by driving the overexpression of an oncogene, or by the production of a new 
fusion protein that promotes oncogenic activity. One of the most commonly 
recognized genomic alterations is the BCR:ABL fusion gene, otherwise known as 
the Philadelphia chromosome in Chronic Myeloid Leukaemia (Sawyers 1999). 
With the identification of the novel tyrosine kinase inhibitor, imatinib, successful 
treatment for this cancer has since become available (Druker et al. 2001). One of 
the most frequently observed alterations in human cancer is the fusion of the AR-
driven TMPRSS2 upstream region with the ERG gene (Tomlins et al. 2005) (see 
section below).   
1.2.3 ETS fusion genes in cancer 
The ETS fusions genes were first discovered when strong outlier profiles of two 
ETS family genes, ERG and ETV1 were identified by oncomine. After this initial 
discovery RLM-RACE studies and subsequent sequencing anaylsis revealed 
fusion of ERG and ETV1 with the androgen responsive promoter region of 
TMPRSS2, a transmembrane serine protease (Tomlins et al. 2005). Fusions 
between TMPRSS2 and other ETS variants including ETV4, ETV5 and ELK4 were 
subsequently identified but are not as prevalent as the TMPRSS2:ERG fusion 
(Tomlins et al. 2006, Helgeson et al. 2008). As well as TMPRSS2 a number of 
alternative 5’ fusion partners have been identified in ETS gene fusions, including 
SLC45A3, ERVK-24, HNRPA2B1, C150RF21 and NDRG1 (Lapointe, Kim, et al. 
2007, Pflueger et al. 2009), of which SLC453A and NDRG1 are also androgen 
responsive, suggesting that androgen responsive genes are prone to creating 
recurrent gene fusions or have a selective cell growth advantage in PCa. 
1.2.3.1 TMPRSS2:ERG fusion. 
TMPRSS2 is a transmembrane serine protease and belongs to the serine 
protease family. Serine proteases are known to be involved in many physiological 
and pathological processes (http://www.genecards.org/). TMPRSS2 promoter 
expression has been demonstrated to be prostate specific, with the promoter 
activated by binding of AR to androgen response element(s) (AREs) in its 5’-end. 
However, low levels of expression have also been found in the colon, liver, lung, 
kidney and pancreas (Lin et al. 1999). Studies have shown that the levels of 
TMPRSS2 expression are higher in PCa tissues in comparison to benign prostate 
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tissue (Vaarala et al. 2001). The TMPRSS2:ERG fusion gene accounts for 40-
70% of all reported ETS fusion genes and is found in more than 50% of PCa 
patients (Tomlins et al. 2005).  
The role of TMPRSS2:ERG fusion is not fully elucidated. It is possible that the 
fusion gene may play a role in disease progression through increased levels of 
ERG expression, and could therefore possibly be used as a marker to differentiate 
between localised cancer, and more advanced aggressive forms of the disease. 
Overexpression of ERG has been shown to promote the invasive potential of PCa 
cells (Li et al. 2011). Patients with TMPRSS2:ERG fusion gene have shown a 
higher risk of disease recurrence (58.4% at 5 years) in comparison to 
TMPRSS2:ERG negative patients (8% recurrence) (Nam et al. 2007). However, 
similar studies have shown opposing outcomes (FitzGerald et al. 2008, Gopalan et 
al. 2009, Fine et al. 2010). Additionally, TMPRSS2:ERG is also expressed in 
castration resistant forms of the disease due to reactivation of AR (Cai et al. 
2009).  
Furthermore, TMPRSS2:ERG is more commonly found in poorly differentiated 
tumours than in well differentiated tumours (Rajput et al. 2007), but evidence also 
exists to suggest that the TMPRSS2:ERG fusion has been associated with 
disease stage, but does not predict recurrence or mortality amongst men treated 
with radical prostatectomy (Pettersson et al. 2012). Furthermore, a study in 
Brazilian patients showed no correlation between ERG expression and clinical and 
pathological parameters, but suggested that the frequency and specificity of 
TMPRSS2:ERG fusion may aid as a diagnostic tool (Eguchi et al. 2014). 
TMPRSS2 is located 3 Mb upstream of ERG on human chromosome 21q22.2. 
The upstream regulatory elements and promoter of the TMPRSS2 gene drive the 
over expression of ERG upon the formation of the fusion gene (Mani et al. 2011) 
(Figure 5). The most common fusion is between Exon1 of TMPRSS2 and Exon4 
of ERG, occurring in 85% of cases, followed by Exon1-2 of TMPRSS2 fused with 
Exon4 of ERG (20% of cases). Fusions with Exon2 of TMPRSS2 have been 
associated with more aggressive forms of PCa (Wang et al. 2006). Evidence 
exists to suggest that TMPRSS2:ERG fusion is an early, or perhaps even initiating 
event in PCa tumourigenesis, TMPRSS2:ERG is detected less frequently in PIN 
than in PCa, however TMPRSS2:ERG fusion events are frequently detected in 
  44 
 
PIN lesions that are adjacent to TMPRSS2:ERG positive tumours (Perner et al. 
2007, Carver et al. 2009). 
The mechanism underlying TMPRSS2:ERG fusion is not yet fully understood. 
However, gene fusion can be induced by AR, in both malignant and non-malignant 
prostate cells. LNCaP cells treated with DHT (the more potent and physiologically 
relevant testosterone-derivative) for 24 hours induced the TMPRSS2:ERG fusion 
and cells treated for just 3 hours showed co-localization of the TMPRSS2 and 
ERG genes (Bastus et al. 2010, Mani et al. 2009, Lin et al. 2009). Non-malignant 
cells (PNT1A and PNT2) were capable of inducing the fusion gene after prolonged 
treatment with DHT for 5 months, and also showed increased gene proximity after 
DHT treatment for just 3 hours (Bastus et al. 2010). This is suggestive of an early 
role for TMPRSS:ERG fusion in prostate carcinogenesis. 
Population differences in the occurrence of TMPRSS2:ERG fusion has also been 
demonstrated through high-resolution SNP array genomic copy number analysis. 
Differences in the frequency of the TMPRSS2:ERG fusion gene have been 
described between Chinese and UK-based populations (Mao et al. 2010), as well 
as western and Asian countries (Lee et al. 2010, Magi-Galluzzi et al. 2011), with 
significantly higher incidences of TMPRSS2:ERG fusion in patients that reside in 
western countries. 
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Figure 5 Fusion of the TMPRSS2 and ERG genes found in PCa 
Exons (boxes) for TMPRSS2 are shown in blue and ERG in orange. Black arrows indicate 
the first in-frame translation initiation site in each fusion transcript. Adapted from (Wang et 
al. 2006). 
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1.3 Androgen structure, function 
and role in PCa development and 
progression 
1.3.1 Androgen production and metabolism 
AR is a steroid hormone receptor that is required for growth of the normal 
prostate. Gonadotropin-releasing hormone (GnRH), otherwise known as 
luteinizing-hormone releasing hormone (LHRH), is synthesised and released by 
the hypothalamus in a pulsatile fashion (Conn and Crowley Jr 1991). It reaches 
the anterior pituitary gland, where it stimulates the release of luteinizing hormone 
(LH) and follicle stimulating hormone (FSH). LH then travels to the testicles, where 
it induces the Leydig cells to produce testosterone. When testosterone arrives at 
the prostate it is converted by the enzyme 5-α-reductase into 5-α-
dihydrotestosterone (DHT) (Figure 6). DHT is an AR agonist that activates an 
array of AR responsive genes, resulting in normal prostate development (Conn 
and Crowley Jr 1991). 
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Figure 6 Androgen hormonal feedback 
Stimulation is shown by arrows. Negative feedback loop shown by dashed lines. The 
hypothalamus releases GnRH, which induces the Pituitary gland to release LH. Leuprolide 
and goserelin act as agonists stimulating the release of more GnRH, degarelix is an 
antagonist which blocks the production of GnRH. When LH enters the testicles, 
testosterone is released and feeds back to the hypothalamus and the pituitary gland in a 
negative feedback loop. Testosterone also travels to the prostate, where it is converted to 
DHT by 5α-reductase. DHT is then free to bind to AR. Bicalutamide and Flutamide act as 
AR antagonists and compete with DHT for binding to the AR. GnRH= Gonadotropin 
releasing hormone; LH= luteinizing hormone; DHT= dihydrotestosterone. 
1.3.2 Androgen Receptor biology 
Androgen receptor plays a critical role in male sexual differentiation, development 
and maintenance and is activated by binding of androgenic hormones 
testosterone or DHT (Roy et al. 1999). AR is a member of the nuclear hormone 
receptor of transcription factors that responds to androgenic signals from the 
testes in the form of testosterone/dihydrotestosterone (DHT) (Gaughan et al. 
2011). Testosterone is converted to the more active form of androgen, DHT by 5-
α-reductase. Following catalysis, DHT binds to AR causing AR homodimerization 
followed by its translocation into the nucleus. Once homodimerized, AR binds to 
androgen response elements (AREs) on target genes, contributing to 
transcriptional activation of prostate specific genes (Culig 2003).  
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AR is a 110 kDa steroid hormone receptor composed of 919 amino acids, located 
on the X chromosome at Xq11-12. AR contains four domains; 1) an amino 
terminal activation domain (NTD), encoded by Exon1. The NTD is the least 
conserved of the four domains, allowing recruitment of AR co-regulators for 
activation of prostate specific genes. 2) A DNA-binding domain (DBD), encoded by 
exons 2 and 3 that is responsible for binding to AREs of prostate specific genes 
(Shaffer et al. 2004). 3) A hinge region (HiR) encoded by Exon4, containing sites 
essential for phosphorylation, accetylation and degradation of AR and 4) A ligand-
binding domain (LBD) encoded by Exons5-8, central for recognition and binding of 
androgens (Figure 7). AR contains two activation domains, AF-1, located in the 
NTD and AF-2 located in the LBD. AF-1 is responsible for the majority of AR 
transactivation (Bennett et al. 2010), whereas AF-2 mediates NTD/CTD 
interaction, which has been shown to interact with a number of co-regulators and 
is important in stabilising bound ligand (Saporita et al. 2003). 
The AR consists of 12 alpha helices that undergo conformational changes in order 
to provide an interface for the recruitment of nuclear co-regulator proteins 
essential for controlling the activation of androgen-dependent genes via binding to 
AREs (Gaughan et al. 2011). These genes are involved in important processes, 
for example angiogenesis and apoptosis, and the interface is created when the 12 
alpha helices line up creating a closed conformation. 
 
Figure 7 Genomic position of the AR gene 
The AR gene spans 80 kb with intron and exon regions shown in the second panel. The 
three codon repeat regions of the first exon are shown, these constitute the N-terminal 
domain and this region is responsible for transcriptional activation. The DNA binding 
domain is located adjacent to the N-terminal domain. The ligand binding domain is 
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adjacent to the hinge region. This is the region that many AR agonists bind to in 
competition with DHT. From (Gelmann 2002) 
1.3.3 Role of AR in metastatic castration resistant PCa 
Androgen signalling plays a large role in PCa development and is therefore the 
initial target for therapeutic intervention (Culig et al. 2000). Decreasing the levels 
of circulating androgens by chemical castration frequently results in regression of 
tumours (see section 1.4.4.1). However, recurrence of castration resistant PCa 
eventually occurs (Shen and Abate-Shen 2010). Castration resistant tumours 
express AR as well as AR target genes, for example PSA, suggesting that 
pathway activity is intact (Gao, Arnold, and Isaacs 2001). Mechanisms described 
for this signalling have included amplification of AR gene copy number (Visakorpi 
et al. 1995), gain of function mutations of AR that may confer increased protein 
stability and sensitivity to androgens (Taplin et al. 1995), and expression of 
alternative splice isoforms that encode a constitutively active AR (Figure 8) (Dehm 
et al. 2008). Androgen synthesis and conversion of weaker androgens to 
testosterone and DHT, by the endogenous expression of androgen synthetic 
enzymes from the tumour tissue have also been reported to cause increased AR 
signalling (Stanbrough et al. 2006). Genomic alteration studies have identified a 
number of somatic mutations that can influence the outcome of cancer. The AR 
gene is the most commonly mutated steroid hormone receptor gene, with more 
than 660 mutations identified so far (Koochekpour 2010). Mutations in AR are 
found in 25-50% of androgen-independent (AI) and metastatic PCas in 
comparison to around 2% of untreated localised PCas (Gottlieb et al. 2004, Linja 
and Visakorpi 2004, Koochekpour 2010). Over 70 different somatic missense 
mutations have been described in PCa patients, yet only a few have been studied. 
The first AR mutation was described in the LNCaP PCa cell line (Veldscholte et al. 
1990). The T877A mutation occurs in the ligand binding domain of AR, resulting in 
decreased ligand specificity and promiscuous binding and activation of AR by non-
androgenic steroids.  
It is currently difficult to pinpoint the exact time at which PCa progresses to 
castration resistance. It is thought that castration resistant cells arise through 
genetic/epigenetic conversion of androgen-dependent cells during androgen 
deprivation (Shen and Abate-Shen 2010). Another model proposes that the cells 
arise from a population of rare, castration resistant cells within an androgen-
dependent tumour. It is suggested that androgen deprivation allows for the 
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selection of these cells due to elimination of sensitive cells (Isaacs and Coffey 
1981, Tso et al. 2000, Feldman and Feldman 2001). 
It is this castration resistant form of the disease that is increasingly difficult to treat, 
5 year survival rates for men at this advanced stage are 33% compared to 100% 
survival rates for localized disease (eMedTV July 2013). 
 
Figure 8 Mechanisms of androgen receptor gain of function in castration resistant 
PCa 
1. Upregulation of AR through gene amplification or enhanced sensitivity to AR.  In 
addition more testosterone is converted to DHT. 2. The specificity of AR is altered, 
allowing activation by non-androgenic molecules that are already present in the circulation. 
3. AR is phosphorylated through an alternative pathway either by AKT (protein kinase B) or 
the mitogen-activated protein kinase pathway (MAPK) resulting in ligand independent 
activation of AR. 4. Parallel survival pathways negate the need for AR or its ligand e.g. the 
anti-apoptotic protein BCL2 (B-Cell lymphoma 2). Adapted from (Feldman and Feldman 
2001). 
1.3.4 AR Promoter and enhancer- transcriptional control, 
coactivators and corepressors of AR 
Following its activation, AR binds to AREs on gene promoters and enhancers, 
where it recruits co-regulators including coactivators and corepressors that 
orchestrate chromatin remodelling and transcriptional regulation. The number of 
coactivators and corepressors now exceeds 200. AR dependent gene expression 
is therefore regulated by relative levels of AR coactivators and corepressors that 
modulate AR activity in response to changing hormone levels. These 
transcriptional regulators do not typically interact with the DNA, but co-operate 
with AR at target gene promoter and/or enhancer regions for four purposes: 1) to 
assist DNA binding, 2) to induce chromatin remodelling and 
accetylation/deacetylation of chromatin through recruitment of histone 
acetyltransferases (HAT) and histone deacetyltransferases (HDACs) respectively, 
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3) to control cofactor binding to the AF-2 coactivators binding groove through 
regulation of AR N/X interaction and finally 4) to recruit transcription factors that 
form the pre-initiation complex (PIC). 
1.3.4.1 Promoter and enhancer transcriptional control 
Maintaining control of gene function is essential for the development of all 
organisms, little is known about how the correct patterns of gene activation are 
maintained genome-wide, due to the complexity of this process. Genes lie 
adjacent to each other and many have multiple differentially regulated transcripts. 
Additionally, chromatin is arranged in a three-dimensional fashion, bringing genes 
that are located on different chromosomes into close proximity in order to interact 
with one another (Atkinson and Halfon 2014). 
The core promoter is typically located 35-40 bp upstream or downstream of the 
transcription start site (TSS). This sequence is usually sufficient to activate gene 
expression in a reporter assay and is required for transcription by eukaryotic RNA 
polymerase II. Basal transcription machinery, essential for promoter activation, 
interacts with core motifs found within the core promoter (Zhu and Halfon 2009). 
Identification of these core motifs is hindered by the fact that there are no 
universal motifs that are common to all promoters and no universally required 
element within promoters necessary for promoter activity. Despite this, the most 
common promoter motif is the TATA box, which binds the TATA-box binding 
protein (TBP) and is present in 5-20% of mammalian promoters (Cooper et al. 
2006, Gershenzon and Ioshikhes 2005). The TATA box consists of a canonical 
sequence, typically TATAAAAA, but many variations of this sequence have been 
found and this sequence has been conserved throughout evolution, further 
demonstrating its importance in promoter activation (Patikoglou et al. 1999). 
In order to fully understand promoter activation many attempts have been made to 
use large-scale mapping of TSSs, that have revealed different classes of 
promoters based on TSS distribution (Carninci et al. 2006, Hoskins et al. 2011). 
These can be grouped into single or broad. Single peak promoters span only one 
or several bp, whereas broad promoters can span up to 100 bp, further 
complicating the identification of gene specific promoters. Additionally a role in 
gene regulation has been suggested for the extended promoter region, up to 350 
bp upstream of the TSS (Cooper et al. 2006).  
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In addition to the complex nature of promoter regions, enhancers also play a vital 
role in the activation of specific genes. Transcriptional enhancers are distal non-
coding sequences that positively regulate transcription, regardless of orientation or 
distance in relation the gene being transcribed (Banerji, Rusconi, and Schaffner 
1981) and have been known to be able to activate transcription of genes located 
on a different chromosome (Geyer, Green, and Corces 1990, Lomvardas et al. 
2006). The complex regulation of a gene can be controlled by multiple enhancers, 
up to a few hundred base pairs in length. The main function of an enhancer is to 
act as a platform on which activators, repressors and chromatin modifying 
enzymes can bind to modulate gene expression (Atkinson and Halfon 2014). 
Upstream/downstream enhancers are thought to interact with DNA through 
chromatin looping, resulting in the stabilization of RNA polymerase binding or 
release of stalled polymerase. Evidence that enhancers are marked by specific 
sets of histone modifications is mounting, monomethylation of histone 3 lysine 4 
(H3K4me1) and accetylation of histone 3 lysine 27 (H3K27ac) are hallmarks of 
enhancers and have been used to predict the position of enhancers in a number of 
human cell lines, identifying over 400,000 enhancers. However, the majority of 
these have not been confirmed in vivo (Dunham et al. 2012).  
Some enhancers are known to solely interact with specific promoters (Butler and 
Kadonaga 2001). Whereas others have been shown to interact with similar 
promoters but not dissimilar promoters in zebrafish (Gehrig et al. 2009). Evidence 
also exists to suggest that enhancers are not gene specific and can interact with a 
number of different promoters (Kermekchiev et al. 1991). This suggests a more 
complex role for enhancers in gene specific activation. Additionally, in order to 
facilitate/prevent promoter/enhancer interaction coactivators and corepressors 
must bind to specific regions on promoters and enhancers to support/prevent 
interaction. A number of gene specific coactivators and corepressors have also 
been identified, which support gene specific activation. 
1.3.4.2 AR coactivators 
When a cell is not undergoing DNA replication the genomic DNA is tightly packed 
into chromatin, generating a barrier for transcriptional activities. In order for AR to 
stimulate transcription, it must open the chromatin structure to facilitate assembly 
of the PIC. AR fulfils this task by binding coactivators. These are specific proteins 
that are generally part of larger complexes that implement specific functions 
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essential for transcription. Two mechanisms exist to open up the chromatin 
structure. This first relies on covalent modification of histones thorough 
(de)acetylation, (de)methylation, (de)phosphorylation, ubiquitnation and 
sumoylation (Rosenfeld, Lunyak, and Glass 2006). Consequently, the 
modifications loosen or tighten the DNA-histone interactions by changing the net 
charge of the nucleosome (Heemers and Tindall 2007) (Figure 9).  
 
Figure 9 Schematic demonstrating AR coactivator interaction with AR 
AR contains a DNA-binding domain (DBD) and activation function 1 (AF1) region in the 
NH2-terminal region. The AR FxxLF motif interacts with ARA54, ARA55 and ARA70 as 
well as SRC1/p160. SRC1/p160 also interacts with the AF2 domain of AR through its 
LxxLL domain. The AF2 domain additionally interacts with the FxxLF motif in the NTD, 
generating the androgen-dependent N/C interaction. 
The most well understood of the histone modifiers are the histone 
acetyltransferases (HATs), which catalyze the addition of an acetyl group to 
specific lysine residues, opening up the DNA. The best characterised AR 
coactivators are the p160/SRC-family of proteins, together with p300 and CBP 
(Table 4). 
In fact, immunohistochemical studies have shown that SRC1 expression is 
increased by 50% in androgen-dependent PCa samples compared to benign or 
normal prostate tissues. This figure increased to 63% in CRPC samples (Gregory, 
He, et al. 2001). The p160 coactivators interact with the AR NTD and LBD and 
directly influence AR transactivation via their histone acetyltransferase activity. 
These coactivators also act indirectly by acting as a platform for the binding of 
secondary coactivators such as p300. Interestingly, p300 levels were also found to 
correlate with proliferation in vivo and were associated with larger tumour 
volumes. In vitro, levels of p300 have increased under conditions of androgen 
deprivation, offering a growth advantage in androgen insensitive cells (Heemers et 
al. 2007). 
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P300/CBP functions as a coactivator through bridging of DNA transcription factors 
to the basal transcriptional machinery whilst simultaneously acting as a scaffold for 
the nucleation of various transcription factors. It acetylates all four histones at a 
specific lysine residue on the histone tails, this process loosens histone-DNA 
interaction through neutralization of the negative charge (Iyer, Ozdag, and Caldas 
2004).
 
Table 4 Summary of the major AR coactivators involved in transcriptional activation 
of AR dependent genes. 
Coactivator  Function  AR binding site  Effect on AR signalling  
CBP/p300  • Bridges DNA 
transcription factors to 
the basal transcription 
machinery 
• Posses HAT activity  
AF2 via the 
LxxLL motif.  
Renders chromatin more 
easily accessible to AR 
and transcription factors, 
increasing AR signalling  
p160  • Acetylates histones to 
unfold chromatin for 
access  
• Acts as platform for 
binding of secondary 
coactivators  
AF2 via the 
LxxLL motif. 
AF1 via FxxLF 
motif  
Renders chromatin more 
easily accessible to AR 
and transcription factors, 
increasing AR signalling  
SRC1  • Nuclear receptor 
coactivator  
AF1 or AF2 via 
LxxLL motif  
 
ARA54  • AR coactivator  FxxLF 
interaction with  
LBD not 
through AF2  
Enhances AR-
dependent 
transcriptional activation  
ARA55  • Role in stromal-
epithelial interaction in 
development 
• AR coactivator  
FxxLF 
interaction with  
LBD not 
through AF2  
Modulates AR specificity 
in response to 
agonists/antagonists  
ARA70  • Potentiates AR 
transactivation in the 
presence of androgen 
• AR coactivator  
FxxLF 
interaction with  
LBD not 
through AF2  
Enhances AR-
dependent 
transcriptional activation  
SWI/SNF  • Alters the chromatin 
structure through 
remodelling  
N/A  Allows AR access to AR 
binding sites  
 
Binding to coactivators takes place through a short helical motif, LxxLL, which 
binds to a groove on the LBD. This groove is formed by charged and hydrophobic 
residues in helices 3, 4, 5 and 12. The three leucine residues of the structure are 
orientated towards the LBD surface and line one face of the helix, with the first and 
last leucine residues embedded within the hydrophobic groove. This binding is 
further stabilized by hydrogen bonds between the peptide backbone and charged 
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residues at the opposing end of the groove. Several coactivators contain multiple 
LxxLL motifs for binding, however, AR interacts relatively weakly with LxxLL motifs 
in many AR coactivators. AR preferentially binds to related FxxLF sequences, 
these were initially identified in the AR NTD (He, Kemppainen, and Wilson 2000),  
and were later shown to play a crucial role in the recruitment of AR cofactors 
ARA54, ARA55, ARA70 and hRAD9 (He et al. 2002, Wang et al. 2004). Binding 
through FxxLF motifs modulates the association of the AR NTD with the carboxy 
terminal domain (N/C) and interacts with the hydrophobic groove in the C-terminal 
AF-2 domain. Moreover, FxxLF motifs are unable to bind to other nuclear 
receptors, suggesting that cofactors with FxxLF sequences will preferentially bind 
to AR (Dubbink et al. 2006). 
The second method of regulating chromatin structure is through chromatin 
remodelling, utilising large coactivator complexes such as SWI/SNF, WINAC and 
NUMAC. These complexes can utilise the energy derived from ATP hydrolysis to 
alter the stability of the nucleosomes (van de Wijngaart et al. 2012). These 
chromatin remodelling complexes always contain a catalytic subunit belonging to 
the SNF2 family of ATPases, usually BRG1 or BRM along with 10-12 BRG1-
associated factors (Figure 10). 
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Figure 10 Mechanisms of AR coactivator action 
Upon ligand binding to AR, interaction takes place between the N/C terminals. This 
interaction is disrupted upon binding to AREs on the DNA, allowing recruitment of 
cofactors. This process results in accumulation of various complexes that modulate 
chromatin and initiate transcription regulation. AR= androgen receptor, HSP= heat shock 
protein, AREs= androgen response elements, RNA PolII= RNA polymerase II, DHT= 
dihydrotestosterone, GTF= general transcription factor, PIC= preinitiation complex. 
Adapted from (van de Wijngaart et al. 2012). 
1.3.4.3 AR corepressors 
Whilst a number of genes are upregulated by AR expression, some genes are 
downregulated, suggesting that AR can also function as a transcriptional repressor 
(see section 1.3.5). More recent evidence has suggested that AR does not directly 
repress transcription, but that downregulation of target genes is due to the binding 
of corepressors. These corepressors most commonly function through: 1) 
inhibiting DNA binding and coactivator binding, 2) regulation of AR N/C interaction, 
3) abrogation of AR-chromatin association or nuclear translocation and 4) playing 
an active role in condensing the chromatin to its inactive state (Figure 11). 
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Figure 11 Mechanisms of AR corepressor action 
Binding of AR to AREs on the DNA, and subsequent coactivator recruitment is essential 
for transcription of AR dependent genes. AR corepressors can interfere with AR activity 
through at least four differing mechanisms; 1) inhibition of AR nuclear translocation, 2) 
Inhibition of N/C interaction, 3) inhibition of DNA biding and finally 4) inhibition of 
coactivator recruitment. AR= androgen receptor, HSP= heat shock protein, AREs= 
androgen response element, HDAC= histone deacetylase, PolII= RNA polymerase II. 
Adapted from (Burd, Morey, and Knudsen 2006). 
The most well understood AR corepressors are nuclear receptor corepressor 
(NCoR) and silencing mediator of retinoic acid (SMRT), that repress transcription 
through Sin3 and recruitment of HDACs. Additionally, these corepressors disrupt 
AR N/C interaction and compete with SRC/p160 AR coactivators. Upon ligand 
binding, NCoR and SMRT function as huge scaffold proteins that are recruited by 
AR, requiring both the LBD and NTD and an extended LxxLL like motif, termed 
corepressor nuclear receptor (CoRNR) (Hu and Lazar 1999). Additional AR 
corepressors such as ErbB3-binding protein (EBP1), DJ1-binding protein (DJBP) 
and TG-interacting factor (TGIF) utilise Sin3 complexes, consisting of Sin3a and 
Sin3b together with either HDAC1 or HDAC2 to modulate transcriptional 
repression. Most importantly, EBP1 is recruited to AR targets in the presence of 
therapeutic antagonists together with HDAC2. 
As mentioned previously, ligand binding induces the binding of the FxxLF motif to 
the hydrophobic surface of the AR LBD. Corepressors have been shown to 
  58 
 
interfere with this N/C interaction through multiple mechanisms. Firstly they can 
compete for binding to prevent the formation of N/C interaction, the FxxLF domain 
within hRad9 has been shown to compete for binding to the AR LBD, blocking AR 
activity as a result (Wang et al. 2004). Secondly, corepressors can bind directly to 
regions of AR that mediate N/C interactions, this is the case for large tumour 
suppressor 2 (lats2), which binds directly to a residue on the LBD of AR that is 
essential for N/C interaction (Powzaniuk et al. 2004). Finally, a number of 
corepressors, including SMRT, block N/C interaction through an unknown 
mechanism. Thus, these examples of targeting N/C interaction highlight a major 
pathway in which corepressors function to inhibit AR transcription. 
A small group of corepressors can prevent AR translocation to the nucleus and 
subsequent binding to the DNA. One example of which is the phosphatase and 
tensin homolog (PTEN) deleted on chromosome 10, which sequesters AR in the 
cytoplasm in LNCaP cells, although the mechanism by which this occurs is 
currently unknown (Lin et al. 2004). p21-activated kinase (PAK6) has also been 
shown to inhibit nuclear translocation through interaction with the DBD (Schrantz 
et al. 2004) and Rack1 has been associated with a decline in AR promoter 
occupancy due to its activation of the protein kinase C pathway (Rigas et al. 
2003). 
A small number of corepressors can also compete with coactivators for 
recruitment to the AR complex, through interaction with the coactivator, or AR. 
NCoR and SMRT have been shown to function by binding to AR. In fact, Yoon et 
al showed that ablation of either of these corepressors leads to enhanced 
recruitment of steroid receptor coactivator 1 and p300 (Yoon and Wong 2006). 
Conversely, corepressors can modulate coactivators to prevent binding to AR in a 
number of ways, for example: GSK-3β targets the ß-catenin AR coactivator 
specifically for degradation (Masiello et al. 2004) and proline-rich tyrosine kinase 2 
(PYK2) can phosphorylate the ARA55 coactivator, preventing AR association 
(Wang et al. 2002).  
Finally, there are a group of corepressors that function to inhibit AR transactivation 
through unknown mechanisms. An example of such a corepressor is amino-
terminus enhancer of split (AES), which is known to interact with TFIIE. However, 
the relevance of this is not yet understood. A second family of corepressors are 
the protein inhibitor of activated STAT (PIAS). A number of members of this family 
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act as coactivators, but have also been found to function as corepressors. They 
are thought to modulate AR function by post-translational modification through 
sumoylation of AR (Schmidt and Müller 2003). 
In summary, AR corepressors can function to impede AR transactivation through a 
number of mechanisms, the deregulation of these corepressors in PCa could 
potentially offer new therapeutic avenues for the treatment of cancer, due to the 
importance of AR regulation. The major AR corepressors and their function are 
listed in Table 5. 
Table 5 Summary of the major AR corepressors involved in restricting expression of 
AR dependent genes. 
Corepressor  Function  AR binding site  
lats2  • Disrupts AR N/C interaction  LBD of AR  
PAK6  • Inhibits nuclear translocation through 
interaction with the DBD  
N/A  
PTEN  • Sequesters AR in the cytoplasm in 
LNCaP  
N/A 
GSK-3β  • Targets β-catenin AR coactivator for 
degradation  
N/A  
PYK2  • Phosphorylates ARA55 preventing AR 
association  
N/A  
SMRT/ 
NCoR  
• Binds to and sequesters AR  Binds to LBD of AR 
through CoRNR 
boxes  
CoRNR= corepressor nuclear receptor boxes 
1.3.5 Androgen regulated genes and prostate specificity. 
Androgen responsive/regulated genes are characterised by significantly altered 
expression levels upon androgen treatment and are essential for prostatic 
development through proliferation, differentiation, cell cycle and apoptosis 
(Vaarala et al. 2012). Consequently, the identification of androgen responsive 
genes can lead to novel targets for PCa treatment and biomarkers to detect and 
monitor disease progression.  
Over the last decade, researchers have undertaken genome-wide analysis to 
identify androgen-responsive genes, resulting in the identification of an 
unparalleled number of genes differentially regulated by AR, that reaches well into 
the thousands with the introduction of microarray analysis (Jin, Kim, and Yu 2013). 
Androgen responsive LNCaP cells have been critical to these studies in order to 
identify differentially regulated genes before and after androgen stimulation. Whilst 
the majority of research has focussed on those genes that are upregulated by 
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androgen receptor stimulation, a more complex global expression profile is 
emerging, whereby androgen receptor stimulation can both up-regulate (DePrimo 
et al. 2002, Velasco et al. 2004) or down-regulate genes (Ngan et al. 2009), 
suggesting a more composite role for AR in prostate carcinogenesis. 
AR is a hormonal transcription factor, activated by binding of androgen, resulting 
in translation of AR protein, a DNA binding protein that binds to cis-regulatory 
elements in androgen responsive genes. Upon ligand binding, AR undergoes a 
conformational change, where heat shock proteins dissociate and AR becomes 
phosphorylated, leaving AR free to translocate to the nucleus and homodimerise 
(van Royen et al. 2012). In the nucleus AR binds to AREs located along the DNA 
of specific genes (Figure 12). AREs consist of a DNA binding motif comprising of 
15 nucleotides, this motif is an imperfect palindrome separated by 3 nucleotides 
(AGAACAnnnTGTTCT). Despite the general palindromic sequence, functional 
AREs can differ from the consensus sequence by several nucleotides 
(Khorasanizadeh and Rastinejad 2001). Binding of AR is also tightly regulated by 
a number of transcriptional coactivators including GATA2, OCT (Wang et al. 2007) 
and FOXA1 (Gao et al. 2003) and growing evidence suggests that AR primarily 
binds to distal enhancers, interacting with promoters through chromatin looping 
(Wang, Carroll, and Brown 2005, Wu et al. 2014). These enhancers can range 
from several, to hundreds of kb away from the gene specific promoters with which 
they interact. 
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Figure 12 Activation of AR target genes 
Upon binding of DHT, HSP dissociates from AR, leaving AR free to homodimerise and 
enter the nucleus. Within the nucleus AR homodimers bind to AREs on the DNA to 
activate transcription of AR dependent genes. AREs = Androgen Response Elements, 
HSP= Heat Shock Protein. 
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1.4 PCa treatment strategies 
1.4.1 Overview of PCa treatment 
Due to the heterogeneity and indolent nature of PCa, selection of the most 
suitable treatment to limit patient mortality and ensure quality of life remains a 
fundamental challenge in tackling the disease. Treatment strategies are 
dependent on age of the patient, cancer stage and grade and the overall health of 
the patient. An overview of PCa treatment strategies can be seen below (Figure 
13). 
 
Figure 13 Overview of PCa therapy 
This diagram shows the standard therapy for each stage of PCa. Therapeutic options are 
dependent on PCa grade and stage, patient age, general health and personal preference. 
Based on EAU guidelines the treatments in the dotted frame are not considered standard 
therapy. HT= hormone therapy, ADT= androgen deprivation therapy, CAB= combined 
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androgen blockade, NSAA= non-steroidal antiandrogen. Adapted from (Helsen et al. 
2014). 
1.4.2 Localised PCa treatment. 
Localised PCa is often left untreated in the UK, in order to avoid ‘over treatment’. 
Depending on the age and general health of the patient, doctors may choose to 
monitor the patient by ‘watchful waiting’. This is most often the case in men who 
are diagnosed with PCa, but are presenting with no symptoms, or who have other 
medical problems that render treatment unsuitable. Patients with localised cancer 
can also be monitored by ‘active surveillance’ (AS). This is undertaken by regular 
PSA testing, monitoring the size of the prostate and evaluation of Gleason score 
by biopsies. Disease progression is monitored to allow for radical treatment at a 
later stage (Parker 2004). A study monitored a cohort of 450 patients with clinical 
stage T1c or T2a, PSA <10 ng/ml, Gleason score ≤6 and patients over the age of 
70 with a Gleason score <7 and PSA up to 15 ng/ml, not all patients had been 
diagnosed with the disease (Klotz et al. 2010). The overall survival rate was 78.6% 
at 6.8 years witht the prostate cancer specific survival rate at 97%. Additional 
studies have demonstrated a low rate of progression and disease specific death in 
patients that have been carefully selected to undergo AS due to low risk (Klotz 
2010).  Overall AS is a well accepted strategy for the treatment of low-risk 
localised PCa. However, the many benefits of this strategy, including lower costs 
to the healthcare system, reduction of the unwanted side effects of surgery and 
better quality of life must be carefully weighed against the risks involved in 
delaying therapy. This calls for more stringent measures to assess the risk of 
localised PCa to the patient including more reliable biomarkers to distinguish 
aggressive from indolent forms of the disease. 
Methods to treat localised PCa include radical prostatectomy, brachytherapy, and 
radiotherapy as well as hormonal therapies, including androgen ablation, all of 
which produce adverse side effects including incontinence, bleeding and erectile 
dysfunction (Gomella, Johannes, and Trabulsi 2009). Men who do undergo 
prostatectomy in comparison to no treatment are more likely to suffer from erectile 
dysfunction (80% vs 45%) and urinary leakage (49% vs 21%) over a 5-year period 
(Bergman and Litwin 2012). Approximately 25% of patients present with localised 
PCa at diagnosis. If receiving treatment most are given single-modality treatments 
including radical prostatectomy or radiotherapy. There are a number of types of 
radical prostatectomy, including: radical retropubic prostatectomy, laparoscopic 
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radical prostatectomy and robotic-assisted laparoscopic prostatectomy (Ficarra et 
al. 2009). Localised and locally advanced cancer can also be treated by androgen 
deprivation therapy, which aims to reduce the levels of circulating testosterone 
that are responsible for growth of PCa. This treatment can be utilised at all stages 
of the disease, however this often leads to more aggressive, incurable forms of 
PCa known as ‘castration resistant’, a term used to describe PCa that is 
unresponsive to hormonal treatment, due to the sustained activation of the AR 
signalling pathways (Gao, Arnold, and Isaacs 2001). Patients that present with 
higher Gleason scores and rising PSA levels often benefit from a combinational 
therapy including ADT in conjunction with radiotherapy (Heidenreich 2012).   
1.4.3 Metastatic castration resistant PCa   
The major cause of patient mortality is due to the propensity for PCa to 
metastasize to the lymphatic tissue and the bone, conveying osteoblastic rather 
than osteolytic lesions (Bubendorf et al. 2000). Metastatic PCa is a debilitating 
disease that includes symptoms such as bone pain, spinal cord compression, 
renal failure and anaemia. Little is known about this mechanism of metastasis, 
partly as there have been inadequate mouse models for metastatic PCa and also 
due to unavailability of human metastatic samples (Shen and Abate-Shen 2010). 
The presence of circulating tumour cells in the blood stream and the bone marrow 
have been shown, yet these have not obtained full metastatic capabilities. These 
cells do, however, show multiple chromosomal rearrangements typical of those 
found in advanced PCa (Holcomb et al. 2008). Treatment for metastatic PCa 
usually involves the combination of androgen deprivation therapy with cytotoxic 
drugs. Chemotherapy is mainly palliative and reduces the symptoms, but does not 
cure the disease. Chemotherapy drugs that are most commonly used to treat PCa 
include docetaxel (Taxotere) and mitoxantrone (Novantrone). 
1.4.4 Targeting AR for PCa therapeutics 
1.4.4.1 Medical and chemical castration 
As PCa begins to advance, treatments include hormone therapy, radiotherapy 
alone, or radiotherapy in combination with hormone therapy and radical 
prostatectomy. Whilst radical prostatectomy and radiotherapy are still the most 
effective treatments for locally advanced PCa, adverse side effects including 
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erectile dysfunction, infertility and incontinence make less invasive procedures 
more attractive. 
By inhibiting the release of androgens, prostate cells are deprived of proliferative 
stimulation, and as a result undergo apoptosis.  There are several methods of 
inducing androgen deprivation that are used for the treatment of locally advanced 
androgen-dependent PCa that include: castration (surgical or chemical), 
antiandrogens and androgen blockade (Chen, Clegg, and Scher 2009). Surgical 
castration involves the removal of the stimulatory input of testosterone in the body 
by orchiectomy; complete removal of both testicles. However, the development of 
GnRH agonists and antagonists resulted in a non invasive method of inducing 
castrate levels of testosterone in the body, known as chemical castration. 
Chemical castration involves the use of GnRH agonists or antagonists that block 
the messenger processes to the brain, and prevent the release of testosterone.  
GnRH agonists work by continuous stimulation of the pituitary gland, overcoming 
the pulsatile release of GnRH from the hypothalamus in order to shut down the 
production of LH. Typically used GnRH agonists include leuprolide, usually 
administered as an intramuscular injection and goserelin, usually administered 
subcutaneously into the abdomen. After the initial administration of GnRH 
agonists, testosterone levels can temporarily rise ‘flare’, resulting in increased 
prostate cell growth. This growth may cause an increase in patient symptoms; 
therefore the rise in testosterone is often blocked by co-administration of a 
nonsteroidal androgen receptor antagonist.  In order to avoid the initial flare in 
testosterone levels, GnRH antagonists can be used to directly block GnRH and 
instigate a fast reduction in testosterone (Crawford and Hou 2009). The most 
commonly used GnRH antagonist is degarelix, which is administered 
subcutaneously as 2 injections (Xu, Jiang, and Wu 2012). Men who have 
undergone castration either by surgical or chemical means have 90-95% less 
testosterone in their bodies than normal healthy males. 
1.4.4.2 Antiandrogens. 
Current hormonal therapies for PCa treatment are not capable of completely 
inhibiting AR. Changes that occur in AR during cancer progression, for example 
mutation and over-expression, result in resistance to castration. Therefore, 
methods of inhibiting AR transcriptional activation by using antagonists that 
compete with endogenous androgens for binding to the ligand binding domain 
  66 
 
(LBD) of AR have been developed (Chen, Clegg, and Scher 2009) (Figure 14). 
Antiandrogens can be either steroidal or non-steroidal. Steroidal antiandrogens 
include progesterone analogues and cyproterone acetate (CPA). CPA is non-
specific and can activate the glucocorticoid, mineralcorticoid and progesterone 
receptor, thus it is not currently used as a first line treatment. Non-steroidal 
antiandrogens were developed in the 70’s as a means of avoiding the off-target 
side effects of steroidal antiandrogens. The most commonly used antiandrogens 
are bicalutamide, nilutamide and flutamide (Chen, Clegg, and Scher 2009). The 
exact mechanism by which antiandrogens bind to and inhibit AR has not yet been 
fully elucidated and appears to be more complex than just competitive binding for 
AR with DHT. Bicalutamide was approved for use by the Federal Drug 
Administration in 1995. It is given as an oral dose of 150 mg/day for monotherapy, 
although when given as a monotherapy patients median survival was 6 weeks 
shorter in comparison to castration (Tyrrell et al. 1998). Despite this, the American 
Society of Clinical Oncology recommend treatment with Bicalutamide 
monotherapy as an alternative for the gold standard ADT and it is the most widely 
used antiandrogen for treatment of androgen responsive PCa. Bicalutamide has a 
relatively low affinity for AR, at least 30-fold less than DHT, suggesting that 
modifications to improve ligand binding could improve AR antagonism (Kolvenbag, 
Furr, and Blackledge 1998). Nilutamide is only used for concomitant therapies and 
as there are currently no trials published that use nilutamide as a monotherapy it is 
not currently registered for use as one (Helsen et al. 2014). 
1.4.4.3 Novel antiandrogens 
Due to the eventual clinical failure of current antiandrogens, much emphasis has 
been placed on the development of novel AR antagonists. Enzalutamide (Enz), 
formally known as MDV3100, is a thiohydantoin derivative with a higher binding 
affinity for AR than Bicalutamide. As well as binding directly to AR, Enz also 
inhibits AR function by blocking nuclear translocation and DNA binding (Tran et al. 
2009). In 2012 Enz was approved by the FDA after the AFFIRM trial demonstrated 
that Enz treatment increased overall survival in patients who progressed after 
docetaxel treatment in comparison to the placebo treated group (Ning et al. 2013, 
Scher et al. 2012). Patients also benefited from significant improvements in quality 
of life, including pain palliation and the drug was well tolerated, with limited side 
effects. A larger Phase III PREVAIL trial was conducted between September 2010 
and September 2012 in 1717 men with metastatic castration resistant PCa, who 
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had not received chemotherapy previously. Interim results showed that Enz 
treatment improved overall survival by 29% and reduced the risk of radiographic 
progression of disease by 81%. Due to this promising outcome, the trial was 
stopped prematurely and all patients on the placebo were offered Enz (Beer et al. 
2014). This novel antiandrogen offers an exciting new treatment for men with 
metastatic castration resistant PCa that is effective in chemo treated patients who 
have progressed.  
1.4.4.4 Steroid biosynthesis inhibitors 
Traditional therapies for PCa treatment have focused on the development of drugs 
that target the AR pathway by direct inhibition or decreasing levels of circulating 
testosterone. However, these are not effective at completely eradicating serum 
testosterone levels, due to androgens produced in the adrenal glands. Therefore, 
newer therapies have focused on targeting the androgen biosynthesis pathway. 
Abiraterone specifically inhibits CYP17A1, the enzyme responsible for catalysing 
the conversion of the adrenal androgen precursors pregnenolone and 
progesterone into DHEA-S and androstenedione (Figure 14). These weak 
androgens are later synthesised into testosterone and DHT in peripheral tissues 
and PCa tumours (Cai and Balk 2011). 
More recently, abiraterone has also been shown to bind and inhibit AR (Richards 
et al. 2012). Abiraterone is a derivative of progesterone; its main function is 
inhibition of CYP17A1, therefore inhibiting the conversion of pregnenolone and 
progesterone and the subsequent formation of dehydroepiandrosterone (DHEA) 
and androstenedione, precursors of testosterone. Abiraterone has demonstrated 
clinical efficacy in both chemo treated and chemo-naive patients, resulting in 
prolonged progression free survival, prolonged overall survival and delayed clinical 
decline of patients (de Bono et al. 2011, Ryan et al. 2013). Despite promising 
results in abiraterone treated patients, PCa continues to progress due to continued 
AR pathway activation, possibly due to increased AR mutation.  
  68 
 
 
Figure 14 Schematic representation of the Steroid biosynthesis pathway and drugs 
that target the pathway and inhibit AR function 
Testosterone is converted to DHT via SRD5A2 and binds to AR to activate AR-dependent 
transcription. Drugs that prevent the action of AR include cyproterone acetate, 
bicalutamide, flutamide, nilutamide and enzalutamide. As well as testosterone, the pituitary 
gland, adrenal androgen precursors pregnenolone and progesterone can activate 
testosterone through androstenedione. Abiraterone targets the Cyp17 enzymes 
responsible for the production of DHEA and androstenedione. 
1.4.4.5 Combined androgen blockade.  
Medical castration has been shown to lower testosterone levels by 95%. However, 
circulating androgens from the adrenal glands, dehydroepiandrosterone (DHEA) 
and androstenedione still remain, and continue to be converted to androgens in 
PCa cells (Labrie et al. 1993). Combined androgen blockade (CAB) works by 
combining both castration and antiandrogen therapy so that not only are the 
majority of circulating androgens eliminated, but any remaining androgens of 
adrenal origin are prevented from binding to AR (Hellerstedt and Pienta 2002).  
  69 
 
1.4.5 Castration resistant PCa 
   1.4.5.1 Chemotherapy 
Docetaxel (C43H53NO14) (Figure 15) has a molecular weight of 807.88 g/mol and 
functions by inhibiting mitosis through microtubule disruption. It achieves this by 
binding to free tubulin, promoting assembly of stable microtubules whilst inhibiting 
their disassembly. Docetaxel is a semi-synthetic taxane analogue initially 
approved by the FDA in 1996 for the treatment of advanced breast cancer (BCa), 
before demonstrating promising results in early phase trials for the treatment of 
CRPC (Picus and Schultz 1999). This led to a phase III study that showed a 24% 
reduction in the risk of death in a group of men treated with docetaxel in 
combination with prednisone in comparison to mitoxantrone in combination 
(Tannock et al. 2004). 45% of men in the docetaxel group also experienced a 50% 
reduction in serum PSA and improved quality of life including pain reduction. After 
an extended follow-up of this study 18.6% of patients survived ≥ 3 years in the 
docetaxel group in comparison to 13.5% in the mitoxantrone group (Berthold et al. 
2008). Despite clinical advances made by treatment with docetaxel, PCa 
continues to progress, leading to a surge in the number of drugs approved for the 
treatment of mCRPC.  
Cabazitaxel is a more recent second-line treatment for mCRPC. Cabazitaxel 
(C45H57NO14) (Figure 15) has a molecular weight of 835.93238 g/mol and functions 
through microtubule inhibition. Initially, patients who progressed on docetaxel were 
given mitoxantrone, which produced only marginal PSA responses and no survival 
benefit. Cabazitaxel is a novel taxane that has proven efficacious in vitro and in 
vivo  in docetaxel resistant cells (Galsky et al. 2010). It has been given as a 
second line chemotherapy to patients who progressed on docetaxel (Mottet et al. 
2011). The TROPIC trial randomised 755 patients with mCRPC pre-treated with 
docetaxel and treated with either Cabazitaxel (25 mg/m2) or mitoxantrone (12 
mg/m2), each in combination with a daily dose of prednisone (10 mg). Progression 
free survival was 2.8 months in the Cabazitaxel group compared to 1.4 months in 
the mitoxantrone group (de Bono et al. 2010). Despite improved quality of life and 
pain control with Cabazitaxel the National Institute for Clinical Evidence 
recommended against the routine use of Cabazitaxel for PCa treatment (NICE 
press release) in the UK, due to the price of the drug, weighed against the 
benefits. Despite the high number of drugs available for the treatment of castration 
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resistant PCa, each drug has limited activity and none are curative, leading to the 
need for more effective therapies.  
 
Figure 15 Schematic representation of the Docetaxel/Cabazitaxel 
The schematic shows the structure of Docetaxel and the structural difference for 
Cabazitaxel. The red circles highlight the methoxy side chains that are substituted for the 
hydroxyl groups that are normally found in docetaxel.  
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1.5 Tissue specific Gene-directed 
Enzyme-prodrug therapy (GDEPT) 
1.5.1 Gene-directed enzyme prodrug therapy 
Gene directed enzyme prodrug therapy, also known as suicide gene therapy, was 
first proposed by Moolten over 25 years ago (Moolten 1986). It was developed as 
an alternative to chemotherapy as a way to solely target cancer cells, avoiding off-
target side effects as a result. An ideal suicide gene therapy system must: 1) Use 
a prodrug that is non-toxic or minimally toxic to cells and highly toxic after 
activation, 2) The prodrug must be capable of entering the tumour and be taken up 
by the cells, 3) the drug must not be lost from the cells before the metabolite can 
kill the cells, therefore the metabolite half-life must be long enough to induce 
sufficient cell death, for example the half life of 5-Fluorocytosine (5-FC) in patients 
is 3-4 hours (Vermes, Guchelaar, and Dankert 2000) and, 4) the enzyme must be 
expressed specifically in the targeted cells in order to avoid off target toxicity. 
Cytosine deaminase (CD), cytosine deaminase uracil phosphoribosyl transferase 
(CD/UPRT) herpes simplex thymadine kinase (HSV-tk) and nitroreductase are 
four of the most well established enzymes utilized for enzyme prodrug therapy 
(Bourbeau et al. 2004, Koyama et al. 2000, Fogar et al. 2007, Ayala et al. 2006, 
Miles et al. 2001, Patel et al. 2009, Young et al. 2008).  
HSV-1 encodes 70 genes, of which some are immediate early genes such as 
thymidine kinase (TK). TK forms a 376 long amino acid protein that is necessary 
when the virus enters the lytic cycle from a dormant stage. HSV-tk has a very 
broad substrate specificity including pyrimidines and pyrimidine analogs. HSV-tk 
converts ganciclovir (GCV), a purine analog, into a toxic metabolite as well as 
phosphorylating the nucleoside anaologs penciclovir and acyclovir. Once 
phosphorylated, these analogs are further phosphorylated by cellular kinases to 
their corresponding nucleoside triphosphates that mimic guanosine. These 
analogs are incorporated into nascent DNA and inhibit DNA synthesis, leading to a 
halt in replication and apoptosis (Kokoris and Black 2002). 
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Figure 16 HSV/tk + Ganciclovir enzyme prodrug therapy 
GSV, a purine analog is converted by HSV-tk into a toxic metabolite. GSV is further 
phosphorylated by cellular kinases to the corresponding nucleoside triphosphates that 
mimic guanoisine. This anolog incorporates into the nascent DNA, resulting in replication 
halt and apoptosis. 
The first phase I clinical trial utilising HSV-tk for PCa therapy was conducted by 
Baylor college of medicine in 1999 (Herman et al. 1999). Treatment lead to 
increased PSA doubling time, a significantly increased reduction in mean PSA 
levels, and a significantly longer time to return to initial PSA levels after preliminary 
or repeat vector injections, as well as demonstrated safety of Ganciclovir gene 
therapy in men (Miles et al. 2001). Since this initial trial there have been several 
other phase I/II clinical trials incorporating HSV-tk that demonstrated safety after 
repeat cycles with limited efficacy (Shalev et al. 2000, Hassan et al. 2000, Teh et 
al. 2004). 
Another well characterised prodrug activating enzyme is CD/UPRT (cytosine 
deaminase/ uracil phosphoribosyl transferase). The CD prodrug therapy system 
was initially created using bacterial CD. However, this gave a poor turnover rate of 
5-FC by CD and was therefore replaced by the yeast CD (yCD). yCD displayed 
increased efficacy in CD/5-FC therapy and much greater kinetic properties 
towards 5-FC with a 22-fold lower km (Kievit et al. 1999). CD is a pyrimidine 
salvage enzyme that catalyses the deamination of cytosine to uracil. As a 
consequence of this, CD converts 5-FC to 5-Fluorouracil (5-FU) which is then 
converted to 5-FUMP by UPRT (Lundegaard and Jensen 1999) (Figure 17). UPRT 
is a member of the pyrimidine salvage pathway and is responsible for catalysing 
the synthesis of UMP or 5-FUMP from uracil or 5-FU. 5-FUMP is an active 
metabolite that inhibits RNA synthesis, DNA replication and thymidylate synthase 
(TS) activity (Longley, Harkin, and Johnston 2003), resulting in lethal DNA 
damage. It has been shown that some tumour cells display resistance to 5-FU due 
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to possible defects in downstream cellular metabolism or over expression of 
catabolic enzymes (Harris et al. 1994). Due to this, co-expression of CD with 
UPRT was tested and shown to enhance cell killing (Tiraby et al. 1998).  
 
Figure 17 5-FC CD/UPRT enzyme prodrug system 
CD catalyses the conversion of 5-FC to 5-FU. 5-FU is then further converted to 5-FUMP by 
UPRT, resulting in lethal DNA damage.  
Finally, nitroreductase has been extensively used in a number of gene therapy 
vectors (Latham et al. 2000, Young et al. 2008), including a number of clinical 
trials, where is has proven its safety in a clinical setting in PCa and liver cancer 
(Palmer et al. 2004, Patel et al. 2009, Crack 2013).  
CB1954 was found to be highly active in vitro against Walker rat 256 Carcinoma 
cells (Roberts, Friedlos, and Knox 1986). In this setting CB1954 was converted to 
a highly potent cytotoxic agent by endogenous rat DT-diaphorase (Knox et al. 
1988), not present in humans, and therefore explaining why activity was poor in 
human tumours. Later studies demonstrated that the nitroreductase enzyme, 
encoded by the nfsB gene found in E.coli B, can convert CB1954 into its cytotoxic 
form 100-fold more efficiently than rat DT-diaphorase (Knox et al. 1992). 
Subsequently, numerous studies have investigated the clinical benefit to using 
nitroreductase and CB1954 in a gene-directed enzyme prodrug system and have 
proven efficacy and safety in combination with the CB1954 prodrug. Patel et al 
trialled a replication-deficient adenovirus (CTL102) encoding nitroreductase, 
driven by the CMV promoter, in combination with CB1954 in a phase I/II clinical 
trial and demonstrated safety and tolerability, as well as preliminary evidence of a 
change in PSA kinetics in patients (Patel et al. 2009). Furthermore, this system 
has worked particularly well in combination with granulocyte macrophage colony-
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stimulating factor (GM-CSF), immunotherapy in vitro and phase I/II clinical trials 
are currently ongoing (Young et al. 2008, Crack 2013). 
One advantage to using suicide gene therapy is the bystander effect; the ability of 
toxic metabolites to diffuse into and be taken up by surrounding cells. This allows 
less prodrug to be administered to the patient with enhanced levels of cell killing. 
Where toxic metaboliates are unable to diffuse into and be taken up by 
surrounding cells the bystander effect works through Gap junctions. These are 
narrow connecting channels between 2-3 nm in diameter that exist between cells. 
Gap junctions facilitate the exchange of small molecules including small 
metabolites, second messengers and electric signals through a procedure known 
as Gap Junctional Intercellular Communication (GJIC) (Goodenough and Paul 
2009). Bystander activity of the 5-FU toxic metabolite has been previously 
demonstrated, though it has been revealed that unlike other drugs 5-FU does not 
require cell-cell contact to diffuse into neighbouring cells (Huber et al. 1994). 
Therefore, the mechanism of diffusion is not through intracellular gap junctions 
(Huber et al. 1994). 5-FU is a small molecule that is capable of diffusing into and 
out of cells; consequently this is thought to be the mechanism of spread for the 
toxic metabolite.  However, studies have also demonstrated that the CD/UPRT 
fusion gene negatively influences bystander activity in vivo due to the fusion of 
UPRT and CD and therefore diminishes the therapeutic value of the CD/5-FC 
system (Johnson et al. 2011). This system will therefore suffer from reduced 
therapeutic window. 
Suicide gene therapy needs to be targeted in order to avoid the off target side 
effects that are a result of chemotherapy. One approach is to utilize TSPs to drive 
enzyme expression and ensure that 5-FUMP is only produced in the cancer cells.  
For example if the CD/UPRT gene is placed downstream of a promoter containing 
androgen response elements, CD/UPRT will only be transcribed in cells that 
express functional AR. As AR is a key driver of PCa progression and survival, 
promoters that contain AR elements are suitable for use in targeted enzyme 
prodrug therapy (see section 1.6.2.4). 
1.5.1 Utilising androgen responsive promoters for targeted 
therapy of PCa 
Extensive studies have been performed that exploit the AR-dependent 
transcriptional activation of prostate specific promoters and enhancers for PCa 
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gene therapy, in order to increase safety and specificity of cytotoxic therapies, 
including prodrug converting enzymes, cytokines, siRNA and p53. A variety of 
prostate specific gene promoters have been investigated for this purpose including 
PSA, PSMA, Osteocalcin, human glandular kallikrein 2 (hK2) and the rat probasin 
promoter. Despite the discovery of thousands of novel Androgen regulated genes 
over the past decade, PSA still remains one of the most well characterised 
prostate specific genes (O’Keefe et al. 1998, Young et al. 1992, Balk, Ko, and 
Bubley 2003). PSA is currently used as a biomarker for the detection of PCa and 
is expressed in normal prostate epithelial cells and at all stages of prostate 
carcinogenesis, rendering it an ideal candidate for restricting gene expression to 
prostate cells. Previous studies have utilized the 6 kb regulatory region upstream 
of the PSA promoter that encompasses a TATA box, two AREs and upstream 
enhancer regions that have been shown to augment prostate specific expression 
(Cleutjens et al. 1997, Pang et al. 1997, Schuur et al. 1996). Within the entire 6 kb 
region a high affinity ARE was located (Cleutjens et al. 1996) together with four 
non-consensus AREs (Huang et al. 1999), consisting of 440 bp that collectively 
became known as the core PSA enhancer. Despite promising levels of activity 
from the PSA promoter and enhancer, this promoter was still inherently weak. 
Details of further PCa clinical trials that utilise androgen responsive promoters can 
be found in section 1.6.2.4, Table 9. 
1.5.2 Increasing transgene expression levels from tissue 
specific promoters 
In recent years many prostate-specific gene regulatory regions have been 
investigated for their specific activity, however they are inherently weak, resulting 
in low level transgene expression from these promoters. A number of methods 
have been investigated to enhance transgene expression from weak TSPs 
including; 1) Posttranscriptional enhancement of transgene levels (Choi et al. 
1991), 2) creating chimeric promoters that are still capable of maintaining tissue 
specificity (Wu, MATHERLY, et al. 2001, Li et al. 1999, Latham et al. 2000), and 
finally 3) transcriptional amplification from a TSP (Iyer et al. 2001).  
1.5.2.1 Chimeric promoters 
Creating chimeric promoters has been one of the most popular methods of 
increasing transgene expression, often including the use of enhancers in 
combination with a tissue specific promoter (TSP). These promoters are aimed at 
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targeting the heterogeneous nature of PCa, utilising promoters that function in a 
number of different cancer types, whilst simultaneously increasing transgene 
expression.  
To date the most effective PSA promoter has been chimeric, including a 
duplicated core enhancer together with the proximal promoter (Wu, Matherly, et al. 
2001, Latham et al. 2000), that drove 20-fold higher expression than the PSA 
promoter alone (Wu, Matherly, et al. 2001). However there is still no effective 
therapy in clinical trials that utilises this chimeric promoter. 
More recent chimeric promoters have included the incorporation of critical 
transcriptional elements from different prostate specific promoters. It was 
hypothesised that this would allow transgene expression in a much larger 
percentage of cells due to the heterogeneous nature of cancer, leading to 
increased efficacy. Perhaps the most elegant example was fusion of the regulatory 
enhancer regions of PSA and PSMA genes, resulting in high levels of luciferase 
expression in PSA and PSMA expressing PCa cell lines, irrespective of androgen 
expression (Lee et al. 2002). This chimeric enhancer, known as PSES, was later 
inserted into a conditionally replicating adenovirus, whereby viral replication was 
placed under the control of the PSES promoter (Li et al. 2005). Systemic 
administration resulted in the dramatic inhibition of CWR22rv tumours injected with 
AdE4PSESE1a, compared to tumours treated with a control virus. The PPT 
promoter, containing a T-cell receptor gamma-chain alternate reading frame 
(TARP), PSMA enhancer and PSA enhancer is the most complex chimeric 
promoter described to date and has also reported high level activity in androgen 
positive and negative cancers (Cheng et al. 2004). However, despite promising 
preliminary results with these novel promoter/enhancers they were still unable to 
drive sufficiently high levels of transgene expression. 
1.5.2.2 Transcriptional amplification -the two-step 
transcriptional amplification system 
A number of Two Step Transcriptional Amplification Systems (TSTA) have been 
developed that allow the amplification of a transgene from a TSP, while retaining 
target cell specificity. Transgene expression is amplified from a TSP via 
expression of the yeast transcriptional activator GAL4, fused to VP16, a strong 
transactivation domain from HSV-1 VP16. The GAL4-VP16 fusion protein binds to 
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multiple Gal4 binding sites upstream from the transgene, thereby amplifying 
transgene expression (luciferase in Figure 18), while retaining tissue selectivity.  
Zhang.et.al modulated the activity of the TSTA system by: 1) placing potent PSA 
enhancers upstream of GAL4-VP16, 2) increasing the number of Gal4 binding 
sites from 1 to 5, this modification increased transgene expression with the PSA 
promoter/enhancer activator by 240-fold, 3) duplication of the VP domain, resulting 
in 2-fold increase in expression and 4) placing all the TSTA components on a 
single plasmid, rather than the traditional approach of keeping the gene specific 
promoter and reporter gene on separate plasmids. Overall, the modifications 
made drove 10-fold higher transgene expression than when using separate 
constructs (Zhang, Adams, et al. 2002). This construct was then gifted to Xie and 
colleagues for their work on pancreatic cancer. 
Xie and colleagues proved the efficiency of the transcriptional amplification system 
in pancreatic cancer using the CCKAR promoter, that is overexpressed in 
pancreatic cancer (Weinberg et al. 1997). CCKAR is a G-protein coupled receptor, 
that upon binding by Cholecystokinin (CKK), takes part in regulating the secretion 
of enzymes and postprandial effects in the gall bladder (Takata et al. 2002). The 
promoter region is 724 bp long and has been identified upstream of the start site. 
It lacks the typical TATA and CAT binding sites for transcriptional regulation (Miller 
et al. 1995). The induction of the TSTA was able to increase the expression of 
luciferase from the original promoter present in the original construct by between 
252 and 826-fold in three different pancreatic cancer cell lines, AsPC-1, PANC-1 
and Panc02 (Xie et al. 2007). Xie and colleagues then replaced the luciferase 
gene with BikDD, a potent proapoptotic gene, and inhibited growth of Colo357FG 
and Colo357l3.6pl pancreatic tumours in vivo (p=<0.01) (Xie et al. 2007). 
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1.6 Utilising Adenovirus for 
improved therapeutic transduction. 
1.6.1 Adenovirus biology 
1.6.1.1 Adenovirus classification 
Adenoviruses were first identified in 1953, when Rowe and colleagues found 
pathogenic changes in primary cell cultures derived from adenoid tissues, which 
were a result of replication of a previously unidentified virus. This virus induced 
cytopathic changes in cultures of human cells (ROWE et al. 1953). However, it 
was not until 1954, when Hilleman and Werner isolated agents from respiratory 
secretions of army recruits, that the relationship between these viruses was 
established. They were later named adenoviruses after the original adenoid tissue 
in which the virus was discovered (HILLEMAN and WERNER 1954). The human 
adenovirus is part of the adenoviradea family, of which there are four genera: 
Mastadenovirus, Aviadenovirus, Atadenvirus and Siadenovirus. Mastadenovirus 
infect mammals and aviadenovirus infect birds, while the other two genera infect a 
broad range of hosts including reptiles and amphibians. Human adenoviruses 
belong to the Mastadenovirus genus and 53 different human adenovirus serotypes 
have been identified (Smith et al. 2010). These serotypes can be divided into 
seven species (A-G) based on their ability to agglutinate human erythrocytes and 
their biological, physiochemical and genetic properties (Table 6).  
Table 6 Classification of Adenoviruses (Shenk 2001, Zhang and Bergelson 2005) 
Species Serotypes Receptors Tropism Disease 
A 12, 18, 31 CAR, FIX, FX Cryptic (enteric and 
respiratory) 
Mainly asymptomatic 
B1 3, 7, 16, 21, 50 CD46, DSG-2, FX, 
CD80, CD86 
Respiratory, ocular Respiratory and ocular 
diseases 
B2 11, 14, 34, 35 CD46, DSG-2, FX, 
CD80, CD86 
Renal, ocular, 
respiratory 
Respiratory diseases 
C 1, 2, 5, 6 CAR, FIX,FX, Lf, 
DPPC, VCAM-1, 
HSPG, MHC1-α2 
Respiratory, ocular, 
lymphoid 
Respiratory and Ocular 
diseases 
D 8-10, 13, 15, 17, 
19, 20, 22-30, 32, 
33, 36-39, 24-49, 
SA, CD46, CAR, fx Ocular (enteric) Ocular diseases 
Figure 18 Plasmid map of CCKAR plasmid 
Binding of CKK to the CCKAR promoter results in transcription of the GAL4/VP16 fusion protein. 
The fusion protein binds to 5 Gal4 binding sites upstream of the luciferase gene, resulting in 
increased transgene expression 
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51 
E 4 CAR Ocular, respiratory Respiratory and ocular 
diseases 
F 40, 41 CAR Enteric Gastroenteritis 
G 52 ND Enteric Gastroenteritis 
 
1.6.1.2 Adenovirus structure 
The human adenovirus has a molecular weight of ~150 MDa. The adenoviridae 
are icosahedral particles with a diameter of ~950Å, containing non-enveloped viral 
dsDNA, 36 kb in size (13% of mass), encoding more than 40 different proteins 
(87% of the mass, 13 of which have been demonstrated to form the virus particle), 
no membrane or lipids and trace amounts of carbohydrate (Smith et al. 2010). The 
icosahedral morphology of the adenovirus is a product of the interactions of three 
primary capsid proteins (pII, pIII and pIV), and four minor proteins (pIIIa, pVI, pVIII 
and pIX) (Vellinga, Van der Heijdt, and Hoeben 2005) (Figure 19). 
A virion consists of a protein shell (capsid) made of 252 subunits (capsomeres), of 
which 240 are homotrimeric hexons made from the major protein pII, and 12 are 
pentons (pIII). There are four hexons that are positioned in different areas of the 
capsid: H1, H2, H3 and H4 (Burnett 1985). H1 hexons are termed peripentonal 
hexons, of which 60 are associated with the pentons at the 12 apices. The 
remaining hexons are known as ‘groups of nine’ present on the 20 faces of the 
icosahedrons and further defined as H2 (on the two-fold axes) H3 (on the three-
fold axes) and H4. There are hexon differences that are dependent on serotype 
including up to nine hyper variable regions situated on top of the molecule, 6 of 
which are resolved as α-helical rods in the 6 A˚ structure (Saban et al. 2006). A 
major part of the virus-neutralizing activity is as a result of at least one of these 
hypervariable regions. 
The 12 pentons are located on each of the 12 apices and consist of the major 
capsid protein penton base at the base, with an extended trimeric fibre protein 
(pIV). The fibre protein is composed of three polypeptide pIV molecules, 
incorporating an N-terminal domain (attached to the penton through a non-
covalent interaction), a central shaft and a C-terminal knob region. This is a major 
virus capsid protein and the first component to interact with target cell receptors 
and tissues. As well as association with a trimeric fibre protein, each penton is 
also associated with the minor capsid protein pIIIa, which stabilises the capsid 
through interaction with both hexons and pentons. The remainder of the four minor 
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capsid proteins, pVI and pVIII also work to stabilise the capsid. pVIII specifically 
stabilises the bond between peripentonal hexons and the rest of the capsid, while 
pVI and pIX stabilise the capsid through interaction of adjacent hexons and 
pentons. 
 
Figure 19 Adenovirus structure 
Representation of adenovirus structure based on cryo-electron microscopy and 
crystallography. Image taken from (Russell 2009). 
The remaining structural components; V, VII, Mu, Iva2 and terminal protein (TP) 
are associated with the dsDNA genome, constituting a 23K virion protease which 
is essential for assembly of the virion. There are about 160 copies of pV and very 
little is known about this polypeptide. However, evidence suggests that pV is 
directed to the nucleus and nucleolus in Ad5-infected cells and may aid the 
dissociation of core proteins, unveiling the viral DNA for replication/transcription. 
pV is also loosely associated with pVII and viral DNA (Harpst, Ennever, and 
Russell 1977, Russell, McIntosh, and Skehel 1971), with tighter interactions with 
polypeptide VI, of which there are 360 copies (Matthews and Russell 1998). Over 
800 copies of polypeptide VII exist in each virion, spread along the length of virus 
DNA to which it binds strongly due to its highly basic nature (Russell and Precious 
1982). pVII is thought to play a role in nuclear import of the viral DNA, targeting 
the genome to the nucleus and nucleolus. pVII has also been shown to restrict 
viral transcription at the early stages, but facilities late transcription and viral 
assembly at the end of the adenoviral life cycle, due to E1A transcription-
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dependent release of pVII. Mu displays similar properties to protamines. Little is 
known about this core protein, however it can duplicate the nucleolar functions of 
pV and act as a precursor to modulate early expression of E2 proteins through its 
precursor (preMu), resulting in a shift in late protein expression. The core protein 
pIVa2, present in only a few copies, is critical for adenoviral packaging. It mediates 
encapsidation through interaction with pVII and L4 22K, a non-structural 
adenoviral protein, and binds to a specific stretch of the adenoviral DNA via repeat 
sequences. Finally terminal protein (TP) functions as a primer for DNA replication 
as well as binding of the viral genome to the nuclear matrix. 
1.6.1.3 Genome organisation 
Ad5 is one of the most well characterised adenovirus serotypes. The Ad5 genome 
was completely sequenced in 1992 and is 35935 bp in length. Adenoviral DNA is 
made up of inverted terminal repeat sequences that range from 40 to 160 bp, 
these inverted terminal repeats are responsible for circularization of single-
stranded viral DNA through base-paring with their terminal sequences to produce 
panhandles, that are thought to be important for viral DNA replication (Shenk 
2001). The adenovirus contains two identical origins for DNA replication present in 
each terminal repeat. Additionally, the viral genome also includes a cis-acting 
packaging sequence that directs interaction of the viral DNA with its encapsidating 
proteins, this sequence must be located within several hundred base pairs of the 
end of a chromosome to function correctly (Shenk 2001). 
The adenoviral infectious cycle comprises of two phases, the early and late 
phases that occur before and after DNA replication respectively. The early phase, 
lasting around 6-8 h covers entry of the virus into the host cell, internalisation of 
the viral genome into the nucleus and transcription and translation of early genes. 
E1A, E1B, E2, E3 and E4 genes are responsible for this stage of the viral life cycle 
and the viral chromosome is subdivided into these early transcription units (Figure 
20). IVa2 and IX genes are expressed at very high levels after the onset of DNA 
replication and are responsible for low basal levels of late transcription occurring 
at an early stage after adenoviral infection. The late phase of the infectious cycle 
takes around 4-6 h. The major late promoter is activated by IVa2 and IX gene 
products and is responsible for the primary transcription of late phase genes, 
which is subsequently split into five cassettes of transcripts termed L1-L5. This 
phase is responsible for the production of virus structural components and 
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maturation of the virus particle within the nucleus, including encapsidation of the 
particle. All viral genes are transcribed by RNA polymerase II, except for virus-
associated (VA) I and II genes that are transcribed by RNA polymerase III (Shenk 
2001). The functions of adenoviral proteins and their corresponding genes are 
summarised in Table 7. 
 
Figure 20 Schematic representation of adenovirus genome organisation 
The early genes responsible for preparing the infected cell for replication and modulating 
immune response are shown in red (E1A, E1B and E3), whilst early genes involved in 
regulating viral DNA replication are shown in purple (E2A and E2B). The late set of early 
genes are shown in blue (E4). The late genes are transcribed from the major late promoter 
as one primary transcript that is subsequently processed, these are shown in green. 
Structural proteins are pII to pIX. Both strands of DNA are transcribed and arrows 
demonstrate the direction of transcription. The 103 bp inverted terminal repeats (ITRs) are 
located at the termini of the genome and are involved in viral DNA replication. The 
packaging signal (ψ) located from nucleotides 190 to 380 at the left end is involved in 
packaging of the genome into virion capsids. Adapted from (Russell 2000). 
Table 7 Function of human Ad5 adenoviral particle proteins (Russell 2009, 2000, 
Gallimore and Turnell 2001, Wiethoff et al. 2005) 
Gene  Protein  Function  
E1A  E1A12S  Represses transactivating function of E1A13S through p300 
binding as well as binding to many other cellular proteins including 
pRB (p107 &p130) & STAT1. p53 activator  
 E1A13S  Essential for viral replication as it transactivates viral genes and 
binds to cellular proteins TBP, Sp1, CREB, DR1  
E1B  E1B19Kd  Acts as an anti-apoptotic Bcl2 homolog  
 E1B55Kd  Binds to p53 and represses transcriptional activity of p53.  Works 
together with E4orf6 to stimulate late viral nuclear mRNA export, 
inhibits host cell mRNA export and degrades cellular proteins in 
an E3 ubiquitin ligase complex.  
E2A  Polymerase  5’-3’ polymerase activity and 3’to 5’ exonuclease activity- viral 
polymerase 
  DBP DNA-binding protein Chain elongation for DNA replication 
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E2B  Pre-terminal 
protein  
Core protein: essential for viral DNA replication, and 
circularisation of the genome  
E3A  12.5Kd  Unknown  
 6.7Kd  Unknown  
 gp19Kd  Prevents presentation of viral antigens in infected cells by binding 
and sequestering MHC in the endoplasmic reticulum  
  (ADP)  Adenovirus death protein -Promotes viral release  
E3B  10.4/14.5Kd 
RID  
Mediates internalisation of the FAS receptor and inhibits pro-
apoptotic phospholipase A2  
 14.7Kd  Interacts with caspase-8 in FLICE to inhibit FAS and TNF ligand-
induced apoptosis as well as inhibiting pro-apoptotic 
phospholipase A2 and binding and blocking pro-apoptotic FIP 
proteins  
E4  Orf 1  Facilitates transformation  
 Orf 2  Unknown  
 Orf 3  Interacts with E1B55K  
 Orf 4  Inhibits E1A activation of E2F  
 Orf 6  Interacts with E1B55K for late viral RNA export and shuts off 
cellular mRNA processing  
 Orf 6/7  Transactivates E2A promoter by binding to E2F-binding sites  
Delay
ed 
early 
gene  
IX  Minor capsid protein: stabilizes viral capsid through association 
with hexons and pentons  
 IVa2  Core protein: crucial to the packaging process- binds DNA and 
activates late viral gene transcription  
L1  IIIa  Minor capsid protein: Stabilizes virion capsid through association 
with hexons and pentons  
L2  III -penton  Major capsid protein:  essential for virus internalisation and 
transport into endosomes through interaction of αvβ3/αvβ5 with 
RGD peptide on penton base.  
 V  Core protein: provides bridge between the core and the capsid 
and facilitates final uncoating stages of capsid proteins  
 VII  Core protein: spreads along the length of viral DNA and binds 
tightly due to highly basic nature, mediates localisation of virion to 
nucleus and diminishes early transcription  
L3  II- hexon  Major capsid protein: Associates in trimers to form hexon 
capsomere-there are four kinds of hexons, (H1, H2, H3 and H4) 
and 240 hexons in an adenoviral capsid.  
 Protease  Core protein: cleaves the precursors to the structural proteins IIIa, 
VI, VII, VIII, pTP and X. Essential for production of the infectious 
viral particle and uncoating during virion internalisation  
 VI  Minor capsid protein: stabilizes virion capsid through hexon and 
penton interaction. Ruptures the membrane of early endosomes 
to mediate virion escape during infection  
L4  100K  Associates with hexons during virion assembly and stimulates late 
viral translation  
 VIII  Minor capsid protein: stabilizes virion through interaction with 
hexons and pentons providing a bond between peripentonal 
hexons and the rest of the capsid  
L5  IV  Major capsid protein: associates in trimers to form penton,  the 
first virus component to interact with a target receptors/tissues  
VA 
RNA  
VA1 &VA2  Prevents PKR-mediated protein synthesis shutoff and blocks α- 
and β- interferon anti-viral response as a result  
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Mu   Core protein: Similar properties to protamines. Modulates E2 gene 
expression to switch from early to late viral transcription and 
condenses chromatin during packaging.  
 
1.6.1.4 Adenovirus life cycle 
1.6.1.4.1 Virus attachment, internalisation and 
trafficking to the nucleus 
Human adenovirus will primarily infect epithelial cells, even if other cell types can 
be infected, they are poor supporters of the adenoviral life cycle. Attachment of 
adenovirus subtype 5 is mediated in two-steps; firstly through the distal carboxy-
terminal domain of the fiber protein. This domain terminates in a knob that binds to 
CAR (coxsackie adenovirus receptor) protein. CAR is a 46 kDa transmembrane 
cellular receptor belonging to the immunoglobulin superfamily, that serves as a 
high affinity receptor for all subtypes of adenovirus excluding B and G (Shenk 
2001) (Table 6). Ad5 also interacts with a number of other cellular receptors to 
facilitate viral attachment in vitro, including; vascular adhesion molecule (VCAM-
1), heparin sulphate proteoglycans (HSPG), and the major histocompatibility 
complex one alpha domain (MHC1-α2).  
The second step in adenoviral attachment following CAR binding involves binding 
of the adenovirus penton protein to αvβ3/αvβ5 integrins, through an arginine-
glycine-aspartic acid (RGD) motif, resulting in viral internalisation. This step is 
essential for most adenoviruses, with the exception of species F, which do not 
contain an RGD binding motif. This penton base-integrin interaction results in 
integrin clustering, stimulating activation of PI3K, MAPK and ERK downstream 
signalling pathways as a result. Induction of the PI3K/AKT pathway induces 
downstream events including the polymerization and reorganization of actin 
filaments for clathrin mediated endocytosis. The p38/MAPK pathway activation 
results in increased IL-8 production, suggestive of the host immune defence 
system and ERK1/2 activation, stimulating increased CAR clustering and 
activation of β-integrin subunits, whilst simultaneously up-regulating the 
p38/MAPK pathway (Coughlan et al. 2010, Russell 2000). 
After successful attachment to cellular integrins by the RGD motif, internalization 
of the virion via clathrin-coated pits and subsequent endocytosis or 
macropinocytosis begins. Once internalised, the vesicles are acidified by the 
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vacuolar H+/ATPases, causing a change in pH to pH4.6-6.0, this is responsible for 
driving conformational changes to the structure of the virion, including the loss of 
capsomeres from the apices. The infecting particle must then exit the endosome 
and enter the cytosol, this process is mediated by the lytic action of pVI. After 
these processes are complete, 90% of the partially degraded virion successfully 
moves into the cytosol with a half time of 5 min, suggesting that the virus escapes 
the endosome prior to formation of a lysosome (Shenk 2001). Once in the cytosol, 
virus particles are transported across the cytoplasm through microtubules to the 
nucleus, via the microtubule associated motor dynein, which facilitates Ad 
attachment to microtubules. pVII is thought to be the primary viral mediator of this 
process. Hsc70 and nuclear histone H1 and H2 import factors, importin β and 
importin 7 are recruited by capsid interactions with CAN/Nup214. This facilitates 
complete capsid disassembly and delivery of viral genomic DNA to the nucleus 
(Coughlan et al. 2010). 
1.6.1.4.2 Viral gene transcription 
As previously discussed (section 1.6.1.3), viral gene transcription comprises a 
two-phase event that can be split into early and late phases. In order to induce 
adenoviral gene expression three main goals must be achieved. Firstly S phase of 
the cell cycle must be induced in the host cell, providing an optimal environment 
for viral replication. This stage utilises E1A, E1B and E4 gene products. Secondly, 
the infected cell must be protected from various host cell defence responses by 
expressing viral defence factors, including the E1B, E3, E4 and VA RNA genes 
that contribute to these defences. Finally, viral gene products required for viral 
gene replication must be synthesised. Accomplishment of all three of these goals 
is dependent on activation of the viral genome. The principal activating proteins of 
adenovirus are encoded by the E1A gene (Shenk 2001). 
The E1A promoter is constitutively active and E1A is the first transcription unit to 
be expressed after the viral chromosome enters the nucleus. E1A encodes two 
mRNAs during the early phase of infection, with three additional E1A mRNA 
species, of no distinct function, accumulating at a later stage in the infectious 
cycle. The two early E1A mRNAs contain identical 5’ and 3’ ends with differing 
internal sequences that result in alternative splicing, encoding identical proteins, 
except for an additional 46 amino acid segment present in the larger polypeptide. 
These differential polypeptides are referred to as E1A12S (243 amino acids) and 
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E1A13S (289 amino acids) (Figure 21). The E1A proteins of different subtypes of 
human adenoviruses are comprised of three conserved regions, CR1, CR2 and 
CR3 that are separated by less highly conserved domains. These three domains 
play a large role in protein-protein interactions, facilitating the role that E1A12S 
and E1A13S play in binding to cellular proteins to modulate their function, rather 
than directly binding with the DNA. In fact, the E1A proteins bind to a variety of 
cellular transcription factors and regulatory proteins to activate transcription in 
three ways: 1) they mediate basal transcription through direct interaction with 
auxiliary factors, 2) they interact with activating proteins that bind to upstream 
promoter and enhancer elements and 3) they influence the activity of DNA binding 
factors by interaction with regulatory subunits (Shenk 2001). A list of E1A binding 
partners can be found in Table 8. 
 
Figure 21 Diagram of E1A mRNAs and the polypeptides they encode 
Diagrammatic showing the two different E1A mRNAs and the polypeptides they encode. 
Cellular proteins bind through the conserved regions (CRs) of E1A. E1A13S contains an 
additional CR3 domain, which functions as a strong activation domain. 
E1A12S and E1A13S differ only in the presence of the CR3 domain in E1A13S, 
which functions as a strong activation domain through direct binding to the TATA-
binding protein (TBP) as well as MED23, a subunit of the MED complex and 
CREB. TBP is the DNA-binding subunit of the auxiliary transcription factor IID 
(TFIID), which binds to the TATA box, an element present 25-30 bp upstream of 
transcription initiation sites in many genes. The cellular tumour suppressor protein 
p53 can also bind to TFIID. In fact, the p53 binding domain overlaps that of 
E1A13S, resulting in the displacement of p53 binding due to E1A binding and a 
relief in p53 mediated transcriptional repression. E1A12S can also activate 
transcription through the TATA box, but in a more indirect way, the 12S and 13S 
proteins can both bind directly to Dr1, a factor that normally binds to TBP, and 
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inhibits transcription. The 12S and 13S proteins sequester Dr1 through direct 
binding preventing Dr1 interaction with TBP.  
E1A proteins can also activate transcription through E2-F binding sites. E2-F 
forms a complex with the cellular retinoblastoma tumour suppressor protein pRB, 
which in turn inhibits transcriptional activation by E2F. Both E1A proteins bind 
through CR1 and CR2 to pRB, releasing E2F and driving transcriptional activation 
as a result. This E2F activation not only affects the expression of viral genes, but 
also accelerates cell cycle progression through upregulation of cellular genes, 
including genes important for S phase and cell growth (Shenk 2001). Despite 
evidence pointing towards the absolute requirement for E1A in adenoviral gene 
transcription, E1A-deleted mutants have been shown to replicate in some cell 
types. Dl312, a virus lacking the E1A gene, replicated at a similar rate to wild-type 
virus in HeLa cells that were infected at a high MOI, but not in numerous other cell 
types. E2F and E4F sites have also been identified in E2 and E4 promoter 
regions, suggesting that cellular transcription factors could bind to other early viral 
promoters in the absence of E1A, stimulating low levels of transcriptional initiation 
(Shenk 2001). 
Table 8 Major E1A-binding partners 
E1A-binding protein  Binds 12S E1A  Binds 13S E1A 
pRB  +  +  
p107  + + 
p130  + + 
p300 + + 
TBP  -  + 
hTAF  -  + 
SUR-2  -  + 
Dr1  +  + 
ATF-2  -  + 
YY1  +  + 
Sp1  ?  + 
MAZ  ?  + 
STAT1  +  + 
 
1.6.1.4.3 Induction of S-phase in the host cell 
Adenovirus infection can induce quiescent cells to enter the S phase of the cell 
cycle. Protein products of the early adenoviral genes create the optimal cell 
environment for viral DNA replication, through interaction with cellular proteins 
including pRB pocket proteins and the p300/CBP proteins. This modulation is 
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mediated by CR2 and the non-conserved amino-terminal domains of the E1A 
proteins. 
E1A-binding through the CR2 domain to pRB is primarily responsible for entry into 
S phase. Over expression of pRB inhibits cell cycle progression through E2F 
binding, causing cells to arrest in middle to late G1 phase. The activity of pRB is 
regulated by cyclin-dependent kinases and hyperphosphorylation of pRB prevents 
the formation of the cell cycle inhibitory pRB-E2F complex. The LxCxG motif 
sequence present in the CR2 domain binds to pRB. The E1A-binding domain on 
pRB, referred to as the binding pocket, also binds E2F. Therefore, E2F can be 
released from pRB by E1A, leaving E2F free to activate cellular genes that 
promote cell cycle progression (Berk 2005). Similarly, CR1 also weakly interacts 
with pRB, playing an auxiliary role in stabilising the CR2-pRB interaction (Shenk 
2001). E1A can also interfere with the function of pRB independent of competitive 
binding. pRB functions as a transcriptional repressor through interaction with  
HDAC containing complexes and hBRM and BRG1 members of the SWI/SNF 
transcriptional regulators to promoter complexes, resulting in cell cycle arrest. 
Thus, the binding of E1A to pRB disrupts these interactions, consequently 
inhibiting transcriptional repression (Gallimore and Turnell 2001). 
E1A can also stimulate cell cycle progression through an alternative pathway 
involving p300/CBP. These proteins bind to the poorly conserved region in CR1 
and are therefore able to stimulate DNA synthesis in viral mutants that lack the 
CR2 domain, essential for pRB dependent cell cycle progression. More recently, 
p300/CBP have also been demonstrated to bind to the CR3 domain (Pelka et al. 
2009). p300/CBP proteins exhibit intrinsic histone acetyltransferase activity and 
recruit other HAT proteins including PCAF, as well as acting as coactivators of a 
number of  transcription factors that include CREB, STATs and nuclear receptors. 
Consequently, binding of p300/CBP to E1A displaces and inhibits the intrinsic 
acetyltransferase activity of PCAF. Thus, S-phase entry is facilitated by the ability 
of E1A to inhibit the function of p300/CBP. p300/CBP also serves as a coactivator 
of p53, whose loss of function contributes towards tumour progression. 
Consequently, E1A proteins antagonise p53 function through inhibition of 
p300/CBP activity, resulting in the unblocking of cell cycle progression. This 
process is not however enough to stimulate progression into S phase (Pelka et al. 
2009). 
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1.6.1.4.4 Viral genome replication 
Accumulation of E2 gene products is required for viral DNA replication. This takes 
place between 5-8 h after initial infection of the cell, when the products of the early 
genes have established optimum conditions for DNA synthesis and continues until 
the host cell dies. 
Viral replication takes place in two stages, in the first stage only one of the two 
DNA strands acts as a template for DNA synthesis, displacing the other strand of 
DNA and producing a duplex that consists of a daughter and parental strand. The 
complement to the displaced strand is then synthesised in the second stage. This 
process requires circularisation of the second strand, through the self-
complementary termini, resulting in a duplex termed a panhandle. This panhandle 
allows recognition of the replication machinery to initiate DNA synthesis, resulting 
in completed duplexes that consist of one parental and one daughter strand 
(Figure 22). In order for this process to take place the ITRs located at both ends of 
the viral DNA act as replication origins comprised of cis-acting sequences. Three 
functional domains have been defined within the 51 bp terminus of the ITRs, 
termed A, B and C. The first 18 bp of viral DNA is termed domain A, functioning as 
a minimal origin of replication with base pairs 9 to 18 being fully conserved among 
all serotypes of human adenovirus, that recruits viral encoded pTP and DNA 
polymerase. Domain B (base pairs 9-39) and domain C (base pairs 40 to 51) bind 
cellular factors including nuclear factor 1 (NF1) and NFIII respectively. pTP binds 
covalently to the 5’ end of the viral chromosome and acts as a primer for DNA 
replication, whilst preserving the integrity of the viral chromosomes ITR sequence 
throughout multiple rounds of replication. pTP also interacts with CAD, a 
multifunctional pyrimidine biosynthesis enzyme within the nuclear matrix that helps 
to anchor the adenoviral replication complexes close to useful cellular factors. pTP 
and polymerase bind together as a complex and the polymerase utilises both 5’-
to-3’ polymerase activity as well as 3’-to-5’ exonuclease proof-reading activity. 
Chain elongation requires both DNA-binding protein (DBP) and NFII. In the 
presence of DBP, the polymerase is highly processive, travelling the entire length 
of the chromosome after separation from pTP. Furthermore, NFII is necessary to 
overcome DNA structural problems that arise after extensive replication and has 
been identified as having topoisomerase activity (Shenk 2001).  
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Figure 22 Schematic representing adenoviral replication  
DNA synthesis is initiated at the 5’ end of the DNA, as the DNA replication fork proceeds it 
displaces the other strand, leaving a newly synthesised double stranded DNA and the 
displaced single strand. The single strand circularises through its self complimentary 
termini, forming a panhandle, allowing for DNA synthesis to commence from the 5’ end, 
resulting in production of completed duplexes that consists of one parental and one 
daughter strand. 
1.6.1.4.5 Viral assembly and release 
Upon the onset of DNA replication adenoviral late gene expression begins. During 
replication of adenoviral DNA, large quantities of adenovirus structural 
polypeptides are produced that enable viral assembly. The late coding regions are 
organised into a single transcript and subsequent post transcriptional 
modifications result in 5 different mRNA transcripts termed L1 to L5. Accordingly, 
these transcripts encode components essential for viral maturation and 
encapsidation and their expression is controlled by the major late promoter (MLP). 
The MLP exhibits low level activity in the early stages after infection, becoming 
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several hundred-fold more active after DNA replication. This increased expression 
is due to binding of the USF/MLTF transcription factor that binds upstream of the 
MLP after the completion of DNA replication. Additionally, the product of the 
delayed early gene Iva2 also binds to the MLP and contributes to its induction 
through interaction with USF/MLTF (Shenk 2001). 
Upon the initiation of DNA replication and the synthesis of all late mRNAs, 
accumulation of cellular mRNAs in the cytoplasm is halted. This process is 
mediated by the E1B55kD and E433kD polypeptides that exist in a complex, 
facilitating shutdown of host protein synthesis. L4-100K fulfils this function by 
preventing phosphorylation of eIF-4F, an initiation factor that binds to the cap of 
cellular mRNAs and facilitates scanning of the 40S ribosome from the cap to the 
AUG. The five late viral mRNA families encoded by the late transcription unit are 
uncapped and contain a tripartite leader sequence, an identical sequence of 200 
nucleotides in the 5’ non-coding region that is important for mRNA translation in 
the later stages of infection. This sequence is responsible for the preferential 
translation of adenoviral late mRNAs and continued translation well after infection, 
due to a process known as ‘ribosome jumping’, in which the 40S ribosome can 
scan from the cap, to AUG without the requirement of the eIF-4F helicase (Shenk 
2001). 
Viral DNA replication and accumulation of structural proteins initiates viral 
assembly. Assembly of the hexon trimers requires L4 100-kD, which acts as a 
scaffold to facilitate assembly. Experiments have indicated that the penton base 
and fibre assemble independently, subsequently joining to form the penton 
capsomere. Next, the hexon and penton capsomeres assemble in the nucleus, 
where virion assembly is initiated. Viral DNA enters the capsid either coupled to 
encapsidation while DNA replication is taking place, or independent of 
encapsidation, in separate nuclear compartments. It is unclear as to which 
mechanism is correct. It has been established that the viral DNA enters the empty 
capsid via the packaging sequence that allows for DNA-capsid recognition. pIVa2 
subsequently binds to the viral DNA, together with L152.55Kd and pVII to initialise 
encapsidation. The L3-coded proteinase then cleaves the pVI, pVII, pVIII and pTP 
to stabilize the viral particle and render it infectious (Shenk 2001). 
There are two systems in which a virus will escape and spread. Firstly, the 
intermediate filaments that form the cytoskeleton are disrupted. For this purpose 
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the L3 proteinase cleaves the cellular cytokeratins k18, preventing polymerization, 
a process that is required to form filaments. This process compromises the 
integrity of the cell, making the infected cell more susceptible to lysis. The second 
system involves the E311.6Kd protein, otherwise known as the adenovirus death 
protein (ADP). This protein kills as it accumulates in late stage infection and 
facilitates release of the progeny virions (Shenk 2001). The mechanism by which 
this process occurs is unclear, however studies utilising mutated ADP have shown 
loss of localisation to the nuclear envelope and Golgi, correlating with regions 
important for N- and O- linked glycosylation. These processes result in lower 
protein stability and reduced lytic behaviour (Tollefson et al. 2003). A figure 
summarising the adenoviral life cycle can be found below (Figure 23). 
 
Figure 23 Summary of Human adenovirus life cycle 
Adenovirus binds through the fiber knob to CAR receptors expressed on the epithelial cell 
surface. The penton base then binds with the integrin αvβ3 and the virus is internalised. The 
virus is partially disassembled and the capsid travels to the nucleus through the 
microtubule network. Once in the nucleus viral gene transcription is initiated, resulting in 
progeny formation, eventually causing cell lysis and resulting in the release of new 
adenoviruses. 
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1.6.2 Viral gene therapy 
In the year 2000 the first genetically linked disease, X-linked severe combined 
immunodeficiency (SCID-X1), was cured through gene therapy treatment. A total 
of 20 infants were treated across three countries. From a long-term follow up of 
the French trial in 2010, that initially consisted of nine children, eight patients were 
still alive between the ages of 8 and 11 (Hacein-Bey-Abina et al. 2010). 
Unfortunately, 30 months post-treatment one of the 9 patients treated in the 
French trial developed T-cell leukaemia, as a direct result of the integration of the 
retroviral vector used for therapy near the LMO2 proto-oncogene. This insertion 
led to aberrant transcription and expression of LMO2 and disease progression 
(Hacein-Bey-Abina, Von Kalle, et al. 2003). Following this unfortunate turn of 
events, a further three patients from the French arm of the trial and one English 
patient also developed T cell leukaemia. Subsequently, 4 out of 5 patients were 
successfully treated for Leukaemia and remain in complete remission. This turn of 
events lead to the trial being placed on hold while efforts were made to improve 
the safety of viral vectors used for gene therapy. Almost a decade after the initial 
retroviral gene therapy trial, a vector with improved safety has been utilized for 
clinical trials and has demonstrably retained its efficacy for the treatment of SCID-
X1, whilst demonstrating significantly less insertion site clustering within LMO2 
and MECOM. However, the long term effects on leukemogenesis with this new 
vector are still unknown (Hacein-Bey-Abina et al. 2014). This first example of 
utilising gene therapy for the treatment of disease not only highlighted the 
importance of developing a safe vector for transgene introduction, but 
demonstrated the real potential for the role of viral gene therapy in the treatment of 
disease and cancer. Identification and modification of viral vectors that 
demonstrate improved safety, while maintaining clinical efficacy, is therefore one 
of the most fundamental aspects to developing an effective gene therapy strategy. 
1.6.2.1 Oncolytic and replication-defective adenoviruses 
Adenovirus can be used as a classical gene therapy tool for delivering therapeutic 
genes (replication defective viruses), as a drug alone through lysing cancer cells 
and even as a combination of both (oncolytic adenoviruses). Due to higher 
transfection efficiencies viral vectors are most commonly used for gene directed 
enzyme prodrug therapies. Replication defective adenoviruses contain a deletion 
of the E1A gene, responsible for viral replication, but can also include deletions of 
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the E3 genes, generating ~6 kb space for the insertion of therapeutic transgenes. 
Replication defective adenoviral vectors provide higher levels of safety than 
oncolytic viruses, but decreased transduction efficiency leading to poor efficacy in 
the majority of cases. For this reason replication defective adenoviruses are often 
administered in combination with therapeutic drugs that synergistically increase 
target cell death. Alternatively, oncolytic adenoviruses benefit from increased 
transduction and have also demonstrated safety in numerous clinical trials. 
However, replicating viruses can only take up to an additional 10% of the viral 
genome (~3.6 kb), reducing the capacity for the insertion of therapeutic 
transgenes. This becomes problematic when large expression cassettes include 
two-step-transcriptional amplification systems as well as therapeutic transgenes, 
as there is not sufficient space to allow for the incorporation of the whole cassette. 
Thus, it is important to establish which method will increase efficacy and 
transduction whilst remaining clinically safe. 
1.6.2.2 Oncolytic gene therapy as an anticancer agent 
In the beginning of the last century, several observations were made that natural 
viral infections were associated with cancer remission. Since then, adapting 
Human adenoviral vectors (Adv) for use as anti-cancer treatments has been a 
major focus in the application of viral gene therapy due to: 1) adenoviral vectors 
have generated a good safety profile through numerous clinical trials 2) they can 
easily be produced under good manufacturing practice (GMP) conditions 3) 
batches can be purchased that meet high safety standards 4) wild-type Adv 
vectors are only mildly pathogenic 5) they are easily manipulated by genetic 
modifications 6) they can be engineered to include new polypeptide ligands in their 
capsids  that are able to preferentially infect specific cell or tissue types. 7) They 
can be modified to carry therapeutic or reporter genes, including prodrug 
activating enzymes (de Vrij et al. 2010). 8) They do not incorporate into cellular 
DNA in contrast to the viruses described in section 1.6.2. 
To this day Adenoviruses remain the most popular vectors for viral gene and 
immunotherapy evaluated in clinical trials, with a total of 488 adenoviral vectors 
tested at various phases (www.abedia.com/wiley). This accounts for 22.8% of all 
gene therapy clinical trials, but is closely followed by Retrovirus (19.1%) and 
naked/ plasmid DNA (17.7%). Of the 488 gene therapy clinical trials utilising 
adenovirus, 351 are targeted to cancer and are at various clinical phases. There 
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have been 53 clinical trials using Adenovirus to treat PCa 
(www.abedia.com/wiley). 
Other methods to selectively target cancer cells include engineering viruses to 
complement mutations found only in cancer cells. These are normally associated 
with cell cycle and apoptosis. These viruses are known as replication selective, as 
they take advantage of deregulated pathways in cancer cells. Replication selective 
viruses become replication competent in cancer cells, where loss of function 
mutations are dispensable for replication, whilst remaining inactive in normal cells. 
One of the most well studied examples of this is the ONYX-015 virus (Bischoff et 
al. 1996). This virus has a deletion in the E1B55k gene, which ordinarily represses 
p53-mediated transactivation and works together with E4orf6 to promote p53 
degradation and prevent premature cell death. This virus therefore complements 
cancer cells with a non-functional p53, either through direct p53 mutation, or 
mutation in both upstream and downstream regulators of p53. Consequently, 
ONYX-015 will selectively replicate in these cells as the E1B deletion renders the 
virus unable to degrade p53 during viral replication, resulting in ineffective 
replication in normal, p53 expressing cells. Despite promising initial trials utilising 
ONYX-015, further investigations showed that the virus was unable to replicate 
efficiently in some p53-defficient cell lines, or some cell lines harbouring p53-
related mutations (Goodrum and Ornelles 1997, Edwards et al. 2002). More 
worryingly ONYX-015 was also found to replicate in p53-expressing normal cells 
and cancer cells that retained wildtype p53 (Goodrum and Ornelles 1997, 
Rothmann et al. 1998).  
Notwithstanding the varied in vitro data generated with ONYX-015, 18 Phase I and 
II trials have been conducted to date. ONYX-015 has been explored both as a 
monotherapy and in combination with chemotherapeutics. Administration of 
ONYX-015 as a single agent failed to generate efficacy, with less than 15% of 
cases resulting in a clinical benefit to patients with head and neck cancer 
(Nemunaitis et al. 2000). Despite some promising trial results many patients still 
responded poorly to ONYX-015 and the clinical effect was varied. The poor 
responses were due to a number of factors including attenuation of immune 
defence due to the E3B deletion and the virus being unable to support viral 
nuclear mRNA export. Adaptations of ONYX-015 that improved efficacy have 
therefore been investigated, including H101. Various clinical trials have confirmed 
the oncolytic anti-cancer effect of H101, with a response rate of 30.4% in one 
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phase II trial combined with chemotherapy (Lu et al. 2004) and a 78.8% response 
rate for the treatment of head and neck cancer in combination with cisplatin and 5-
FU, compared to a 39.6% response for cisplatin and 5-FU alone (Xia et al. 2004). 
These results led to the approval of H101 for cancer treatment in combination with 
cisplatin and 5-FU by the Chinese government in 2005. Efficacy was reported in 
treated tumours, however the patients were not followed up long-term (Garber 
2006). 
The poor efficacy of ONYX-015 as a monotherapy identified areas for 
improvement in the generation of novel oncolytic adenoviruses to improve 
efficacy. Increased efficacy generated with the H101 virus in combination with 
chemotherapy also highlighted areas in which combinatorial therapies could 
increase efficacy, whilst reducing toxic side effects associated with 
chemotherapeutics. The following strategies to engineer cancer selective oncolytic 
mutants have since been explored: 1) arming adenoviruses with therapeutic 
transgenes, 2) utilising tissue specific promoter to restrict adenoviral replication 
and 3) retargeting adenovirus attachment and infection. 
In recent years the E1ACR2 and E1B19K oncolytic adenoviral mutants have 
demonstrated high selectivity and efficacy in combination with chemotherapeutics. 
These viruses retain functions essential for the viral life cycle by deletion of 
smaller gene regions (Oberg et al. 2010). Various E1ACR2 deleted mutants have 
demonstrated high efficacy in preclinical studies (Lamfers et al. 2002, Raki et al. 
2008, Suzuki et al. 2002). E1ACR2 deleted mutants have also been tried in clinical 
phase 1 trials for Glioma and Ovarian cancer to establish the maximum tolerated 
doses of the viruses (Glioma Ad∆24RGD-4C (DNX-2401) NCT00805376, MD 
Andersen, Ovarian completed Ad24RGD NCT00562003 (https://clinicaltrials.gov). 
Double deleted mutants (AdΔΔ), with a deleted E1ACR2 and E1B19K region have 
been used in combination with cytotoxic drugs docetaxel and mitoxantrone to 
enhance cell killing in a number of PCa cell lines (Oberg et al. 2010). In fact, the 
double deleted virus was able to inhibit DU145 and PC3 tumour xenograft growth 
in combination with docetaxel, suggesting a potential clinical treatment for solid 
tumours in combination with chemotherapeutics (Oberg et al. 2010). Additionally, 
AdΔΔ was combined with a number of phytochemicals that have previously 
proven anticancer activities. The combination of  AdΔΔ with equol and resveratrol 
synergistically increased cancer cell killing in PC-3 cells and tumour xenografts, 
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suggesting a safer alternative to more traditional combinatorial therapies with 
chemotherapeutics (Adam et al. 2012). 
1.6.2.3 Challenges for AdV as a therapeutic vector 
1.6.2.3.1 Immune system response to oncolytic 
viral infection 
Although initial trials using adenoviral vectors have accumulated interesting 
results, they appear to be ineffective as monotherapies; there are still many 
hurdles that are necessary to overcome, including the innate immunity and 
increasing viral uptake into target cells. The adenovirus enters the cell by binding 
to CAR and integrins on the cell surface; however these are only expressed in 
very small quantities. Therefore, applications that specifically target adenoviral 
therapies to cancer cells, and as a result increase the concentration of virus 
entering the target cancer cells are desired. Most adenoviral therapies are injected 
directly into the tumour, and therefore interference from the immune system is not 
a major issue for the initial treatment. However, many gene therapy trials require 
repeat administration, risking host immune interference. Additionally, direct 
injection into the tumour does not target metastatic cancer cells, thus, more 
effective ways to evade the host immune system are required. 
The innate immunity provides immediate protection against infection and is 
governed by type 1 interferons. Once they bind their receptors they trigger the 
transcription of many gene products called interferon stimulated genes (ISGs). As 
tumours evolve they become non-responsive to interferons and lose expression of 
key ISGs such as MHC genes, the protein products of which are required for 
antigen presentation to immune system cells. The tumour therefore becomes 
invisible to the host immune system (Parato et al. 2005).  
After initial activation of the innate immune system the adaptive immune system is 
triggered by free circulating virion-associated or cell-associated gene products. 
Some viruses for example measles and HSV retain their therapeutic activity 
despite a large neutralizing antibody response, it is not yet known whether these 
viruses could be effectively delivered to disseminated tumours if injected 
intravenously. Using certain viruses including vaccinia, measles and poliovirus can 
harbour problems as many patients will already have a mature adaptive immune 
response of antibodies to the virus due to previous vaccination programs. 
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However, studies have shown that by administering naturally occurring mutants 
that have a propensity to form Extracellular enveloped viruses (EEV) it might be 
possible to evade pre-existing immunity, increasing tumour infectivity and spread 
of the oncolytic viral vector. 
Another option is to mask the therapeutic virus from antibody neutralisation with 
chemical conjugates. Coating adenovirus with multivalent co-polymers renders the 
virus resistant to antibodies (Fisher et al. 2001, Green et al. 2004). This process 
has been shown to prevent complement activation and reduce the uptake of the 
virus by liver cells during systemic administration, resulting in a 10 fold increase in 
circulating virus. The only problem with this method of masking the virus is that the 
virus loses its infectivity as its cell attachment protein is conjugated. Therefore, a 
second targeting molecule must be linked to the polymer to facilitate viral infection 
(Parato et al. 2005).  
1.6.2.3.2 Ad5 binding to human erythrocytes 
Recent advances in research into adenoviral vectors have shown that Ad5 binds 
to human erythrocytes due to the presence of the coxsackievirus adenovirus 
receptor and the complement factor C4BP on the cell surface (Carlisle et al. 
2009). It is thought this may have occurred through evolution to protect the body 
from systemic infection. Unfortunately, this binding dramatically reduces 
extravasation and infectivity, allowing erythrocytes to work as circulating ‘virus 
traps’. Carlisle and colleagues showed that excess Ad5 fiber protein or anti-CAR 
antibody inhibits binding of Ad5 to human erythrocytes (Carlisle et al. 2009). CAR 
is the primary binding interaction between Ad5 and erythrocytes in PBS but 
complementation is also involved in the binding. Interestingly, the binding of 
erythrocytes to Ad5 only takes place in humans, not in other animals. Carlisle and 
colleagues therefore showed that the circulation time of Ad5 increases when 
washed human erythrocytes were injected into mice together with Ad5. The 
increased levels of Ad5 were predominantly associated with blood cells. The 
sequestration of Adv prevents the use of adenoviral vectors to treat metastatic 
PCa. If injected intravenously, the high affinity binding of virus to erythrocytes 
lower the amount of virus that would reach the tumour.  
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1.6.2.3.3 Adenovirus sequestration in the liver 
After intravenous administration, adenovirus is predominantly sequestered by the 
Kupffer cells in the liver within minutes, resulting in hepatocyte uptake and liver 
toxicity (Shayakhmetov et al. 2004). This hepatocyte uptake poses a massive 
problem in generating viral efficacy after intravenous injection. Ad5 primarily binds 
and attaches to host cells through CAR and the fiber knob, followed by binding to 
cellular integrins (as discussed previously section 1.6.4.1). However, elimination of 
binding to both CAR and integrins in several studies have failed to abolish 
adenoviral liver transduction (Martin et al. 2003, Smith et al. 2002), suggesting an 
alternative pathway for Ad5 infection of liver cells. Understanding the mechanism 
by which adenovirus is cleared from systemic circulation is therefore crucial in the 
construction of more efficacious, targeted vectors. 
1.6.2.4 Optimising adenoviral gene therapy through 
tumour selectivity 
Wildtype adenoviruses target most epithelial cells as well as cancer cells, requiring 
viruses to be engineered to ensure tumour selectivity. As mentioned previously 
(see section 1.5.2), one method to ensure tumour selectivity is through the use of 
TSPs. Prostate specific promoter/enhancer regions have been widely used to 
restrict transgene expression in several clinical trials (Table 9). These TSPs 
promoters can be placed either upstream of the E1A gene in order to restrict E1A 
expression and viral replication to the prostate, or any other cell type, or in place of 
the E1A gene to control transgene expression in a replication deficient virus. 
Examples of this include the CG7060 adenovirus in which the PSA 
promoter/enhancer was inserted between the E1A promoter and the E1A coding 
region, resulting in replication in prostate tissues with elevated PSA levels. Clinical 
trials demonstrated the safety of this virus and evidence of decreased PSA levels 
was seen in patients with locally recurrent PCa (DeWeese et al. 2001) 
Similarly, Yu et al showed efficacy in vitro utilising an adenovirus with the E1B 
gene expression controlled by the hK2 promoter, closely related to PSA and E1A 
gene expression by the PSA enhancer. This virus was significantly attenuated in 
non-prostate tissue resulting in a high therapeutic index (Yu, Sakamoto, and 
Henderson 1999). However, PSA promoter viruses were evaluated clinically with 
good safety but were unable to drive sufficient cell death in vivo due to their weak 
promoter activity. Steps were therefore taken to increase the activity of the PSA 
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promoter and enhancer, whilst continuing to restrict gene expression/viral 
replication to the prostate.  The most effective method to achieve this so far has 
been to duplicate the core enhancer in combination with the promoter, responsible 
for achieving nearly 20-fold higher activity in comparison to the single enhancer 
construct. After successful insertion of this promoter/enhancer element into an 
adenovirus driving luciferase, strong prostate specific expression was 
demonstrated in comparison to the CMV promoter (Wu, Matherly, et al. 2001). 
Most prostate-specific promoters that have been investigated are regulated by the 
AR, however the osteocalcin (OC) and PSMA promoters have also been utilised in 
targeted therapies. OC is expressed in osteoblasts as well as primary and 
metastatic PCa cells. Koeneman et al demonstrated that OC driven HSV/tk 
therapy in combination with ganciclovir was effective in destroying PCa cell lines in 
vitro and tumour xenografts in vivo (Koeneman et al. 2000). This was later tested 
in a phase I/II clinical trial in combination with valacyclovir for the treatment of six 
men with androgen-independent PCa. All patients tolerated the therapy with no 
serious adverse side effects. However, only one PSA response from 318.3 to 4.9 
ng/ml was observed and three of the patients who were docetaxel-naive had to 
receive chemotherapy after PSA levels progressed (Shirakawa et al. 2007). 
PSMA has also been investigated as a novel biomarker for cancer progression 
and is highly expressed in poorly differentiated adenocarcinomas and metastatic 
cancer (O’Keefe, Su et al. 1998). Furthermore, PSMA is upregulated during 
androgen-deprivation, suggesting that its regulatory regions could be used as a 
TSP to target androgen-independent PCa (O'Keefe et al. 2000, Uchida et al. 
2001). 
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Table 9 Prostate promoter/enhancers utilised for adenoviral gene therapy. 
Regulatory 
element 
Results summary Ref 
Original promoters 
hK2   E1a expression under the control of hk2 showed expression in 
PSA+ cells and prostate tumour selective replication  
(Yu, Sakamoto, 
and Henderson 
1999) 
OC   HSV-TK driven by OC promoter went to phase I clinical trials 
 E1a and E1b expression controlled by OC promoter- replicated in 
OC-expressing cells and inhibited tumour growth in vivo  
(Koeneman et 
al. 2000) 
Improved promoters 
Rat Probasin   E1a placed under the control of Rat probasin selective replication 
in PSA+ cells 
 Apoptotic gene Bas expressed specifically in prostate cells 
causing cell death in vitro and reduction in tumour volume in vivo 
 Rat probasin specific expression of HSV/tk, growth suppression of 
AI tumours  
(Yu et al. 1999, 
Zhang, Yu, et al. 
2002, Furuhata 
et al. 2003) 
PSE (PSA 
promoter/enhanc
er)  
 Nitroreductase gene expression placed under the control of PSE 
was detected in PSA+ cells and was inducible by androgens, 
comparable expression to CMV  
(Latham et al. 
2000) 
Chimeric promoters 
PSMA/PSES   E1A gene expression controlled by PSMA/PSES, replication 
restricted to prostatic AI cells and cell killing of PSMA+ cells in 
vitro and in vivo 
  E1A and E4 expression controlled by PSMA/PSES drove prostate 
specific cell killing in vitro and in vivo  
(Lee et al. 2004, 
Li et al. 2005) 
PPT (PSMA 
enhancer/PSA 
enhancer/T cell 
receptor gamma 
chain)  
 Used to drive a luciferase reporter, demonstrated high prostate 
specificity and high expression levels with and without 
testosterone in vitro and in vivo. Higher activity than CMV 
promoter following I.V administration  
(Cheng et al. 
2004) 
 
1.6.2.4.1 Arming adenoviruses with therapeutic 
transgenes 
1.6.2.4.1.1 Tumour suppressor protein p53 
Introduction of a therapeutic tumour suppressor gene or abrogation of an 
oncogene that specifically targets tumour cells is an attractive prospect for gene 
therapy. p53 is the most widely used tumour suppressor gene in viral gene 
therapy, as it is one of the most commonly mutated genes in cancer. In fact, p53 
mutations have been identified in 50% of human cancers with a total of 25,000 
mutations currently reported (Chen et al. 2014). Ordinarily p53 induces cell cycle 
arrest, senescence and apoptosis in response to DNA damage and other stress 
signals. Mutation of p53 therefore plays an important role in malignant cell 
progression, suggesting restoration of wild type p53 may be an effective antitumor 
therapy. Several studies utilising adenoviral vectors to introduce p53 as a therapy 
have demonstrated dramatic cell death via apoptosis and cell cycle arrest in 
human glioma and glioblastoma cells in vitro and inhibited tumour growth in vivo 
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(Gomez-Manzano et al. 1996, Gomez-Manzano et al. 1997, Köck et al. 1996). The 
first marketable p53 based adenoviral vector was named Gendicine and was 
approved by the food and drug administration (FDA) in China on 16th October 
2003 for head and neck squamous cell carcinoma treatment. Gendicine is a 
replication deficient Ad5 virus where the E1 region has been replaced by wild-type 
p53, linked with a Rous sarcoma virus (RSV) promoter. Gendicine functions by 
triggering apoptotic pathways, activating immune responses, inhibiting DNA repair 
and blocking survival signals (Chen et al. 2014). Gendicine has been clinically 
proven in a number of clinical trials with limited side effects, including fever. 
Evidence also suggests benefits of p53 mediated therapy include mobilising the 
host’s immune system. However, low transduction rate of p53 from a replication 
deficient viral vector limits the effectiveness of this therapy. Replicating viruses 
were therefore developed using cancer-related gene promoters to enhance E1-
dependent viral replication and induce higher p53 expression as a consequence. 
The adenovirus E1B55K protein binds to and blocks p53 function, preventing p53-
induced cell death and apoptosis (Wiman 2007), and promotes viral replication as 
a result. One of the best and well studied of these replicating viruses is ONYX-015 
(discussed previously section 1.6.2.2). ONYX-015 has the E1B55K gene deleted 
and can therefore only replicate in cells with a deregulated (inactivated) p53 
pathway. Numerous clinical trials have demonstrated the low efficacy of ONYX-
015 for the treatment of numerous advanced cancers, including head and neck 
cancer. Poor efficacy of this virus for use as a single agent and varied response 
rates from patients led to the development and licensing of the novel H101 virus 
(described previously section 1.6.2.2).  
Despite proven efficacy and approval of both Gendicine and H101 these viruses 
are still not widely used due to poor efficacy and transport to metastatic sites. 
Ways to improve efficacy and delivery to metastatic sites must be explored to 
improve the clinical impact of these viruses on PCa treatment. 
1.6.2.4.2 Re-targeting and de-targeting of 
adenoviruses 
As mentioned previously (section 1.6.1.4.1), CAR plays a major role in virus cell 
attachment and internalisation. However, adenoviral vectors are inefficient at 
infecting cells in vivo due to neutralisation by pre-existing antibodies. A growing 
body of evidence has suggested that CAR may not be the primary receptor in vivo. 
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Type C adenoviruses have been shown to infect cells that do not express CAR, or 
express it in very low levels in the airway, liver and lymphocytes (Arnberg 2009). 
This suggests that receptors additional to CAR are responsible for adenoviral 
infection. Therefore, genetically engineering adenoviruses to modify their cellular 
receptors offers the opportunity to retarget adenovirus based on cell type specific 
receptors. Two approaches have been used to achieve this: 1) adapter based 
targeting strategies and 2) genetically modifying the capsid (Beatty and Curiel 
2012). 
The adapter based strategy utilises a molecular bridge to retarget the adenovirus 
from its primary receptor to a different cell surface receptor. The most common 
location to adapt the Ad virion is the fiber knob domain, as this allows retargeting 
of vectors, whilst de-targeting adenovirus from its primary CAR receptor. 
Conversely, genetic modification of the adenovirus capsid to retarget ligands has 
been widely investigated.  
1.6.2.4.2.1 Small RNAs 
More recently, studies have taken advantage of the gene silencing mechanisms of 
microRNAs (miRNAs) to control viral replication. miRNAs are small non-coding 
RNA molecules, typically 20-24 bp in length that target and bind specific mRNA 
sequences. Binding results in the catalytic degradation of the target mRNA. This 
method has been utilised to attenuate viral potency to normal tissue, e.g. the liver, 
while wild-type efficacy can be maintained at the tumour sites that do not express 
the relevant miRNA. This was demonstrated when four miRNA122 binding sites 
were inserted into the 3’ UTR of E1A driving luciferase, inclusion of these sites 
caused an 80-fold decrease in luciferase expression in hepatocytes after 
intravenous injection in comparison to wild-type virus (Cawood et al. 2009). Leja 
et.al showed similar results by producing AdCgA-E1A-miR122, an miR122 
targeted oncolytic adenovirus, where E1A gene expression fused to luciferase was 
placed under the control of the chromogranin A (CgA) promoter, with 6 or 12 
repeats of miR122 binding sites in the 3’ UTR of luciferase. CgA is highly 
expressed in neuroendocrine tumours and is used as a sensitive tumour marker. 
Lower E1A expression in murine normal hepatocytes was demonstrated following 
intravenous injection with AdCgA-E1A-miR122 than with wildtype virus. Repeated 
injection of AdCGA-E1A control virus, lacking the miR122 repeats induced liver 
toxicity in mice, whereas AdCgA-E1A-miR122 injection did not have the same 
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effect. This suggests that a combination of a specific transcriptional promoter with 
a post-transcriptional miRNA target will allow higher doses of virus to be 
administered, whilst avoiding off-target liver toxicity (Leja et al. 2010). More 
recently this method has been applied to replication incompetent adenoviruses 
where four repeats of miRNA122 binding sites were inserted into the 3’ UTR of the 
E2A, E4 or pIX genes. Non-specific expression of these genes was suppressed 
from 2 to 100-fold compared with wildtype virus. In particular, the vector carrying 
miRNA122 binding sites targeted to the E4 gene suppressed E4 gene expression 
in the liver, resulting in significantly reduced hepatotoxicity (Shimizu et al. 2014). 
This adds to mounting evidence for the use of tissue-specific miRNAs to inhibit 
unspecific expression of viral genes, reducing off-target side effects as a result. 
1.6.2.4.3 Genetic modification of the adenoviral 
capsid 
1.6.2.4.3.1 Chimeric adenoviruses 
An alternative method to re-targeting adenoviral infection involves genetically 
modifying the adenovirus virion to bind different ligands. It is essential to ensure 
that genetic engineering of the viral capsid does not interfere with capsid 
assembly. Thus, efforts have focussed on genetic manipulation of the fiber 
domain, the primary determinant of Ad infection. As previously mentioned, CAR is 
the primary receptor to most adenovirus serotypes excluding serotype B (Table 6). 
Studies have therefore focussed on utilising serotypes with alternative target cell 
receptors, for example CD46 in B serotype adenoviruses. The entire fiber of Ad5 
is genetically replaced with its structural counterpart from a different adenoviral 
serotype and has shown great efficacy in a number of Ad5 resistant cancer types 
including ovarian (Rein et al. 2011) and prostate (Murakami et al. 2010). These 
viruses can include shaft and knob domains from different adenovirus species, for 
example the knob domains of Adv-3, Adv-11 or Adv-35 together with Adv-5 
(Murakami et al. 2010). Chimeric adenoviruses have even advanced to 
incorporate nonhuman Ad serotypes, however the majority of targets for these 
vectors are still undetermined. 
1.6.2.4.3.2 Peptide targeted adenoviruses 
Studies of the adenoviral fiber knob domain have highlighted two separate 
locations that can be genetically engineered to present different cellular peptides 
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without disruption of fiber function. The first of the two regions is the C-terminus. 
Insertion of an integrin binding RGD motif into this area has previously yielded 
positive results in vitro and in vivo (Wickham et al. 1997). The second region that 
can be genetically engineered is the HI loop. This domain is an exposed loop 
structure connecting β-sheets H and I in the Ad knob domain that can handle 
peptide insertions of up to 100 amino acids without affecting the knob domain. 
Dimitriev et al. Inserted an integrin-binding RGD motif into the HI loop (Dmitriev et 
al. 1998), this virus enhanced efficacy and gene delivery in ovarian cancer cell 
lines (Murugesan et al. 2007). Several groups have also inserted cell-specific 
peptides into the HI loop that are highly specific, to target a range of cancers 
including Hsp47 targeted therapy for head and neck cancer (Li et al. 2008) and 
EGFR targeted therapy for glioma (Piao et al. 2009) 
1.6.2.5 Adenoviral GDEPT clinical trials for PCa 
Over the past decade gene therapy clinical trials have accelerated from the use of 
replication defective adenoviruses that contain a single therapeutic gene, to 
replication-competent oncolytic adenoviruses lacking a therapeutic gene, and 
most recently to oncolytic adenoviruses that contain multiple therapeutic genes. 
These therapies have been trialled as single agents and in combination with 
radiotherapy for the treatment of localized PCa. Replication-competent viruses 
have replaced replication deficient viruses due to their cytolytic activity, 
demonstrable specific anti-tumour activity and safety, high copy number 
replication, resulting in higher transgene expression, and a greater ability to 
spread only within the tumour.  
These trials have also included the use of replication-selective adenoviruses for 
PCa gene therapy, relying on intraprostatic delivery of the virus in combination 
with 5-FC/GCV and intensity-modulated radiotherapy. The most effective 
therapies have included expression of both CD and mutTK in a replication-
competent Adenovirus, whereby CD and mutTK expression is under the control of 
the constitutively active CMV promoter. These transgenes were inserted in the E1 
region and the adenoviral death protein was present in the E3 region. (Freytag et 
al. 2007, Barton et al. 2006), that in one case have demonstrated transgene 
expression for up to 5 months (Barton et al. 2008). Similarly, encouraging results 
were obtained in a Phase I trial that utilized the wild-type HSV-1-TK gene (Herman 
et al. 1999). Only one in 18 patients (6%) suffered from specific treatment related 
  106 
 
toxicity, potentially attributable to leakage of the virus into the systemic circulation. 
Moreover, PSA levels decreased by 50% in 17% of patients, lasting more than a 
year in one case.  
A number of gene therapy trials have used adenoviral vectors expressing HSV-tk 
in combination with ganciclovir for high risk localised and locally recurrent PCa 
(Nasu et al. 2007). Two phase I/II trials replaced the E1 gene with restricted 
expression of HSV-tk using the Osteocalcin promoter, a major bone matrix protein 
expressed prevalently in PCa epithelial cells, for the treatment of metastatic PCa 
(Kubo et al. 2003, Shirakawa et al. 2007), but were not efficacious enough for 
further studies.  However, despite increasing evidence of safety and efficacy, 
these viruses have never moved past phase III clinical trials. A summary of some 
of the adenoviral gene therapy clinical trials for PCa can be seen in Table 10. 
Whilst hundreds of adenoviral gene therapy systems have been clinically tested, 
only Gendicine and H101 are licensed cancer treatments. However, these viruses 
are still not used worldwide for standard treatment. Although adenoviral vectors 
still remain the most promising and widely used gene therapy platform, problems 
still lie with generating efficacy. Steps to improve this, including the use of TSP’s, 
targeting oncolytic viruses to cancer cells thorough modifications to viral proteins 
and improving transduction through altering surface molecules of adenovirus 
receptors have all enhanced the efficacy of many gene therapy strategies. 
Nonetheless, further modifications need to be performed in order to generate a 
vector with enhanced transduction that retains its cancer cell specificity, in order to 
produce an effective gene therapy system for cancer. 
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Table 10 Recorded adenoviral gene therapy clinical trials for PCa (http://www.abedia.com/wiley/). 
Phase Trial description Result Admin Transgene Ref 
I Adenovirus-mediated suicide gene therapy for PCa No virus related cytopathic effect could be observed. Dose-dependent infiltration of T and B 
lymphocytes in the whole prostate and in tumour areas was observed. Boosting of adenovirus-
specific antibody responses was observed in 7 patients, and an increased adenovirus-specific 
PBMC proliferation and IFN-gamma production was seen after Adv-HSV-tk stimulation. 
I.T HSV-tk (van der Linden et al. 
2005) 
I Trial of Adenoviral-Mediated Herpes Simplex 
Thymidine Kinase Gene Transduction in 
Conjunction with Ganciclovir Therapy as Neo-
adjuvant Treatment for Patients with Clinically 
Localized (Stage T1c and T2b&c) PCa Prior to 
Radical Prostatectomy 
Produced limited toxicity and evidence of antitumor activity following injection of the prostate. 
Furthermore, this system has been shown to direct systemic antitumor activity in several 
experimental cancer models, including that of PCa, which may serve as the basis for in-situ 
immunomodulatory gene therapy. In a mouse model of PCa, natural killer (NK) cells have been 
identified as the mediator of anti-metastatic activity following Ad-HSV-tk + GCV, resulting in the 
combination of Ad-HSV-tk and adenovirus-mediated expression of interleukin 12 (Ad.IL-12) 
I.T HSV-tk (Hassan et al. 2000) 
I AdUP: A replication defective type 5 adenovirus 
vector expressing nitroreductase and GMCSF 
(AdNRGM) followed by intravenous CB1954, in 
patients with locally relapsed hormone-refractory 
PCa 
Ongoing- initiated in 2013 the gene therapy is based on the intraprostatic injection of a viral 
vector (AdNRGM) carrying the GMCSF gene, which is able to induce a strong immune response 
against the PCa, and nitroreductase which is able to CB1954 (prodrug) to a powerful anti-cancer 
drug. 
I.T NTR/GMCSF (Crack 2013) 
I Ad-OC-TK Plus Valacyclovir for the Treatment of 
Metastatic or Recurrent PCa 
One prostate-specific antigen (PSA) response (from 318.3 to 4.9 ng/ml) was observed with a 
time to PSA progression (TTP) of 12 months. Docetaxel (30 mg/m
2
 per week) and estramustine 
(560 mg/day). Combination chemotherapy (DE) was given to three docetaxel-naive patients on 
PSA failure after gene therapy. All three patients had a PSA response to DE therapy with 21, 7, 
and 4 months of TTP. These results suggest that additional trials are warranted. 
I.T TK/VAL (Shirakawa et al. 2007) 
I Combined Suicide Gene Therapy and Radiation 
Therapy for Locally Advanced Carcinoma of the 
Prostate. 
The results demonstrate that replication-competent adenovirus-mediated double-suicide gene 
therapy can be combined safely with conventional-dose 3D-CRT in patients with intermediate- to 
high-risk PCa. 
I.T CD/HSV- TK (Freytag et al. 2003) 
I E1B-Attenuated Replication Competent Adenovirus 
Vector containing the E. coli Cytosine 
Deaminase/HSV-1 Thymidine Kinase Fusion Gene 
in Conjunction with Two Prodrugs, 5-Fluorocytosine 
and Ganciclovir for Patients with Local Recurrence 
of PCa after Radiation Therapy 
Seven of 16 (44%) patients demonstrated a >or=25% decrease in serum prostate-specific 
antigen, and 3 of 16 (19%) patients demonstrated a >or=50% decrease in serum prostate-
specific antigen. Transgene expression and tumour destruction at the injection site were 
confirmed by sextant needle biopsy of the prostate at 2 weeks. Two patients were negative for 
adenocarcinoma at 1 year follow-up. 
I.T CD/HSV- TK (Freytag et al. 2002) 
I CV706 Replication-competent, adenovirus lacking 
therapeutic gene, E1A gene driven by PSA 
promoter, no E3 region genes 
Short term—low toxicity, no DLTs, no MTD up to 1 × 1013 vp; encouraging PSA responses, five 
objective (25%) responses  with one lasting 11 mo. Possible dose effect 
I.T - (DeWeese et al. 2001) 
I Study of Adenoviral Vector Delivery of the HSV-tk 
Gene and the Intravenous Administration of 
Ganciclovir in Men with Local Recurrence of PCa 
after Radiation Therapy 
Three patients achieved an objective response, one each at the three highest dose levels, 
documented by a fall in serum PSA levels by 50% or more, sustained for 6 weeks to 1 year. This 
study is the first to demonstrate the safety of ADV/HSV-tk plus GCV gene therapy in human PCa 
and the first to demonstrate anticancer activity of gene therapy in patients with PCa. 
I.T Hsv-tk (Herman et al. 1999) 
I RTVP-1 gene therapy for PCa prior to radical 
prostatectomy 
Toxicities included urinary tract infection, flu-like syndrome, fever, dysuria and photophobia. No 
pathologic complete remission was seen. Morphologic cytotoxic activity, induction of apoptosis 
and nuclear p27
Kip1
 upregulation was observed. Preliminary evidence suggests anti-tumour 
activity and systemic immune response. 
I.T RTVP-1 (Sonpavde et al. 2011) 
I Ad5-CMV-NIS  therapy for locally recurrent PCa that 
did not respond to external-beam radiation therapy 
The study is currently ongoing in human trials- experiments in canines demonstrated no vector-
related toxicity and evidence of safety and efficacy. 
I.T NIS  (Dwyer et al. 2005) 
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I/II Gene therapy in patients with PCa Study ongoing Previous studies have demonstrated suppressed tumour growth in mouse models 
of prostate, breast and testicular cancer. Ad-REIC up-regulates systemic anti-cancer immunity. 
I.T REIC/Dkk-3 (Edamura et al. 2007) 
I/II Gene directed enzyme prodrug therapy for the 
treatment of PCa 
No correlation between pre-existing immunity or the magnitude of the immune response to vector 
and the clinical outcome as measured by changes in serum prostate-specific antigen (PSA) level. 
Increased frequency of T cells recognizing prostate-specific antigens PSA or prostate-specific 
membrane antigen (PSMA) was detected in 3 of 11 patients after therapy, suggesting that this 
direct cytotoxic strategy can also stimulate tumour-specific immunity. 
I.T NTR + cb1954 (Onion et al. 2009) 
(Patel et al. 2009) 
I/II Study Evaluating HSV-tk + Valacyclovir Gene 
Therapy in Combination with Radiotherapy for PCa 
Biopsy data was encouraging and appeared to show no evidence of malignancy earlier than 
historical data. Combined RT, short-course hormonal therapy, and in situ therapy appeared to 
provide good locoregional control but inadequate systemic control in patients with positive pelvic 
lymph nodes. 
I.T HSV/TK (Teh et al. 2004) 
I/II Combination with IMRT Versus IMRT Alone for the 
Treatment of Newly-Diagnosed Intermediate-Risk 
PCa 
Forty-four men with intermediate-risk PCa were randomly assigned to receive either OAMCGT 
plus IMRT or IMRT only. There was a 60% relative reduction in biopsy positivity. None of the 
patients developed hormone-refractory or metastatic disease and none have died from PCa. 
Now entered phase III clinical trials 
I.T CD/HSV/TK (Freytag et al. 2014) 
I/II HSV-TK + Valacyclovir in combination with 
Brachytherapy for recurrent PCa without metastatic 
disease 
Ongoing trial- Awaiting results I.T HSV/TK  
III A Randomized Controlled Trial of ProstAtak? as 
Adjuvant to Up-Font Radiation Therapy for Localized 
PCa 
Ongoing trial- Awaiting results I.T TK  
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1.7 Research rationale 
Localised PCa it currently treated in the UK through watchful waiting or active 
surveillance in order to avoid ‘overtreatment’, which can be incurred through 
invasive therapies, including radical prostatectomy and radiotherapy. However, as 
PCa progresses, treatment with ADT, including medical castration and AR 
antagonists, results in reactivation of the AR signalling pathway, leading to a 
hormone resistant cancer phenotype. Treatment of this castration resistant 
phenotype with chemotherapeutics is a palliative measure, eventually becoming 
ineffective, resulting in an urgent need for novel therapeutics that target CRPC. 
Many studies have demonstrated the efficacy of GDEPT and have moved on to 
restrict expression of this therapy through prostate TSPs, providing a safer 
treatment strategy for PCa. Whilst targeting GDEPT specifically to PCa cells 
improved efficacy, traditional prostate specific promoters were inherently weak, 
resulting in poor transduction. Steps were therefore taken to improve transduction 
through the use of TSTAs (Zhang, Adams, et al. 2002), and fusion of upstream 
regulatory elements, forming chimeric promoters (Latham et al. 2000, Schuur et al. 
1996).  
Whilst these later promoter systems have demonstrated some improved efficacy, 
they are relatively ineffective in androgen-independent cancer, due to the 
requirement for AR binding to AREs in their regulatory regions. TMPRSS2 is an 
androgen regulated gene; its regulatory elements are commonly fused to ERG in 
50% PCa cases (Tomlins et al. 2005), forming the TMPRSS2:ERG fusion, the 
most common fusion gene in human malignancy. The role of TMPRSS2:ERG in 
PCa progression has not yet been fully elucidated and contradictory reports 
suggest that it may be involved in malignant cell progression (Li et al. 2011, 
FitzGerald et al. 2008). Despite this, it is clear is that ERG expression through 
TMPRSS2:ERG fusion remains high in CRPC (Cai et al. 2009), suggesting that 
the regulatory elements of TMPRSS2 can still function throughout castration 
resistance. Utilising these regulatory elements to restrict GDEPT to PCa cells may 
offer a novel therapy that is functional in both localised and castration resistant 
PCas.   
We therefore hypothesised that the regulatory elements of TMPRSS2 could offer a 
novel method with which to target PCa. We proposed to restrict the expression of 
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the CD/UPRT suicide gene through TMPRSS2 regulatory elements, whilst 
additionally increasing transgene expression using a TSTA system.  We therefore 
cloned the TMPRSS2-VISA-CD/UPRT expression cassette, whereby expression 
of the CD/UPRT suicide gene was under the control of the TMPRSS2 promoter 
region upstream of exon1, with enhanced transcriptional activation due to the 
VP16-GAL4-WPRE integrated systemic amplifier (TMPRSS2-VISA-CD/UPRT). 
We proposed to replace the adenoviral E1 and E3 regions with the 5.7 kb 
TMPRSS2-VISA-CD/UPRT expression cassette, producing a replication defective 
adenovirus that targets PCa cells specifically, in order to improve safety and 
transduction. To improve upon this system further, we aimed to clone a novel 
chimeric TMPRSS2 regulatory element, consisting of two regulatory elements 
upstream of Exon1 and Exon2 and compare its promoter activity to that of the 
more traditionally used PSA promoter. We further hypothesised that fusion of two 
regulatory elements of TMPRSS2 would drive higher levels of prostate specific 
expression than any previously validated TSP. 
1.7.1 Previous work 
Three putative TMPRSS2 promoters were identified from a combination of a 
review of the literature (Wang et al. 2007, Lin et al. 1999) (Figure 24) and use of 
the online software tool Genomatix promoter prediction (http://www.genomatix.de). 
The three promoters were inserted into the VISA vector (a kind gift from Professor 
Hung, MD Anderson, TX, USA), replacing the CCKAR promoter, and named L-
VISA, W-VISA, and G-VISA (Table 11) (Kevin Sharp, our team, unpublished data). 
Tissue specific expression and promoter activity was analysed in these vectors by 
employing the luciferase gene as the gene of interest in 22RV1, HEK293, PC3 
and LNCaP cells. 
 
 
 
  
Figure 24 Genomic position of each of the TMPRSS2 promoters used.  
L-VISA (L) sequence position circled upstream of exon 2 (horizontal line) G-VISA (G) 
sequence position circled upstream of exon 2 (horizontal line) W-VISA (W) sequence 
position circled upstream of Exon1 (horizontal line).   
  111 
 
Table 11 Three TMPRSS2 promoters explored in the VISA-amplification vector and 
the respective location on chromosome 21. 
Construct 
name 
Source Description Position on Chr:21 Length 
(bp) 
G-VISA Genomatix 
software 
Promoter region 
upstream from Exon2 
41791831-41792406 576 
L-VISA Lin et al (Lin et al. 
1999) 
Promoter region 
upstream from Exon2 
41791861-41793048 1,188 
W-VISA Wang et al (Wang 
et al. 2007) 
Promoter region 
upstream from Exon1 
41801925-41802935 1,011 
 
The W-VISA promoter demonstrated the strongest activity in all cell lines tested, 
including the AR-positive cell line LNCaP. However, this promoter specificity was 
compromised due to non-specific luciferase expression detected in HEK293 and 
PC3 cells. L-VISA appeared to be the most promising candidate as it showed 
tissue specificity in the AR-positive PCa cell line 22RV1, along with significantly 
stronger expression of luciferase than G-VISA in 22RV1 cells; however this was 
not the case in any other cell line (Table 12). 
Table 12 Luciferase activity of the three TMPRSS2 promoter regions inserted in the 
VISA-vector and transfected into PCa and non-PCa cell lines. 
Vector Cell line Mean Standard 
Deviation 
t-stat (versus 
HEK293) 
p-value (versus 
HEK293) 
G-VISA 22RV1 248 55 10.8 0.0001 
 LNCaP 5 3 0.4 0.3457 
 PC-3 1 1   
 HEK 293 5 2   
L-VISA 22RV1 362 84 10.4 0.0001 
 LNCaP 7 4 0.9 0.1855 
 PC-3 1 1   
 HEK 293 5 2   
W-VISA 22RV1 771 223 4.8 0.0011 
 LNCaP 257 148 0.5 0.3061 
 PC-3 122 68   
 HEK 293 295 95   
Mean values and standard deviation measurements refer to firefly luciferase/ renilla 
luciferase. Values are representative of two independent experiments, each consisting of 
triplicate wells. t-stat and p-value assess whether there is a statistically significant 
difference between the expression levels from 22RV1 and LNCaP and the most active 
negative control, HEK 293, using each of the different VISA constructs.  
L-VISA was taken forward for further studies because it showed the most 
promising specificity, while still driving high levels of luciferase expression. The 
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poor luciferase expression in LNCaP cells was assumed to be due to difficulties in 
transfection of this cell line. The luciferase gene was replaced with the CD/UPRT 
suicide gene and cell specific killing was demonstrated upon the addition of 5-FC 
pro-drug in 22RV1 cells alone (Ahmet Imrali, our team, unpublished observations) 
(Figure 25).  
 
Figure 25 Decrease in cell viability after addition of pro-drug in combination with the 
L-VISA plasmid 
The L-VISA plasmid was transfected into 22RV1 cells and treated in combination with 
three different doses of drug at 0.1, 0.01 and 0.001 mg/ml over six replicates. Cell viability 
was measured after 72 hours by MTS assay. Cell viability decreased with increasing 
concentration of 5-FC. Data generated by Ahmet Imrali, our team, unpublished 
observations. 
Ad5-TV-CU was constructed (Ahmet Imrali, our team, unpublished observations), 
but showed no expression of CD/UPRT protein after infection in 22RV1 or LNCaP 
cells, as well as no dose dependent shift in EC50 values when the virus was 
combined with 5-FC.  
In summary these results demonstrate that the TMPRSS2 promoter can be 
utilised to drive high level prostate specific expression of a luciferase transgene. 
Replacement of the luciferase transgene with the CD/UPRT gene and addition of 
22RV1
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increasing doses of 5-FC drove enhanced prostate cell specific killing in a 5-FC 
dose dependent manner. This evidence suggested that this system could be 
utilised as a novel enzyme prodrug therapy for the treatment of PCa.   
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1.8 Aims of this thesis 
This research project was conducted with the aim of utilising the AR regulated 
TMPRSS2 promoter to drive tissue specific suicide gene therapy in PCa cells. 
Specific systems to enhance the promoter activity and the ability to deliver the 
gene into cells were developed to increase transduction and efficacy of the 
therapy. Based on previous unpublished findings generated in our team the 
following steps to produce the optimal therapy were investigated. 
1. Exploring the potential for amplification of the optimal TMPRSS2 promoter 
construct, by insertion in the VISA amplification system and using a 
replication-deficient adenovirus for efficient transduction in all available 
PCa cell lines, and transformed prostate cells. 
2. Comparing the TMPRSS2 promoter to other prostate-specific promoters, 
including the ‘classical’ PSA promoter constructed in the same system.  
3. Investigating the cell line specificity and 5-FC dose dependent activity of 
this gene directed enzyme prodrug therapy using a replication-deficient 
virus construct in vitro, including castration-resistant LNCaP-CDXR3 and 
LNCaP-104R1 cells. 
4. Investigating the efficacy of this replication-deficient virus in vivo in 
combination with 5-FC. 
5. Comparing a range of TMPRSS2 promoter regions and producing chimeric 
promoters to increase specific promoter activity. 
Therefore, in this thesis I produced and characterised the replication deficient Ad5-
TMPRSS2-VISA-CD/UPRT (Ad5-TV-CU) virus, whereby transgene expression 
was placed under the control of TMPRSS2 regulatory elements to drive prostate 
specific expression of the CD/UPRT suicide gene. This PCa specific enzyme 
prodrug therapy was evaluated in vitro and in vivo for efficacy and prostate 
specificity. I also sought to clone a new chimeric TMPRSS2 promoter, with 
superior promoter activity and prostate specificity compared to the previously 
validated TMPRSS2 and PSA promoters. 
 
CHAPTER 2  
 
 
 
MATERIALS AND METHODS 
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2.1 Cell lines and cell culture. 
2.1.1 Cell Culture. 
The PCa cell lines, 22RV1, LNCAP, VCaP, DU145 and PC3 were obtained from 
American type culture collection (ATCC). Normal human prostate epithelial cell 
lines (PrEC) were purchased from LONZA. Two SV40-immortalised prostate 
epithelial cell lines PNT1a and PNT2 were obtained from Norman Maitland and 
Colin Cooper, respectively. The LNCaP sublines LNCaP-104-S (androgen-
sensitive) and the androgen ablation-resistant and bicalutamide-resistant cells 
LNCaP-104-R1 and LNCaP-CDXR3 respectively, were a generous gift from Dr 
John M. Kokontis (University of Chicago, Chicago, USA). Molecular status of these 
cell lines, including p53, TMPRSS2:ERG fusion, and cell type are described in 
Table 13.  
The transformed human embryonic kidney (HEK293) cell line was used for primary 
viral expansions, as well as a negative control for transfection experiments, as 
they do not express the androgen receptor (AR). These cells have been 
transformed with the first 4344 nucleotides of Ad5, and therefore express the E1 
gene, providing the basis for viral replication of mutants not expressing E1A. 
JH293 cells are a sub-clone of HEK293s and were used for tissue culture infected 
dose (TCID50) assays. Both HEK293 and JH293 were obtained from Cancer 
Research UK Cell Services. All experiments were carried out using cells between 
3 and 30 passages. All PCa cells, as well as HEK293 and JH293 cells, were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
fetal calf serum (FCS) (PA laboratories UK), with the exception of PC3, PrEC, 
LNCaP-CDXR3 and LNCaP-104-R1. PC3 cells were grown in Roswell Park 
Memorial Institute (RPMI) supplemented with 10% FBS. The LNCaP cell lines 
LNCaP-104-R1 and LNCaP-CDXR3 were cultured in DMEM supplemented with 
10% charcoal-stripped FBS (Sigma Aldrich). All three LNCaP cell lines were 
supplemented with 0.2nM DHT. Medium for LNCaP-104-S, LNCaP-104-R1 and 
LNCaP-CDXR3 cells was changed every 2-3 days if cells were not passaged. The 
normal PrEC cells were grown in specialised media (PrEBM) according to the 
manufacturer’s instructions (Lonza). All cells were grown at 37°C in a humidified 
atmosphere with 5% CO2. All cell lines were short tandem repeat (STR) profiled to 
  117 
 
confirm the cell line and vials of STR profiled cells frozen down and stored in liquid 
nitrogen to form long term stocks and avoid cross-contamination. 
22RV1 cells obtained from ATCC have previously been shown to test positive for 
the presence of replication-competent xenotropic murine leukemia virus-related 
virus (XMRV) (Knouf et al. 2009). XMRV is associated with prostate 
carcinogenesis most frequently in men with a defect in the antiviral defense protein 
RNase L. This discovery could potentially impact the interpretation of experimental 
results. 
2.1.2 Cell storage. 
Cells were stored in liquid nitrogen in 10% dimethyl sulfoxide (DMSO), 20% FCS 
and 70% respective culture medium. PrEC cells were stored in 10% DMSO, 10% 
FCS and 80% clonetics PrEBM media (Lonza). Cells were revived by thawing in a 
37°C water bath and immediately adding in a drop wise manner to 10 ml full (10% 
FCS, 1% penicillin/streptomycin) pre-warmed DMEM (22RV1, LNCaP, DU145, 
VCaP, HEK293, LNCaP-104-S),  full RPMI (PC3), PrEBM (PrEC cells), or DMEM 
containing 10% charcoal stripped media (LNCaP-CDXR3 and LNCaP-104-R1). 
The cells were pelleted by centrifuging at 1200 rpm for 5 min and then 
resuspended in 2 ml of culture media. All cells were then added to a T75 flask 
containing 10 ml of pre-warmed culture media and incubated under standard 
conditions (37ºC humidified atmosphere with 5% CO2).  
2.1.3 Cell maintenance. 
Cells were sub-cultured every 3-5 days, or when they reached 80-90% confluency, 
by washing with 10 ml phosphate buffered saline (PBS) and addition of 2 ml 1x 
trypsin EDTA to detach cells. Trypsin was deactivated by the addition of 5 ml of 
culture media. The cells were finally split 1 in 5 by taking 1/5th of the cell 
suspension and adding to a new flask with fresh culture media (22RV1, DU145, 
HEK293, PC3, PNT2, PNT1A LNCaP). VCaP cells were cultured every 7 days 
using the same protocol but splitting the cells only 1:3. PrEC cells were 
subcultured every 7 days with media changes every 3 days. Cells were washed 
with 10 ml hepes buffered saline solution and then 3 ml 1x trypsin EDTA was 
added to detach the cells. Trypsin was deactivated by adding 6 ml trypsin 
neutralising solution (TNS) and the cell pellet spun down at 1200 rpm for 5 min. 
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The cell pellet was resuspended in 6 ml of PrEBM media, and the cells split 1:3 
into flasks containing pre-warmed PrEBM.  
2.1.4 Cell counting. 
Cells were left to grow to 80% confluency and trypsinised. The trypsin was 
neutralised by addition of 5 ml 10% FCS DMEM/RPMI and spun at 1200 rpm for 5 
min. The cell pellet, 6x106 cells, was resuspended in 20 ml of respective culture 
media and 10 μl of cell suspension added to 10 μl of trypan blue (Sigma Aldrich, 
USA). 10 μl of the solution was added to a cell counting slide, counted using the 
biorad cell counter system and seeded at the appropriate density for the 
experiment using the following equation. 
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Table 13 Cells status and origin 
 22RV1 VCaP DU145 PC3 LNCaP PrEC PNT2 PNT1A 
Origin Primary tumour from CRW33Rv 
xenograft serially passaged in 
mice 
Metastatic tumour in 
the lumbar vertebral 
body xenografted on 
SCID mice 
Carcinoma brain 
metastasis 
Grade IV 
adenocarcin
oma bone 
metastasis 
Carcinoma 
supraclavicular lymph 
node metastasis 
Primary 
prostate 
epithelial cells 
Normal prostate 
epithelium 
immortalized with 
SV40. 
Normal prostate 
epithelium 
immortalized 
with SV40. 
Androgen 
dependency 
A.I 
Sensitive 
A.I 
Sensitive 
A.I A.I A.D 
Sensitive 
A.D N/A N/A 
TMPRSS2:ERG - + - - - - - - 
AR status Three mutated types full length 
AR Ex
3dup
 and constitutively 
active truncated AR
1/2/2b 
and 
AR
1/2/3/2b
 
Wild type amplified 
gene locus and 
AR
1/2/2b
 
- - Full length mutated 
T877A converts 
antagonist flutamide into 
agonist 
Wild type Wild type Wild type 
p53 status Mutated (Q331R) Mutated (A248W) Mutated (P223L 
and V274F) 
Stop codon 
at 169 
Wild type Wild type Wild type Wild type 
PTEN + + + - - + + + 
AKT + + + + + + Unknown Unknown 
BCL-2 ++ + - + + Unknown - Unknown 
Established 1999 2001 1978 1979 1980 N/A 1995 1991 
Reference Sramkoski, Pretlow et al. 1999 Korenchuk S et al 
2001 
Stone, Mickey et 
al. 1978 
Kaighn, 
Narayan et 
al. 1979 
Horoszewicz, Leong et 
al. 1980 
(Ltd 2014) (Berthon et al. 
1995) 
(Cussenot et al. 
1991) 
+=positive - = negative A.I= androgen-independent, A.D= androgen-dependent
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2.2 Cloning. 
2.2.1 PCR amplification of DNA 
20 ng of DNA was added to 1 μl 10 mM dNTPs, 5 μl 10x PCR buffer, 1 μl forward 
primer (10μM), 1 μl reverse primer (10μM) and 2 units taq polymerase. The final 
volume was made up to 50 μl with water and underwent 35 cycles of PCR. 
94 °C 5 min 
94 °C 30 sec 
60 °C 45 sec 
72 °C 2 min 
72 °C 2 min 
2.2.2 Restriction digest 
5 μl of DNA was added together with 10 units (1 μl) of each of the required 
restriction enzymes (New England biolabs, (NEB), Table 16). 3 μl of 1x BSA was 
added to each reaction as well as 3 μl of the specific 10x buffer for the enzyme, 1, 
2, 3 or 4 (NEB). The final volume was made up to 30 μl with water and left to 
digest at 37°C for 2 h. If the product then required blunting 4 μl 10 mM dNTPs was 
added with 1 μl blunt enzyme mix (100 mM KCl, 10 mM Tris-HCl(pH 7.4), 0.1 mM 
EDTA, 1 mM dithiothreitol, 0.1% Triton X-100 and 50% Glycerol) and 10mM 
dithiothreitol (DTT) and incubated at room temperature for 15 min and 
subsequently  heated to 70°C to inactivate the enzymes. Digested vectors were 
additionally treated with Antarctic phosphatase by addition of 3 μl Antarctic 
phosphatase buffer and 1 μl Antarctic phosphatase (NEB) to remove 5’ 
phosphatase groups, which consequently prevented self-ligation of the vectors. 
Digested products were then run on a gel for gel extraction or DNA product size 
analysis.  
2.2.3 Phenol:chloroform clean-up of DNA 
An equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added  to the 
DNA solution, mixed well and centrifuged at 10,000 rpm for 3 min.  The aqueous 
layer was transferred to a new tube and an equal volume of chloroform added, 
X34 
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mixed and centrifuged at 10,000 rpm for 3 min. The aqueous layer was again 
removed and 2.5 volumes of 100% ethanol and 1/10 volumes of 3 M NaAc added 
to the DNA and kept overnight (O/N) at -20°C. The solution was centrifuged at 
14,000 rpm for 20 min at 4°C and the supernatant decanted. 1 ml of 70% ethanol 
was added and incubated at room temperature (RT) for 5 min. The solution was 
centrifuged at 14,000 rpm at 4°C for 20 min, the pellet was dried and then 
resuspended in 30 μl of dH2O. 
2.2.4 Gel extraction protocol 
The gel was placed on a UV light box in the dark room and the DNA cut from the 
gel using a sharp scalpel. DNA was extracted using the QIAQUICK gel extraction 
kit (Qiagen, Germany). Briefly, the gel piece was weighed and three times the 
volume of buffer QG added to one volume of the gel. The gel was then warmed at 
50°C until it dissolved into the buffer. 1x gel volume of isopropanol was added and 
mixed and the solution added to a QIAquick column. The DNA was bound to the 
column by centrifugation at maximum speed for 1 min.  The column was washed 
with 750 μl of buffer PE and centrifuged for 1 min. The DNA was then eluted into a 
new microcentrifuge tube by addition of 50 μl of dH2O. 
2.2.5 Cracking gel protocol 
1 ml bacterial growth was spun down at 14,000 rpm. Cell pellets were 
resuspended in dH2O and a standard phenol/chloroform extraction protocol 
performed to obtain plasmid DNA. 5 μl DNA was loaded onto a gel and potential 
recombinants identified due to size differences. Potential recombinants were 
miniprepped (section 2.4.6) for further analysis.  
2.2.6 Miniprep 
Wizard® Plus SV Minipreps DNA Purification System, USA was used to miniprep 
bacterial DNA. 1-5 ml of bacteria were spun down and resuspended in 250 μl of 
cell resuspension solution and 250 μl of cell lysis solution added and mixed. 10 μl 
of alkaline protease was then added and incubated for 5 min at RT. 350 μl cell 
neutralising solution was added, inverted 4 times, and centrifuged for 10 min at 
RT. The cleared lysate was decanted into the spin column and centrifuged at top 
speed for 1 min at RT. 750 μl column wash solution was added and the tube 
centrifuged for 1 min. A further 250 μl column wash solution was added and the 
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tube centrifuged for 2 min. The column was transferred to a new eppendorf and 50 
μl dH2O added, the tube was spun for 1 min at RT to elute the bound DNA. 
2.2.7 Blue/white colony screening 
1 μl of PCR product, 2 μl of T4 DNA ligase reaction buffer, 2 μl pCR2.1 vector and 
1 μl express link T4 DNA ligase was made up to a total volume of 10 μl with sterile 
water. The ligation mixture was left at RT for 30 min and then transformed into 25 
μl TOP10 chemically competent cells (Invitrogen) and placed on ice for 5 min. 
Meanwhile, agar plates containing 100mg/ml ampicillin were spread with 40 μl of 
x-gal (40 mg/ml) and left to dry. After 5 min the transformed cells were 
immediately spread on the agar plates (ampicillin resistance gene is immediately 
expressed), the plates were inverted and incubated O/N at 37˚C. The following 
day white colonies (those containing the insert due to interruption of the lacZ 
gene) were picked and grown in lysogeny broth (LB) containing ampicillin, ready 
for miniprep and restriction digestion analysis. 
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2.3 The VISA plasmids. 
The PSA promoter was cut directly from the pDRIVE-PSA-hPSA plasmid 
(Invivogen) using Nco1 and Spe1 restriction enzymes and the PSA 
promoter/enhancer were PCR amplified from pDRIVE-PSA-hPSA using primers 
with SmaI and PmeI restriction sites (Table 14). The DNA was run on an agarose 
gel, extracted (section 2.4.4) and blunted by adding 4 μl 10 mM dNTPs, 1 μl blunt 
enzyme mix and 10mM DTT, incubated at RT for 15 min and ligated into E-VISA 
(empty VISA expression cassette) using the 3:1 cloning ratio (see below), 
producing P-VISA and PE-VISA. 
                                  
           
           
  
 
 
 
Plasmids were then sequenced using the primers listed below (Table 14) 
Table 14 PSA VISA plasmids sequencing primers 
PE-VISA sequencing P-VISA sequencing 
PSA1 TGAATGGCTGGGATGTGTC F2 VISA TCAGTAGAAATAGCTGTTCCAGTC 
PSA2 CTGGGTCCCCTCCTATCTCT PSA2 CTGGGTCCCCTCCTATCTCT 
PSA3 TGATCTTGGATTGAAAACAGACC  
PSA4 TTCTAGGTCCCGATCGACTG  
PSA5 GCACGTGAGGCTTTGTATGA  
 
2.3.1 The PGL3 plasmids. 
The N-PGL3 plasmid was previously made by ligating the NKAIN2 promoter into 
the empty PGL3 plasmid (our lab, Lara Boyd). S-PGL3 is a commercial plasmid 
containing the SV40 promoter (Promega, USA). The remaining PGL3 plasmids 
were made by PCR amplifying the various TMPRSS2 promoter elements from a 
combination of the L-VISA vector, the W-VISA vector and genomic DNA, using 
primers with appropriate flanking restriction sites (Table 15). The DNA was run on 
an agarose gel, extracted (section 2.2.4) and ligated into the pCR2.1 vector 
(Invitrogen). Colonies containing the inserts were miniprepped and sent for 
sequencing. The PCR products were digested from the pCR2.1 vectors using the 
appropriate restriction enzymes and ligated into complementary sites in the E-
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PGL3 plasmid (Table 16) using the rapid DNA ligation kit (Roche, Germany). 
Briefly, 5 μl of DNA ligation buffer, 1 μl DNA ligase and 1 μl of both the vector and 
insert were mixed in an eppendorf and left at RT for 5 min. Subsequently, the 
entire 10 μl of ligation mixture was added to 50 μl of TOP10 chemically competent 
cells and spread on agar plates containing 100 mg/ml ampicillin. Plates were 
incubated overnight. The following day colonies were picked and grown in LB 
containing ampicillin ready for miniprep and restriction digestion analysis (section 
2.2.2). Potential recombinants were sent for sequencing to confirm inserts using 
the primers listed in Table 17. 
Table 15 PCR primers for amplifying TMPRSS2 promoter DNA and PSA promoter 
and enhancer DNA. 
Construct F primer R primer 
LLW-PGL3 AAGCTTAGGACAACAAGCAAAATGGC AAGCTTCCCTCCGCCTCCTGCTTAG 
PPE-PGL3 GGTTTTTTGTTGGTACCCCTGCAGGCCTCT ATGAGAACCCCTCGAGGTGACACAGCTC 
P-PGL3 CTCAGGAGGTACCCTAGTACATTGTTT ATGAGAACCCCTCGAGGTGACACAGCTC 
PEW-PGL3 GGTTTTTTGTTGGTACCCCTGCAGGCCTCT CAAACAATGGGTACCTCGGGATCCT 
PEL-PGL3 GGTTTTTTGTTGGTACCCCTGCAGGCCTCT CAAACAATGGGTACCTCGGGATCCT 
L-PGL3 GGTACCAGGACAACAAGCAAAATGGC AAGCTTCAGAAGGGACAAGGGAACAA 
PE-VISA GGGTTTTTTGTTCCCGGGCCTGCAGGCCTCT GAGCTGTGTCACGTTTAAACGTTCTCATCAT 
LW-PGL3 TGAACGGTACCTGCCGTGTGAGGCAGATAA GTTGGAAGCTTCAGAAGGGACAAGGGAACA 
WE-PGL3 CATTGCAATAAGAACTTC GCCTTGTGACACTTCACCC 
PE-VISA GGGTTTTTTGTTCCCGGGCCTGCAGGCCTCT GAGCTGTGTCACGTTTAAACGTTCTCATCAT 
W-PGL3 GGTACCTGCCGTGTGAGGCAGATAA AAGCTTCCCTCCGCCTCCTGCTTAG 
 
Table 16 Restriction enzymes used for cloning and the vectors, insert and new 
plasmid information 
Plasmid to be generated Original plasmid  digestion PCR product digestion Vector digestion 
P-VISA pDRIVE PSApEnh 
NcoI/SpeI 
N/A N-VISA EcorV/SpeI 
PShuttle-TMPRSS2-VISA-
CD/UPRT 
L-VISA SalI/NotI N/A pShuttle SalI/NotI 
PShuttle CMV-GFP pEGFP–C2 AseI and MluI N/A PShuttle EcorV 
pAdEasy-TMPRSS2-
VISA-CD/UPRT 
PShuttle-TMPRSS2-VISA-
CD/UPRT PmeI 
N/A pAdEasy- No digestion 
PE-VISA N/A pDRIVE PSApEnh 
PCR product digested  
SmaI/PmeI 
N-VISA EcorV/SpeI 
L-PGL3 N/A L-VISA PCR product 
digested KpnI/HindIII 
PGL3 KpnI/HindIII 
E-VISA N-VISA Ecorv/SpeI N/A N/A 
PW-PGL3 N/A PSA enhancer Kpn1 W-PGL3 Kpn1 
PL-PGL3 N/A PSA enhancer Kpn1 L-PGL3 Kpn1 
LLW-PGL3 N/A LW HindIII L-PGL3 HindIII 
PEP-PGL3 N/A PSA 
enhancer/promoter 
Kpn1/XhoI 
PGL3-B KpnI/XhoI 
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PP-PGL3 N/A PSA promoter 
Kpn1/XhoI 
PGL3-B KpnI/XhoI 
W-PGL3 N/A W-VISA PCR product 
digested Kpn1/HindIII 
PGL3 KpnI/HindIII 
LW-PGL3 L-PGL3 Kpn1/Hind III and 
blunted 
N/A W-PGL3 kpn1 and 
blunted 
EW-PGL3 W enhancer Kpn1/BglII 
and blunted 
N/A W-PGL3 Kpn1 and 
blunted 
EL-PGL3 W enhancer Kpn1/BglII 
and blunted 
N/A L-PGL3 Kpn1 and 
blunted 
 
Table 17 PGL3 plasmid sequencing primers 
PGL3 plasmid sequencing 
All PGL3 plasmids RV primer 3 CTAGCAAAATAGGCTGTCCC LLW-PGL3 R2 CACTCTCCCACAACCCTC 
PGL2 TGGAAGACGCCAAAAACATAAAG R3 CGCTGCACTTACAATTGC 
L-PGL3 VISA TTTGGGACCCACTTGTG LW-PGL3 GTCCGGGAACAGCTCTCTT 
VISA AAGACCTGGGCCAGTTC PW-PGL3 PSA1 TGAATGGCTGGGATGTGTC 
 
VISA TCAGAGCCAACCATTTTG PSA2 CTGGGTCCCCTCCTATCTCT 
 
LW-PGL3 LW-PGL33 CACAAGTGGGTCCCAAA PSA3 
TGATCTTGGATTGAAAACAGACC 
 
LW-PGL3 GTCCGGGAACAGCTCTCTT PSA4 TTCTAGGTCCCGATCGACTG 
 
LW-PGL32 GAACTGGCCCAGGTCTT PL-PGL3 PSA1 TGAATGGCTGGGATGTGTC 
 
EW-PGL3 WPE-PGL3  GGGTGACAGAAAGGAATGGG PSA2 CTGGGTCCCCTCCTATCTCT 
 
WPE- PGL3 CCCATTCCTTTCTGTCACCC PSA3 
TGATCTTGGATTGAAAACAGACC 
 
EL-PGL3 EL-PGL3 GGGGTTTGAGGCCTCTGG PSA4 TTCTAGGTCCCGATCGACTG 
 
EL-PGL3  CCAGAGGCCTCAAACCCC F3 TTTGGGACCCACTTGTG 
 
LLW-PGL3 LLW-PGL3 CACTCTCCCACAACCCTC PPE-PGL3 PSA1 TGAATGGCTGGGATGTGTC 
 
LLW-PGL3 CGCTGCACTTACAATTGC PSA2 CTGGGTCCCCTCCTATCTCT 
 
LW-PGL3 GTCCGGGAACAGCTCTCTT PSA3 
TGATCTTGGATTGAAAACAGACC 
 
PW-PGL3 PSA1 TGAATGGCTGGGATGTGTC 
 
PSA4 TTCTAGGTCCCGATCGACTG 
 
PSA2 CTGGGTCCCCTCCTATCTCT 
 
PSA5 GCACGTGAGGCTTTGTATGA 
 
PSA3 TGATCTTGGATTGAAAACAGACC 
 
PSA4 TTCTAGGTCCCGATCGACTG 
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2.4 Protein expression analysis. 
2.4.1 Plasmid transfection 
Cells were seeded at 1.5x105 (LNCaP, PC3, DU145) and 3x105 (22RV1, VCaP, 
PNT1A, PNT2) in 2 ml respective culture media (10% FCS, 1% pen/strep) in 6 
well plates. The following day the media was replaced with 1 ml 2% respective 
culture media (2%FCS, 0% pen/ strep). 2 μg of plasmid DNA per well was mixed 
with 125 μl 0% respective culture media (0% FCS, 0% pen/ strep). 5 μl 
lipofectamine (Invitrogen) was mixed separately with 125 μl 0% respective culture 
media per well. The lipofectamine and DNA solutions were combined and 
incubated for 30 min at RT, in order for the DNA/lipid complexes to form. After 
incubation the full 250 μl was added to the 6 well plates containing cells. 4 h later 
1 ml of the respective full media was added to each well. Cell lysates were 
extracted at 24, 48 and 72 h post transfection for protein and/or RNA analysis. 
2.4.2 Preparation of protein lysates. 
Cells were lysed in 1x LYSIS buffer containing 1x protease inhibitor cocktail 
(Roche, Diagnostics, Mannhein, Germany), 1% triton-x-100 and PBS. 200 μl was 
added to 3x105 cells. Lysates were centrifuged at 14,000g for 15 min at 4C. The 
supernatant was transferred to a new Eppendorf and stored at -80C. Protein 
concentrations were determined by Bradford assay (BioRad, Philadelphia, PA, 
USA) using bovine serum albumin (BSA) (NEB) stock at 1 μg/μl to make a 
standard curve from 0 to 1 μg. Proteins were diluted 1:10 and 10 μl added to 190 
μl of 1x BioRad reagent (5x stock diluted with dH2O) in duplicate. Absorbance was 
measured by the Opys 96-well microplate reader (DYNEX) spectrophotometer at 
595 nm and the protein concentrations calculated based on the standard curve 
generated by the absorbance of BSA standards. 
2.4.3 Western Blotting. 
Total protein (20 μg) from cell lysates was mixed with 7.5 μl 1X loading buffer 
(NuPAGE LDS Sample Buffer; Novex) and 3 μl 1X reducing buffer (NuPAGE 
Sample Reducing Agent; Invitrogen, UK), and incubated at 95ºC for 5 min to 
denature the proteins. 30 μl was loaded onto 10% sodium dodecyl sulphate 
reducing polyacrylamide gels (SDS-PAGE), together with 10 μl of spectra 
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multicolour broad range protein ladder (Fermentas, UK) to determine protein size. 
The proteins were separated by electrophoresis at 120 V in running buffer (25 mM 
Tris, 250 mM glycine and 0.1% SDS, pH 8.3). Proteins were transferred to 
polyvinylidene fluoride membranes (PVDF) with a 0.45 μm pore size (Millipore) by 
a wet transfer technique, at 200 mA for 100 min in transfer buffer (10% 25 mM 
Tris-250 mM glycine, 20%, Methanol, pH 8.5). Membranes were blocked with 5% 
(w/v) dry milk (Marvel, Dublin, Ireland) in Phosphate-buffered saline, Tween-20 
buffer (PBS-T; 20 mM Tris-HCl pH 7.4, 500 mM NaCl) with 0.05% Tween-20. After 
blocking, membranes were washed 3x 10 min in 0.05% PBS-T. The membranes 
were incubated overnight at 4°C with primary antibodies (Table 18) in 5% BSA 
(Sigma) in PBS-T, washed and incubated with secondary antibodies (Table 19), 
conjugated to horseradish peroxidase (DakoCytomation) in 5% (w/v) dry milk in 
PBS-T for 1 h at RT. The membranes were washed 3x 10 min with PBS-T after 
each antibody incubation. Proteins were visualised using Immobilon Western 
Chemiluminescent HRP Substrate (Millipore), by mixing equal volumes of luminol 
reagent and peroxide solution and incubating the membrane in the solution for 5 
min at RT. Finally, the blot was exposed to autoradiography films (Fujifilm 
Düsseldorf, Germany) for 30 s-5 min and developed in a Curix 60 Developer 
(Agfa, Middlesex, UK).  
Table 18 List of primary antibodies used for western blotting 
Protein Species and clone Catalogue number Company Dilution 
Cytosine 
deaminase 
Polyclonal Sheep ab35251 Abcam 1:500 
AR Polyclonal Rabbit-N20 sc-816 Santa Cruz 1:300 
β-actin Monoclonal Mouse A5441 Sigma Aldrich 1:10,000 
 
Table 19 List of secondary antibodies used to detect primary antibodies in Western 
blotting 
Species and clone Catalogue number Company 
Rabbit anti-sheep p0163 Dako 
Goat anti-mouse 32430 Thermo scientific 
Goat anti-rabbit 32460 Thermo scientific 
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2.4.4 Transgene expression in response to mibolerone/ 
Bicalutamide 
One day before seeding, cell culture medium was changed to 10% charcoal-
stripped FBS-containing media to remove residual hormones. 22RV1 and LNCaP 
cells were seeded in 96-well plates at 2x104 and 1x104 respectively, in 10% 
charcoal-stripped FBS, DMEM. The following day the media was removed and 
replaced with 90 µl charcoal-stripped FBS DMEM. Cells were infected at fixed 
doses of Ad5-TV-CU at 1000, 2000, 3000 ppc. 2 h later a fixed concentration of 
either mibolerone or Bicalutamide at 1nM and 20µM respectively was added to the 
cell. 48 hours after the combined treatment cells were lysed for western blot 
analysis of CD/UPRT protein expression. 
2.5 Cell viability assays. 
2.5.1 Determining Ad5-TV-CU EC50 values 
1x104 cells/well (DU145, LNCaP, PC3 and PNT2) or 2x104 cells/well (22Rv1, 
VCaP and PNT1A) were seeded in 96-well plates in a volume of 200 μl/well of 
their respective culture media (10% FCS 1% Pen/Strep). PrEC (5x104 cells/well) 
were seeded in 96-well plates in a volume of 200 μl/well of PREBM media. The 
next day the medium was replaced with 90 μl/well (2%FCS 1%Pen/Strep). An 
initial viral dose of 1x105 ppc was made and serially diluted 5-fold in serum-free 
media. 10 μl of the viral dilutions were added to the wells, therefore the viral 
dilution was initially made at 10x concentration to account for the further 1/10 
dilution in the wells of the plate.  Viability was assessed 3 days post-treatment 
using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) viability assay, carried out according to the 
manufacturer’s protocol (Promega, WI, USA). Briefly, media was removed and 
100 μl MTS reagent added. Phenazine methosulfate (PMS) is added to MTS, and 
in the presence of live cells (the mitochondrial NAD(P)H-dependent cellular 
oxidoreductase  enzyme) the tetrazolium salt is converted to a formazan product 
that absorbs light at 490-500 nm. The absorption is proportional to the number of 
live cells, as the production of formazan relies on the mitochondrial 
dehydrogenases present only in live cells. After addition of the MTS reagent, cells 
were incubated at 37ºC for 5 h (22Rv1), 2h (DU145, PC3, PNT1A, PNT2) or 9 h 
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(VCaP) and absorbance read using a microplate reader (Opsys, MR, Dynex 
Technologies) at a wavelength of 495 nm. Control wells containing only media 
were used to subtract background and untreated wells were used as positive 
controls. The percentage cell death for each treatment was calculated using the 
untreated control cells as 100% live cells. Sigmoidal dose-response curves were 
generated by non-linear regression analysis using GraphPad Prism Version 5.03 
(GraphPad Software, San Diego, CA, USA) to determine the effective 
concentration (EC50 values) required to kill 50% of cells. 
                  
                    
                       
  
 
2.5.2 Determining effective concentration of 5-FC and 5-FU 
drugs 
1x104 cells/well (DU145, LNCaP, PC3 and PNT2) or 2x104 cells/well (22Rv1, 
VCaP and PNT1A) were seeded in 96-well plates in a volume of 90 μl/well of their 
respective media (10% FCS 1% Pen/Strep). Cells were treated with 5-fold serial 
dilutions of the non-toxic pro-drug 5-FC and the toxic metabolite 5-FU at a starting 
dose of 10 mg/ml in serum free media. The drugs were made up at 10-fold higher 
concentration to allow for the dilution when added to the plate, 10 µl of each 
dilution was added to 90 µl medium in the well in duplicate or triplicate. Medium 
alone and untreated cells served as controls. Cell viability was determined by MTS 
three days after treatment (section 2.5.1). 
2.5.3 Combination of virus and 5-FC  
Once the dose limiting toxicity of 5-FC was established, cells were seeded in 80 
μl/well where both virus and drug were added in combination and 90 µl/well where 
only one treatment was given. Ad5-GFP was used as a negative control. Viruses 
were serially diluted 5-fold from 105 ppc and 5-FC added at selected fixed 
concentrations that were non-toxic to the cells, selected as a result of analysing 
EC50 values for titrations of drug alone. Cell viability was assessed by MTS assay 
3 days post treatment as described in section 2.5.1. Results were corrected 
against background wells containing medium only and expressed as a percentage 
of cell death compared with untreated control cells for virus alone, or compared 
with drug treatment alone for combination of virus and 5-FC.   
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2.6 Viruses. 
2.6.1 Adenoviruses. 
The pAdEasy adenoviral backbone plasmid and the pShuttle plasmid (Dr Halldén, 
BCI) were used to clone Ad5-TV-CU (section 2.6.2). Ad5-GFP was non-
replicating; with the E1 genes replaced by a CMV-GFP cassette, but still contained 
the E3 genes. Ad5-GFP and Ad5 wild type (wt) were obtained (Dr Halldén, BCI) 
and had previously been characterised by Dr Halldén’s team, using specific PCR 
primer sets for identification and assays to determine particle and pfu section 
2.7.1-2.7.2, Table 20).  
Table 20 Viruses used and transgene expression 
Virus Characteristics Transgene 
expression 
Ad5-TV-CU TMPRSS2-VISA-CD/UPRT replacing E1. Non-
replicating. 
CD/UPRT 
Ad5-GFP CMV-GFP replacing E1 genes. Non-replicating GFP 
Ad5wt - - 
 
2.6.2 Constructing a prostate specific Ad5-TV-CU 
The pAdEasy system (Stratagene, CA, USA) was used to generate Ad5-TV-CU. 
The TMPRSS2-VISA-CD/UPRT expression cassette was first cloned into the 
pShuttle vector (Stratagene, CA, USA) (section 2.6.2.1), linearised with PmeI and 
electroporated with pAdEasy into BJ5183 cells (section 2.6.3). Recombinant 
colonies were selected for by restriction digestion and plasmids purified. 
Recombinant pAdEasy was digested with Pac1 to expose its inverted terminal 
repeats (ITR) and transfected into HEK293 cells for bulk viral production (see 
section 2.6.5).  
2.6.2.1 Construction of pShuttle-CD/UPRT. 
The pShuttle vector was a different stock from that previously used but the same 
as that used for the CMV-GFP shuttle (Dr Katrina Sweeny, Centre for Molecular 
Oncology, BCI). L-VISA was digested with SalI and NotI restriction enzymes and 
the digested product run on a gel. The 5.7 kb expression cassette (TMPRSS2-
GAL4-VP16-GAL4 binding sites-CD/UPRT) was gel extracted and ligated into the 
pShuttle vector (Stratagene, CA, USA), via the complementary sticky ends, using 
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the rapid DNA ligation kit (Roche, Germany). Briefly, 5 μl of DNA ligation buffer, 1 
μl DNA ligase and 1 μl of both the vector and insert were mixed in an eppendorf 
and left at RT for 5 min.  
1 µl of the pShuttle-CD/UPRT ligation reaction was added to 25 µl thawed 
chemically competent TOP10 bacteria and incubated on ice for 30 min. The 
TOP10 cells were transferred to a 42 ºC water bath for 30 s and then returned to 
ice for 2 min. 250 µl pre-warmed super optimal broth with catabolite repression 
(S.O.C) medium was added and the vials incubated at 37 ºC in a shaking 
incubator for 1 hour at 225 rpm. The bacterial culture was the plated onto agar 
plates containing 20 µg/ml Kanamycin. Plates were inverted and incubated 
overnight at 37ºC. 
The following day colonies were picked and grown in 5 ml LB containing 20 µg/ml 
Kanamycin. The vials were placed in a shaking incubator at 37 ºC and left at 
225rpm overnight. The following day 1.5 ml of each bacterial culture was 
miniprepped (Promega Wizard plus SV Minipreps, section 2.2.6). The miniprep 
DNA was digested with EcorV and BglII and run on a 0.8% agarose gel alongside 
both cut and uncut pShuttle DNA. Restriction digestion analysis and sequencing 
identified recombinant clones. All sequencing analysis was performed by the 
Genome Centre at Barts Cancer Institute (London) using a Sanger sequencing 
method and the primers listed below (Table 21). 
Table 21 pShuttle-CD/UPRT sequencing primers 
Primer name Primer sequence 
PshCDU 2 F TGTCCAATTATGTCACACCACA 
PshCDU 3 F ATTCCGGCGATACAGTCAAC 
PshCDU 4 F GCTGTTCCAGTCTTTCTAGCC 
PshCDU 5 F CAGGACTGTAATATTTCCATACCA 
PshCDU 6 F GCATCCTGCTGGACTTAACC 
PshCDU 7 F CAGGGCTCAGCACCAAATA 
PshCDU 8 F TGGTGGAGGTCAGAAAGAGC 
PshCDU 9 F CTGTGAGGGAGACTGTGCAA 
PshCDU 10 F CCATCAAAACAAAACGAAACAA 
PshCDU 11 F TTCAAAGTGGGACCAGAAGG 
PshCDU 12 F AGGTGGTTGTGGTGGATGAT 
PshCDU 13 F GGGAGACTTTGGGGACAGAT 
PshCDU 14 F TATTGCCACGGCGGAACT 
PshCDU 15 F CGCTTCGAGCAGACATGATA 
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2.6.3 Homologous recombination 
2 µg of pShuttle-CD/UPRT was linearised with Pme1 (NEB) in a 50 µl reaction 
volume containing 5 µl NEBuffer 4, 5 µl BSA, 1 µl Pme1, made up to 50 µl with 
distilled H2O and incubated for 3 h at 37ºC. Linearised pShuttle-CD/UPRT was 
dephosphorylated by adding 10 µl Antarctic Phosphatase reaction buffer and 1 µl 
Antarctic Phosphatase and incubated at 37ºC for 15 min. The linearised and 
dephosphorylated pShuttle-CD/UPRT was cleaned using a standard 
phenol/chloroform protocol (section 2.2.3) and homologous recombination 
performed according to the manufacturer’s instructions in BJ5183 cells (Figure 
26). Briefly, linearised pShuttle-CD/UPRT was mixed together with the pAdEasy 
adenoviral backbone in BJ5183 cells (Addgene, USA) in a 3:1 ratio (section 2.4.8). 
BJ5183 are a recombination proficient bacterial strain that are deficient in certain 
enzymes that mediate recombination in bacteria (endA, sbcB-, recBC-, strR), but 
supply the components necessary for homologous recombination to take place. 
Potential recombinants were grown on Kanamycin plates and sequenced using 
the primers listed in Table 22. 
Table 22 Recombinant pAdEasy sequencing primers 
Primer name Primer sequence 
Psh 1 F GGGACTTTCCTACTTGGCAGT 
Psh R CACAATGCTTCCATCAAACG 
PshCDU 2 F TGTCCAATTATGTCACACCACA 
PshCDU 3 F ATTCCGGCGATACAGTCAAC 
PshCDU 4 F GCTGTTCCAGTCTTTCTAGCC 
PshCDU 5 F CAGGACTGTAATATTTCCATACCA 
PshCDU 6 F GCATCCTGCTGGACTTAACC 
PshCDU 7 F CAGGGCTCAGCACCAAATA 
PshCDU 8 F TGGTGGAGGTCAGAAAGAGC 
PshCDU 9 F CTGTGAGGGAGACTGTGCAA 
PshCDU 10 F CCATCAAAACAAAACGAAACAA 
PshCDU 11 F TTCAAAGTGGGACCAGAAGG 
PshCDU 12 F AGGTGGTTGTGGTGGATGAT 
PshCDU 13 F GGGAGACTTTGGGGACAGAT 
PshCDU 14 F TGTCCAATTATGTCACACCACA 
PshCDU 2 F TATTGCCACGGCGGAACT 
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Figure 26 Diagrammatic showing homologous recombination between the pAdEasy 
and pShuttle vectors 
TMPRSS2-VISA-CD/UPRT expression cassette was excised from L-VISA CD/UPRT and 
ligated into pShuttle. Homologous recombination between pShuttle and p-AdEasy resulted 
in the recombinant pAdEasy viral backbone containing the TMPRSS2-VISA-CD/UPRT 
expression cassette. 
2.6.4 Generation of the novel Ad5-TV-CU. 
Recombinant pAdEasy was linearised with PacI and cleaned (phenol/chloroform, 
section 2.4.3). 2 wells of a 6 well plate were transfected with either 0.4 μg or 0.8 
μg of linearised recombinant pAdEasy (effectine, QIAGEN, Germany). Cells were 
incubated at 37ºC in a humidified atmosphere with 5% CO2 and monitored for 
signs of cytopathic effect (CPE is determined by the presence of plaques; cells 
become rounded and large gaps appear between the monolayer of cells), typically 
between 7-10 days.  
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2.6.5 Large scale bulk production of virus 
In order to produce a replication-defective adenovirus, the adenovirus packaging 
cell line HEK293 is required to provide the E1 proteins essential for assembly of 
infectious virus particles. Large scale bulk production of virus was performed as 
previously described (Wang et al. 2003). HEK293 cells are transformed with the 
first 4344 nucleotides (E1 gene) of Ad5, allowing them to produce adenovirus from 
backbone vectors without the E1 gene. Recombinant pAdEasy was linearised with 
Pac1, to liberate both inverted terminal repeats (ITR’s) and transfected into two 
wells of a 6 well plate containing ~80% confluent HEK293 cells, as described in 
section 2.4.1). Cells transfected with recombinant pAdEasy were collected and 
freeze thawed three times in liquid nitrogen (N2)(l) and heated at 37°C to release 
the virus from the cells. Cell debris was removed by centrifugation at 1200 rpm 
and media containing virus was transferred to a T75 flask containing HEK293 cells 
at ~80% confluency. The flask was monitored for signs of CPE, which typically 
occurred 48-96 h later. The cells were collected in a 50 ml falcon by gentle tapping 
of the flask and freeze thawed three times to release the virus. Half the viral lysate 
(~5 ml) was added to another T175 flask containing ~90% confluent HEK293 cells 
and incubated until signs of CPE occurred (typically 48-72 h). The cells were 
collected, freeze thawed three times, spun down at 1200 rpm to remove the cell 
debris and the viral supernatant split equally between 16x T175 flasks of 90% 
confluent HEK293. These flasks were left to incubate and monitored for signs of 
CPE, which typically occurred 48 h later. The cells were detached from the flasks 
and the media poured into two large centrifuge tubes. The tubes were spun at 200 
rpm for 10 min at 4°C. The supernatant from each tube was aspirated and the 
pellet resuspended in 15 ml of cold PBS and transferred to a 50 ml centrifuge 
tube. The pellet was centrifuged for 10 min at 1000 rpm at 4°C, the supernatant 
aspirated and the pellet resuspended in 12 ml cold 10 mM Tris.HCL (PH 8.0). The 
cell suspensions were then ready for caesium chloride (CsCl) banding. 
2.6.6 Caesium chloride banding 
To produce a pure virus the fully encapsulated virion particles must be separated 
from the empty capsid particles. The standard method for purification is based on 
using a CsCl density gradient combined with ultracentrifugation. The viral 
suspension was freeze thawed three times to promote viral release and 
centrifuged at 6000 rpm.  CsCl gradients were prepared in a 3.5” ultracentrifuge 
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tube (Beckman Coulter, High Wycombe, UK) by adding 10 ml 1.25 g/ml CsCl 
under-layered with 7.6 ml 1.4g/ml CsCl solution. The viral supernatant was layered 
on top and the tubes spun for 2 h at 25000 rpm at 15 °C in a Beckman SW28 
swing-out rotor in an Optima LE-80K ultracentrifuge. After centrifugation 3 bands 
exist in the ultracentrifuge tube, a 19G needle was used to extract the bottom 
band that contained the encapsulated virus. The remaining bands were discarded. 
The encapsulated virus suspension was then split equally and layered onto 2.4 ml 
1.35 g/ml CsCl solution in 4 2” ultracentrifuge tubes (Beckman) and centrifuged at 
15°C, 4000rpm O/N. Again the purified virus was extracted using a 19G needle 
and the volume diluted 2-3 fold (up to 12 ml) with TSG buffer (96mM NaCl, 2.8mM 
KCl, 0.3mM MgCl2, 0.5mM CaCl2 and 30% (v/v) glycerol, 0.5mM Na2-HPO4, 
adjusted to pH7.5). The diluted viral suspension was injected with a 19G needle 
into a 3-12 ml Slide-a-Lyser (Pierce Biotechnology, IL, USA) and rotated in 1L 
buffer containing 10 mM Tris-HCl (pH7.5), 1 mM MgCl2, 150 mM NaCl and 10% 
(v/v) glycerol for 24 h at 4C. The purified virus was then removed from a separate 
port of the dialysis chamber, aliquoted and stored at -80C. 
2.6.7 Analysis of infectability of PCa cell lines by flow 
cytometry (FACS). 
Cells were seeded in 6-well plates at a density of 3x105 (22RV1, VCaP) or 1.5x105 
(LNCaP) in 2 ml of their respective media. The following day cells were infected 
with Ad5-GFP at 10 ppc, 100 ppc, and 1000 ppc in their respective 2% media (2% 
FCS 1% pen/strep). Uninfected cells were used as a negative control.  After 2 h 
the media was removed and replaced with 2 ml of their respective full media (10% 
FCS 1% pen/strep). Cells were incubated at 37°C for 48 h before analysis via flow 
cytometry. Cells were trypsinised in the wells by addition of 500 μl trypsin followed 
by neutralising with 500 μl 10% FCS DMEM. Suspensions were added to FACS 
tubes and spun at 1800 rpm for 5 min. After washing twice with 2 ml cold PBS the 
cell pellet was resuspended in 500 μl PBS and left on ice until acquisition. 10,000 
events were acquired by flow cytometry on a FACS calibur cytometer (Becton 
Dickinson, Immunocytometry Systems, Belgium) with CellQuest Pro Software. The 
number of live events were gated using forward side scatter (FSC) versus right 
angle side scatter (SSC). The percentage of GFP positive cells were quantified by 
plotting green fluorescence (FL-1) versus FSC and setting the marker to 
encompass <1% of the uninfected control.  
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2.7 Ad5-TV-CU characterisation 
2.7.1 Viral replication assay (TCID50) 
The median tissue culture infected dose (TCID50) is defined as the amount of virus 
that will produce a cytopathic effect in 50% of cells. TCID50 values were 
determined by seeding 1x104 JH293 cells/well in a 200 µl volume in 10% FCS 
DMEM. The following day the purified Ad5-TV-CU virus was diluted to 1x10-5 and 
1x10-3 in serum free DMEM and a previously purified and characterised Ad5wt 
virus was diluted to 1x10-7 as an internal control for the assay. 20 µl of the stock 
concentrations of both viruses were added to infect the top row of a 96-well plate, 
in triplicate for each virus and each stock dilution. The virus was serially diluted 
down the plate by transferring 20 µl from the top row into the second row and so 
on. The last row of the plate was left uninfected as a control. The plates were 
incubated for 7 to 10 days and each well scored for signs of CPE. The titre of each 
plate was calculated as infectious units and expressed as plaque forming units 
(pfu)/ml as follows: 
The total number of cells exhibiting CPE was calculated per row and the following 
calculation used to determine the TCID50 value. 
TCID50 = 
10 A-D (S - 0.5) 
TCID50/ml = TCID50 x v 
A = Log of the highest dilution showing CPE in more than 50% of wells 
D = Log of the dilution factor 
S = summation of the proportion of CPE-positive wells in each row 
V = infection volume = 0.02ml 
pfu/ml = Log TCID50 x μ 
where μ = -In p = 0.69 
According to the Poisson distribution: μ is the mean concentration of infectious 
particles at a given dose. p is the proportion of cultures remaining uninfected = 0.5 
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2.7.2 Virus particle count determination 
2.7.2.1 PicoGreen 
The particle count of purified virus was determined using the Quanti-iT PicoGreen 
dsDNA assay kit (Invitrogen), using the Tecan Infinite F200 plate reader (Tecan, 
Mannedorf, Switzerland) and Magellan software version 6.3 (Tecan). Viruses were 
heat inactivated at 56ºC for 10 min by diluting 1:2 in Tris-EDTA (TE) buffer (10 mM 
Tris-HCL (pH8), 1 mM EDTA) containing 0.5% SDS. After heat inactivation the 
viruses were serially diluted 1:6 and 1:10 in 1xTE buffer to make dilution B and C 
respectively. This was then later diluted 1:120 and 1:200 (Table 23). A standard 
curve of Lamda-phage DNA (provided in the kit) starting at 750 ng/ml was 
prepared using TE (Figure 27, Table 24). 100 µl of each virus or Lamda-phage 
DNA dilution in triplicate was transferred to a well of a 96-well plate. Picogreen 
reagent was diluted 200-fold in TE and 100 µl of PicoGreen reagent added to each 
well containing Lamda-phage DNA or virus. A linear regression curve was 
constructed by plotting DNA concentration vs. fluorescence (linear regression 
coefficient >0.98) using the fluorescent measurements from the Lambda DNA. The 
DNA concentration for each virus dilution was calculated using the standard curve, 
taking into account the dilution factor for each sample. It is assumed that 1 µg 
DNA is equivalent to 2.7x1010 viral particles and the number of viral particles per 
ml (vp/ml) was calculated based on this assumption. As an internal control Ad5wt 
of known particle count was included as a reference. 
 
Figure 27 Picogreen lambda DNA curve 
Lambda DNA was diluted as described in table 24 and a standard curve created using the 
Quanti-iT PicoGreen dsDNA assay kit. The standard curve was used to determine the viral 
particle count of Ad5-TV-CU. 
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Table 23 Virus dilutions for PicoGreen 
Virus Sample Volume of 
1xTE/0.5% SDS (l) 
Volume of 1xTE 
(l) 
Volume of neat/diluted 
virus sample (l) 
Neat (A) 42 336 42 
1:2 Diluted Virus (A) 42 357 21 
1:6 Diluted Virus (B) 42 357 21 
1:10 Diluted Virus 
(C) 
42 357 21 
 
Table 24 Control curve lambda DNA dilutions 
 
2.7.2.2 Optical density 
2x 100 µl aliquots of virus were removed and named VA and VB. 100 µl 2x lysis 
buffer was added and the viruses heated to 56 ºC for 10 min, including controls 
(100 µl TSG and 100 µl lysis buffer, termed CA and CB). After heating, 300 µl 
distilled H2O was added to make a final volume of 500 µl. The optical density 
(OD260) was then measured using a quartz cuvette and an eppendorf 
Biophotometer plus. The spectrophotometer was blanked using 500 µl dH2O and 
the OD260 of control sample A (CA) was read, followed by two reading of virus A 
(VA). The machine was again blanked using 500µl distilled water and the second 
control sample B (CB) measured, followed by two measurements of virus B (VB). 
The average of the two repeat values was subtracted from the control OD260 
reading. An average was taken of sample A and B and multiplied by the dilution 
factor (5). The result was divided by 9.09x10-13, giving the viral particle count (see 
equation below).  
      
                         
        
 
DNA Concentration 
(ng/ml) 
Volume of 1xTE/0.5% 
SDS (l) 
Volume of 
1xTE (l) 
Volume of 1mg/ml 
Lambda DNA (l) 
750 42 63 315 
500 42 168 210 
100 42 336 42 
50 42 357 21 
25 42 367.5 10.5 
10 42 373.8 4.2 
1 42 377.6 0.42 
0 42 378 0 
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Virus particle/plaque forming units (vp/pfu) ratio was determined for each virus. A 
vp/pfu of <50 is desirable, however it is not possible to obtain these values for a 
non-replicating virus (Table 25). 
Table 25 Virus particle and titre count 
 Virus particle (vp) (vp/ml) Viral titre (pfu/ml) Vp/pfu ratio 
Ad5-TV-CU #1 2.33X10
11
 3.6 X10
8
 1:647 
Ad5-TV-CU #2 8.9X10
11
 4.94X10
9
 1:180 
Ad5wt 4.63 X10
11
 5.38X10
10
 1:8.6 
Ad5 GFP 2.78X10
11
 2.0 X10
8
 1:1390 
 
2.7.3 Confirmation of E1 and E3 deletions by PCR 
2.7.3.1 Adenoviral DNA extraction 
Extraction of viral DNA for use in PCR reaction was performed using QIAamp 
DNA Blood Mini Kit (Qiagen). 20 µl of proteinase K (Qiagen) was added to 200 µl 
of virus followed by 200 µl of buffer AL (supplied with the extraction kit) and 
incubated at 56ºC for 10 min. 200 µl of ethanol was added to the sample, vortexed 
for 15 sec and transferred to a QIAamp spin column within a 2 ml collection tube. 
The sample was centrifuged at 8000 rpm for 1 min. 500 µl buffer AW1 (supplied 
with the kit) was added to the tube and the sample centrifuged for 1 min at 8000 
rpm. The column was placed in a new collection tube and 500 µl buffer AW2 
(supplied with the kit) added to the column and centrifuged at 14000 rpm for 3 min 
followed by another 1 min after transfer to a new collection tube. The column was 
then placed in a sterile eppendorf tube and 40 µl of distilled H2O was added to the 
column and centrifuged at 8000 rpm for 1 min to elute the purified DNA. The 
concentration of purified DNA was measured using a nanodrop 
spectrophotometer, DNA absorbs light at 260 nm, as the nanodrop emits light at 
260 nm, the more concentrated the DNA, the less light hits the photodetector, 
producing a higher OD260. Once the concentration was identified samples were 
stored at -20ºC. 
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2.7.3.2 Adenoviral PCR 
Ad5-TV-CU used in this project was non-replicating and therefore lacked the E1 
and E3 regions of the viral genome. The absence of the E1A, E1B and E3 regions 
were confirmed for both batches of replication-deficient Ad5-TV-CU using PCR 
primers specific for these regions as well as a primer pair specific to TMPRSS2 to 
show the presence of the promoter region (Table 26). PCR was performed using 
wildtype Ad5 and the pAdEasy backbone plasmid DNA as a control. PCR was set 
up using a standard Taq polymerase master mix (section 2.2.1). Briefly, each 
reaction contained 50 ng purified viral DNA, 2.5 µl each of the forward and reverse 
primers (10 µM), 3 µl 10x dNTPs (10 mM each), 3 µl 10x PCR buffer and 2 units 
(0.4 µl) Taq polymerase and made up to a final volume of 30 µl with dH2O. DNA 
was amplified by 35 cycles (94°C 40s, 62°C 60s, 72°C 90 s) in a Gene Amp PCR 
system 9700 (Applied Biosystems; Thermo Scientific). The amplified PCR 
products were separated on a 1% agarose gel using a 1 kb + DNA ladder 
(Invitrogen) as a marker to determine the size of the PCR products (Figure 28). 
The expected sizes of the products were calculated from the known sizes of each 
sequence (Table 27) Representative gel image shown below (Figure 28). 
Table 26 Adenoviral PCR primers used 
Primer set  Direction Sequence 
1 5’ forward CCCGGTGAGA TTCCTCAAGAGGCCAC 
3’ reverse  CCGGACCCAAGGCTCTCTGCTCTCCGGCTGCTCGGGC 
2 5’ forward GTAATGTTGGCGGTGCAGGAAGGGATTG 
3’ reverse GGGTCCCCCGTATTCCTCCGGTGATAATGAC 
3 5’ forward GTGTTCGCTTTGCTATATGAGGACCTGTGGC 
3’ reverse CCTCGATACATTCCACAGCCTGGCGACGCCCACC 
4 5’ forward CCTGTGATTGCGTGTGTGG 
3’ reverse GACAACAGTAGCAGGCGATTC 
5 5’ forward GCATCTGTGGAGAGCGGTTGTGAGACAC 
3’ reverse GCGCCAGCAGATCAAGCTCATTAGCGC 
6 5’ forward GCTTAATGACCAGACACCGTCCTGAGTG 
3’ reverse GCACCAAGTGA TCGGGCCTCAGCTCC 
7 5’ forward CGCTGGGGTCGCCACCCAAGATGATTAGG 
3’ reverse GAGTAGGGTACAGACCAAAGCGAGCACTG 
TMPRSS2 5’ forward GGTACCAGGACAACAAGCAAAATGGC 
3’ reverse AAGCTTCAGAAGGGACAAGGGAACAA 
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Table 27 Binding sites of adenoviral PCR primers 
Primer set 5’ binding 
site 
3’ binding 
site 
Target 
sequence 
Expected Ad5 size 
(bp) 
1 476 853 E1A start 377 
2 767 1029 E1A inc CR2 262 
3 1069 1453 E1A end 384 
4 1554 2086 E1B-19K 532 
5 2073 2440 E1B-55K 367 
6 2383 3434 E1B-55K 1051 
7 28715 29135 E3-gp19K 420 
TMPRSS2 42,869,985  42,871,184 TMPRSS2 
promoter 
1200 
 
 
Figure 28 Adenoviral PCR 
Adenoviral PCR was performed on Ad5-TV-CU to confirm the presence of the TMPRSS2 
promoter and the absence of E1 and E3 regions. C= control, a wild-type replicating Ad5 V= 
Ad5-TV-CU, N= negative, pAd1= pAdEasy backbone which Ad5-TV-CU is based on. 
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2.8 Promoter activity assays  
2.8.1 Luciferase assays. 
Cells were seeded in 96-well plates at 2x104 (22RV1, VCaP, Panc1) or 1x104 
(LNCaP) in 100 μl 2% respective culture media (2% FCS 0% pen/strep). The 
following day 0.25 μg of plasmid DNA was added to 25 μl plain media. 1 μl of 
lipofectamine was added to 25 μl plain respective culture media (0%FCS, 0% 
pen/strep). The solutions were then mixed and allowed to incubate at RT for 30 
min. Following incubation 50 μl of the DNA/lipid complexes was added to the cells 
in the 96-well plate in triplicate. After 24/48 h 150 μl of luciferase assay reagent 
(Promega, USA) was added to each well on the plate and the total 300 μl was 
transferred to a white 96 well plate. Luminescence was read using the wallac 1420 
manager plate reader. 
2.8.2 Dual luciferase assays. 
Cells were seeded in 96-well plates at 2x104 (22rv1, VCaP, Panc1) or 1x104 
(LNCaP) in 100 μl respective culture media (2% FCS 0% pen/strep). The following 
day 20 ng of plasmid was added to 25 μl plain media as well as 2 ng of a control 
luciferase plasmid pRL, expressing renilla luciferase. 0.5 μl of lipofectamine was 
added to 25 μl plain media (0% FCS 0% pen/strep). The solutions were mixed and 
allowed to incubate at RT for 30 min. Following incubation, 50 μl of the DNA/lipid 
complexes were added to the cells in the 96-well plate in triplicate. After 24/48 h 
the media was removed from the cells and the cells PBS washed. 20 μl of protein 
lysis buffer was added to each well and left to rock gently for 20 min at RT. 5 μl of 
the cell lysates were added to each well of a 96-well white plate and 25 μl LARII 
added on top. The luminescence was read using the wallac 1420 manager plate 
reader. Then, 25 μl of Stop and Glo reagent (1xbuffer) was added before the 
renilla luciferase luminescence was read. 
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2.9 In vivo 
All in vivo experiments were performed within the Biological Services Unit (BSU) 
at Queen Mary University of London under UK Home Office personal and project 
license authority.  
Tumour growth was monitored twice weekly by calculating the volume for an 
ellipsoid approximated for tumour volume using the following equation: 
                           
Tumours were allowed to grow to a maximum area of 1.4 cm2 or until there were 
signs of ulceration or poor health. 
2.9.1 Establishing LNCaP-CDXR3 and LNCaP-104-S tumours 
xenografts in male BALB/C mice 
LNCaP-CDXR3 and LNCaP-104-S cells were trypsinised and cell pellets spun 
down and resuspended in 10 ml of their respective culture media. Cells were 
counted using the BioRad cell counter system. The total number of cells required 
were spun down and resuspended in the required volume of cold sterile PBS. 
1x106 LNCaP-CDXR3 cells in 100 μl PBS were mixed with 100 μl of cold BD 
matrigel basement membrane complex (life science, United Kingdom) (must be 
kept on ice to maintain the correct consistency) and injected subcutaneously into 
both left and right flanks of 7 male BALB/c immunodeficient (or nu/nu) mice that 
had undergone orchiectomy (Charles River, Margate, UK). 1x106 LNCaP-104-S 
cells in 100 μl PBS were mixed with 100 μl of cold matrigel and injected 
subcutaneously into each flank of 7 intact male BALB/c mice in combination with 
the insertion of a 1.25 mg 60-day release testosterone pellet under the skin.  
2.9.2 Establishing LNCaP-104-S tumours xenografts in male 
NOD/SCID mice 
Three 7 week old male NOD/SCID mice were injected with a 1.25 mg 60-day 
release testosterone pellet and three 7 week old male NOD/SCID mice were left 
without a pellet. 3 days later LNCaP-104-S cells were trypsinised and cell pellets 
spun down and resuspended in 10 ml of their respective culture media. Cells were 
counted using the Biorad cell counter system. The total number of cells required 
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were spun down and resuspended in the required volume of cold sterile PBS. 
2x106 LNCaP-104-S cells in 100 μl PBS were mixed with 100 μl of cold matrigel 
and injected subcutaneously into each flank of the 6 male NOD/SCID mice. 
2.9.3 Establishing 22RV1 tumours xenografts in male CD-1 
mice 
22RV1 cells were trypsinised and cell pellets spun down and resuspended in 10 
ml of their respective culture media. Cells were counted using the BioRad cell 
counter system. The total number of cells required were spun down and 
resuspended in the required volume of cold sterile PBS. 1x106 22RV1 cells in 100 
μl PBS were mixed with 100 μl of cold matrigel and injected subcutaneously into 
the left flank of 12 male 5 week old CD-1 immunodeficient nu/nu mice the other 
flank was left untreated. 
2.9.4 Intratumoural toxicity of Ad5-TV-CU in combination with 
5-FC in BALB/c mice bearing LNCaP-CDXR3 and LNCaP-104-S 
xenografts 
When tumours reached 100 mm3, mice were randomly allocated to receive a 
single intratumoural does of 1x1010vp of either Ad5-TV-CU (n=3), Ad5-GFP (n=3) 
or 50 μl  PBS n=6) on days 1, 3 and 5 directly into the tumour on the left flank of 
animals. The right flank tumour received a control dose of 50 μl PBS alone. On 
days 2, 4, 6 and 15 weight dependent doses (100 mg/kg) of 5-FC were 
administered intraperitoneally (IP) to half the mice injected with Ad5-TV-CU (n=3) 
and half the mice injected with Ad5-GFP (n=3) the remaining mice in the group 
received an equal volume control PBS injection IP. Mice were monitored for signs 
of ill health (loss of body weight and grooming behaviour) and tumour volume was 
monitored regularly for decreased growth rate. All mice were culled after 62 days 
and tumours harvested along with the kidneys and sent for H&E staining. Under 
UK Home Office regulations, mice were killed accordingly when tumours reached 
the maximum allowed size of 1.4 cm2, or when there were signs of ulceration. 
2.9.5 Intratumoural toxicity of Ad5-TV-CU in combination with 
5-FC in CD-1 mice bearing 22RV1 xenografts 
When tumours reached 100 mm3 mice were randomly allocated to receive a single 
intratumoural does of 1010 pt of Ad5-TV-CU (n=8) on days 1, 3 and 5 directly into 
in the 22RV1 xenografts. The tumours on the remaining 4 mice were left 
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untreated. On days 2, 4 and 6 weight dependent doses (100 mg/kg) of 5-FC were 
administered intraperitoneally (IP) to half the mice injected with Ad5-TV-CU (n=4) 
the remaining mice injected with Ad5-TV-CU received an equal volume control IP 
PBS injection. Mice were monitored for signs of ill health and tumour volume was 
monitored regularly for decreased growth rate. All mice were culled by day 31 and 
tumours harvested for H & E staining. Under UK Home Office regulations, mice 
were killed accordingly when tumours reached the maximum allowed size of 1.4 
cm2, or when there were signs of ulceration. 
2.9.6 Tissue preservation and processing 
Harvested tumour samples and organs were prepared for paraffin processing by 
fixing at RT overnight in 4% formalin before transfer to 70% ethanol. Paraffin-
embedded tissue sectioning and Haematoxlin and Eosin (H&E) straining were 
carried out by George Elia (Pathology Service, Barts Cancer Institute). 
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CHAPTER THREE 
 
 
 
GENERATION OF NON-REPLICATING 
AD5-TMPRSS2-VISA-CD/UPRT 
(AD5-TV-CU) VIRUS 
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3.1 INTRODUCTION 
Recombinant adenoviruses are useful tools for gene delivery and expression. 
They have been successfully used for gene therapy, vaccine therapy and in basic 
research (Graham and Prevec 1992, Breyer et al. 2001, McConnell and Imperiale 
2004). They are capable of infecting a broad range of epithelial cell types and 
infection is not dependent on host cell division. Ad5 is the most commonly used 
human adenovirus serotype and can be rendered replication-defective by deletion 
of the E1A gene. The E1A gene is essential for viral replication, the E1B genes for 
preventing premature apoptosis and the E3 genes are responsible for evading the 
host immunity. Thus, deletion of all of these viral genes not only renders the virus 
replication-deficient, but also generates space for up to 7.5 kb foreign DNA, this is 
important due to the packaging limitations of the particle (Benihoud, Yeh, and 
Perricaudet 1999). 
There are three main cloning strategies used for generating recombinant 
adenoviruses. These include: 1) Direct ligation of DNA sequences containing 
transgenes, into the adenoviral genome by complementary restriction sites. This 
approach is not widely used due to difficulties in finding unique restriction sites in 
the adenoviral genome, difficulty purifying large viral genomic DNA fragments and 
low ligation efficiency. 2) Utilizing site specific recombinases for example Cre 
recombinase/lox P that allows targeted insertion of a transgene into the adenoviral 
genome. 3) Homologous recombination in mammalian or bacterial cells using a 
two vector system. Homologous recombination requires a shuttle vector, usually 
containing the 5’ end of the genome in which the E1 and other non essential 
genes are replaced with a transgene and the pAdEasy backbone vector that 
contains the majority of adenoviral DNA, but lacks essential genes for viral 
replication if making a replication-deficient virus (deleted in E1 and E3 genes). 
After homologous recombination the pAdEasy adenoviral backbone will contain 
the transgene of interest (Luo et al. 2007, Figure 29). This is a commonly used 
strategy for generating non-replicating adenoviruses and has been selected by me 
as the approach for cloning Ad5-TV-CU, as it has been used successfully to 
generate numerous replication-deficient viruses including several transgene-
expressing non-replicating Ad5 mutants in the Halldén team (e.g. (Miranda et al. 
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2012, Leitner et al. 2009); Sweeney et al, manuscript in preparation) as well as in 
a number of other labs (Youlin et al. 2010, Ohs et al. 2013).  
 
Figure 29 Schematic demonstrating the pAdEasy system. 
The gene of interest is initially cloned into the empty shuttle vector and digested with 
Pme1. Linearised pShuttle is electroporated together with pAdEasy in BJ5183 cells to 
produce recombinant pAdEasy. After linearization with Pac1, recombinant pAdEasy is 
transfected into HEK293 cells for packaging of the virus. Adapted from (Luo et al. 2007). 
For homologous recombination to take place the pShuttle vector containing the 
gene of interest must share regions of homology with the p-AdEasy adenoviral 
backbone vector. There are four different commercially available pShuttle vectors 
to choose from for this purpose: empty pShuttle, CMV driven pShuttle, pAdTrack 
and pAdTrack-CMV (Figure 30), the latter two of which contain an expression 
cassette encoding GFP in order to assess the transduction efficiency of the virus. 
Although the ability to quantify transduction efficiency is beneficial, it reduces the 
capacity for inserting the gene of interest, due to essential space being taken up 
by GFP. All four vectors share a homologous left and right arm with the pAdEasy 
backbone plasmid. The generation and production of all adenoviruses used in this 
thesis was performed in a registered biosafety level 2 laboratory. 
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For this study the empty pShuttle was used in order to place transgene expression 
(CD/UPRT) under the control of the TMPRSS2 promoter. Additionally, the whole 
expression cassette is too large to insert into a plasmid containing GFP. There are 
also two non-replicating pAdEasy backbone vectors to choose between: pAdEasy-
1 or pAdEasy-2. pAdEasy-1 is an E1 and E3 double deleted vector, whereas 
pAdEasy-2 is an E1, E3 and E4 triple deleted vector. pAdEasy-1 can be easily 
propagated in 293 cells that express E1, however, in order to produce pAdEasy-2 
derived viruses, cell lines that express both E1 and E4 are required, these are 
hard to come by as E4-expressing cells are often lost after serial passages. 
Therefore, the most commonly used backbone is pAdEasy-1, and has been 
chosen as is the most suitable and appropriate backbone plasmid for this study. 
 
Figure 30 pShuttle plasmids available with the pAdEasy system.  
There are four different shuttle plasmids available for use with the pAdEasy system empty 
pShuttle, CMV driven pShuttle, pAdTrack and pAdTrack-CMV, the latter two of which 
contain encode GFP (green) in order track viral transduction.  
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3.2 RESULTS 
3.2.1 Generation of Ad5-TV-CU 
3.2.1.1 Lack of CD/UPRT expression using a previously 
engineered Ad5-TV-CU adenovirus. 
A replication-defective adenovirus construct had previously been generated, in 
which the TMPRSS2 promoter controlled the expression of the CD/UPRT suicide 
gene by a TSTA system (see introduction section 1.7.1); constructed by Ahmet 
Imrali in our team, unpublished data). However, no expression of CD/UPRT after 
viral infection in AR-positive cell lines was detected despite potent expression from 
the original VISA plasmid. Steps were therefore taken to establish at which point 
the viral CD/UPRT expression had become compromised. Transfection of cells 
with the L-VISA vector, the original two-step-transcriptional amplification (TSTA) 
plasmid that has the TMPRSS2 promoter inserted, showed good CD/UPRT 
expression (Figure 31). The expression cassette from this plasmid was inserted 
into a shuttle vector (pShuttle) in order to create a new Ad5-TV-CU by homologous 
recombination with a pAdEasy viral backbone. No expression of CD/UPRT was 
detected at protein level from pShuttle-CD/UPRT. The possible reasons for this 
were 1) the pShuttle-CD/UPRT plasmid is larger in size than the L-VISA plasmid 
and, therefore harder to transfect into cells (12kb in comparison to L-VISA which is 
8kb), 2) essential elements of the expression cassette may have been removed in 
the cloning of pShuttle-CD/UPRT, 3) there may be an element in the pShuttle 
vector that interferes with the transcription of the CD/UPRT gene and 4) the 
orientation of the expression cassette within the pShuttle vector may affect 
transcription. The decision was therefore made to re-clone pShuttle-CD/UPRT. 
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Figure 31 CD/UPRT cannot be detected after transfection with pShuttle-CD/UPRT   
Western blots of protein lysates transfected with L-VISA and pShuttle-CD/UPRT in 22RV1, 
HEK293 and PNT1A cell lines. CD/UPRT protein expression (43 kDa) was visualised from 
L-VISA 22RV1 transfected cell lines, however only slight expression is demonstrated from 
pShuttle-CD/UPRT in 22RV1 cells. 22RV1 cell lysate previously transfected with L-VISA 
was used as a positive control (+ve). ß-actin was used as a loading control. 
3.2.1.2 Generation of pShuttle-CMV-EGFP. 
A pShuttle-CMV-EGFP control plasmid was constructed, to determine transfection 
efficiency of the pShuttle vector. pShuttle is required for homologous 
recombination with the pAdEasy adenoviral backbone (see section 2.6.3). The 
1.65 kb CMV-EGFP construct was removed from the pEGFP–C2 plasmid (Dr. M. 
Yuan, Centre for Molecular Oncology, BCI) by digestion with AseI and MluI, 
blunted and ligated into an empty pShuttle vector (analogous to the CD/UPRT 
construct described above). Transformation of bacteria with the plasmid, selection 
of colonies and preparation of stock in LB Kanamycin resulted in preparation of 
pShuttle-CMV-EGFP (Figure 32). At 24 h after transfection of 22RV1 cells, more 
than 50% of cells were positive for GFP expression as observed by fluorescence 
microscopy, demonstrating that the pShuttle plasmid used in previous transgene 
constructions was fully functional.  
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Figure 32 Plasmid map of pShuttle CMV-EGFP 
CMV-GFP was cloned into the pShuttle vector as a control for pShuttle transfection 
efficiency. Activation of the universal CMV promoter drives expression of EGFP. 
3.2.1.3 Generation of a new pShuttle-CD/UPRT. 
Following demonstrable functionality of the original pShuttle the decision was 
made to re-clone pShuttle-CD/UPRT. Thus, the TMPRSS2-VISA-CD/UPRT 
expression cassette was again excised from L-VISA and cloned into an empty 
pShuttle vector.  
7/8 of the colonies gave bands of 3.9 kb and 8.4 kb in size, corresponding to 
recombinant pShuttle-CD/UPRT. One colony out of eight was empty pShuttle (6 kb 
in size) (Figure 33A). Recombinants that showed bands at the right size after 
digestion were sent for sequencing (The Genome Centre, Barts Cancer Institute). 
Sequencing confirmed the insertion of the entire TMPRSS2-VISA-CD/UPRT 
expression cassette and miniprep 5 was chosen for maxiprep, resulting in 
preparation of pShuttle-CD/UPRT (Figure 33B).  
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Figure 33 Plasmid map of pShuttle-TMPRSS2-VISA-CD/UPRT 
A. Gel image showing 3.9 kb and 8.4 kb bands that correspond to recombinant pShuttle-
CD/UPRT for eight different miniprep samples alongside the uncut plasmid. All miniprep 
samples except for sample 6 were recombinant. B. Diagrammatic showing the TMPRSS2-
VISA-CD/UPRT expression cassette cloned into the pShuttle vector. The pShuttle vector 
has complementary left and right arms to the pAdEasy backbone, for the first step in 
production of Ad5-TV-CU. 
3.2.1.4 CD/UPRT is more potently expressed from the L-
VISA plasmid than from the pShuttle-CD/UPRT construct in 
22RV1 cells. 
pShuttle-CMV-EGFP, pShuttle-CD/UPRT and L-VISA were transfected into 22RV1 
and HEK293 cells. pShuttle-CMV-EGFP was utilized as a control to confirm 
transfection efficiency, 60% of the cells showed EGFP expression at 48 h. Protein 
lysates were prepared 24 h and 48 h later from cells transfected with L-VISA 
(Figure 34A) or pShuttle-CD/UPRT (Figure 34B) and levels of CD/UPRT 
expression determined by Western blot. Expression levels were noticeably lower 
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in pShuttle-CD/UPRT transfected cells. This is likely due to the fact that the 
pShuttle-CD/UPRT is a much larger plasmid (12.2 kb) than L-VISA (8.3 kb) and 
therefore has lower transfection efficiency. This was confirmed by Quantitative-
PCR (Figure 34C) 
 
Figure 34 CD/UPRT is more potently expressed from the L-VISA plasmid than from 
the pShuttle-CD/UPRT construct in 22RV1 cells 
Western blots of protein lysates from cells transfected with L-VISA (A) or pShuttle-
CD/UPRT (B) in both 22RV1 and HEK293 cell lines. Sheep Anti-CD/UPRT Antibody was 
used to reveal protein expression (43 kDa). Protein expression was visualised from L-VISA 
22RV1 transfected cell lines at 24 h and 48 h. However, only slight expression was 
demonstrated at 48 h upon transfection with pShuttle-CD/UPRT. A 22RV1 cell lysate 
previously transfected with L-VISA was used as a positive control (+ve). ß-actin was used 
as a loading control (42 kDa). Blots are representative of 3 independent experiments. C. 
Quantitative-PCR results relative to genomic DNA 48 h after transfection. One experiment 
with samples in duplicate, showing 7x the concentration of L-VISA plasmid entering cells 
compared to pShuttle- CD/UPRT. 
3.2.1.5 Generation of a new recombinant pAdEasy-
TMPRSS2-VISA-CD/UPRT 
In order for efficient homologous recombination to take place the pAdEasy 
adenoviral backbone plasmid must be in its supercoiled form. A new preparation of 
7.2x 
1x 
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pAdEasy-1 was therefore made and run on a gel to determine the supercoiled 
status of the plasmid. The majority of the plasmid was not supercoiled after the 
new stock was prepared (Figure 35) but the decision was made to go ahead with 
the homologous recombination.   
 
Figure 35 Generating supercoiled pAdEasy 
pAdEasy was run on a 1% agarose gel to show the percentage of supercoiled plasmid, 
plasmid (not supercoiled) and nicked plasmid DNA. The majority of the plasmid DNA was 
not supercoiled (middle band), with less supercoiled (bottom band) and nicked DNA (top 
band). 
pShuttle-CD/UPRT was completely linearised with Pme1 and dephosphorylated to 
prevent re-ligation. Homologous recombination was performed according to 
materials and methods section 2.6.3 and potential recombinants grown O/N on 
Kanamycin plates (Figure 36). 
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Figure 36 Diagram showing homologous recombination between pShuttle-CD/UPRT 
and the pAdEasy adenoviral backbone. 
Schematic representation of the pAdEasy system. The TMPRSS2-VISA-CD/UPRT 
expression cassette was cloned into the pShuttle vector and linearised by digestion with 
PmeI. The linearised plasmid was electroporated with the pAdEasy backbone into BJ5183 
cells and recombinant colonies selected for by Kanamycin resistance. 
After growth on Kanamycin plates, 20 potential small recombinants (which usually 
represent the recombinant colonies) were selected and grown overnight in 10 ml 
LB containing Kanamycin. Cracking gel analysis was performed on 1 ml of 
bacterial culture from all 20 clones (see section 2.2.5). Four potential different 
populations were generated: 1) non-recombinant (pAdEasy alone 7/20), 2) non-
recombinant (pShuttle-CD/UPRT alone 9/20), 3) recombinant pAdEasy-
TMPRSS2-VISA-CD/UPRT that has undergone HR between the origin of 
replication (3/20) and, 4) recombinant pAdEasy-TMPRSS2-VISA-CD/UPRT that 
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has undergone HR between the left and right arms of the two vectors (1/20) 
(Figure 37).  
 
Figure 37 Cracking gel showing different clones identified after homologous 
recombination 
20 colonies were picked and cracking gel analysis performed on 1 ml bacterial culture. 
Four different populations were generated (shown in white). Of the 20 colonies six were 
chosen for further analysis (circled) by miniprep and Pac1 digestion to confirm the four 
different populations. 
Six of the potential recombinants were miniprepped from 1.5 ml bacterial culture 
and digested with Pac1 to confirm which of the recombinants contained the entire 
5.7 kb TMPRSS2-VISA-CD/UPRT expression cassette (Figure 38). Digestion 
confirmed the four different populations that were seen on the cracking gel. Clone 
20 was identified as the correct recombinant, where recombination had taken 
place between the left and right arms, (giving a 3 kb band plus a higher band) 
clones 8 + 10 (giving a 5 kb band plus a higher band) were recombinant within the 
origins of replication and were therefore not used any further. Clones 1 + 7 
showed a 3 kb digested band and a higher band that corresponded to pAdEasy 
alone and finally clone 13 consisted of a 3 kb digested product and a lower band 
that corresponded to the pShuttle plasmid alone. 
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Figure 38 Restriction digest identified clone 20 as recombinant pAdEasy-TMPRSS2-
VISA-CD/UPRT 
Six colonies were miniprepped and digested with Pac1 to establish which clones were 
recombinants. Clones that were recombinant between the left and right arms generated a 
3 kb band (clone 20, due to the removal of the origin of replication and the Kanamycin 
resistance gene). Clones that were recombinant between the origin of replication produced 
a slightly higher band at 5 kb (clones 8 +10) and finally clones that were pAdEasy alone 
produced a 3 kb band with an additional smaller band (clones 1, 7 and 13) 
Clone 20 was electroporated into chemically competent Top10 bacteria, to prevent 
further homologous recombination within the BJ5183 bacterial cells. 3 clones were 
picked and digested with; Nhe1 or Pac1, all clones gave the same restriction 
digestion pattern and sample 20.1 was selected for maxiprep (Figure 39).  
 
Figure 39 Restriction digest of clone 20 from electroporated TOP10 cells 
All three subclones from clone 20 (20.1, 20.2 and 20.3) were digested with Pac1 to 
generate two bands of 3 kb and >12 kb and Nhe1 to generate multiple bands of 3168 bp, 
3429 bp, 3848 bp, 8194 bp, 9100bp and 10342 bp. All three clones generated the same 
restriction profile. 
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Following identification of recombinant colonies via restriction digestion analysis, 
Ad5-TV-CU was produced in bulk, purified and characterised (see methods 
sections 2.6.5, 2.6.6 and 2.7) Caesium Chloride banding was performed to purify 
the virus and the correct band, corresponding to fully encapsulated Ad5-TV-CU 
dialysed, aliquoted into 1 ml volumes and stored at -80ºC ready for virus 
characterisation (Figure 40). The purified virus had a particle count of 2.33 x1011 
(Ad5-TV-CU #1) and 8.9 x1011 (Ad5-TV-CU #2) and a viral titre of 3.6 X108 (Ad5-TV-CU 
#1) and 4.94X10
9 (Ad5-TV-CU #2). 
  
Figure 40 Caesium chloride banding 
After ultracentrifugation three bands can be seen in the ultracentrifuge tube corresponding 
to: fully encapsulated viral particles (red) empty particles (blue) and cell debris (cream). 
The lower red band containing the fully encapsulated particles is extracted and dialysed. 
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3.3 DISCUSSION 
The biggest barrier preventing the production of an effective gene therapy is the 
absence of a safe and efficient vector system that can transport therapeutic genes 
into target cells. The predominant viral vectors utilised for cancer gene therapy are 
currently Adenovirus, Adeno-associated virus, retrovirus and vaccinia virus, of 
which adenovirus is the most commonly used and best characterised in cancer. In 
order to produce an effective adenoviral construct steps must be taken to limit 
toxicity to target cells, in order to safely deliver large concentrations of adenovirus 
for therapeutic efficacy (Duffy et al. 2005). Targeting the activity of adenoviral gene 
therapy systems through use of tissue specific promoters is a good way to limit off-
target toxicity. However, tissue specific promoters have not been able to generate 
sufficiently high levels of transgene expression to induce cell killing alone. 
Therefore, steps to improve transgene expression through a number of methods, 
including the identification of optimal promoter/enhancer regions, duplication of 
enhancers and promoter/enhancer fusion (Latham et al. 2000), as well as the use 
of two-step-transcriptional amplification systems, have resulted in increased 
therapeutic efficacy. In this case, Ad5-TV-CU contains the CD/UPRT transgene 
under the control of TMPRSS2 promoter elements. In order to increase transgene 
expression from this promoter, a two-step-transcriptional amplification system 
(VP16-GAL4-WPRE integrated systemic amplifier VISA) was cloned into the 
vector to intensify CD/UPRT expression levels. In addition to high level gene 
expression, adenovirus purity is essential, as with any drug or biological product 
that is destined for use in humans, as it affects the potency and safety of the 
treatment. The production of these viruses must adhere to Good Manufacturing 
Processes (GMP) to even be considered for use in humans (Working, Lin, and 
Borellini 2005). 
An original preparation of the Ad5-TV-CU virus failed to work in subsequent in vitro 
studies. There are several possible reasons for the poor activity of the original 
preparation of Ad5-TV-CU that could include; 1) selection of the wrong 
recombinant, 2) poor packaging due to the size of the TMPRSS2-CD/UPRT 
expression cassette, 3) failed homologous recombination and 4) an impure 
production of the virus. All of which led to the need to re-clone the pShuttle-
CD/UPRT vector. Although pShuttle-CD/UPRT was unable to generate sufficiently 
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high levels of CD/UPRT expression after transfection, further investigation 
suggested that this was due to the poor transfectability of pShuttle-CD/UPRT, 
most probably due to its large size (section 3.2.1.4). In fact, a previous study 
identified difficulties in transfecting larger plasmids into primary human myoblasts 
(Campeau et al. 2001). PCa cells are traditionally difficult to transfect, and very 
few plasmid based therapies exist for PCa, therefore, in order to improve 
transduction of the TMPRSS2 driven CD/UPRT expression cassette, it was 
inserted into a non-replicating adenoviral backbone, producing Ad5-TV-CU. To 
accomplish this pShuttle-CD/UPRT was electroporated together with pAdEasy into 
BJ5183 cells to promote homologous recombination between the two plasmids 
and consequently produce the adenoviral backbone containing the TMPRSS2 
driven CD/UPRT expression cassette. The new preparation of Ad5-TV-CU was 
subsequently tested in vitro and demonstrated CD/UPRT expression post-
transfection. 
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CHAPTER FOUR 
 
 
 
 
 
 
ACTIVITY OF AD5-TV-CU IN VITRO 
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4.1 INTRODUCTION 
Prostate specific promoters have been employed to restrict transgene expression 
from non-replicating viruses in a number of in vitro studies (Latham et al. 2000, 
Wu, Matherly, et al. 2001), however poor transgene expression due to weak 
promoter activity has led to clinical failure of these viruses.  Attempts to increase 
transgene expression have included two-step transcriptional amplification systems 
and chimeric promoters (Wu, Matherly, et al. 2001, Li et al. 2005). In total there 
have been 351 cancer adenoviral gene therapy clinical trials. Of the 351 trials, 64 
have focussed on the introduction of a suicide gene to induce cell killing. Only 2 of 
these viral vectors have progressed to phase III clinical trials for the treatment of 
PCa in combination with radiotherapy and they are currently ongoing 
(NCT01436968 and US-0842 (Barton et al. 2008, Aguilar, Guzik, and Aguilar-
Cordova 2011)). These include a virus expressing CD/HSV-TK in combination with 
intensity modulated radiotherapy (IMRT) and the ProstAtak virus expressing HSV-
TK in combination with radiation therapy (see introduction Table 10). Neither of 
them utilise prostate specific promoters to drive transgene expression. Therefore, 
there is a need for more targeted and effective therapies for PCa. 
Previous studies in our team demonstrated the strength and specificity of the ‘L’ 
promoter (in the TMPRSS2 gene), located upstream of Exon2, driving a luciferase 
plasmid in 22RV1 cells (Kevin Sharp, unpublished see introduction Section 1.7.1). 
After cloning the L-VISA expression cassette into a pShuttle vector and 
subsequent homologous recombination with the pAdEasy backbone, Ad5-TV-CU 
was produced (Section 3.2.1.5). 22RV1 AR-positive cells demonstrated high level 
expression of both luciferase and CD/UPRT after plasmid transfection. 
Experiments were therefore performed to establish whether Ad5-TV-CU would be 
effective in a panel of AR-positive cell lines, including AR-positive BCa. 
MM453 and MCF7 BCa cell lines belong to the apocrine subtype of BCa, with a 
gene profile characterized by active AR signalling. MM453 have demonstratably 
expressed similar levels of AR to LNCaP (Hall et al. 1994), with cell proliferation 
stimulated by androgens, presenting the potential for the application of Ad5-TV-CU 
(activated by AR stimulation of the TMPRSS2 promoter) in this cell line (Birrell et 
al. 1995). Some studies have also reported a role for ER in the transcriptional 
activation of the TMPRSS2 promoter and upregulation of the TMPRSS2:ERG 
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fusion gene in PCa as a consequence (Setlur et al. 2008, Bonkhoff and Berges 
2009). This evidence highlights the cross-talk between ER and AR target genes 
and pathways.   
It is therefore important to establish: 1) the therapeutic potential of Ad5-TV-CU in 
AR-positive PCa 2) the therapeutic potential of Ad5-TV-CU in AR-positive BCa 
and 3) whether ER is responsible for TMPRSS2 promoter activity as opposed to 
AR. 
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4.2 RESULTS 
4.2.1 An initial proof of concept study in 22RV1 cells. 
4.2.1.1 AR expression in PCa cell lines. 
In order to establish in which cell lines the Ad5-TV-CU virus would be active, 
expressing the enzyme from the androgen-regulated TMPRSS2 promoter, AR 
expression levels in PCa cell lines were established. AR levels in MCF7 cells, a 
BCa cell line that has previously been shown to express AR, were also evaluated 
(Guthrie et al. 1997, Cochrane et al. 2014).  
Only 22RV1, VCaP and LNCaP cells expressed AR (Figure 41). 22RV1 cells 
showed two bands on the western blot, due to the three spliced isoforms of AR in 
this cell line. A full-length version with duplicated exon 3 (Ex3dup at approximately 
115 kDa) (Tepper et al. 2002) and two truncated versions lacking the COOH 
terminal domain (CTD) (AR1/2/2b and AR1/2/3/2b 70-80 kDa) (Dehm et al. 2008). 
These isoforms are constitutively active and similar in size, promoting expression 
of endogenous AR-dependent genes. VCaP cells also express two forms of AR; 
an amplified AR gene locus that encodes full length wildtype AR protein (110 kDa) 
and the shorter version of AR found in 22RV1 cells (AR1/2/2b 75 kDa). LNCaP cells 
express only the full length 110 kDa AR. The PNT2 and PNT1A normal 
immortalized prostate epithelial cells did not express AR protein. However, there is 
evidence to suggest that these cells express low levels of AR mRNA and protein 
(Coll-Bastus et al. 2015). In fact, AR protein expression has previously been 
detected in PTN2 cells with a sensitive Western blotting method (Blanchere et al. 
1998) and in PNT2 and PNT1A cells by immunoprecipitation (Coll-Bastus et al. 
2015). No AR protein expression could be detected in the MCF7 BCa cell line, 
Panc1 pancreatic cancer cell line or the primary prostate epithelial and stromal 
cells PrEC and PrSC.   
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Figure 41 AR expression in seven PCa cell lines, the MCF7 BCa cells and the Panc1 
pancreatic cancer cells  
Cell lysates were collected and 30 µg loaded on a protein gel. Rabbit anti-AR antibody was 
used to reveal AR expression in all cell lines. AR was only detected in 22RV1, VCaP and 
LNCaP as expected. Mouse anti-ß-actin antibody was used as a loading control (42 kDa).  
4.2.1.2 CD/UPRT protein expression was detected in 
22RV1 cells following viral infection. 
To verify the activity of Ad5-TV-CU in AR-positive cell lines and evaluate 
CD/UPRT transgene expression, 22RV1 AR-positive, androgen-independent cells, 
were used for an initial proof of concept study. TMPRSS2 is an androgen-
regulated gene. It is therefore expected the promoter of TMPRSS2 is activated by 
binding of AR to one or several of the identified AREs in the 5’ UTR of the gene. 
Therefore, we expected that the Ad5-TV-CU virus would express the CD/UPRT 
protein in cells with a functional AR (22RV1, VCaP and LNCaP) and not in AR-
negative cells (DU145, HEK293, Panc1). A dose dependent increase in CD/UPRT 
expression (43 kDa) was detected in 22RV1 cells, while the AR-negative DU145 
cells showed no expression of CD/UPRT, demonstrating that CD/UPRT 
expression from Ad5-TV-CU is specific to AR-expressing cells (Figure 42). 
 
 
Figure 42 CD/UPRT protein expression was detected in 22RV1 cells but not DU145 
cells following viral infection 
22RV1 and DU145 cells were infected with 1000 ppc, 2000 ppc and 3000 ppc of Ad5-TV-
CU and protein lysates collected at 48 h. 30 µg lysate was run on a protein gel. A 22RV1 
cell lysate previously transfected with L-VISA was used as a positive control (+ve). Sheep 
anti-CD/UPRT antibody was used to reveal CD/UPRT expression (43 kDa). Mouse anti-ß-
actin antibody was used as a loading control (42 kDa). Representative blot of 5 
independent experiments. 
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4.2.1.3 CD/UPRT protein expression did not increase in 
22RV1 cells upon addition of Mibolerone nor decrease upon 
addition of Bicalutamide. 
It was important to establish whether the levels of CD/UPRT expression could be 
increased upon addition of the synthetic androgen Mibolerone, or decreased by 
the anti-androgen Bicalutamide due to AR dependent transcriptional activation of 
Ad5-TV-CU in 22RV1 cells. To establish whether the levels of CD/UPRT 
expression could be increased by activation of AR, the AR agonist mibolerone was 
added to 22RV1 cells after infection with Ad5-TV-CU at 1000 and 2000 ppc. No 
apparent increase in CD/UPRT protein expression was detected with the addition 
of 1 nM mibolerone at 48 h or 72 h. Western blot showing transgene expression at 
48 h is shown in Figure 43A.  
To test whether the mutated AR expressed in 22RV1 cells is also less responsive 
to antagonism, the AR antagonist Bicalutamide was added to cells after infection 
with Ad5-TV-CU and levels of CD/UPRT transgene assesed at 48 and 72 h. No 
apparent decrease in CD/UPRT protein expression was detected after infection 
with Ad5-TV-CU at 1000 and 2000 ppc in combination with 5 µM Bicalutamide. 
Western blot showing transgene expression is shown in Figure 43B. These data 
suggest a potential new treatment strategy for PCa that simultaneously targets 
PCa specific cell death through Ad5-TV-CU, whilst limiting PCa cell growth 
through Bicalutamide, with no effect on Ad5-TV-CU efficacy. This would need to 
be further explored in a number of AR dependent cell lines to establish the true 
clinical benefit of this concomitant therapy. 
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Figure 43 CD/UPRT protein expression did not increase in 22RV1 cells upon addition 
of synthetic androgen mibolerone, nor decrease upon addition of anti-androgen 
Bicalutamide. 
22RV1 cells were infected with 1000 and 2000 ppc of Ad5-TV-CU. Two hours after 
infection the media was removed and replaced with 10% C/S media containing A. 
mibolerone (1 nM) or B. Bicalutamide (5 µM). Cells were lysed after 48 h and 30 µg of 
protein run on a gel, UN= uninfected. Sheep Anti-CD antibody was used to reveal 
CD/UPRT expression (43 kDa). Mouse anti-ß-actin antibody was used as a loading control 
(42 kDa). Representative blots of 3 independent experiments. 
4.2.1.4 Addition of the non-toxic prodrug 5-FC to 22RV1 
cells infected with Ad5-TV-CU, results in dose-dependent cell 
killing. 
It was important to establish the specificity and toxicity of the replication-defective 
adenoviral mutant (Ad5-TV-CU) alone in 22RV1 cells, to establish the potency of 
the virus in 22RV1 AR-positive cells in comparison to other AR-positive and AR-
negative PCa cell lines. Dose response curves were generated and cell death 
assessed three days post-infection to determine viral EC50 (Effective 
Concentration, the dose required to kill 50% of cells) values. One representative 
graph out of 5 independent experiments is shown in Figure 44A and the mean 
EC50 value for these experiments was 485 ppc ± 96.7 ppc.  
Following on from this, the toxicity of 5-FC (pro-drug) and 5-FU (toxic metabolite) 
were determined to establish an appropriate concentration at which to add 5-FC in 
combination with Ad5-TV-CU. Dose response curves were generated for both 
drugs in 22RV1 cells from the highest feasible dose (dependent on stock 
concentration) of 1 mg/ml (Figure 44B). 5-FC alone is non-toxic to 22RV1 cells up 
  169 
 
to 500 µg/ml, however the highest feasible dose of 1 mg/ml resulted in 35-45% cell 
death. As expected 5-FU is highly toxic to 22RV1 cells, the average EC50 value 
from five independent experiments was 1.75±0.42 μg/ml. These results confirm 
that 22RV1 cells can tolerate doses of 5-FC up to 500 µg/ml before cell killing is 
initiated, doses below 500 µg/ml are therefore defined as suboptimal. However, 
doses of 1.75 μg/ml 5-FU are sufficient to kill 50% of cells, confirming that only a 
very small quantity of 5-FU, converted from 5-FC by CD/UPRT, is required to 
induce high levels of cell killing. Therefore, the optimal dose of 500 µg/ml 5-FC in 
combination with Ad5-TV-CU will induce the maximum levels of 5-FU specific cell 
death. 
 
Figure 44 Dose-response assays to establish EC50 values for Ad5-TV-CU, 5-FC and 
5-FU in 22RV1 cells.  
A. Ad5-TV-CU was diluted 1/5 from 1x10
5
 to 0.2 ppc. 10 µl of the viral dilution was added 
to 90 μl or media containing 2x10
4
 22RV1 cells in each 96-well. MTS was performed after 
72 h and cell viability calculated relative to untreated control wells. The mean EC50 was 
485±96.7 ppc, n=5. B. 5-FU and 5-FC drugs were diluted 1/5 from 1 mg/ml to 2.5 ng/ml, 10 
μl of the dilutions were added to 90 μl of media containing 2x10
4 
22RV1 cells in a 96 well 
plate. MTS was performed after 72 h and cell viability calculated relative to untreated 
control wells. It was not possible to establish a dose response curve with 5-FC, while the 
addition of 5-FU resulted in an average EC50 of 1.75 ± 0.42 μg/ml, n=5. Data shown is 
mean of duplicates ± SEM from one experiment, representative of five. 
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Once the EC50 values for Ad5-TV-CU, 5-FC and 5-FU alone had been generated, 
5-FC was combined with Ad5-TV-CU in prodrug sensitization assays to 
demonstrate enhanced and AR-specific cell killing, due to the target cell selectivity 
of Ad5-TV-CU. Doses of 5-FC were selected from the dose-responses to 5-FU 
covering a range of concentrations (1-500 µg/ml). None of the selected 
concentrations of 5-FC induced toxicity in 22RV1 cells alone, apart from the 
highest concentration of 500 ug/ml, that induced 45% cell death alone (Figure 
44B). Cell viability was calculated relative to untreated control well for virus alone, 
or cells treated with drug alone for combination of Ad5-TV-CU and 5-FC. The 
combination of Ad5-TV-CU and increasing concentrations of 5-FC resulted in 5-FC 
dependent increased cytotoxicity (Figure 45A), illustrated by decreased viral EC50 
values in response to increasing doses of 5-FC (Figure 45B). Increased 
cytotoxicity was accomplished with all doses of 5-FC, except for the lowest dose of 
1 µg/ml, that had no effect on virus-mediated cell killing. There was a significant 
decrease in EC50
 values with the combination of Ad5-TV-CU and 100 µg/ml 5-FC 
in comparison to Ad5-TV-CU alone (p-value <0.05). This difference became highly 
significant when 500 µg/ml 5-FC was added in combination with Ad5-TV-CU (p-
value <0.01). Representative data from four independent experiments is shown 
(Figure 45B). Average EC50 values ± SEM of virus alone and in combination with 
5-FC can be seen (Table 28).  
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Figure 45 Combination of Ad5-TV-CU and 5-FC in 22RV1 cells generates 5-FC dose 
dependent shifts in EC50 values  
A. Ad5-TV-CU was diluted 1/5 from 1x10
5 
ppc to 0.2 ppc. 10 µl of the viral dilution was 
added to 80 μl (for the combination with 5-FC or 90 μl for virus alone) of media containing 
2x10
4
 22RV1 cells/well. Fixed doses of 5-FC were added at 1 μg/ml, 10 μg/ml, 100 μg/ml 
and 500 µg/ml and MTS performed after three days. Cell viability was calculated relative to 
untreated control wells for virus alone, or cells treated with drug alone for combination of 
Ad5-TV-CU and 5-FC. Data shown is mean of duplicates ± SEM from one experiment, 
representative of four. B. Graph shows reduction in EC50 values in 22RV1 cells treated 
with fixed 5-FC prodrug at 10 μg/ml, 100 μg/ml and 500 μg/ml. Statistical analysis was 
performed using the 1 way ANOVA test with Tukey’s multiple comparison test. * p-value 
<0.05, ** p-value <0.01, n=4. 
Table 28 Average EC50 values for combinations of Ad5-TV-CU and 5-FC ± SEM in 
22RV1 cells 
TREATMENT 
Ad5-TV-CU dose response + 5-FC (µg/ml) 
Ad5-TV-CU EC50-values  
(ppc) 
0  485.4 ± 96.7  
1 µg/ml  560.2 ± 118.8  
10 µg/ml  327.6 ± 63.1  
100 µg/ml  265.2 ± 52.8 * 
500 µg/ml  145.0 ± 31.1 ** 
* p-value <0.05, ** p-value <0.01 
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4.2.2 Activity of Ad5-TV-CU in other AR-positive cell lines. 
4.2.2.1 No 5-FC dose dependent cytoxicity is observed 
in prodrug sensitization assays with AR-positive, androgen-
dependent cell lines LNCaP and VCaP 
Whilst the enhanced cell killing in 22RV1 cells was encouraging, it was important 
to also validate these results in a larger panel of AR-positive cell lines to determine 
the AR specific transcriptional activation of Ad5-TV-CU. To fit this purpose the 
same experiments were conducted in two additional AR-positive cell lines, LNCaP 
and VCaP. Dose-dependent increases in CD/UPRT expression were observed 
following infection of VCaP cells with Ad5-TV-CU at 1000, 2000 and 3000 ppc 
(Figure 46A).  However, only small dose-dependent increases in CD/UPRT 
expression could be detected in LNCaP cells following Ad5-TV-CU infection, that 
could not be replicated in two further experimental repeats (representative blot in 
Figure 46B). The doses of Ad5-TV-CU selected to infect LNCaP cells were much 
higher than 22RV1 and VCaP AR-positive cell lines, yet were unable to induce 
CD/UPRT transgene expression. Possible reasons for this may be that LNCaP 
cells are less infectable than 22RV1 and VCaP, or that they are not capable of 
stimulating AR-dependent transcriptional activation of Ad5-TV-CU (discussed 
below). 
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Figure 46 CD/UPRT protein expression was detected at high levels in VCaP cells but 
not LNCaP cells following Ad5-TV-CU viral infection  
A. VCaP cells were infected with Ad5-TV-CU at 1000 ppc, 2000 ppc and 3000 ppc. Protein 
lysates were collected at 48 h and 30 µg of protein run on a gel. A dose dependent 
increase in CD/UPRT expression was detected. Representative blot of two independent 
experiments. B. LNCaP cells were infected with Ad5-TV-CU at 1000 ppc 3000 ppc and 
5000 ppc. Protein lysates were collected at 48 h and 30 µg protein/lane was separated on 
a gel. Low levels of dose-dependent CD/UPRT expression were detected in one 
experimental repeat. Representative blot from three independent experiments. Previously 
infected 22RV1 cells were used as a positive control for CD/UPRT expression. Sheep Anti-
CD antibody was used to reveal CD/UPRT expression (43 kDa). Mouse anti-ß-actin 
antibody was used as a loading control (42 kDa). 
As described in section 4.2.1.4, it was important to establish the toxicity of 5-FC 
(pro-drug) and 5-FU (toxic metabolite) in the two additional AR-positive cell lines, 
LNCaP and VCaP in order to establish an appropriate dose of 5-FC for prodrug 
sensitization assays. Dose-response curves to 5-FC and 5-FU were generated in 
LNCaP and VCaP cells (Figure 47A+47C). 5-FC was non-toxic to LNCaP cells up 
to 500 µg/ml, similar to the toxicity seen in 22RV1 cells. The highest feasible dose 
of 5-FC at 1 mg/ml resulted in <50% cell death in LNCaP cells. LNCaP cells were 
also highly sensitive to the toxic metabolite 5-FU, low doses of 1.3 µg/ml were 
sufficient to kill 50% of the cells (Figure 47A), suggesting that very low levels of 5-
FU could induce high levels of LNCaP cell death. VCaP cells were resistant to 5-
FC, with no detectable cell killing at any dose. VCaP cells also appeared more 
resistant to 5-FU than LNCaP cells and cell death reached only 75% with 
treatment at the highest feasible dose of 5-FU (1 mg/ml) (Figure 47C), indicating 
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that higher doses of 5-FC would be required to generate sufficiently high levels of 
cytotoxic 5-FU in VCaP cells compared to 22RV1 and LNCaP cells. 
Unsurprisingly, there were no shifts observed in dose-response curves, and 
therefore no changes in EC50-values, in the AR-positive LNCaP cells upon addition 
of 5-FC in combination with Ad5-TV-CU (Figure 47B). This was expected, since 
CD/UPRT protein was only detected at very low levels post-infection in one 
experimental repeat (Figure 46B). Moreover, no additional cell killing was 
observed in VCaP cells, which expressed high levels of CD/UPRT after infection 
(Figure 47E + 47F). This is likely due to the high insensitivity of the cells to both 5-
FC and 5-FU (Figure 47D). Therefore, even if CD/UPRT is expressed and can 
convert 5-FC to 5-FU in VCaP cells, the levels are not sufficient to cause 
significant cell killing. A possible reason for this insensitivity might be that VCaP 
cells have a long doubling time (5-6 days) and 5-FUdMP causes cell death by 
thymidylate synthase inhibition and incorporation into the DNA and RNA, resulting 
in lethal DNA and RNA damage that requires cells to enter S-phase (see 
introduction section 1.5). Therefore, three days may not be long enough to 
generate sufficient cytotoxicity in cells with slow passage through the cell cycle, 
resulting in minimal cell death through 5-FU treatment (discussed further below, 
Figure 49). 
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Figure 47 Combination of Ad5-TV- CU and 5-FC in VCaP and LNCaP cells does not generate significant 5-FC dose-dependent decreases in 
EC50-values 
 
A + D 5-FC and 5-FU were titrated 1/5 across a 96 well plate from a starting concentration of 1 mg/ml to 2.5 ng/ml. 10 μl of the titration was added to 90 
μl of media containing 1x10
4
 LNCaP or 2x10
4
 VCaP cells. It was not possible to establish a dose response curve for LNCaP or VCaP cells administered 
with 5-FC. However, EC50 in LNCaP cells administered with 5-FU was 1.3 µg/ml and the highest feasible dose of 5-FU (1 mg/ml) killed only 75% of 
VCaP cells. B + E Ad5-TV-CU was titrated 1/5 across a 96 well plate and 10 μl added to 80 μl (or 90 μl for virus alone) of media containing 1x10
4
 
LNCaP or 2x10
4 
VCaP cells. Fixed concentrations of 100 μg/ml and 200 μg/ml (LNCaP) or 1 μg/ml, 10 μg/ml, 100 μg/ml and 500 μg/ml (VCaP) 5-FC 
were added. There was no shift in dose response observed upon addition of the 5-FC prodrug in either cell line. Data shown is mean of duplicates ± 
SEM from one experiment representative of 2. C + F Bar charts show no significant decrease in average EC50 ± SEM in LNCaP or VCaP cells infected 
with Ad5-TV-CU in combination with increasing doses of 5-FC. MTS assays were performed after 3 days and cell killing calculated relative to untreated 
control wells or wells containing drug alone (for combination) (n=2). 
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In order to rule out poor infectability as the cause of limited CD/UPRT transgene 
expression in LNCaP cells after Ad5-TV-CU infection, and to establish the 
infectability of a wide range of prostate cancer cell lines, LNCaP-104-S, LNCAP-
104R1, LNCaP-CDXR3, HEK293, Panc1, 22RV1, VCaP and LNCaP cells were 
assessed using a non-replicating Ad5-GFP virus. All cell lines were infected with 
100 ppc Ad5-GFP and the % of GFP positive cells analysed by flow cytometry. All 
three of the LNCaP sublines (LNCaP-104-S, LNCaP-104R1 and LNCaP-CDXR3) 
demonstrated similar infectability (~25%), whilst the LNCaP subline in our group 
(ATCC) had a much higher percentage of GFP positive cells (~48%). There were 
only 10% more infected 22RV1 cells than LNCaP, and a similar percentage of 
VCaP cells to 22RV1 cells were positive for GFP, suggesting that all three AR-
positive cell lines used for preliminary studies had similar infectability (Figure 48). 
Therefore, this does not explain the lack of CD/UPRT expression post infection in 
LNCaP (ATCC). 
 
Figure 48 Infectability of AR-positive PCa cell lines 
Cells were seeded in 6 well plates and the following day infected with non-replicating Ad5-
GFP at 100 ppc. After 2 h the media was removed and replaced with 10% DMEM. At 48 h 
post infection, cells were harvested for flow cytometry analysis. Results shown are mean 
of duplicates from one experiment. 
To establish if resistance to 5-FU in VCaP cells is due to the slow doubling time of 
the cell line, VCaP cells were treated with 5-FC and 5-FU for 6 days. This 
extended treatment increased 5-FU sensitivity in VCaP cells so that 100% cell 
killing was achieved with 100 µg/ml 5-FU and EC50 was 1.8 µg/ml (Figure 49). 
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However, this result could not be replicated in two further experiments as all cells 
died including the untreated control wells. 
 
Figure 49 Extended treatment of VCaP cells with 5-FC and 5-FU for 6 days 
VCaP cells were treated as previously described (Figure 47D). MTS was performed after 6 
days and cell death calculated relative to untreated control wells. Data shown is mean of 
duplicates ± SEM from one experiment. 6 day extended treatment increased 5-FU 
sensitivity in VCaP cells. However this was not replicable in two further experiments. 
4.2.3 Combination of Ad5-TV-CU and 5-FC in AR-negative cell 
lines does not induce 5-FC dependent cytoxicity 
4.2.3.1 Dose-dependent cell killing in response to Ad5-
TV-CU is generated in the AR-negative cell lines HEK293 and 
DU145  
It was disheartening to see that the results generated in 22RV1 cells with a 
combination of Ad5-TV-CU and 5-FC could not be replicated in AR-positive 
LNCaP and VCaP cells. However, it was still important to show that Ad5-TV-CU 
was inactive in a panel of AR-negative cell lines, including immortalized prostate 
epithelial cells (PNT1A), primary normal prostate basal epithelial cells (PrEC), 
metastatic PCa cell lines (PC3, DU145), and human embryonic kidney cells 
(HEK293) (Figure 50). 
To confirm the AR driven specificity of Ad5-TV-CU, HEK293 and DU145 cells 
were used as AR-negative controls. HEK293 was previously used in luciferase 
assays, demonstrating the lack of activation of the TMPRSS2 promoter in these 
AR-negative cells (see section 1.7.1 Table 12). DU145 cells were previously used 
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in western blot analysis to demonstrate the absence of CD/UPRT expression in 
these AR-negative cells (Figure 42). Initially, dose-responses to 5-FC and 5-FU 
were established in both cell lines. Both were sensitive to 5-FU treatment 
(HEK293 EC50 = 1 µg/ml, DU145 EC50 =3 µg/ml), but were insensitive to 5-FC up 
to 100 µg/ml (Figure 50A+C). To further demonstrate the AR, prostate specific 
expression of CD/UPRT from Ad5-TV-CU, HEK293 and DU145 were infected with 
increasing doses of Ad5-TV-CU. Infection of HEK293 with the non-replicating Ad5-
TV-CU resulted in an EC50-value of 30 ppc. In contrast, DU145 were highly 
insensitive to infection with Ad5-TV-CU (EC50 = 10000 ppc). At the same time 
DU145 cells were infected with the non-replicating Ad5-GFP resulting in a similar 
EC50-value, demonstrating the intrinsic toxicity of Ad5-GFP and Ad5-TV-CU in 
DU145 cells. Due to the high quantities of virus required for studies in DU145 
cells, they were no longer used for combination experiments (Figure 50B+D). 
 
Figure 50 Dose-responses to Ad5-TV-CU were generated in DU145 and HEK293 cells 
despite no detectable CD/UPRT protein expression 
Representative dose-response curves to 5-FC, 5-FU or virus in HEK293 cells (A+B) or 
DU145 cells (C+D). A+C 5-FC and 5-FU drugs were titrated 1/5 across a 96 well plate 
from a starting concentration of 1 mg/ml. 10 μl of the titration was added to 90 μl of media 
containing 1x10
4 
HEK293 or DU145 cells. MTS viability assays were performed after 3 
days and cell death calculated relative to untreated control cells. B+D Ad5-TV-CU was 
titrated 1/5 across a 96 well plate and added to 90 μl of media containing HEK293 or 
DU145 cells. MTS was performed after 3 days and cell viability calculated relative to 
untreated control wells. Ad5-GFP was used as a control to measure intrinsic toxicity of 
DU145 cells to adenovirus infection. MTS was performed after 3 days and cell viability 
calculated relative to untreated control wells. Data shown is mean of duplicates ± SEM 
from one experiment representative of two.  
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4.2.3.2 Dose-dependent cell killing by Ad5-TV-CU 
infection was not observed in primary prostate epithelial cells 
PrEC or the AR-negative cell lines PC3 and PNT1A. 
Due to the difficulties in using HEK293 and DU145 cells as AR-negative control 
cell lines (discussed previously), three additional prostate cell lines were selected 
to further confirm the inactivity of Ad5-TV-CU in AR-negative cells, including 
normal prostate epithelial cells. The AR-negative cell lines PC3 and PNT1A and 
the primary prostate epithelial cells, PrEC, that are negative for AR at protein level 
(Figure 41), were infected with Ad5-TV-CU alone and in combination with 50 µg/ml 
or 100 µg/ml 5-FC. No dose response to Ad5-TV-CU was detected in any of the 
AR-negative cell lines (Figure 51). This is potentially due to lack of infectability, or 
more likely lack of AR-dependent CD/UPRT transcription, which is inherently 
cytotoxic in the AR-positive cell lines, and therefore responsible for Ad5-TV-CU 
induced cell killing. As could be expected, no increased cytotoxicity was observed 
in 5-FC prodrug sensitization assays in any of the AR-negative cell lines tested 
(PC3, PNT1a and PrEC), due to the lack of AR dependent transcriptional 
activation of Ad5-TV-CU and, as a result the lack of CD/UPRT protein expression. 
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Figure 51 Dose response to Ad5-TV-CU could not be generated by infection of AR-
negative cell lines PNT1A and PC3 and the AR-negative primary epithelial cells PrEC 
Representative dose response curves to virus in combination with 5-FC prodrug for A 
PNT1A B PC3 C PrEC. Ad5-TV-CU was titrated 1/5 across a 96 well plate and 10 μl 
added to 80 μl of media (or 90 μl for virus alone) containing 2x10
4
 PNT1A, PC3 or PrEC 
cells in combination with 50 μg/ml or 100 μg/ml 5-FC. MTS was performed after 3 days 
and cell death calculated relative to untreated control wells for virus alone, or drug alone 
for combinations. No dose response to Ad5-TV-CU was observed. Data shown is mean of 
duplicates ± SEM from one experiment representative of two. 
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4.2.4 Identification of new AR expressing cell lines for in vivo 
efficacy studies with Ad5-TV-CU  
Due to the poor efficacy of Ad5-TV-CU in combination with 5-FC in VCaP and the 
failure to detect high levels of CD/UPRT protein post-infection in LNCaP AR-
dependent cells, three new LNCaP sublines were tested, LNCaP-104-S, LNCAP-
CDXR3 and 104-R1 (see materials and methods section 2.1.1), along with three 
murine cell lines, RM1, RM2 and TRAMPC. AR expression levels were 
established in each cell line (Figure 52A). All the LNCaP sublines expressed the 
same form of androgen receptor, identical to that of the original LNCaP cells 
(obtained from ATCC) previously used in our studies (110 kDa). AR expression in 
LNCaP-104R1 and LNCAP-CDXR3 was higher than the parental LNCaP-104-S 
cells, as previously described (Kokontis et al. 2005). AR was also detected in all 
murine PCa cell lines, TRAMPC, RM1 and RM2. However, AR in murine cell lines 
was a different size to AR protein in LNCaP or 22RV1 cells. Protein prediction 
software suggested that mouse AR is 98 kDa in size, however it appears much 
larger on the western blot. Further investigation showed that the human AR 
consists of 919 amino acids while the murine AR is 899 amino acids (20aa 
smaller) (www.uniprot.org/). Comparison between the two protein sequences 
showed 88% homology between the two species (Figure 52B). Despite the aa 
sequence of murine AR being shorter, it has a larger mass than human AR. The 
difference in weight may therefore be due to post-translational modifications of AR 
in the murine cell lines, which could potentially affect the binding of AR to the 
TMPRSS2 promoter elements in the murine cell lines. 
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Homo            MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQ 60 
Mus             MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREAIQNPGPRHPEAANIAPPGACL------ 54 
                ********************************.************. *****.*       
 
Homo            QQQQQQQQQQQQQQQQQETSPRQQQ-QQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSA 119 
Mus             -------------QQRQETSPRRRRRQQHTEDGSPQAHIRGPTGYLALEEEQQPSQQQAA 101 
                             **:******::: **: ******** *******.*:******* *:* 
 
Homo            LECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLK 179 
Mus             SEGHPESSCLPEPGAATAPGKGLPQQPPAPPDQDDSAAPSTLSLLGPTFPGLSSCSADIK 161 
                 * *** .*:******.*..****** *****:*************************:* 
 
Homo            DILSEASTMQLLQQQQQ---------------EAVSEGSSSGRARERSGAPTSSKDNYLG 224 
Mus             DILNEAGTMQLLQQQQQQQQHQQQHQQHQQQQEVISEGSS-ARAREATGAPSSSKDSYLG 220 
                ***.**.**********               *.:***** .**** :***:****.*** 
 
Homo            GTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPL 284 
Mus             GNSTISDSAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYASLLGGPPAVRPTPCAPL 280 
                *.*****.***********************************.*** ************ 
 
Homo            AECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSL 344 
Mus             PECKGLPLDEGPGKSTEETAEYSSFKGGYAKGLEGESLGCSGSSEAGSSGTLEIPSSLSL 340 
                .****  **:..*****:*****.*****:*************: ********:**:*** 
 
Homo            YKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCR 404 
Mus             YKSGALDEAAAYQNRDYYNFPLALSGPPHPPPPTHPHARIKLENPLDYGSAWAAAAAQCR 400 
                *************.**********:*** ****.************************** 
 
Homo            YGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGG 464 
Mus             YGDLGSLHGGSVAGPSTGSPPATTSSSWHTLFTAEEGQLYGP--------------GGGG 446 
                ****.****...***.:***.*::******************              **** 
 
Homo            GGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPW 524 
Mus             GSSSPSDAGPVAPYGYTRPPQGLTSQESDYSASEVWYPGGVVNRVPYPSPNCVKSEMGPW 506 
                *... .:**.*************:.****::*.:******:*.*******.********* 
 
Homo            MDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRA 584 
Mus             MENYSGPYGDMRLDSTRDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRA 566 
                *:.**********:::******************************************** 
 
Homo            AEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEAS 644 
Mus             AEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGENS 626 
                ********************************************************** * 
 
Homo            STTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNE 704 
Mus             NAGSPTEDPSQKMTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNE 686 
                .: ****:.:**:*********************************************** 
 
Homo            LGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAP 764 
Mus             LGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAP 746 
                ************************************************************ 
 
Homo            DLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKF 824 
Mus             DLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKF 806 
                ************************************************************ 
 
Homo            FDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHM 884 
Mus             FDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHM 866 
                ************************************************************ 
 
Homo            VSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ 917 
Mus             VSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ 899 
                ********************************* 
Figure 52 AR expression in LNCaP sublines and murine prostate cell lines. 
A. Cell lysates were collected and 30 µg run on a protein gel. Rabbit anti-AR antibody was 
used to reveal AR expression in all cell lines. AR (110 kDa), containing the T877A 
mutation was detected in all LNCaP sublines, LNCaP-104-S, LNCAP-CDXR3 and LNCaP-
104R1 and murine AR was detected in all murine prostate cell lines TRAMPC, RM1 and 
RM2. Mouse anti-ß-actin antibody was used as a loading control (42 kDa). B. Protein 
sequence alignment between human and murine AR sequences showed 88% homology 
between the species. 
A 
B 
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4.2.4.1 The murine cell lines TRAMPC, RM1 and RM2 are 
highly sensitive to 5-FU but insensitive to infection by AD5-TV-
CU. 
In order to establish a reliable in vivo model to study the activity of Ad5-TV-CU, 
three AR-positive murine PCa cell lines were investigated for efficacy of Ad5-TV-
CU in combination with 5-FC, as murine tumour xenografts could be easily and 
reliably established in animals with intact immune responses.   
TRAMPC, RM1 and RM2 were treated with increasing doses of 5-FC and 5-FU to 
determine their sensitivity to the non-toxic prodrug 5-FC and the toxic metabolite 
5-FU. RM1 and RM2 were highly sensitive to 5-FU, 0.1 µg/ml resulted in 100% cell 
killing (Figure 53). TRAMPC were more resistant to 5-FU, requiring 4 µg/ml to kill 
100% of cells. Whilst all three murine cell lines were sensitive to treatment with 5-
FU, much higher doses of the non-toxic 5-FC prodrug were required to achieve 
100% cell killing, suggesting that high doses could be used for combination 
studies.  
Dose-response curves to Ad5-TV-CU were generated to determine the inherent 
toxicity of the CD/UPRT transgene in the murine PCa cells, with 5-FC sensitization 
assays performed in parallel. The highest concentration of 5-FC that did not 
induce intrinsic toxicity to the murine cells alone was selected for sensitization 
assays, as well as a lower concentration of 5-FC. These doses were different for 
all 3 murine cell lines depending on the sensitivity to 5-FC. MTS assays were 
performed after 3 days. Only 75% cell killing was observed in RM2 cells infected 
with Ad5-TV-CU alone at the highest dose (1x105 ppc), and no increased 
sensitization was observed with the combination of 5-FC prodrug at either 10 
µg/ml or 5 µg/ml. 50% cell killing was observed in TRAMPC cells at the highest 
dose of 105 ppc and the combination with 5-FC enhanced cell killing minimally with 
5 µg/ml and 10 µg/ml 5-FC. There was no dose response to Ad5-TV-CU 
generated in RM1 cells, it was therefore not possible to establish whether the 
combination with 5-FC enhanced cell killing. 
In conclusion, it was not possible to achieve 100% cell killing at the maximum 
dose of Ad5-TV-CU (1x105 ppc) in any of the murine PCa cell lines, and was 
therefore impossible to establish accurate EC50
 values. Due to the difficulties in 
establishing a dose response to Ad5-TV-CU, and therefore the inability to perform 
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prodrug sensitization assays, the murine cell lines were not used for further in vitro 
studies. 
Figure 53 TRAMPC, RM1 and RM2 are sensitive to 5-FU treatment but no increased 
cell killing is detected with Ad5-TV-CU in combination with 5-FC 
 
Representative 5-FC, 5-FU and virus dose response curves in murine cell lines TRAMPC 
(A+B), RM1 (C+D) and RM2 (E+F). A, C + E 5-FC and 5-FU drugs were titrated 1/5 
across a 96 well plate from a starting concentration of 1 mg/ml. 10 μl of the titration was 
added to 90 μl of media containing TRAMPC, RM1 or RM2 cells. MTS was performed after 
3 days and cell viability calculated relative to untreated control wells.  All three murine cell 
lines were highly sensitive to 5-FU (TRAMPC EC50 0.4 μg/ml, RM1 EC50 0.2 μg/ml and 
RM2 EC50 3.75 ng/ml). B, D + F Ad5-TV-CU was titrated 1/5 across a 96 well plate and 10 
μl added of the titration added to 90 μl of media containing 2x10
4
 murine PCa cells alone 
or to 80 μl in combination with a fixed concentration of 5-FC (TRAMPC 30 μg/ml and 60 
μg/ml, RM1 100 μg/ml and 200 μg/ml or RM2 5 μg/ml and 10 μg/ml). Cell viability was 
calculated relative to untreated control wells for virus alone, or drug only control wells for 
combination. Data shown is mean of duplicates ± SEM from one experiment 
representative of three. 
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4.2.4.2 LNCAP-CDXR3, LNCaP-104R1 and LNCaP-104-S 
cells express CD/UPRT post Ad5-TV-CU infection and are 
sensitive to 5-FU treatment. 
To establish whether the new sublines of LNCaP AR-positive, AR dependent cells 
would be suitable for studying Ad5-TV-CU in vivo, I infected LNCaP-104-S, 
LNCaP-104R1 and LNCaP-CDXR3 with increasing doses of Ad5-TV-CU at 1000, 
2000 and 3000 ppc. I detected dose dependent increases in CD/UPRT transgene 
expression post infection in all three sublines (Figure 54). CD/UPRT expression 
was highest in LNCAP-CDXR3 and LNCaP-104R1 cells in comparison to LNCaP-
104-S cells, correlating with higher AR expression in these cell lines (Figure 54). 
 
Figure 54 CD/UPRT protein expression is detected in LNCAP-CDXR3, LNCaP-104R1 
and LNCaP-104-S cells following viral infection  
LNCAP-CDXR3, LNCaP-104R1 and LNCaP-104-S cells were infected with 1000 ppc, 
3000 ppc and 5000 ppc Ad5-TV-CU and protein lysates collected at 48 h. 30 µg of protein 
was loaded onto a gel. A dose dependent increase in CD/UPRT expression (43 kDa) was 
detected in all three cell lines. Sheep Anti-CD antibody was used to reveal CD/UPRT 
expression. Mouse anti-ß-actin was used as a loading control (42 kDa). A 22RV1 cell 
lysate previously infected with Ad5-TV-CU was used as a positive control (+ve). 
Representative blot of three independent experiments. 
To establish the toxicity of 5-FC (prodrug) and 5-FU (toxic metabolite) and 
therefore determine an appropriate concentration at which to add 5-FC in 
combination with Ad5-TV-CU, dose response curves were generated for both 
drugs in the LNCaP sublines (Figure 55). 5-FC is slightly toxic in all three LNCaP 
cell lines at the highest concentration of 1 mg/ml, resulting in ~50% cell death. 
However, 5-FU is highly toxic to the cells, the average EC50 from 3 independent 
experiments was 1.89±0.88 μg/ml in LNCaP-104-S, 4.11±0.17 μg/ml in LNCAP-
CDXR3 and 1.63±0.21 μg/ml in LNCaP-104R1, suggesting that these cell lines will 
be sensitive to treatment with Ad5-TV-CU in combination with 5-FC if 5-FC is 
successfully converted to the 5-FU toxic metabolite. 
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Figure 55 LNCaP-104-S, LNCAP-CDXR3 and LNCaP-104R1 cells are sensitive to 
treatment with 5-FU, but insensitive to the 5-FC prodrug 
5-FC and 5-FU drugs were titrated 1/5 across a 96 well plate from a starting concentration 
of 1 mg/ml. 10 μl of the titration was added to 90 μl of media containing; A. LNCaP-104-S 
B. LNCAP-CDXR3 and C. LNCaP-10R1. MTS was performed after 3 days and cell viability 
calculated relative to untreated control wells. All three cell lines were insensitive to the 5-
FC prodrug, but concentrations of 5-FU as low as 4 µg/ml induced ≥ 50% cell death. Data 
shown is mean of duplicates ± SEM from one experiment representative of three. 
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4.2.4.3 Combination of Ad5-TV-CU and 5-FC 
significantly enhances cell killing in LNCaP-104-S, LNCaP-
CDXR3 and LNCaP-104R1 cells 
In order to establish if the expression of CD/UPRT was sufficient to catalyse the 
conversion of 5-FC to 5-FU and therefore enhance cell killing in the LNCaP 
sublines, increasing doses of 5-FC prodrug were added in combination with Ad5-
TV-CU in prodrug sensitization assays. Doses of 5-FC prodrug were selected 
based on EC50 values obtained for treatment with 5-FU (ranging from 1-100 
µg/ml). Cell killing was enhanced in a 5-FC dose-dependent manner in all three 
cell lines (Figure 56). EC50 in LNCaP-104-S was significantly reduced upon 
addition of as little as 1 µg/ml 5-FC from 9454± 890 ppc (Ad5-TV-CU alone) to 
4052 ± 45.5 ppc (Ad5-TV-CU in combination with 1 µg/ml 5-FC, p-value <0.01, 
Figure 56B). LNCaP-CDXR3 EC50 values were significantly decreased upon 
addition of 100 µg/ml 5-FC, from 1602 ± 353.6 ppc (Ad5-TV-CU alone) to 478 ± 81 
ppc (Ad5-TV-CU in combination with 100 µg/ml 5-FC, p-value <0.01, Figure 56D). 
LNCaP-104R-1 EC50 values decreased upon addition of increasing concentrations 
of 5-FC (from 5474 ± 1013 ppc (Ad5-TV-CU alone) to 1921 ± 594.3 ppc (Ad5-TV-
CU in combination with 100 µg/ml 5-FC, Figure 56F). However due to variability in 
the biological replicates when generating the data, the decreases in EC50 were not 
significant at any concentration of 5-FC in LNCaP-104R-1. Full details of EC50 
values ± SEM at increasing concentrations of drug can be found below (Table 29). 
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Figure 56 Combination of Ad5-TV-CU and 5-FC in LNCaP-104-S, LNCaP-CDXR3 and 
LNCaP-104R1 cells generates 5-FC dose dependent shifts in EC50 values 
A, C & E Representative Ad5-TV-CU dose-response curves in combination with 5-FC 
prodrug. Cells were treated with a 1/5 titration of Ad5-TV-CU starting from 1x10
5
 ppc to 0.2 
ppc. 10 µl of the viral dilution was added to 80 µl media containing 2x10
4 
cells/well. 10 µl 5-
FC was immediately added in combination with Ad5-TV-CU at fixed doses of 1 µg/ml, 10 
µg/ml and 100 µg/ml. MTS assays were performed at three days and cell death calculated 
relative to untreated control wells, or wells containing drug alone for the combination of 
Ad5-TV-CU and 5-FC. Data shown is mean of duplicates ± SEM from one experiment 
representative of four. B, D & F show histograms of average EC50s for the LNCaP sublines 
with virus alone, or in combination with 5-FC prodrug. Statistical analysis was performed 
using the one way ANOVA test with Tukey’s multiple comparison test *is p-value <0.05, ** 
p-value<0.01,  (A + B) LNCaP-104-S, (C + D) LNCaP-CDXR3, (E + F) LNCaP-104R1. 
Data shown is mean of four independent experiments. 
Table 29 Average EC50 values ± SEM (ppc) for Ad5-TV-CU in combination with 
increasing doses of 5-FC. 
5-FC concentration LNCAP-CDXR3 LNCaP-104R1 LNCaP-104-S 22RV1 
Ad5-TV-CU alone 1602.3 ± 353.6 5474.7 ± 1013.6 9454 ± 890 485.4 ± 96.7 
Ad5-TV-CU + 1 µg/ml 5-FC 997.4 ± 286.2 3603 ± 1092.3 4052.5 ± 45.5 ** 560.2 ± 118.8 
Ad5-TV-CU + 10 µg/ml 5-FC 599.3 ± 178.4 2671.7 ± 888.8 3513.5 ± 30.5 ** 327.6 ± 63.1 
Ad5-TV-CU + 100 µg/ml 5-FC 478.5 ± 80.9 * 1921.3 ± 594.3 1689 ± 255 ** 265.2 ± 52.8 
*is p-value <0.05, ** p-value<0.01. 
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To verify that the increased cell killing upon addition of 5-FC is due to the 
activation of the 5-FC prodrug by tissue-specific expression of CD/UPRT from 
Ad5-TV/CU, Ad5-GFP was used as a control virus. Dose response to Ad5-GFP 
was combined with the same fixed doses of 5-FC at increasing concentrations and 
MTS cell viability assays performed after 3 days. The cytotoxicity did not change 
with the addition of 5-FC in combination with Ad5-GFP in any of the LNCaP 
sublines (Figure 57), confirming that the enhanced cell killing in combination with 
Ad5-TV-CU was due to CD/UPRT expression from this virus and the subsequent 
conversion of the non-toxic prodrug (5-FC) to the toxic metabolite (5-FU). EC50-
values for Ad5-GFP in comparison to Ad5-TV-CU alone were only similar in 
LNCaP-104R1 cells (Ad5-TV-CU EC50 5475 ± 1013 ppc, Ad5-GFP EC50 5756 ± 
316.7 ppc). EC50-values in LNCaP-CDXR3 cells were much lower when infected 
with Ad5-TV-CU (EC50 1602.3 ± 353.6 ppc) in comparison to Ad5-GFP (EC50 3707 
± 1174 ppc). The higher levels of AR expression in LNCaP-CDXR3 resulted in 
higher CD/UPRT expression, which is intrinsically toxic to the cells. Ad5-GFP 
induced more cell killing (EC50 2245 ± 423 ppc) than Ad5-TV-CU (EC50 9454 ± 890 
ppc) in LNCaP-104-S cells, which is most likely due to the lower levels of AR 
dependent transcriptional activation of Ad5-TV-CU and as a result lower levels of 
CD/UPRT expression. 
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Figure 57 Combination of Ad5-GFP and 5-FC in LNCaP-104-S, LNCaP-CDXR3 and 
LNCaP-104R1 cells did not generate dose dependent shifts in dose response 
Ad5-GFP was titrated 1/5 from 10
5 
ppc to 0.2 ppc. 10 µl of the viral dilution was added to 
80 µl media containing 2x10
4
 cells/well (or 90 µl for virus alone). 10 µl of 5-FC was 
immediately added in combination with Ad5-TV-CU at fixed doses of 1 µg/ml, 10 µg/ml and 
100 µg/ml. MTS assays were performed at three days and cell death calculated relative to 
untreated control wells, or wells containing drug alone for the combination of Ad5-TV-CU 
and 5-FC. No 5-FC dose dependent increased cytotoxicity was observed in any of the 
three cell lines tested. A LNCaP-104-S B LNCaP-CDXR3 and C LNCaP-104R1. Data 
shown is mean of duplicates ± SEM from one experiment representative of three. 
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To demonstrate that enhanced cell killing in LNCaP-104-S, LNCaP-CDXR3 and 
LNCaP-104R1 was due to target cell sensitization with the combination of Ad5-TV-
CU and 5-FC prodrug, doses of Ad5-TV-CU that would kill 10, 20 or 30% (EC10, 
EC20 or EC30) of the cells alone were selected and added in combination with a 
sub-optimum dose of 5-FC, which did not induce cell death alone (10 mg/ml), but 
had demonstrated proven increased cytotoxicity in combination with Ad5-TV-CU in 
the LNCaP sublines. Addition of 5-FC alone at a fixed concentration of 10 µg/ml 
caused slight toxicity in LNCaP-104-S and LNCaP-CDXR3 cells (<3%) and no 
toxicity in LNCaP-104R1 cells. As expected, after the addition of 5-FC, cell killing 
was enhanced in all three cell lines compared with equal doses of Ad5-GFP 
control virus in combination with 10 µg/ml 5-FC (Figure 58). Due to the variable 
nature of the cell viability assay the percentage of cell death induced by Ad5-TV-
CU varied between experiments, however the extent of cell death induced by the 
combination of Ad5-TV-CU and 5-FC was consistently higher than the theoretical 
additive value of Ad5-TV-CU in combination with 5-FC in all five experimental 
repeats performed in all three cell lines. A significant increase in cell killing was 
observed in LNCaP-104R1 cells with the combination of Ad5-TV-CU at EC20 and 
10 µg/ml 5-FC (p-value <0.05), which became highly significant when Ad5-TV-CU 
was added at EC30 in combination with 10 µg/ml 5-FC (p-value <0.01). There were 
no significant increases in cell killing when Ad5-GFP was added in combination 
with 5-FC at any dose. 
These results demonstrate that Ad5-TV-CU was able to sensitize the LNCaP 
sublines to 5-FC in a dose-dependent manner. Failure to replicate the 
sensitization using Ad5-GFP in combination with 5-FC demonstrated that the 
increased sensitization was specific to cells treated with Ad5-TV-CU and likely the 
conversion of 5-FC to toxic 5-FU. Ad5-GFP was therefore selected as a control 
virus for future in vivo studies in LNCaP-104-S and LNCaP-CDXR3 tumour 
xenograft models. 
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Figure 58 Cell killing is enhanced upon addition of the 5-FC prodrug in LNCaP-104-
S, LNCaP-CDXR3 and LNCaP-104R1 cells. 
Fixed doses of Ad5-TV-CU were selected that would kill 10%, 20% or 30% of the LNCaP 
sublines (EC10, EC20 or EC30). The same ppc count was fixed for Ad5-GFP. Ad5-TV-CU 
was added in combination with a fixed dose of 5-FC (10 µg/ml) that had previously been 
shown to increase cytotoxicity in combination with Ad5-TV-CU. Cell death was determined 
3 days post treatment by MTS and cell viability calculated relative to untreated control 
wells. Histograms show relative cell death as a percentage of total living cells. A LNCaP-
104-S, B LNCaP-CDXR3 and C LNCaP-104R1 Results are a mean of triplicate wells from 
five independent experiments ± SEM. Statistical analysis was performed using the one 
way ANOVA test with Tukey’s multiple comparison test. *is p-value <0.05, ** p-value<0.01, 
n=3. theo= theoretical additive value. 
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4.2.4.4 STR profiling highlights genetic differences 
between the parental LNCaP-104-S cells and LNCaP-CDXR3 
and LNCaP-104R1 sublines. 
In order to confirm the parentage of the LNCaP Chicago sublines (Dr Kokontis), 
STR profiling was performed on genomic DNA extracted from LNCaP (ATCC), 
LNCaP104-S, LNCaP-CDXR3 and LNCaP-104R1 (the genome centre, Barts 
Cancer Institute). All eight core loci of our initial LNCaP cells matched the ATCC 
reference. However, STR profiling revealed differences between the LNCaP 
ATCC reference profile and LNCaP-104-S cells in 3/8 core markers. Additionally, 
LNCaP-CDXR3 differed by 7/8 core markers and LNCaP-104R1 differed by 6/8 
core markers in comparison to the ATCC LNCaP reference respectively. LNCaP-
CDXR3 differed by 5/8 core markers and LNCaP 104-R1 differed by 6/8 core 
markers in comparison to the parental LNCaP-104-S respectively (Table 30). 
Table 30 STR profiling of LNCaP sublines 
Powerplex16  
Loci  
 
 
ATCC 
reference 
CRL-1740 
Customer 
sample 
LNCaP ATCC 
 
LNCaP-104-S LNCaP-CDXR3 LNCaP-104R1 
AMELO X,Y X,Y X,X X,X X,X 
THO1 9,9 9,9 9,9 9,10 9,11 
D5 11,12 11,12 11,12 9,11,12 9,?,11,12 
D13 10,12 10,12 10,12 10,12 10,12 
D7 9.1,10.3 9.1,10.3 9,?,11 ?,?,11 ?,?,? 
D16 11,11 11,11 11,12 10,11,12 10,11,12 
CSF 10,11 10,11 10,11 10,12,? 10,12,? 
VWA 16,18 16,18 15,17,18 17,18,19,20 17,18,20 
TPOX 8,9 8,9 8,9 8,8 8,9 
Table shows comparison of core marker. STR core markers that differed are highlighted in 
red.  
4.2.4.5 CD/UPRT protein expression is not stimulated by 
Mibolerone or inhibited by Bicalutamide after Ad5-TV-CU 
infection in LNCaP 104-S cells. 
In previous studies I was unable to detect an increase/decrease in CD/UPRT 
protein expression after treatment with 1 nM mibolerone or 5 µM Bicalutamide in 
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combination with Ad5-TV-CU in the androgen-independent cell line 22RV1. This 
was thought to be due to the mutated androgen receptor in this cell line, that is 
constitutively active, and therefore unaffected by stimulation or inhibition. To test 
the AR responsiveness of Ad5-TV-CU in an androgen-dependent cell line, 
LNCaP-104-S cells were infected with Ad5-TV-CU and stimulated with 1 nM 
mibolerone. This experiment was repeated three times and reproduced the 
original findings, with no significant differences in transgene expression after 
Mibolerone- treatment. A representative blot is shown in (Figure 59). LNCaP-104-
S cells were also infected with Ad5-TV-CU, treated with 5 µM Bicalutamide and 
CD/UPRT protein expression assessed by western blot. As I observed with 
mibolerone treatment, there was no significant effect on transgene expression 
after treatment with Bicalutamide. However, visualisation by western blot is not the 
most sensitive method to measure small changes in transgene expression, a more 
sensitive approach would be by Q-PCR or luciferase reporter assay that are able 
to detect small changes in transgene expression levels (discussed later, section 
6.2.3). 
 
Figure 59 CD/UPRT expression following treatment with 1 nM mibolerone and 5 µM 
Bicalutamide  
LNCaP-104-S cells were infected with 2000 ppc and 4000 ppc Ad5-TV-CU in 10% C/S 
serum. Two hours after infection the cells were treated with mibolerone (1 nM) or 
Bicalutamide (5 µM). Cells were lysed after 48 h and 30 µg of protein run on a gel. There 
was no significant increase or decrease in the CD/UPRT protein expression after 
stimulation with mibolerone or bicalutamide respectively. Sheep Anti-CD antibody was 
used to reveal CD/UPRT expression (43 kDa). Mouse Anti-ß-actin was used as a loading 
control (42 kDa). Representative blot of three independent experiments.  
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4.2.5 AR-positive BCa and the role of ER in TMPRSS2 promoter 
activation 
4.2.5.1 Combination of Ad5-TV-CU and 5-FC does not 
enhance cell killing in the AR-positive BCa cell lines, MCF7 
and MM453. 
Having previously demonstrated the activity and efficacy of Ad5-TV-CU in AR-
positive 22RV1 cells and the LNCaP sublines LNCaP-104-S, LNCaP-CDXR3 and 
LNCaP-104R1 it was desirable to establish if Ad5-TV-CU was also active in MCF7 
and MM453 BCa cell lines, that have been previously reported to express AR 
(Cochrane et al. 2014), and could potentially be used as a BCa therapy alongside 
PCa therapy. Despite publications that show AR expression in MCF7 cells, AR 
was undetectable under the conditions used in my study (Figure 41). 
Nevertheless, MCF7 and MM453 cells were tested for sensitivity to 5-FC/5-FU 
with and without simultaneous infection with Ad5-TV-CU (Figure 60). MCF7 cells 
were more sensitive to 5-FU (EC50 3 µg/ml) than MM453 (EC50 50 µg/ml) (Figure 
60 A+C). Both cell lines were resistant to treatment with 5-FC up to doses of 10 
µg/ml. When Ad5-TV-CU was combined with 5-FC in MCF7 cells there was no 
dose response to virus alone, or in combination with 5-FC (Figure 60B). This is 
most likely due to low levels of AR expression in this cell line and limited 
CD/UPRT expression as a result (Cochrane et al. 2014). A dose response to Ad5-
TV-CU was generated in MM453 cells, which were previously reported to express 
higher levels of AR, meaning higher levels of CD/UPRT expression post-infection 
(Cochrane et al. 2014). However, there was no shift in the dose-response to Ad5-
TV-CU in combination with 5-FC (Figure 60D). This may be due to the poor cell 
killing effect of 5-FU in this cell line, as much higher doses of 5-FU are required to 
induce cell killing, or more likely poor expression of CD/UPRT post infection in this 
cell line.  CD/UPRT expression was never quantified due to no efficacy with Ad5-
TV-CU alone or in combination with 5-FC. Further investigation in future studies 
with more AR-positive BCa cell lines could be interesting in the future, in order to 
increase the clinical applications for Ad5-TV-CU as a potential therapy for 
estrogen receptor negative (ER-), AR+ BCa.  
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Figure 60 Dose response to Ad5-TV-CU could only be generated in MM453 AR-
positive breast cell line following Ad5-TV-CU infection 
Representative virus and drug dose response curves in MCF7 (A + B) and MM453 (C + D) 
cells for 5-FC, 5-FU (A + C) and Ad5-TV-CU in combination with increasing doses of 5-FC 
(B + D). A + C 5-FC and 5-FU drugs were titrated 1/5 across a 96 well plate from a starting 
concentration of 1 mg/ml. 10 μl of the titration was added to 90 μl of media containing 
1x10
4
 MCF7 or MM453 cells. MTS assays were performed at 3 days and cell death 
calculated relative to untreated control wells. B + D Ad5-TV-CU was titrated 1/5 across a 
96 well plate and added to 80 μl of media containing MCF7 or MM453 cells in combination 
with 1 µg/ml, 10 µg/ml and 100 µg/ml or 90 μl media for virus alone. MTS assays were 
performed at 3 days and cell death calculated relative to untreated control wells, or wells 
containing drug alone for the combination of Ad5-TV-CU and 5-FC. Data shown is mean of 
duplicates ± SEM from one experiment representative of three. 
4.2.5.2 Investigating the activation of the TMPRSS2 
promoter by ER 
Previous studies have demonstrated that the TMPRSS2:ERG fusion gene can be 
regulated by estrogen receptor-dependent pathways, and demonstrated increased 
ERG  expression after treatment with the ER-α agonist Raloxifene (Setlur et al. 
2008, Bonkhoff and Berges 2009). The sustained expression of the 
TMPRSS2:ERG fusion transcript in castration-resistant PCas has raised questions 
as to whether the TMPRSS2 promoter remains active in CRPC through ER-α 
stimulation. Targeting this novel pathway could provide treatments for late-stage 
CRPC. Therefore, it was important to establish whether the TMPRSS2 promoter in 
Ad5-TV-CU could be stimulated by ER-α agonists. 
In order to establish if ER could activate the TMPRSS2 promoter in Ad5-TV-CU, a 
panel of prostate cell lysates were analysed on a protein gel and ER-α protein 
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expression levels established. The ER-α antibody generated a band at 46 kDa 
(previously shown to correspond to truncated ER-α (Figtree et al. 2003)) that was 
strong in all PCa cell lines tested and could be a truncated version of ER-α (Figure 
61). However, full length ER-α (66 kDa) could only be detected in the MCF7 BCa 
cell line.  
 
Figure 61 ER-α protein expression in panel of PCa cell lines and MCF7 BCa cell line 
Cell lysates were collected and 60 µg run on a protein gel. Rabbit anti-ER-α antibody was 
used to reveal ER-α expression in all cell lines. Full length ER-α was only detected in the 
MCF7 BCa cell line. Truncated ER-α was detected in all cell lines. Anti-mouse ß-actin was 
used as a loading control (42 kDa).  
Due to the results generated after infection with Ad5-TV-CU in combination with 
Mibolerone, and identification of truncated ER-α expression in prostate cell lines, 
the decision was made to investigate whether estradiol, an ER-α agonist, would 
increase CD/UPRT transgene expression when added in combination with Ad5-
TV-CU in LNCaP-104-S cells.  
LNCaP-104-S cells were infected with Ad5-TV-CU in combination with 10 nM 
estradiol or 1 nM mibolerone. Protein expression was analysed after 48 h by 
western blot (Figure 62). Treatment with mibolerone did not affect the levels of 
CD/UPRT expression, as previously seen (section 4.2.4.5). Similarly, no increase 
in transgene expression was observed upon treatment with estradiol. Due to the 
relative insensitivity of immunoblotting quantification (described above) I next 
verified these findings using a reliable and sensitive luciferase reporter assay 
(section 6.2.3). 
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Figure 62 No increase in CD/UPRT expression is detected upon treatment with 
Mibolerone or Estradiol in combination with Ad5-TV-CU 
LNCaP-104-S cells were infected with 2000 ppc and 4000 ppc Ad5-TV-CU in 10% 
Charcoal Stripped (C/S) serum. Two hours after infection the cells were treated with 
mibolerone (1 nM) or estradiol (10 nM). A. Cells were lysed after 48h and run on a protein 
gel. Sheep anti-CD antibody was used to reveal CD/UPRT expression (43 kDa). Mouse 
anti-ß-actin antibody was used as a loading control (42 kDa). Representative blot of two 
independent experiments. There was no detectable increase in protein levels of CD/UPRT 
after stimulation with mibolerone or estradiol.  
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4.3 DISCUSSION 
TMPRSS2 is a prostate specific gene and increased expression in response to AR 
stimulation has been previously described (Lin et al. 1999). The combination of 
Ad5-TV-CU and 5-FC significantly enhanced cell killing in AR-positive 22RV1 cells 
in a 5-FC dose-dependent manner due to AR-dependent transcriptional activation 
of Ad5-TV-CU. CD/UPRT expression was also detected in a dose-dependent 
manner after infection of 22RV1 cells with Ad5-TV-CU. However, attempts to 
demonstrate the AR-responsiveness of Ad5-TV-CU, by upregulation of CD/UPRT 
expression with the synthetic androgen mibolerone (at 1 nM, chosen as it had 
previously been shown to stimulate the mmTV-luc vector in luciferase assays 
(Katrina Sweeny, unpublished studies), or down-regulation with the anti-androgen 
Bicalutamide did not influence CD/UPRT protein expression levels in 22RV1 cells 
(see section 4.2.1.3). This could be because the TMPRSS2 promoter is 
constitutively active in 22RV1 cells, possibly rendering the cells insensitive to AR 
stimulation or inhibition. These findings are in line with previous studies that have 
shown that mibolerone treatment of VCaP PCa cells, which harbour wild-type AR 
protein, strongly upregulated the expression of both PSA and TMPRSS2 androgen 
responsive genes (Dehm et al. 2008). Whereas, treatment of 22RV1 
demonstrated no upregulation, suggesting that AR protein expressed in 22RV1 
cells is less responsive to androgen stimulation in comparison to wildtype AR. 
Previous findings have demonstrated AR responsiveness of the TMPRSS2 
promoter through stimulation with 1 nM of the synthetic androgen R1881 (Lin et al. 
1999) and observed the overexpression of ETS family member genes due to 
fusion of androgen responsive promoter elements in TMPRSS2 to ETS family 
members (Tomlins et al. 2005). The L promoter present in Ad5-TV-CU contains 
three putative androgen response elements; it is therefore highly unlikely that this 
sequence would not respond to transcriptionally active AR.  
Very few studies on transcriptional activation of AR in 22RV1 cells have been 
reported. One previous study, investigating gene expression patterns in 22RV1 
cells when stimulated with either 10 nM DHT or 1nM Mibolerone, showed that 
TMPRSS2 mRNA expression was down-regulated by a factor of 0.6 after 24 h of 
10 nM DHT treatment and was also down regulated after 24 h 0.1 nM mibolerone 
treatment. These findings suggest an inhibitory effect of DHT and mibolerone on 
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TMPRSS2 expression levels in 22RV1 cells and a more complex pathway of AR 
transcriptional activation (Hartel et al. 2003). Similarly, previous reports have 
shown that treatment with 10 µM Bicalutamide alone has a very small inhibitory 
effect on AR mRNA expression in 22RV1 cells (McCourt et al. 2012) and 
decreases 22RV1 cell viability by only 10%, whereas similar decreases in cell 
viability are achieved in LNCaP cells with 1 nM concentrations of Bicalutamide 
(Seaton et al. 2008).  
A further study showed that short isoforms of AR mediated ligand-independent 
activity in 22RV1 cells (Dehm et al. 2008). Dehm.et.al demonstrated that treatment 
of VCaP cells, harbouring wildtype AR, with the synthetic androgen mibolerone, 
upregulated expression of the androgen responsive PSA and TMPRSS2 genes in 
this cell line, but not in 22RV1 cells (Dehm et al. 2008). Therefore, it is most likely 
that the constitutively active AR in 22RV1 cells is responsible for the lack of AR 
agonist/antagonist efficacy. 22RV1 cells express three distinct forms of AR, 1) 
AREX3dup, this isoform has a duplicated exon three, consisting of three zinc fingers 
in its DBD, increasing AR protein size by 5 kDa to 115 kDa, 2) AR1/2/2b, a truncated 
form of AR consisting of the NTD, the first zinc finger in the DBD and 11aa of 
Exon2b and 3) AR1/2/3/2b, a second truncated form of AR consisting of the NTD, the 
entire zinc finger DBD and an Exon2b derived sequence. The two truncated 
isoforms AR1/2/2b and AR1/2/3/2b are constitutively active and have been shown to 
promote an androgen-refractory phenotype (Dehm et al. 2008). These 
constitutively active forms of AR in 22RV1 cells are responsible for the androgen 
independency of this cell line, when Dehm.et.al knocked down AR1/2/2b and 
AR1/2/3/2b specifically, without affecting AREX3dup expression, androgen-independent 
22RV1 cell proliferation was inhibited, as well as androgen-independent 
expression of AR target genes PSA, TMPRSS2 and NKX3.1 (Dehm et al. 2008). 
AREX3dup is therefore the androgen responsive form of AR expressed in 22RV1 
cells. However, AR1/2/2b and AR1/2/3/2b are expressed at higher levels than AREX3dup 
in 22RV1 cells (Figure 41), consequently overriding androgen responsive AREX3dup 
in 22RV1 cells, resulting in decreased sensitivity to AR agonists/antagonists. 
These results suggest that Ad5-TV-CU would still be active in androgen-
independent cell lines, a common character trait of CRPC. Reactivation of AR 
pathways through a number of methods leads to the evolution of CRPC (see 
introduction section 1.3.3). These studies suggest that Ad5-TV-CU could be used 
in concomitant therapies that target the growth of PCa cells through Bicalutamide, 
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while simultaneously driving PCa specific cell death through Ad5-TV-CU 
cytotoxicity, with no effect on efficacy. It may therefore be important to explore the 
efficacy of Ad5-TV-CU in combination with Bicalutamide in CRPC, with intact AR 
signalling. 
Transgene expression could be detected from VCaP cells after Ad5-TV-CU 
infection, while in infected LNCaP cells the CD/UPRT levels were very low. It was 
thought that the possible reasons for this could be: 1) Poor infectability, due to 
differing expression of coxsackie adenovirus receptor (CAR) and/or integrins on 
LNCaP PCa cell surface or 2) the activity of the TMPRSS2 promoter may rely on 
other transcription factors, which are the limiting factors in activation of Ad5-TV-
CU and therefore expression of CD/UPRT. 
Infectability was later ruled out as the explanation for poor CD/UPRT transgene 
expression in LNCaP cells (section 4.2.2.1). This left the absence of transcription 
factors required for activation of the TMPRSS2 promoter in Ad5-TV-CU as the 
probable cause for poor CD/UPRT transgene expression in LNCaP. Previous 
studies have described the requirement for additional transcription factors that 
bind together with AR to stimulate transcriptional activation of AR-dependent 
genes. AR function is activated by several nuclear receptor co-regulators such as 
SRC-1 and CBP (CREB-binding protein) (Jänne et al. 2000). Absence of any one 
of these factors could limit the transcriptional activation of AR-dependent genes. 
Specifically, Menon et al demonstrated that AR requires the chromatin remodelling 
factor chromodomain helicase DNA-binding protein 8 (CDH8) for the recruitment 
of AR to the TMPRSS2 promoter in response to androgen treatment in androgen-
dependent LNCaP cells (Menon, Yates, and Bochar 2010). Reduction of CDH8 in 
this cell line resulted in diminished DHT induced activation of the TMPRSS2 
promoter. However, this was not seen in the androgen-independent cell lines 
22RV1, PC3 or DU145, suggesting that CDH8 may be important in androgen 
responsive transcriptional activation. It is therefore highly plausible that the subline 
of LNCaP use in our group (ATCC) is missing additional transcription factors, for 
example CDH8 that are essential for AR-dependent activation of the TMPRSS2 
promoter in Ad5-TV-CU. 
Despite CD/UPRT transgene expression post Ad5-TV-CU infection in VCaP cells 
and a dose response generated to Ad5-TV-CU, there was no increased cell killing 
in combination with 5-FC. This appears to be due to resistance of VCaP cells to 
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the 5-FU toxic metabolite. There are many well know mechanisms of resistance to 
5-FU (Zhang et al. 2008), including: 1) The slow doubling time of this cell line, 2) 
VCaP cells have a mutated p53 status, p53 mutation has previously been show to 
modulate resistance to 5-FU in colon cancer cell lines (Bunz et al. 1999) and could 
have a similar effect in VCaP cells. 3) VCaP cells may pump 5-FU out of the cell 
by efflux systems before 5-FU can have the desired effect on cell killing.  
A further study to establish whether the doubling time of VCaP cells was 
responsible for the resistance to 5-FU did not generate reproducible results. One 
experiment, in which VCaP cells were subjected to 5-FU treatment for six days, 
demonstrated increased dose-dependent toxicity to 5-FU in this cell line at day six. 
However this was not replicable in two further experiments. Due to the difficulties 
with LNCaP and VCaP AR-positive, AR dependent cell lines and the inconsistent 
results, these cells were not used for further in vivo studies with Ad5-TV-CU. 
Contrary to the results generated with the LNCaP cell line in our lab (ATCC), Ad5-
TV-CU infection of LNCaP sublines LNCaP-104-S, LNCaP-CDXR3 and LNCaP-
104-R1 demonstrated high levels of CD/UPRT protein expression and significantly 
enhanced 5-FC dose-dependent cell killing in prodrug sensitization assays. In an 
effort to understand why this was the case, STR profiling was performed on all 
four LNCaP sublines (genome centre, Barts Cancer Institute). Studies have shown 
that a minimum of eight core STR markers are required to positively identify 
human cell lines. Use of these core loci enables a 1 in 108 discrimination rate for 
unrelated cells (ATCC 2014). The STR profile of each LNCaP subline was 
compared to the ATCC LNCaP reference profile. All eight core STR markers for 
LNCaP (ATCC) cells in our lab matched the ATCC reference. STR profiling 
revealed differences between the ATCC reference profile and LNCaP-104-S cells 
in 3/8 core markers. LNCaP-CDXR3 cell differed by 7/8 core markers and LNCaP-
104R1 differed by 6/8 core markers. The differences in the core STR markers in 
LNCaP-CDXR3 and LNCaP-104R1 cells are most probably due to the castration-
resistant phenotype of these cells, resulting in genetic alterations from the parental 
LNCaP-104-S. Despite these genetic differences all four sublines of LNCaP 
express high levels of full length AR (110 kDa). It is possible that these genetic 
differences are responsible for the altered response of LNCaP-104-S, LNCaP-
CDXR3 and LNCaP-104R1 to Ad5-TV-CU infection, resulting in CD/UPRT 
transgene expression and 5-FC dose dependent increased cytotoxicity. 
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It was therefore desirable to establish whether AR-dependent transactivation of 
the TMPRSS2 promoter in Ad5-TV-CU could be increased upon AR stimulation 
with the synthetic AR agonist mibolerone, or decreased with the AR antagonist 
Bicalutamide in AR-positive, AR dependent LNCaP-104-S cells. As discussed 
previously, this was not possible in 22RV1 cells, due to the constitutively active 
forms of AR (AR1/2/2b and AR1/2/3/2b) expressed in this cell line, which are 
responsible for their androgen-independent state (Dehm et al. 2008). Previous 
studies in LNCaP have shown that addition of the synthetic androgen Mibolerone 
increases AR transcriptional activity, resulting in upregulation of androgen 
regulated genes (Young et al. 1991). Conversely, treatment with the anti-androgen 
Bicalutamide has the opposite effect. However, treatment of LNCaP-104-S cells 
infected with Ad5-TV-CU in combination with 1 nM mibolerone did not increase 
CD/UPRT transgene expression, nor was there a decrease in CD/UPRT 
transgene expression after treatment with 10 µM Bicalutamide. Possible reasons 
for this could be: 1) lack of additional transcription factors required to activate the 
TMPRSS2 promoter or 2) lack of interaction between additional AREs that act as 
enhancers to increase transgene expression from the TMPRSS2 promoter. 
Detection of increases or decreases in protein expression after 
stimulation/inhibition by western blot is an insensitive way to measure AR 
transcriptional activity. These experiments were later repeated in 22RV1 cells 
using luciferase reporter assays, that are able to detect subtle increases or 
decreases in promoter activity (see section 6.2.3). 
No cell killing was induced by Ad5-TV-CU in the AR-negative cell lines (PrEC, 
PNT1A or PC3), except for HEK293 and DU145. Dose response to Ad5-TV-CU in 
HEK293 cells was due to expression of the E1A gene in HEK293 (Graham et al. 
1977), the presence of E1A restores the replication capability of Ad5-TV-CU, 
resulting in higher cell death due to viral replication and cell lysis. As a result, 
HEK293 was not used for further studies, as the replicating status of Ad5-TV-CU 
in this cell line would affect the results of future experiments. A dose response to 
Ad5-TV-CU was also generated in DU145 cells, however high levels of Ad5-TV-
CU were required to induce cell killing in a CD/UPRT independent manner. As 
expected, no dose response to Ad5-TV-CU was generated in AR-negative 
metastatic PCa cell line PC3, normal immortalized cell line PNT1A or prostate 
basal epithelial cell line PrEC.  
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In conclusion Ad5-TV-CU is not functional in AR-negative cell lines. Additionally, 
Ad5-TV-CU sensitizes AR-positive 22RV1, LNCaP-104-S, LNCaP-CDXR3 and 
LNCaP-104R1 to 5-FC prodrug in a dose dependent manner (Table 29), AR-
negative cells infected with Ad5-TV-CU remained resistant to the virus and pro-
drug at the maximum dose of 1x105 ppc and 500 µg/ml respectively, thereby 
demonstrating the AR-positive tissue specificity of this construct. 
Despite previous publications demonstrating AR expression in MCF7 and MM453 
cells (Hall et al. 1994), no enhanced cell killing could be detected with the 
combination of Ad5-TV-CU and 5-FC. This is most probably due to the insensitivity 
of MM453 cells to 5-FU, and insufficient production of high levels of 5-FU when 
Ad5-TV-CU was added in combination with 5-FC. No dose response was 
generated to Ad5-TV-CU in MCF7 cells, most likely due to the relatively low levels 
of AR expression in this cell line.  
Previous studies have suggested a role for ER-α in the transcriptional activation of 
TMPRSS2 (Setlur et al. 2008, Bonkhoff and Berges 2009), and as a result 
upregulation of the TMPRSS2:ERG fusion gene. Due to the difficulties in 
increasing transgene expression in both 22RV1 and LNCaP-104-S cells with the 
synthetic AR agonist mibolerone, the potential role of ER-α in TMPRSS2 promoter 
activation was investigated. All PCa cell lines tested expressed a truncated form of 
ER-α (46 kDa), but none expressed the full length version (66 kDa). Full length 
ER-α is weakly expressed in MCF7 breast cells and is responsible for 
transcriptional activation of ER target genes. The truncated form of ER-α has been 
found in human endothelial cells and has been shown to activate eNOS in 
response to estrogen stimulation (Figtree et al. 2003). However, estrogen 
stimulated transcriptional activation mediated by the 46 kDa truncated form of ER-
α is much lower (Figtree et al. 2003) than the 66 kDa full length version.  
Similar to the results generated with mibolerone, treatment of LNCaP-104-S cells 
with Ad5-TV-CU in combination with estradiol, an ER-α agonist did not increase 
CD/UPRT transgene expression. There are three possible reasons for this: 1) Full 
length ER-α is not expressed in LNCaP-104-S cells, and cannot therefore bind to 
response elements in the TMPRSS2 promoter. 2) Examining protein expression 
by western blot is not sensitive enough to detect increased transgene expression. 
3) TMPRSS2 is not activated by ER-α. This experiment was not performed in 
MCF7 cells due to time limitations, but could be performed for future clarification. 
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Further studies on more AR+ BCa cell lines and ER+ PCa cell lines would need to 
be performed to fully elucidate the roles of AR and ER in TMPRSS2 promoter 
activation and the possible clinical applications of applying Ad5-TV-CU to AR+ 
BCa.  
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CHAPTER FIVE 
 
 
 
ACTIVITY OF AD5-TV-CU IN VIVO 
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5.1 INTRODUCTION  
To confirm that results generated with Ad5-TV-CU in combination with 5-FC in 
vitro could be translated in vivo, two xenograft models were established with 
androgen-independent and dependent LNCaP sublines LNCaP-CDXR3 and 
LNCaP-104-S respectively. LNCaP-CDXR3 cells express higher levels of AR than 
the parental LNCaP-104-S cells (Kokontis et al. 2005). These cell lines were 
chosen as they had previously demonstrated efficacy in vitro in combination with 
5-FC, and have previously been used by other groups to generate xenografts with 
reliable results in vivo (Kokontis et al. 2005). The remaining cell line that 
demonstrated efficacy in vitro, 22RV1, was not initially chosen for in vivo studies, 
as previous studies in the Halldén lab established that 22RV1 xenograft growth 
was difficult to control, even with intratumoural injection of replicating virus. 
Therefore, two pilot studies, each consisting of seven animals, were initiated to 
confirm efficacy and biodistribution of Ad5-TV-CU in BALB/c male athymic mice 
bearing LNCaP-104-S and LNCaP-CDXR3 xenografts. 
Previous studies in which androgen-dependent LNCaP sublines have been used 
to induce tumour xenografts suggested the requirement for additional testosterone 
to allow for tumour growth in nude mice (Resnick and Thompson 2000). 
Additionally, studies have revealed that BALB/c athymic mice have significantly 
reduced levels of serum gonadotrophins and testosterone compared with their 
normal littermates (Rebar et al,1982). Upon receipt of the LNCaP-104-S cells we 
were recommended by Dr John Kokontis to grow the xenografts in vivo with the 
addition of a testosterone pellet. Consequently, xenografts were grown in male 
BALB/c athymic mice with a 1.25 mg 60-day slow release testosterone pellet 
implanted under the skin. LNCaP-104-S cells are an androgen-dependent cell line. 
However, after further investigation following poor tumour growth, a study by Chuu 
et al. demonstrated that the response of LNCaP-104-S cells to androgens was 
biphasic in vitro. Furthermore, the showed that addition of a 20 mg testosterone 
propionate pellet, which raised serum testosterone levels from 2.5 ± 2.0 to 33.4 ± 
3.2, had no effect on the growth rate of LNCaP-104-S tumour xenografts in vivo. 
Additionally, growth of these cells is repressed by the androgen receptor 
antagonist Bicalutamide in vitro (Chuu et al. 2006). Further in vivo studies were 
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therefore performed to establish the true effect of additional testosterone on the 
growth of LNCaP-104-S xenografts. 
LNCaP-CDXR3 cells were generated by continued growth of LNCaP-104-S cells 
for 3 weeks in the presence of 5 µM Casodex (Bicalutamide), an AR antagonist 
(Kokontis et al. 2005), resulting in the generation of androgen-independent 
LNCaP-CDXR3 cells. LNCaP-CDXR3 cells feature increased AR expression and 
transcriptional activity, while cell proliferation is inhibited by androgens both in vitro 
and in vivo. As a consequence, LNCaP-CDXR3 tumour xenografts cannot be 
generated in the presence of androgens and so must therefore be grown in 
castrated male mice. 
Following difficulties establishing LNCaP-104-S xenografts in BALB/c athymic 
mice, potentially due to evidence of immune cell infiltration, NOD/SCID mice were 
used for further studies with LNCaP-104-S. These mice are severely 
immunodeficient, with both T-cell and B-cell development affected in comparison 
to solely T-cell development in BALB/c athymic mice. Additionally BALB/c athymic 
mice have intact adrenal, thyroidal and gonadal function, which could interfere with 
LNCaP-104-S tumour growth.  
In the fourth and final pilot study 22RV1 cells were subcutaneously injected into 
CD-1 athymic male mice. Similar to BALB/c mice, they are T-cell deficient but 
have normal B-cell function. 22RV1 tumour xenografts have been previously 
established in the CD-1 mice by the Halldén lab, (unpublished data). They 
established that 1x106 22RV1 cells inoculated subcutaneously, resulted in tumour 
development approximately 2 weeks later, reaching a size of 100 mm3, suitable for 
intratumoural injection.  In comparison, LNCaP-CDXR3 and LNCaP-104-S, took 
five to six, and four weeks respectively to develop. 
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5.2 RESULTS 
5.2.1 Pilot study in BALB/C mice with LNCaP-CDXR3 tumour 
xenografts 
5.2.1.1 Ad5-TV-CU in combination with 5-FC impeded 
growth in two out of three animals. 
In the first pilot study, I aimed to investigate efficacy and safety of Ad5-TV-CU in 
combination with 5-FC in vivo in hormonally deficient male BALB/c athymic mice. 
Seven Castrated male BALB/c athymic mice were inoculated with 1x106 
androgen-independent LNCaP-CDXR3 cells in both the left and right flank. 
Palpable tumours developed in both flanks of three out of seven animals within 3 
weeks and three additional animals developed palpable tumours by week 4. One 
animal failed to develop tumours on either flank and was therefore culled at week 
6. Two weeks after palpable tumours developed (between 5 and 6 weeks after the 
cells were injected) tumours on both flanks in five of the six animals reached 
>100mm3 (calculated by W2 x L x 0.52). A tumour only initially developed on the 
right flank in the single remaining animal, with a second tumour developing on the 
left flank by week 10 (Figure 63; purple line), 4 weeks after treatment of the first 
tumours began, demonstrating the slow growing nature of this cell line.  
Once tumours reached >100 mm3 they were injected intratumourally with 1x1010vp 
of either Ad5-TV-CU or Ad5-GFP in either the left or right flank (randomly 
assigned) on days 1, 3 and 6, for a total of three doses. Animals were 
subsequently randomised into groups that would receive an intraperitoneal 
injection of either 5-FC at 100 mg/kg or an equal volume of PBS on days 2, 5, 8 
and 15. Tumour volume was monitored twice weekly. Treatment continued until 
day 15, after which point there was little change in relative tumour volume in any of 
the groups (except for the control tumours treated with Ad5-TV-CU and PBS) 
(Figure 63-64). Five of the six animals were culled between days 50 and 60 post 
treatment initiation. One animal, treated with Ad5-TV-CU and 5-FC, was kept until 
day 62 post treatment initiation because tumour volume continued to decrease 
after day 50 (Figure 63).  
Only one out of nine control tumours grew >800 mm3 (Ad5-TV-CU+PBS), 
suggesting that tumours did not grow well in the BALB/c mice. None of the 
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tumours treated with Ad5-TV-CU in combination with 5-FC grew larger than 200 
mm3 throughout the entire in vivo study. Similarly, only one out of three control 
tumours treated with Ad5-TV-CU in combination with PBS grew larger than 200 
mm3 and neither of the two tumours treated with Ad5-GFP in combination with 
PBS grew larger than 90 mm3 throughout the length of the study. Consequently, 
tumour regression could not be reliably determined. Therefore, the study was 
terminated due to the limited and arbitrary results obtained despite the tumours 
continuing to stay below the Home Office standard guidelines for tumour burden. 
 
Figure 63 LNCaP-CDXR3 tumours treated with Ad5-TV-CU or Ad5-GFP in 
combination with 5-FC or PBS generated variable relative tumour growth results  
Castrated male BALB/c athymic mice were injected subcutaneously with hormone 
independent LNCaP-CDXR3 cells. After allowing the tumours to grow for 5 to 6 weeks to 
100 mm
3
 animals were separated into control groups (Ad5-TV-CU plus PBS, yellow lines, 
Ad5-GFP plus PBS, blue line and Ad5-GFP plus 5-FC, green lines) or Ad5-TV-CU plus 5-
FC (red lines) and the time was designated as day 1. 30 days after treatment initiation a 
tumour developed in the opposite flank of one animal and was left untreated (purple line). 
Intratumoural injections of 1x10
10
vp of either Ad5-TV-CU or Ad5-GFP were administered 
on days 1, 3 and 6 and intraperitoneal injections of 100 mg/kg of either 5-FC or PBS given 
on days 2, 5, 8 and 15. There were two tumours on each animal and each line on the 
graph is representative of one tumour. Graphs showing matched tumours in each 
individual animal can be seen in the appendix section 8.2, Figure_Apx1. Tumour growth 
was normalised relative to the individual starting tumour volume determined on day 1 of 
treatment to illustrate the effect of treatment on relative tumour growth. n= number of 
tumours per group. n=3 (Ad5-GFP +5-FC, Ad5-TV-CU+5-FC, Ad5-TV-CU+PBS) n=2 (Ad5-
GFP +PBS) n=1 (UN) UN= untreated. 
Despite poor tumour growth, treatment with Ad5-TV-CU in combination with 5-FC 
resulted in a reduction in tumour volume in two out of three animals and in the 
third animal tumour size did not increase, resulting in inhibition of tumour growth 
overall (red lines; Figure 63-64). Control animals with LNCaP-CDXR3 xenografts 
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treated with a combination of Ad5-TV-CU and PBS showed a trend towards 
increased relative tumour growth in two out of three animals, resulting in increased 
tumour growth overall (yellow lines; Figure 63-64). The tumour volume did not 
exceed 200 mm3 in one animal (Figure 63). These findings suggest that Ad5-TV-
CU must be combined with the 5-FC pro-drug to truly inhibit relative tumour growth 
of LNCaP-CDXR3 xenografts. 
Surprisingly, treatment with Ad5-GFP in combination with both 5-FC and PBS also 
appeared to inhibit the growth of LNCaP-CDXR3 tumour xenografts in four out of 
five tumours (Figure 63-64). In fact, the biggest decrease in tumour volume was 
observed in one animal treated with Ad5-GFP in combination with PBS (Figure 63-
64). This result was unexpected as Ad5-GFP had been used previously as a 
control virus in vitro in this cell line and found to have no effect on cell growth or 
viability.  
 
Figure 64 Average relative tumour volume increased with treatment of Ad5-TV-CU in 
combination with PBS, but decreased with all other treatments 
Mice bearing 100 mm
3
 hormone independent LNCaP-CDXR3 xenografts were separated 
into control groups (Ad5-TV-CU plus PBS, yellow line, Ad5-GFP plus PBS, blue line and 
Ad5-GFP plus 5-FC, green line) or Ad5-TV-CU plus 5-FC (red line) and the time was 
designated as day 1 for the first treatment. Data shows the average tumour volume 
measurements in mm
3
 ±SEM over a total period of 57 days. Tumour volume was 
normalised relative to the individual starting tumour volume in each animal determined on 
day 1 of treatment and averaged, to illustrate the effect of treatment on relative tumour 
growth and average relative tumour growth plotted over 50 days ± SEM. n= number of 
tumours per group. n=3 (Ad5-GFP +5-FC, Ad5-TV-CU+5-FC, Ad5-TV-CU+PBS) n=2 (Ad5-
GFP +PBS) n=1 (UN) UN= untreated. p>0.05 by one-way anova. 
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5.2.1.2 Treatment with Ad5-TV-CU in combination with 
5-FC resulted in tumour regression in one animal with LNCaP-
CDXR3 xenografts.  
One animal bearing LNCaP-CDXR3 tumour xenografts on the left and right flank 
was injected with Ad5-TV-CU in the left flank and Ad5-GFP in the right flank on 
days 1, 3 and 6. An intraperitoneal injection of 100 mg/kg 5-FC was given on days 
2, 5, 8 and 15. Initially, tumour volume in both flanks decreased from the start of 
treatment (day 1) up to the end of treatment (day 15) and steadily began to rise 
after treatment ended up to ~160 mm3 for Ad5-GFP in combination with 5-FC and 
130 mm3 for Ad5-TV-CU in combination with 5-FC at day 23 (Figure 65A). 
However, post day 37 of treatment initiation the LNCaP-CDXR3 tumour xenograft 
treated with Ad5-TV-CU steadily decreased in volume from 180 mm3 to 36.8 mm3, 
whilst the xenograft treated with Ad5-GFP continued to grow  up to 440 mm3 until 
day 62, at which point the animal was culled (Figure 65A). The LNCaP-CDXR3 
tumour xenograft treated with Ad5-TV-CU had almost completely regressed such 
that only a small flat tumour could be dissected, whilst the tumour treated with 
Ad5-GFP had continued to grow and was large and well rounded (Figure 65B). 
Figure 65 Combination of A5-TV-CU and 5-FC inhibits LNCaP-CDXR3 tumour 
xenograft growth 
A. Tumour volume measurements from one animal treated with either Ad5-GFP (green 
line) or Ad5-TV-CU (red line) in combination with 5-FC. B. LNCaP-CDXR3 tumour 
xenografts from one animal injected intratumourally with Ad5-TV-CU (L) or Ad5-GFP (R) in 
combination with 5-FC.  
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5.2.1.3 Immune cell infiltration of LNCaP-CDXR3 
tumours  
In order to better understand the poor relative tumour growth of LNCaP-CDXR3 
xenografts, H&E staining was performed on treated LNCaP-CDXR3 xenograft 
tissue. There was no difference in the morphology of xenografts infected with Ad5-
GFP in comparison to those infected with Ad5-TV-CU in combination with either 5-
FC or PBS (Figure 66A-H). On closer inspection there was no evidence of an 
inflammatory response in xenografts injected with both Ad5-GFP and Ad5-TV-CU 
(Figure 66B, D, F and G). However there was evidence of necrosis in xenografts 
treated with Ad5-TV-CU in combination with 5-FC. 
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Figure 66 H&E staining of LNCaP-CDXR3 tumour xenografts.  
LNCaP-CDXR3 tumour xenografts were fixed in 4% formalin for 24 h and stored in 70% 
ethanol. Tumours were paraffin embedded and sections cut and stained with H&E. Panels 
show tumours treated with Ad5-TV-CU in combination with 5-FC at A 100x and B 200x, 
Ad5-GFP in combination with 5-FC at C 100x and D 200x magnification, Ad5-GFP in 
combination with PBS at E 100x and F 200x magnification and tumours treated with Ad5-
TV-CU in combination with PBS at G 100x and H 200x magnification. Evidence of necrosis 
could be seen in xenograft tissue treated with Ad5-TV-CU in combination with 5-FC. No 
other inflammatory markers were identified. 
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While the pilot study for efficacy of Ad5-TV-CU in LNCaP-CDXR3 tumour 
xenografts appeared promising on some levels, showing complete tumour 
eradication in one animal, whilst the control tumour continued to grow, the 
ambiguity and varied results in terms both of the length of time it took for tumours 
to establish and grow and the response to viral therapy from both Ad5-GFP and 
Ad5-TV-CU highlights the unreliability of this model in BALB/c male mice. A large 
number of animals would be required to generate sufficient significant results 
using this cell line, and would be too costly for further studies. 
5.2.2 Pilot study in BALB/C mice with LNCaP-104-S tumour 
xenografts 
5.2.2.1 Ad5-TV-CU in combination with 5-FC impeded 
relative tumour growth in two animals. 
In the second pilot study, I aimed to investigate efficacy and safety of Ad5-TV-CU 
in combination with 5-FC in vivo, using LNCaP-104-S tumour xenografts in 
hormonally intact male BALB/c athymic mice. 7 male BALB/c athymic mice with 
60-day slow release 1.25 mg testosterone pellets implanted under the skin (upon 
recommendation from Dr John Kokontis (Kokontis et al. 2005) were injected 
subcutaneously with 1x106 hormone dependent LNCaP-104-S cells.  
Palpable tumours were undetectable by week 5. Initially it was thought that the 
tumour cells died because the testosterone pellets were inserted on the same day 
as the cells were injected, not allowing sufficient time for release of the high levels 
of testosterone required to support growth of the LNCaP-104-S. Due to this, an 
additional inoculation with 2x106 LNCaP-104-S cells in 50% matrigel was applied 
after 5 weeks into both flanks. Three weeks later tumours developed in one flank 
in four out of seven animals. The remaining animals did not develop tumours and 
were therefore culled. LNCaP-104-S tumour xenografts in two of four animals 
reached >100 mm3 within 4 weeks, tumours on the remaining animals were <100 
mm3 on treatment day 1 (Figure 67A).  
After allowing the tumours to grow for a further 4 weeks to ~100 mm3 tumour 
xenografts were injected intratumourally with 1x1010vp of Ad5-TV-CU on days 1, 3 
and 6, for a total of three doses. Animals were subsequently randomised to 
receive intraperitoneal injections of either 100 mg/kg 5-FC (red lines) or an equal 
volume of PBS (yellow lines) on days 2, 5, 8 and 15, totalling 4 doses, so that the 
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total treatment period was 15 days. As a result of poor tumour growth there were a 
total of two tumour xenografts in each treatment group (Ad5-TV-CU plus 5-FC and 
Ad5-TV-CU plus PBS). Treatment with Ad5-TV-CU in combination with 5-FC 
prevented increased tumour growth in both animals (Figure 67). However, in 
control treated animals (Ad5-TV-CU+PBS) only one tumour continued to grow up 
to day 35 after treatment initiation while the second tumour remained stable 
throughout the study. 
Overall the LNCaP-104-S tumours were slow growing with only two out of six 
tumours reaching >200mm3 by the time the study was terminated, 44 days after 
treatment initiation and the largest tumour did not exceed 600 mm3. The animals 
were culled due to the protracted growth of the tumours (including controls), which 
were below the acceptable size limits for tumour burden (Home Office regulations) 
when the pilot study was terminated (Figure 67A+B). Three days after treatment 
was initiated, measureable tumours developed in the opposite flank of the two 
control animals receiving Ad5-TV-CU in combination with PBS. These tumours 
also presented variable growth, one untreated tumour continued to grow 
throughout the experiment, however growth of the second untreated tumour failed 
to reach >200mm3 (Figure 67; purple lines). Additionally, a further 22 days after 
treatment was initiated, tumours developed in the opposing flank of the group of 
animals receiving Ad5-TV-CU in combination with 5-FC and continued to grow, 
albeit to <200 mm3 until the animals were culled at day 44 (additional purple lines 
at day 22, Figure 67A).  
There was a marked reduction in the average relative tumour growth over time in 
the group treated with Ad5-TV-CU in combination with 5-FC in comparison to both 
the control PBS group and the untreated tumour group up until day 35 (Figure 
67A). Conversely, by day 44 the average tumour volume in the Ad5-TV-CU plus 
PBS group dropped. At this stage the study was terminated due to erratic tumour 
growth. The difference in relative tumour volume between the groups at day 35 
was not significant, due to the huge variability in tumour size, the limited number of 
animals (n=2) and as a result the large standard error within the Ad5-TV-CU plus 
PBS treatment group and untreated controls (shown by error bars). Contrary to the 
large variability seen in control groups, treatment with Ad5-TV-CU in combination 
with 5-FC resulted in much less variability in tumour volume, and therefore a 
smaller standard error within the group, suggesting that a combination of Ad5-TV-
CU and 5-FC results in consistent relative tumour growth inhibition. 
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Figure 67 Average relative tumour volume of LNCaP-104-S xenografts remains the 
same with treatment of Ad5-TV-CU in combination with 5-FC, but increases in 
combination with PBS 
Male BALB/c athymic mice with subcutaneous 60-day slow release 1.25 mg testosterone 
pellets were injected subcutaneously with hormone dependent LNCaP-104-S cells. After 
allowing the tumours to grow for 3 weeks to ~100 mm
3 
mice were separated into control 
group (Ad5-TV-CU plus PBS (yellow line), or Ad5-TV-CU plus 5-FC (red line) and the time 
was designated as day 1. Tumours that developed a number of days after treatment began 
were left untreated (purple line). A. Data shows tumour growth post treatment initiation B. 
Data shows the average tumour volume measurements in mm
3 
±SEM over a total period of 
44 days. Tumour volume was normalised relative to the individual starting tumour volume 
determined on day 1 of treatment, to illustrate the effect of treatment on relative tumour 
volume and averages plotted over 44 days ± SEM. n= number of tumours per group. n=2 
(Ad5-TV-CU+5-FC, Ad5-TV-CU+PBS, UN) UN= untreated. p=>0.05 by one-way anova. 
Graphs showing matched tumours in each individual animal can be seen in the appendix 
section 8.2, Figure_Apx2. 
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5.2.2.2 Treatment with Ad5-TV-CU in combination with 
5-FC prevented further tumour growth in one animal compared 
to treatment with 5-FC alone. 
One animal bearing an LNCaP-104-S tumour on the right flank was injected with 
Ad5-TV-CU on days 1, 3 and 6. An intraperitoneal injection of 100 mg/kg 5-FC 
was given on days 2, 5, 8 and 15. Initially tumour volume decreased throughout 
the treatment period up to day 15 (last day of treatment) and then began to 
steadily rise again (Figure 68A). At day 22 a measurable tumour developed in the 
left flank of the animal and continued to grow until the pilot study was terminated. 
At day 35 there was a sudden reduction in tumour volume in the xenograft treated 
with Ad5-TV-CU in combination with 5-FC (Figure 68A).  When dissected from the 
animal, the tumour treated with Ad5-TV-CU in combination with 5-FC was visibly 
smaller than the untreated tumour (Figure 68B). 
 
Figure 68 Combination of Ad5-TV-CU and 5-FC reduced relative tumour volume of 
LNCaP-104-S xenografts 
A. Tumour volumes of two LNCaP-104-S tumour xenografts on the left and right flank of 
one animal, injected with 10
10
vp Ad5-TV-CU in combination with 5-FC (red line), or left 
untreated with intraperitoneal (IP) injection of 5-FC (purple line). B. LNCaP-104-S tumour 
xenografts from one animal injected intratumourally with Ad5-TV-CU (R) or left untreated 
(L) in both with IP 5-FC injection. 
5.2.2.3 H&E staining of LNCaP-104-S tumour xenografts 
highlights highly necrotic areas of the tumours 
In order to better understand the poor tumour growth of LNCaP-104-S xenografts, 
H&E staining was performed on LNCaP-104-S xenograft tissue infected with Ad5-
TV-CU in combination with either 5-FC (Figure 69A+B) or PBS (Figure 69C+D) or 
untreated control tumours (Figure 69E+F). There was little difference in the 
morphology of xenografts infected with Ad5-TV-CU in comparison to uninfected 
  219 
 
xenografts (Figure 69A+C). All xenografts showed areas densely populated with 
erythrocytes and signs of necrosis (Figure 69A-D). On closer inspection there was 
also evidence of an inflammatory response, with Eosinophils and B-lymphocytes 
expressed in the xenografts (Figure 69D). It is possible that the inhibition of 
LNCaP-104-S tumour xenograft growth could be due to a combination of immune 
response initiated in the animals, as they get older, but is more likely due to the 
necrotic areas seen in the tumours or growth inhibition due to exorbitant levels of 
testosterone. Untreated tumours were highly populated with erythrocytes, but did 
not show evidence necrosis (Figure 69E-F). 
  
Figure 69 H&E staining of LNCaP-104-S tumour xenografts highlights necrotic 
tumours 
LNCaP-104-S tumour xenografts were fixed in 4% formalin for 24 h and stored in 70% 
ethanol. Tumours were paraffin embedded and sections cut and stained with H&E. Panels 
show tumours from animals treated with Ad5-TV-CU in combination with intraperitoneal 
(I.P) doses of 5-FC at A 100x and B 200x magnification, tumours treated with Ad5-TV-CU 
in combination with PBS at C 100x, and D 200x magnification and untreated control 
tumours at E 100x and F 200x 
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5.2.3 Establishing a new animal model: NOD/SCID mice with 
LNCaP-104-S tumour xenografts 
Upon further communication with Dr Kokontis it was suggested that the levels of 
testosterone in the mice with 1.25 mg testosterone pellets may in fact be inhibitory 
to the growth of the tumours, referring previous studies (Chuu et al. 2006). In order 
to establish whether the slow growth of LNCaP-104-S tumour xenografts in male 
BALB/c athymic mice was due to exorbitant levels of testosterone and inhibition by 
increasing levels of immune factors, I aimed to explore growth in animals that were 
severely immunodeficient (NOD/SCID; T and B cell development affected) with 
and without testosterone pellets. Six 10-week old male NOD/SCID athymic mice 
were separated into two groups. Three animals were treated as described above 
(60 day slow release subcutaneous 1.25 mg testosterone pellets) and the 
remaining three animals were left without additional testosterone, in order to 
establish a possible inhibitory effect on tumour volume by excess hormone. Two 
days later the animals were injected subcutaneously with either 2x106 or 5x106 
LNCaP-104-S cells in the left and right flank respectively.  
No measureable tumours developed in the animals bearing subcutaneous 
testosterone pellets, suggesting that the high levels of testosterone may in fact 
have a negative effect on the growth of LNCaP-104-S tumour xenografts. 
However, measureable tumours established 33 days after injection the animals 
without testosterone pellets but only developed in one flank. Interestingly, this did 
not correlate with the number of cells that were injected, as tumour growth 
between the left and right flank was random. One animal showed signs of poor 
health on day 14 after measurable tumours developed, and thus had to be culled. 
By day seven, after measurable tumours developed, tumour volume had 
plateaued in one animal (Figure 70), remaining the same size for a further three 
weeks. Tumours were measured twice weekly for one month. Tumour burden was 
well below the limit set by the Home Office before the study was terminated due to 
poor tumour growth. 
Despite the fact that LNCaP-104-S tumour xenografts grew in animals without 
testosterone pellets the protracted growth of the tumours makes this model 
unreliable. As the tumours did not reach larger volumes, this is an unsuitable 
model for efficacy studies using Ad5-TV-CU, as it is impossible to determine 
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whether reduced tumour growth is due to treatment with Ad5-TV-CU or arbitrary 
growth of the tumours. 
 
Figure 70 Growth of LNCaP-104-S tumours in NOD/SCID mice is unreliable 
Three 10 week old male NOD/SCID mice bearing subcutaneous 1.25 mg testosterone 
pellets and 3 10 week old male NOD/SCID mice without pellets were injected 
subcutaneously with 2x10
6
 or 5x10
6
 hormone dependent LNCaP-104-S cells in the left or 
right flank respectively. Only the animals that did not have a subcutaneous testosterone 
pellet implanted grew tumours. Of which, two of the animals grew tumours from 2x10
6
 
injected LNCaP-104-S cells and one animal grew a tumour from 5x10
6
 cells. Tumours 
were measured twice weekly. Data shows the tumour volume over time in mm
3
 in two 
individual mice that developed tumours, the third animal had to be culled due to poor 
health.  
5.2.4 Establishing a new fast growing tumour model, 22RV1 
xenografts in CD-1 athymic mice. 
5.2.4.1 Ad5-TV-CU impedes average relative tumour 
growth in animals treated in combination with 5-FC and PBS. 
Following difficulties in establishing a reliable tumour model with both LNCaP-104-
S and LNCaP-CDXR3, a new model was established in CD-1 athymic mice with 
22RV1 cells. In this fourth pilot study, I aimed to investigate efficacy and safety of 
Ad5-TV-CU in combination with 5-FC in vivo, using 22RV1 tumour xenografts in 
intact male CD-1 athymic mice. Previous studies in the Halldén lab suggested that 
efficacy in response to replicating adenovirus mutants was difficult to achieve 
using the 22RV1 model because of the high cell proliferation rate (Unpublished 
studies). However, I speculated that the combination of Ad5-TV-CU with 5-FC 
could result in more efficient inhibition of tumour xenograft growth, due to the 
combination of virus and drug. To test this idea, twelve 6 week old male CD-1 
athymic mice were inoculated with 1x106 22RV1 cells in 50% matrigel in the left 
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flank. Palpable tumours were detectable by day 12 and were injectable (~100 mm3 
calculated by W2 x L x 0.52) by day 14. 
One group of animals with larger tumours was left completely untreated in order to 
monitor 22RV1 tumour growth. The 22RV1 tumour xenografts were injected 
intratumourally with 1010vp of Ad5-TV-CU in the left flank on days 1, 3 and 6, for a 
total of three doses. The animals were subsequently randomised into groups that 
received an intraperitoneal injection of either 5-FC at 100 mg/kg or an equal 
volume of PBS on days 2, 5, 8 and 15. Tumour volume was monitored twice 
weekly. Treatment continued until day 15. By this time all untreated animals were 
culled due to excessive tumour burden. 
There were a total of four 22RV1 xenografts in each treatment group (Ad5-TV-CU 
plus 5-FC and AD5-TV-CU plus PBS and untreated). Most surprisingly, the 
combination of Ad5-TV-CU with PBS appeared to have the most striking effect on 
tumour volume. Two of the tumours treated with Ad5-TV-CU in combination with 
PBS failed to grow bigger than 250 mm3 up to day 32 post treatment, and those 
animals were culled due to the poor tumour growth. Although these tumours were 
relatively small upon treatment initiation (~70 mm3), they were comparable to the 
starting volume of the tumours treated with Ad5-TV-CU in combination with 5-FC 
(see appendix section 8.2, Figure_Apx3). 22RV1 tumours grew at a fast rate, with 
tumours on seven of twelve animals reaching critical limits shortly before or just 
after treatment finished on day 15. This accelerated growth may prevent any real 
differences between the control groups and the group treated with Ad5-TV-CU to 
be identified. 
Overall there was a marked reduction in the average relative tumour volume over 
time in both groups treated with Ad5-TV-CU in combination with 5-FC or PBS in 
comparison to the untreated tumour group up until day 14 when the first untreated 
control was culled (Figure 71). The difference in relative tumour volume between 
the groups at day 14 is not significant, due to the huge variability in tumour size, 
the limited number of animals (n=4) and as a result the large standard error within 
the groups (shown by error bars). The slow growth rate of the tumours treated with 
Ad5-TV-CU in combination either 5-FC or PBS suggests that manipulation of the 
tumour may attenuate its growth, or that Ad5-TV-CU alone can slow the growth 
rate of 22RV1 tumour xenografts, regardless of whether it is or is not administered 
in combination with the 5-FC prodrug. 
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Figure 71 22RV1 xenografts treated with Ad5-TV-CU in combination with 5-FC or 
PBS grow at a slower rate in comparison to the untreated control 
Male CD-1 athymic mice were injected subcutaneously with 1x10
6
 hormone independent 
22RV1 cells. After allowing the tumours to grow for 2 weeks to ~100 mm
3
 the mice were 
separated into control groups (Untreated (purple line) and Ad5-TV-CU plus PBS (yellow 
line) and a target group Ad5-TV-CU plus 5-FC (red line) and the time was designated as 
day 1. Data shows the average tumour volume measurements in mm
3
 ±SEM up until the 
first mouse was culled on day 14. Tumour volume was normalised relative to the individual 
starting tumour volume determined on day 1 of treatment to illustrate the effect of 
treatment on relative tumour volume. n= number of tumours per group. n=4 (Ad5-TV-
CU+5-FC, Ad5-TV-CU+PBS, UN) UN= untreated p>0.05 determined by one-way anova. 
5.2.4.2 H&E staining of 22RV1 tumour xenografts  
H&E staining was performed on 22RV1 xenograft tissue infected with Ad5-TV-CU 
in combination with 5-FC, PBS or left untreated (Figure 72). There was little 
difference in the structure of xenografts infected with Ad5-TV-CU in comparison to 
uninfected xenografts (Figure 72). Both treated and untreated tumours showed 
areas highly populated with erythrocytes (Figure 72A-F). On closer inspection 
there was also evidence of lymphocyte infiltration (Figure 72B).  
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Figure 72 H & E staining of 22RV1 treated xenografts treated with Ad5-TV-CU in 
combination with 5-FC, PBS or untreated 
22RV1 tumour xenografts were fixed in 4% formalin for 24 h and stored in 70% ethanol. 
Tumours were paraffin embedded and sections cut and stained with H&E. Panels show 
tumours treated with Ad5-TV-CU in combination with I.P dose of 5-FC at A 100x and B 
200x magnification, tumours treated with Ad5-TV-CU in combination with PBS at C 100x  
and D 200x magnification and untreated control tumours at E 100x and F 200x. 
In summary four pilot studies were performed with a range of different animal and 
tumour models to try and establish an effective model with which to test the Ad5-
TV-CU virus. Of these, reliable tumour growth could not be established in three out 
of four models (LNCaP-CDXR3 and LNCaP-104-S in BALB/c and LNCaP-104-S in 
NOD/SCID mice), and the tumours grew too rapidly in the final model (22RV1 in 
CD-1 mice), resulting in unreliable results. These are summarised below in Table 
31. 
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Table 31 Summary of in vivo experiments performed with Ad5-TV-CU 
Cell line Animal 
Model 
Special treatment Outcome 
1x10
6
 
LNCaP-
CDXR3  in 
50% 
matrigel 
BALB/c Castrated male mice Poor tumour growth- majority of 
tumours plateaued at 200 mm
3
 
Trend towards decreased tumour 
volume with Ad5-TV-CU in 
combination with 5-FC compared to 
combination with PBS 
1x10
6 
LNCaP-104-
S in 50% 
matrigel 
BALB/c Intact male mice with 
subcutaneous 1.25 mg 
testosterone pellet 
Poor tumour growth- majority of 
tumours plateaued at 200 mm
3
. 
Trend towards decreased tumour 
volume with 
2x10
6 
LNCaP-104-
S in 50% 
matrigel 
NOD/SCID Half intact male mice 
with subcutaneous 
1.25 mg testosterone 
pellet, half without 
Xenografts did not grow in mice 
with testosterone pellets but grew 
irregularly in animals without 
testosterone pellets 
1x10
6 
22RV1 in 
50% 
matrigel 
CD-1 Intact male mice Rapid tumour growth, but no 
difference between  tumours 
treated with Ad5-TV-CU in 
combination with 5-FC and Ad5-
TV-CU in combination with PBS 
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5.3 DISCUSSION 
There were difficulties establishing a reliable in vivo model with which to test Ad5-
TV-CU. There were a number of potential reasons for this, dependent on both the 
cell type and the animal model. 
For LNCaP-CDXR3 and LNCaP-104-S xenografts that were successfully injected, 
it was difficult to establish if there was a difference between the treatment of 
tumours with Ad5-GFP and Ad5-TV-CU. Most disappointingly, the same trend of 
relative tumour volume inhibition was seen in tumours treated with either Ad5-TV-
CU or Ad5-GFP in combination with both 5-FC and PBS in LNCaP-CDXR3 
tumours. While this data was unexpected, there was little variation in tumour 
volume between the groups, as shown by small standard errors. This small 
variation could be due to one or more of three things: 1) the tumours reached their 
maximum size and were therefore unable to grow further, due to limitations such 
as blood supply 2) Injection with Ad5-GFP alone had off target toxicity in LNCaP-
CDXR3 xenografts 3) An immune response was activated in reaction to viral 
infection and prevented relative tumour growth. Graphs representing each 
individual animal can be found in the appendix section 8.2. 
Previous studies reported that growth of androgen-dependent LNCaP sublines in 
mice required the addition of testosterone for successful tumour growth (Umekita 
et al. 1996) and we were advised upon receipt of the cells (by Dr Kokontis and 
colleagues) that this would be the best course of action to enable xenograft 
growth. Additionally, BALB/c athymic mice have highly reduced levels of 
testosterone in comparison with their immunocompetent littermates, therefore 
testosterone pellets were inserted under the skin of hormonally intact BALB/c male 
athymic mice to support the growth of LNCaP-104-S xenografts. Consequently, it 
is possible that exorbitant levels of testosterone in the animals due to their age (15 
weeks, as the tumours took longer than expected to establish), combined with the 
implantation of the testosterone pellets, resulted in erratic and inhibitory growth of 
the tumours. In fact, LNCaP cells have previously been shown to respond within a 
narrow range of 10−11 to 10−9 M DHT with 10−7 M causing cell growth inhibition 
(Gregory, Johnson, et al. 2001). 
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Contrarily, LNCaP-CDXR3 cells are an androgen-independent cell line, generated 
from the parental LNCaP-104-S cell line (section 5.1), requiring castrated male 
mice for tumour growth in vivo. Previous studies by Kokontis et al have shown that 
introduction of androgens in male mice bearing LNCaP-CDXR3 xenografts results 
in complete tumour regression in 70% of animals (Chuu, Kokontis et al. 2011). 
One possible explanation for the varied tumour growth results in our pilot study 
could be residual levels of circulating androgens in the male BALB/c mice (from 
incomplete orchiectomy). Despite orchiectomy, it is also possible that 
extratesticular androgens were produced due to the older age of the animals. One 
way to determine this in future studies would be by quantifying serum PSA levels 
in the animals or by measuring testosterone/DHT levels. 
It is also possible that as the animals aged there was an elevated immune 
response to LNCaP-CDXR3 and LNCaP-104-S tumour xenografts, which 
contributed to the inhibition of tumour growth.  In fact, H&E staining of LNCaP-
104-S tumour xenograft sections revealed evidence of immune cell infiltration. 
BALB/c athymic mice lack the thymus, resulting in the absence of T-lymphocytes 
from thymus-dependent areas of both lymph nodes and spleen and a reduced 
lymphocyte population, comprised almost entirely of B-cells. This 
immunodeficiency means they are unable to reject xenogeneic skin and tumour 
grafts and therefore make them an ideal model for establishing human tumour 
xenografts. It is known that in older athymic mice, T-cell maturation in an 
extrathymic environment (from spleen and lymph nodes) increases and the 
proportion of CD4+ and CD8+ T-cells increases (Kennedy, Pierce, and Lake 
1992). This results in the accumulation of increasing numbers of lymphocytes that 
could have a detrimental effect on LNCaP-CDXR3 tumour xenograft growth. 
However, the animals were only 20 weeks old when culled so this may not have 
had as much of an effect as the response to viral infection as anticipated due to 
their young age. 
Additionally, the LNCaP-104-S tumour xenografts that developed were highly 
vascularised, with a black appearance under the skin. When the animals were 
culled and the tumours dissected, there was clear evidence of neovascularisation 
and tumours were full of blood. This could also be seen by the highly dense areas 
of erythrocytes in H&E stained sections combined with areas of necrosis in treated 
LNCaP-104-S tumours. It is therefore fair to conclude that the reason for the slow 
growth of LNCaP-104-S tumours cannot be explained by poor blood supply. 
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Neovascularisation was not seen at such high levels in the castration resistant 
subline LNCaP-CDXR3, supporting a potential role of high levels of testosterone in 
the promotion of angiogenesis in these tumours. In fact, previous studies have 
suggested that testosterone-replacement therapy is associated with enhanced 
expression of HIF-1a, SDF-1a and VEGF and promotes angiogenesis after acute 
myocardial infarction in castrated rats (Chen et al. 2012).  
The poor growth of control LNCaP-104-S and LNCaP-CDXR3 tumours treated 
with Ad5-GFP in combination with both PBS and 5-FC suggests that Ad5-GFP is 
intrinsically toxic to these xenografts, or that tumours are very sensitive to physical 
manipulation. However, this would be difficult to investigate, as it would require 
tumours to be injected with PBS alone according to the same schedule as the 
virus; this would not be recommended due to the 3R’s policy, aim at reducing the 
number of animals used for in vivo studies. I previously demonstrated that a 
combination of Ad5-GFP and 5-FC did not enhance cell killing in LNCaP-CDXR3 
and LNCaP-104-S cells grown in vitro (section 4.2.4.3), however Ad5-GFP alone 
is intrinsically toxic in these cells (LNCaP-CDXR3 EC50 3707 ± 1174 ppc and 
LNCaP-104-S EC50 2245 ± 423 ppc). Nevertheless, it is difficult to conclude that 
intrinsic toxicity is responsible for poor tumour growth in this treatment group, as 
this could be due to the slow growing nature of the cell lines in BALB/c mice. In 
fact, one of the LNCaP-CDXR3 tumours did not develop until 10 weeks after 
subcutaneous injection of tumour cells, and LNCaP-CDXR3 tumour xenografts 
failed to grow in one animal. LNCaP-104-S tumours developed in only four of 
seven animals in one flank, with the other flank developing weeks later. The 
protracted development of these tumours demonstrates the slow growing nature of 
LNCaP-CDXR3 and LNCaP-104-S xenografts and exemplifies their unreliability for 
use in in vivo studies, as it was impossible to truly determine whether Ad5-TV-
CU/Ad5-GFP is responsible for causing reduced tumour volume, rather than the 
absence of tumour growth, once a small initial increase in tumour volume was 
reached. What could be established from the Ad5-GFP control, is that there is no 
difference in relative tumour growth between xenografts treated with a 
combination of Ad5-GFP and 5-FC or Ad5-GFP alone, in agreement with my 
observations in vitro. If these studies were to be repeated, a dose response to 5-
FC in the presence of Ad5-TV-CU and GFP should clearly show increased 
efficacy only with Ad5-TV-CU but will, of course, only work if the tumours are 
growing. 
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The poor growth rate of LNCaP-CDXR3 and LNCaP-104-S tumours in Male 
BALB/c athymic mice could be due to a number of reasons, for example the age of 
the animals, their immune responses and inhibition by testosterone. Efforts to 
eliminate some of these variables when working with LNCaP-104-S tumour 
xenografts by using more immunodeficient mice (NOD/SCID, deficient in T-cells 
and B-cells) or injecting LNCaP-104-S cells in mice without subcutaneous 
testosterone pellets were also unsuccessful. Previous studies by Chuu et al 
showed that testosterone levels had no impact on LNCaP-104-S tumour xenograft 
growth (Chuu, Hiipakka et al. 2006). However, results from our pilot study in 
NOD/SCID athymic mice showed that, whilst LNCaP-104-S xenografts grew in 
NOD/SCID mice that did not have a subcutaneous testosterone pellet, tumours did 
not grow in animals with subcutaneous testosterone pellets, suggesting that 
testosterone pellets had an inhibitory effect on the growth of LNCaP-104-S 
tumours in vivo. This evidence, combined with increased neovascularisation of 
LNCaP-104-S tumour xenografts, suggests response to testosterone is more 
complex in this cell line than previously thought, and is different to other LNCaP 
sublines that are dependent on testosterone for tumour take. Thus, high levels of 
testosterone prevent LNCaP-104-S tumour development in NOD/SCID athymic 
mice. This is potentially the inhibitory factor in LNCaP-104-S xenograft growth in 
the initial pilot study. Despite this discovery, LNCaP-104-S relative tumour growth 
was still unpredictable in mice without subcutaneous testosterone pellets, with 
varying growth patterns from animal to animal and it is consequently not an 
appropriate model. Despite difficulties in establishing tumours and inhibiting 
tumour growth in both pilot studies, treatment with Ad5-TV-CU in combination with 
5-FC did show relative tumour growth inhibition in comparison to Ad5-TV-CU in 
combination with PBS in LNCaP-104-S and LNCaP-CDXR3. Whilst these results 
seemed promising, they were not significant in either study. In order to obtain 
significant results, an unreasonably large number of animals would be required. 
Therefore neither the LNCaP-104-S or LNCaP-CDXR3 cells are a reliable tumour 
model for use in larger in vivo studies.  
Due to difficulties in utilising the LNCaP sublines for in vivo studies, 22RV1 
androgen-independent xenografts were investigated, as they had previously 
demonstrated a high degree of cell killing with Ad5-TV-CU in combination with 5-
FC (section 4.2.1.4). Injectable tumours were established within two weeks, a 
marked improvement on 4-6 weeks that the LNCaP sublines took to establish and 
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twelve out of fourteen of the tumours continued to grow until they reached the 
critical limit assigned by the Home Office (1.44 cm2). Unlike the LNCaP sublines, 
the untreated 22RV1 tumours continued to grow to critical limits, demonstrating 
the reliability of 22RV1 xenograft growth. Thus, it could be concluded that any 
restriction on tumour growth was due to the treatments. 22RV1 xenografts 
continued to grow in all treatment groups throughout the duration of the 
experiment at a much faster rate than the LNCaP sublines. However, average 
tumour growth was restricted upon injection of Ad5-TV-CU in combination with 5-
FC and PBS, though this was not significant due to large variation in the data. In 
fact, the combination of Ad5-TV-CU and PBS appeared to have a larger effect on 
restricting tumour growth than the combination with 5-FC. Whilst this was 
surprising to see, the result could be explained by two of the xenografts in the PBS 
control group that failed to reach >250 mm3, even after all the other animals were 
culled due to tumour burden. This could possibly be due to the size of the tumour 
upon treatment initiation (both tumours were <100 mm3 on treatment day 1), 
perforation of the tumour alone could be responsible for the poor growth, although 
tumours in the Ad5-TV-CU + 5-FC group, that were also of a similar size upon 
treatment initiation, continued to grow. Despite this, the majority of 22RV1 
xenografts grew at a rapid rate with 10 out of 12 of the mice culled shortly after the 
treatment period ended (by day 25, 10 days after final treatment on day 15). This 
accelerated growth may prevent a real treatment effect being seen. As mentioned 
previously, the Halldén lab was unable to prevent the growth of 22RV1 xenografts 
with a replicating virus (unpublished data), due to accelerated tumour growth. 
Taken together, these findings suggest that despite potent CD/UPRT gene 
expression from the replication-deficient Ad5-TV-CU, the virus could not spread 
within the rapidly proliferating tumour mass and even in combination with 5-FC 
only a fraction of the tumour cells were eliminated. Furthermore, H&E staining of 
22RV1 xenografts revealed dense areas of erythrocytes, suggestive of 
neovascularisation and efficient tumour blood supply with no obvious signs of 
necrosis. 
In conclusion, we have still not established a suitable model for testing Ad5-TV-CU 
in vivo; the LNCaP sublines, LNCaP-CDXR3 and LNCaP-104-S failed to reliably 
grow. Most importantly, the androgen-dependent LNCaP-104-S cells would not 
grow efficiently with the addition of 1.25 mg slow release testosterone pellets, 
which is contradictory to previous in vivo studies that utilised other androgen-
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dependent cell lines. The difficulty in establishing these xenografts meant that 
tumour volume measurements after treatment could not confirm whether tumour 
growth inhibition was due to treatment, or unreliable tumour growth. Whilst 22RV1 
xenografts demonstrated more promising results, with continued tumour growth in 
10 out of 12 animals there was still no clear difference between the groups treated 
with Ad5-TV-CU in combination with 5-FC compared to PBS. In order to generate 
significant results for Ad5-TV-CU treatment in combination with 5-FC in any of 
these animal models the number of animals that would be required, would not be 
in accordance with the Home Office 3R regulations. Therefore, identification of 
novel AR expressing PCa lines, patient ex vivo tissue specimens or an alternative 
model system for example zebrafish should be investigated to fully elucidate the 
effect of Ad5-TV-CU in combination with 5-FC in vivo. 
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CHAPTER SIX 
 
 
 
IDENTIFYING THE OPTIMAL CHIMERIC 
TMPRSS2 PROMOTER FOR EFFICIENT 
ENZYME-PRODRUG THERAPY OF PCA 
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6.1 INTRODUCTION 
Two of the most well characterised prostate specific genes are PSA and prostate 
specific membrane antigen (PSMA) (O'Keefe et al. 1998, Young et al. 1992a, 
Balk, Ko, and Bubley 2003a). PSA is currently used as a biomarker for PCa 
diagnosis, as elevated levels suggest the presence of PCa. As a result of this PSA 
has been extensively investigated for use as a prostate tissue specific promoter for 
PCa therapy (Segawa et al. 1998, Latham et al. 2000, Wu, Matherly, et al. 2001). 
However, due to poor levels of transgene expression that are obtained by using 
tissue specific promoters, there is still no widely used and effective tissue specific 
therapy for PCa. 
Producing chimeric promoters has been one of the most successful methods of 
increasing transgene expression, often including the use of enhancers in 
combination with a tissue specific promoter. Previous studies had identified a 6 kb 
regulatory region of PSA, including the promoter and upstream regions (Schuur et 
al. 1996).  Latham et al went on to demonstrate that a 1.6 kb enhancer region 
upstream of the PSA promoter was able to drive maximal transcriptional activity, in 
comparison to the entire 6 kb regulatory region of PSA (Latham et al. 2000). By 
combining the upstream 1.6 kb PSA enhancer sequence with either PSA or 
Kallikrein (Hklk2) promoters, transgene expression was increased 20-fold in 
comparison to the PSA promoter alone, in the PSA-positive cell line LNCaP, but 
not in PSA negative cell lines. Other groups have also used the PSA promoter in 
combination with enhancers to increase transgene expression. Wu et al were able 
to increase luciferase transgene expression 18.9-fold when duplicating the core 
PSA enhancer element in combination with the PSA promoter, in comparison to a 
single core PSA enhancer element with the PSA promoter (Latham et al. 2000, 
Wu, Matherly, et al. 2001, Sato et al. 2003).  Sato et al achieved 20-fold higher 
expression compared to the native PSA promoter and enhancer construct, 
incorporation of this optimal chimeric promoter and enhancer into a TSTA system 
increased transgene expression by 1000-fold (Sato et al. 2003). Furthermore, the 
duplicated enhancer has been used in a number of adenoviruses to drive prostate 
specific expression of a reporter gene. Zhang et al found that incorporation of the 
duplicated enhancer into a TSTA system in an adenoviral vector drove 20-fold 
higher levels of luciferase expression than the CMV promoter (Zhang, Adams, et 
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al. 2002). However, many of these vectors suffered from poor efficacy in further 
studies. 
Previous studies have identified the TMPRSS2 promoter as an androgen 
regulated, prostate specific promoter (Lin et al. 1999, Lucas et al. 2008). Fusion of 
the promoter region of TMPRSS2 and ERG functional sequence results in 
overexpression of ERG gene, which occurs in greater than 50% of PCa cases and 
is the most common fusion gene in human cancer (Mosquera et al. 2007). It has 
been shown that the fusion may promote malignant cell survival and proliferation 
(Demichelis et al. 2007). There are no other prostate specific promoters that 
frequently form fusion genes. We therefore hypothesised that, a specific element 
to the TMPRSS2 promoter allows exceptionally high levels of oncogenic 
expression in comparison to any other previously validated prostate specific 
promoter, for example PSA. This promoter may therefore allow us to drive higher 
transgene levels than any other prostate specific promoters. We therefore set out 
to compare the promoter capabilities of TMPRSS2, including the L region (present 
in Ad5-TV-CU) and the original W region (discussed earlier), to the PSA promoter 
and the chimeric PSA promoter/enhancer, through evaluation of luciferase 
transgene expression. 
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6.2 RESULTS 
6.2.1 TMPRSS2 promoter regions drive higher levels of 
prostate specific expression in the VISA system than the previously 
validated PSA promoter. 
In order to further validate the use of the TMPRSS2 promoter, the PSA promoter 
alone and the PSA promoter and enhancer (pDRIVE-PSA-hPSA, Invivogen), that 
have previously been demonstrated to drive high levels of prostate specific 
expression (Latham et al. 2000)(Figure 73A), were cloned into the original L-VISA 
plasmid in place of the L-ARE of TMPRSS2 to compare potency of the two 
promoter and enhancer systems (Figure 73B).  
 
Figure 73 pDRIVE PSAenh/prom plasmid map purchased from Invivogen and VISA 
plasmids used in this study 
A. The PSA promoter (green) was cloned into the empty VISA vector alone, or in 
combination with the PSA enhancer (purple) prom = promoter enh= enhancer B. 
Diagrammatic of VISA luciferase plasmids used in this study. Each system contains a 
Gal4-VP2 domain downstream of the specific promoter. Binding of the Gal4-VP16 fusion 
protein product to five Gal4 binding sites upstream of the Luciferase reporter gene results 
in targeted luciferase expression. Each construct contains a different promoter. L-VISA 
contains the L-ARE of TMPRSS2, W-VISA contains the W-ARE of TMPRSS2, C-VISA 
contains the CCKAR promoter, P-VISA contains the PSA promoter, E-VISA does not 
contain a promoter and finally N-VISA contains the NKAIN2 promoter.  
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The different promoter constructs coupled to the VISA-TSTA system, expressing 
luciferase as a reporter gene were transfected into three AR-positive cell lines, 
VCaP, LNCaP and 22RV1 and one AR-negative cell line, Panc1. Relative 
luciferase expression was determined using pRL (a plasmid expressing renilla 
luciferase under the control of SV40) as a control for transfection. The levels of 
expression from the plasmids were compared to the levels of that from the control 
E-VISA plasmid, which does not contain a promoter. The ideal vector for tissue 
specific promoter gene therapy must be both specific to the tissue, whilst driving 
high levels of expression of the transgene. 
L-VISA activity was significantly high in 22RV1 cells, driving 76-fold more 
luciferase expression in comparison to the E-VISA control. However, there was no 
activity of this promoter in LNCaP cells and only 7-fold more luciferase expression 
in VCaP cells than E-VISA. Furthermore, there was no activity of L-VISA in Panc1 
cells, demonstrating the specificity of this promoter. The level of expression from 
the W-VISA construct (based on a paper by Wang, containing a 1,011 base 
sequence located upstream from TMPRSS2 Exon1) was 12076-fold higher 
compared with E-VISA in LNCaP cells (Figure 74). This was followed by VCaP 
cells, in which W-VISA drove 196-fold higher levels of luciferase in comparison to 
E-VISA. Finally, 22RV1 cells exhibited 126-fold higher levels of luciferase from W-
VISA compared to the E-VISA. This was a smaller difference than VCaP because 
basal levels of luciferase in the E-VISA were much higher in 22RV1 cells than in 
VCaP cells. However, despite the promising results from W-VISA in AR-positive 
cell lines, there was no clear tissue specificity, as similarly high levels of luciferase 
expression from the W-VISA plasmid were seen in Panc1 cells.  
Initially the activity of the original VISA plasmids was compared with that of the P-
VISA plasmid, to establish whether the TMPRSS2 promoter in L-VISA was 
capable of driving higher levels of transgene expression than the PSA promoter. 
Interestingly, the PSA promoter did not appear to demonstrate prostate specificity, 
and similar levels (~10-fold) of luciferase expression were seen in all four P-VISA 
transfected cell lines, including AR-positive 22RV1, VCaP and LNCaP and AR-
negative Panc1 cells. Additionally P-VISA drove 26-fold, 610-fold, 268-fold and 18-
fold higher levels of expression than E-VISA in 22RV1, LNCaP, Panc1 and VCaP 
respectively. This decreased specificity is similar to what is seen after transfection 
with W-VISA. Regardless of this the specific L-VISA vector is still able to drive 3-
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fold higher levels of luciferase in comparison to P-VISA, suggesting that it is a 
stronger, more specific promoter. 
The CCKAR (cholecystokinin type A receptor) promoter, a pancreatic-cancer-
specific promoter that was originally received as the C-VISA vector from the MD 
Anderson centre, was included as a control for promoter activity in Panc1 cells. 
There was no pancreatic cancer specific transgene expression when C-VISA was 
transfected into the same panel of cell lines. In fact, luciferase expression from C-
VISA was 2-fold higher in 22RV1 cells than Panc1, despite sequencing confirming 
that the CCKAR promoter was present. Additionally, another promoter for a non-
prostate specific gene, NKAIN2 was cloned into the VISA vector as a control and 
luciferase expression levels quantified in 22RV1, HEK293, Panc1 and VCaP cells. 
NKAIN2 is not regulated by AR; however, luciferase expression levels driven by 
this promoter are 2-fold higher in the AR dependent prostate cell line 22RV1 in 
comparison to non-prostate cell lines, similar to what is seen with the C-VISA 
(Figure 74).  
 
Figure 74 W-VISA is a much stronger promoter of luciferase expression but is not 
specific to AR-positive cell lines 
2x10
4
 22RV1, LNCaP, Panc1 or VCaP cells were seeded and co-transfected the following 
day with 150 ng per well of the 6 different plasmids and 15 ng pRL-SV40 per well for 
normalisation, using lipofectamine 2000.  The experiment was carried out in triplicate and 
luminescence values normalised to control renilla luciferase. 24 hours later cells were 
lysed and luciferase expression detected using a dual-luciferase reporter assay system. 
Graph shows averages of three independent experiments. Luciferase activity was 
measured as raw light units (RLU) per microgram of cellular protein.  
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6.2.2 Back to basics- using the PGL3 basic luciferase reporter 
plasmid to asses TMPRSS2 promoter activity  
When the newly cloned VISA plasmids were sent for sequencing it was highlighted 
that the original VISA plasmid already contained a PSA enhancer sequence. 
Whilst this sequence is not the entire sequence used in previous reports (~660 bp, 
Figure 75A), it poses questions as to what advantage/ disadvantage if any, the 
presence of this sequence gives to the promoter activity of Ad5-TV-CU. In silico 
analysis revealed that the PSA enhancer in VISA contains 4/6 AR binding sites of 
the PSA enhancer (Figure 75B), this sequence is therefore present in all VISA 
constructs as well as Ad5-TV-CU as the plasmid was cut at SalI and NotI and 
ligated into the p-shuttle vector. Therefore, we do not know what contribution this 
gives to the levels of transgene expression, whether this sequence is solely 
responsible for transgene expression, or works in combination with the TMPRSS2 
promoter to drive prostate specific expression from Ad5-TV-CU. 
 
 
A 
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VISA            ------------------------------------AGTGTGATGG---------ATG-T 14 
PSA             CTGTCCACCAGTCATGCTAGCCATACCATGATGATGATGATGATGAGAACCCCCCATGGT 240 
                                                    *  .*****.         *** * 
 
VISA            GACACAGCTCTCCGGGTGCAGGTGGTAAGCTTGGGGCTGGGGAGCCTCCCCCAGGAGCCC 74 
PSA             GACACAGCTCTCCGGGTGCAGGTGGTAAGCTTGGGGCTGGGGAGCCTCCCCCAGGAGCCC 300 
                ************************************************************ 
 
VISA            TATAAAACCTTCATTCCCCAGGACTCCGCCCCTGCCCTGCTGGCACCCAGAGGCTGACCA 134 
PSA             TATAAAACCTTCATTCCCCAGGACTCCGCCCCTGCCCTGCTGGCACCCAGAGGCTGACCA 360 
                ************************************************************ 
 
VISA            AGGCCCTCCCCATGCTGCTGGAGGCTGGACAACCCCCTCCCACACCCAGAGCTGTGGAAG 194 
PSA             AGGCCCTCCCCATGCTGCTGGAGGCTGGACAACCCCCTCCCACACCCAGAGCTGTGGAAG 420 
                ************************************************************ 
 
VISA            GGGAGGGAGAGCTAGCACTTGCTGTTCTGCAATTACTAGATCACCCTGGATGCACCAGGC 254 
PSA             GGGAGGGAGAGCTAGCACTTGCTGTTCTGCAATTACTAGATCACCCTGGATGCACCAGGC 480 
                ************************************************************ 
 
VISA            CCTGTAGCTCATGGAGACTTCATCTAGGGGACAAAGGCAGAGGAGACACGCCCAGGATGA 314 
PSA             CCTGTAGCTCATGGAGACTTCATCTAGGGGACAAAGGCAGAGGAGACACGCCCAGGATGA 540 
                ************************************************************ 
 
VISA            AACAGAAACAGGGGGTGGGTACGATCCCCGATTCTTCATACAAAGCCTCACGTGCCTAGA 374 
PSA             AACAGAAACAGGGGGTGGGTACGATCCCCGATTCTTCATACAAAGCCTCACGTGCCTAGA 600 
                ************************************************************ 
 
VISA            TCCTTTGCACTCCAAGACCCAGTGTGCCCTAAGACACCAGCACTCAGGAGATTGTGAGAC 434 
PSA             TCCTTTGCACTCCAAGACCCAGTGTGCCCTAAGACACCAGCACTCAGGAGATTGTGAGAC 660 
                ************************************************************ 
 
VISA            TCCCTGATCCCTGCACCACTCTGAGACCAGAAACTAGAACTTTTATTCCTCATGCTCCTG 494 
PSA             TCCCTGATCCCTGCACCACTCTGAGACCAGAAACTAGAACTTTTATTCCTCATGCTCCTG 720 
                ************************************************************ 
 
VISA            AAATAGATGTCTTGGCATTTAGTACATTCTTTTCCTTGCACTCCCAACCCAGAATCCAGC 554 
PSA             AAATAGATGTCTTGGCATTTAGTACATTCTTTTCCTTGCACTCCCAACCCAGAATCCAGC 780 
                ************************************************************ 
 
VISA            TCCACAGATACATTGCTACTGTCATCATAAAAAGATCTTGTGGTCCACAGATCCTCTAGC 614 
PSA             TCCACAGATACATTGCTACTGTCATCATAAAAAGATCTTGTGGTCCACAGATCCTCTAGC 840 
                ************************************************************ 
 
VISA            CCAGAAATATGAGTCTCCCAAAGTTCCCTAGCATTTCAAAATCCAACGTGCAGCAAACAA 674 
PSA             CCAGAAATATGAGTCTCCCAAAGTTCCCTAGCATTTCAAAATCCAACGTGCAGCAAACAA 900 
                ************************************************************ 
 
VISA            TGTACTAGTGG 
PSA             TGTACTAGTCG 
              ********* *                                                  
Figure 75 In silico analysis of PSA enhancer sequence already existing in the 
original C-VISA vector (Prof Hung).  
A Plasmid map highlighting the PSA enhancer upstream of the CCKAR promoter in the 
original C-VISA promoter. B DNA sequence alignment of 660 bp of the PSA enhancer 
identified in C-VISA (top line) alongside the wild type PSA sequence (bottom line), 
containing 4/6 published AR binding sites. *=conserved sequence 
The presence of the PSA enhancer in the VISA plasmid posed questions as to the 
nature of the promoters in terms of their prostate specific activity. In order to 
establish the true activity of the L-ARE, W-ARE and W-enhancer the three regions 
containing AREs were cloned into the PGL3 basic empty vector (Promega) and 
named L-PGL3, W-PGL3 and WE-PGL3 (W enhancer). For full details of location, 
size, sequencing results and number of AREs see appendix section 8.1. 
B 
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6.2.2.1 The previously identified TMPRRS2 AREs do not 
drive prostate specific expression in a PGL3-B reporter vector 
L-PGL3, W-PGL3 or WE-PGL3 were transfected into AR-positive 22RV1 cells, 
AR-negative HEK293 (normal human embryonic kidney cells) and Panc1 
(Pancreatic cancer cell line) cells. Surprisingly, none of the regions were able to 
drive prostate specific expression (Figure 76). The L-PGL3 plasmid generated 
similar levels of luciferase expression in both 22RV1 AR-positive PCa cells and 
Panc1 pancreatic cancer cells, with lower expression in HEK293. Similarly, when 
the W-PGL3 plasmid was transfected into all three cell lines there were similar 
levels of luciferase expression in 22RV1 and Panc1 cells, but the levels of 
luciferase expression in 22RV1 were 4.1-fold higher than in HEK293 and 15-fold 
higher than the PGL3-B vector, demonstrating strong promoter activity in 
comparison to L-PGL3.  
The previously published TMPRSS2 enhancer, located -13.5 kb upstream of 
Exon1 of TMPRSS2 (Wang et al. 2007), demonstrated negligible activity, similar to 
PGL3-B vector.  
 
Figure 76 E-ARE, L-ARE and W-ARE are not prostate specific promoter regions 
alone  
A. Cells were co-transfected with 150 ng/well of L-PGL3, W-PGL3 WE-PGL3 or PGL3-B 
and 15 ng/well renilla luciferase under the control of the SV40 promoter (pRL-SV40). Cells 
were lysed the following day and luciferase expression detected using a dual luciferase 
reporter assay system. Luciferase expression is relative to the control pRL. Data is a mean 
of 3 independent experiments. Luciferase activity was measured as raw light units (RLU) 
per microgram cellular protein. B. Diagram of promoter constructs used to express the 
luciferase reporter gene. 
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6.2.2.2 Combination of the L and W AREs restores 
prostate specific luciferase transgene expression to AR-
positive 22RV1 cells 
Combining the L-ARE with the W-ARE to make LW-PGL3 resulted in 8.9 and 1.5-
fold higher luciferase expression in 22RV1 cells transfected with LW-PGL3 in 
comparison to L-PGL3 and W-PGL3, respectively (Figure 77). However, as well as 
increasing expression in 22RV1 cells, Panc1 and HEK293 cells transfected with 
LW-PGL3 also demonstrate increased promoter activity in comparison to L-PGL3. 
In HEK293 cells this promoter activity was the same as seen after transfection with 
W-PGL3 alone, however the activity in Panc1 cells was 2-fold lower than when W-
PGL3 alone was transfected alone. This suggests that a combination of the L and 
W AREs results in higher levels of more prostate specific expression than L or W 
alone.  
The combination of the TMPRSS2 enhancer (E) with L-PGL3 (EL-PGL3) drove 5-
fold higher luciferase expression than E-PGL3 alone in 22RV1 cells, but more 
importantly, increased luciferase expression 1.4-fold in comparison to L-PGL3. 
The combination of E and L has no effect on luciferase expression in either of the 
AR-negative Panc1 or HEK293 cells, demonstrating possible low level enhancer 
activity. 
Furthermore, when the TMPRSS2 enhancer was cloned in combination with W-
PGL3 (EW-PGL3), luciferase expression increased 1.2-fold in 22RV1 cells in 
comparison to cells transfected with W-PGL3 alone. However, EW-PGL3 was also 
marginally more active in Panc1 cells, showing that the combination of E and W 
does not have the same effect on restricting tissue type specific expression as the 
combination of L and W AREs. 
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Figure 77 Combination of the L-ARE and W-ARE restores prostate specific 
expression to 22RV1 cells  
A. 2x10
4
 22RV1, HEK293 or Panc1 Cells were co-transfected with 150 ng/well of the 
luciferase plasmids shown and 15 ng/well renilla luciferase under the control of the SV40 
promoter (pRL-SV40) using lipofectamine 2000. Cells were lysed the following day and 
luciferase expression detected using a dual luciferase reporter assay system. Data is a 
mean of four independent experiments. Luciferase activity was measured as raw light units 
(RLU) per microgram cellular protein. B. Diagram of promoter constructs used to express 
the luciferase reporter gene. 
In order to further show that the TMPRSS2 promoter elements are superior to PSA 
promoter or enhancer elements, in an empty vector, the PSA promoter and 
chimeric PSA promoter/enhancer were cloned into PGL3-B (Figure 78) and activity 
compared to the TMPRSS2 promoter constructs. Surprisingly, when Panc1 cells 
were transfected with P-PGL3, containing the PSA promoter alone, higher levels 
of luciferase transgene expression were detected than in 22RV1 cells transfected 
with the same plasmid (Figure 78). Additionally, luciferase expression levels in P-
PGL3 transfected Panc1 were 1.8-fold higher in comparison L-PGL3 transfected 
Panc1. This expression was reduced when Panc1 cells were transfected with 
PEP-PGL3, containing the PSA promoter and enhancer, indicating an inhibitor 
effect of the PSA enhancer on PSA promoter driven expression in these cells.  
Luciferase expression levels in 22RV1 cells transfected with P-PGL3 were 1.3-fold 
higher than cells transfected with L-PGL3, suggesting that the PSA promoter 
drives higher levels of luciferase transgene expression in 22RV1 cells than the L 
promoter of TMPRSS2. However, W-PGL3 remains a much stronger promoter, 
driving 4.4-fold higher levels of luciferase expression than P-PGL3 in 22RV1 cells. 
When the PSA enhancer is added in combination with the PSA promoter there is 
reduced luciferase expression in 22RV1 cells, suggesting an inhibitory effect of 
this combination. 
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Figure 78 Combination of AREs from TMPRSS2 and PSA and evaluation of activity  
A. 2x10
4
 22RV1, HEK293 or Panc1 cells were co-transfected with 150 ng/well of the 
luciferase plasmids shown, in combination with 15 ng/well renilla luciferase under the 
control of the SV40 promoter (pRL-SV40) using lipofectamine 2000. 24 h later cells were 
lysed and luciferase expression detected using a dual-luciferase reporter assay system. 
Average results from four independent experiments are shown. Luciferase activity was 
measured as raw light units (RLU) per microgram cellular protein. B. Diagram of promoter 
constructs used to express the luciferase reporter gene. 
6.2.2.3 Combination of two L AREs with W looses AR-
positive cell line specificity. 
A previous publication using the PSA promoter stated that a combination of the 
PSA promoter with two PSA enhancers drove high and prostate specific 
expression (Latham et al. 2000). To investigate whether this is also the case with 
the TMPRSS2 promoter, I cloned two L-AREs upstream of W-ARE in the PGL3-B 
plasmid, as well as a number of other plasmids containing the PSA enhancer in 
combination with L-ARE and W-ARE (Figure 79B). Luciferase expression in 
22RV1 cells transfected with LLW-PGL3 was lower in comparison to LW-PGL3, 
but when Panc1 cells were transfected with LLW-PGL3 expression increased 1.6-
fold in comparison to cells transfected with LW-PGL3. Levels of luciferase 
expression in HEK293 cells were similar whether transfected with LW-PGL3 or 
LLW-PGL3 (Figure 79A).  
To establish whether the high levels of specific expression in the L-VISA plasmid 
are due to the interaction between the PSA enhancer present in the VISA plasmid 
and the L-ARE, the PSA enhancer was cloned in combination with either the L or 
W-ARE (PW-PGL3, PL-PGL3).  There was no difference in luciferase transgene 
expression levels when the PSA enhancer was cloned in combination with either 
the W-ARE or the L-ARE in comparison to the chimeric PSA promoter/enhancer, 
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except that the prostate specificity appeared to increase when the PSA enhancer 
was cloned in combination with L. (Figure 79A). This was shown by reduced 
expression in Panc1 cells, similar to what is seen in L-VISA. When luciferase 
transgene expression is compared between W-PGL3 and L-GPL3 alone and in 
combination with the PSA enhancer (PW-PGL3 or LW-PGL3) in 22RV1 cells there 
is a 3.1 and 1.3-fold reduction in luciferase transgene expression respectively. 
There is also decreased expression in HEK293 and Panc1 cells transfected with 
PW-PGL3 or PL-PGL3 in comparison to W-PGL3 and L-PGL3. This mirrors the 
results seen when the PSA enhancer was combined with the PSA promoter, 
showing an inhibitory effect of the PSA enhancer in combination with prostate 
tissue specific promoters. 
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Figure 79 Combination of PSA enhancer with W and L inhibits promoter activity 
compared to L and W alone 
A. 2x10
4
 22RV1, HEK293 or Panc1 cells were co-transfected with 150 ng/well of the 
luciferase plasmids shown in combination with 15 ng/well renilla luciferase under the control 
of the SV40 promoter (pRL-SV40) using lipofectamine 2000. 24 hours later cells were lysed 
and luciferase expression detected using a dual-luciferase reporter assay system.  Luciferase 
activity was measured as raw light units (RLU) per microgram cellular protein. Results are a 
mean of four independent experiments. B. Diagram of promoter constructs used to express 
the luciferase reporter gene. 
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6.2.2.4 Comparison of the new optimal TMPRSS2 
promoter, LW, with constitutively active SV40 and CMV 
promoters. 
After demonstrating that the LW-promoter was able to drive the highest levels of 
prostate specific expression, I investigated whether the levels of luciferase 
expression after transfection were comparable to the constitutively active SV40 
and CMV promoters. SV40-PGL3 (Promega) was transfected together with L-
PGL3, W-PGL3 and LW-PGL3 into HEK293, Panc1, LNCaP-104-S and 22RV1 
cells and luciferase expression assessed 24 h later. Interestingly, SV40-PGL3 
expression remained less than 10-fold higher than PGL3-B in all cell lines except 
for Panc1, which demonstrated more than 20-fold higher luciferase expression 
than PGL3-B and up to 10-fold higher luciferase expression than in 22RV1 cells, 
this was unexpected from a universal promoter (Figure 80). As a consequence of 
this, an alternative SV40-PGL3 plasmid was obtained from a different source 
(SV40-PGL3-2, Kunal Shah, Molecular Oncology, Barts Cancer Institute), but 
showed a similar pattern of expression across all four cell lines (data not shown). 
Despite this, LW-PGL3 drove 4.5-fold higher luciferase expression in comparison 
to SV40-PGL3 in 22RV1 cells, but remained 3.6-fold, 4.7-fold and 6.8-fold weaker 
than SV40-PGL3 in LNCaP-104-S, HEK93 and Panc1 respectively.  
 
Figure 80 LW-PGL3 drives 4.5-fold higher levels of luciferase than the constitutively 
active SV40-PGL3 vector 
2x10
4
 22RV1, HEK293 and 1x10
4
 Panc1 and LNCaP-104-S cells were co-transfected with 
150 ng/well of the luciferase plasmids shown, in combination with 15 ng/well renilla 
luciferase under the control of the SV40 promoter (pRL-SV40) using lipofectamine 2000. 
24 h later cells were lysed and luciferase expression detected using a dual-luciferase 
reporter assay system.  Luciferase activity was measured as raw light units (RLU) per 
microgram cellular protein. 
  247 
 
I later cloned the CMV promoter into the PGL3-B vector and compared the levels 
of luciferase activity once again between L-PGL3, W-PGL3, LW-PGL3, and CMV-
PGL3 transfected 22RV1 cells. CMV-PGL3 drove 214-fold higher luciferase 
expression than LW-PGL3, demonstrating that the LW promoter alone in the basic 
vector is not capable of driving higher levels than the constitutively active CMV 
promoter (Figure 81).  
 
Figure 81 CMV promoter drives 214-fold higher levels of luciferase expression than 
the optimal LW-promoter 
2x10
4
 22RV1 cells were co-transfected with 150 ng/well of the luciferase plasmids shown 
in combination with 15 ng/well renilla luciferase under the control of the SV40 promoter 
(pRL-SV40) using lipofectamine 2000. 24 h later cells were lysed and luciferase 
expression detected using a dual-luciferase reporter assay system.  Luciferase activity was 
measured as raw light units (RLU) per microgram cellular protein. 
6.2.2.5 LW-PGL3 is active in AR-positive BCa cell line 
MM453 
After a dose response to Ad5-TV-CU alone was generated in the AR-positive BCa 
cell line MM453, it was desirable to evaluate luciferase transgene expression from 
the new TMPRSS2 reporter plasmid in this cell line, as well as MCF7 AR-positive 
cells, to establish whether future studies should include AR-positive BCa cell lines. 
MCF7 cells express lower levels of AR than MM453 cells, and therefore, 
unsurprisingly have the lowest luciferase transgene expression levels after 
transfection with all plasmids, except for LLW-PGL3 (Figure 82). Luciferase 
transgene expression from LW-PGL3 transfected MM453 cells was 5.1-fold higher 
than L-PGL3, but 1.2-fold lower than W-PGL3, showing that the combination of L 
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and W does not have the same enhancer effect in MM453 cells as it does in 
22RV1 cells. There was very little difference in the level of luciferase transgene 
expression in LW-PGL3 transfected MCF7 cells in comparison to L-PGL3 and W-
PGL3. Furthermore, luciferase transgene expression from L-PGL3 transfected 
MM453 and MCF7 cells was 1.3-fold and 1.6-fold lower than in 22RV1 cells 
respectively and W-PGL3 luciferase expression in MM453 and MCF7 cells was 
7.4-fold and 1.9-fold lower than 22RV1 cells respectively. 
 
Figure 82 Luciferase transgene expression is higher in MM453 AR-positive cells 
transfected with TMPRSS2 luciferase plasmids compared to MCF7 
2x10
4
 22RV1, MCF7 or MM453 cells were transfected with 150 ng/well L-PGL3, W-PGL3, 
LW-PGL3 or LLW-PGL3 in combination with 15 ng/well renilla luciferase under the control 
of the SV40 promoter (pRL-SV40) using lipofectamine 2000. 24 h later cells were lysed 
and luciferase expression detected using a dual-luciferase reporter assay system. 
Luciferase activity was measured as raw light units (RLU) per microgram cellular protein. 
6.2.3 Stimulation/inhibition of AREs in TMPRSS2 constructs by 
mibolerone, Bicalutamide and Estradiol. 
It was important to establish whether transgene expression from the plasmids 
containing the various TMPRSS2 promoters both alone, or in combination could 
be increased upon addition of the synthetic androgen mibolerone or decreased 
upon addition of the anti-androgen Bicalutamide. I was previously unable to detect 
increased/decreased CD/UPRT transgene expression by western blot in both 
LNCaP and 22RV1 cells after treatment with mibolerone, Bicalutamide or Estradiol 
(see sections 4.2.1.3 and 4.2.4.5). Therefore, the same experiments were 
repeated using luciferase assays, as they are more sensitive to slight increases or 
decreases in transgene expression.  
The AR responsive reporter plasmid MMTV-Luc, containing an inducible hormone 
response element regulated by androgen and glucocorticoid, was included in all 
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experiments as a control for drug activity. There was no difference in luciferase 
expression levels when any of the plasmids were combined with either mibolerone 
or Bicalutamide in 22RV1 cells (Figure 83). However, 10-fold more luciferase 
expression was detected when 22RV1 cells transfected with MMTV-Luc were 
treated with either mibolerone or Estradiol, confirming that both drugs are active 
and capable of stimulating AR. Interestingly, there was 20% more expression 
when LW-PGL3 was treated with Estradiol, however this was not comparable to 
the 10-fold increase in expression when the MMTV-Luc plasmid was transfected in 
combination with Estradiol. This experiment was repeated three times and 
expression consistently increased when LW-PGL3 was transfected in combination 
with Estradiol, however the difference was not significant p=>0.05. 
 
Figure 83 Luciferase transgene expression increases by 20% when LW-PGL3 is 
transfected into 22RV1 cells in combination with Estradiol 
2X10
4
 22RV1 cells were seeded in 10% C/S media and transfected the following day with 
L-PGL3, W-PGL3, LW-PGL3, LLW-PGL3, PGL3-B or MMTV-LUC. 4 h after transfection 
media was replaced with media containing 1 nM mibolerone, 5 µM Bicaluatamide or 10 nM 
Estradiol. 24 h later cells were lysed and luciferase expression detected using a dual-
luciferase reporter assay system.  Luciferase activity was measured as raw light units 
(RLU) per microgram cellular protein (n=3). p=>0.05 
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6.3 DISCUSSION 
Previous studies have suggested that gene specific promoters are capable of 
driving low levels of expression; however they are often not tissue specific 
(Riegman et al. 1991) as tissue specificity is most often a result of the gene 
specific enhancers found upstream or downstream of the tissue specific promoter 
(Pang et al. 1997).  
PSA is the most extensively studied prostate specific promoter and has been 
widely used for tissue specific restriction of transgene expression in PCa therapy 
(Wu, Matherly, et al. 2001, Li et al. 2005, Lee et al. 2002, Latham et al. 2000). 
However, studies using the PSA promoter have ultimately failed due to poor levels 
of transgene expression from tissue specific promoters. Efforts to increase 
transgene expression from these promoters by producing chimeric 
promoters/enhancers drove up to 1000-fold higher expression in comparison to 
the PSA promoter alone (Latham et al. 2000). Further studies that have included 
the fusion of the regulatory regions of both the PSA and PSMA genes that were 
able to drive high levels of luciferase transgene expression in both AR expressing 
and non AR expressing cell lines, providing potentially promising therapies for the 
treatment of CRPC (Lee et al. 2002). This chimeric enhancer was subsequently 
inserted into an adenoviral vector and demonstrated dramatic inhibition of 
CWR22rv tumours in vivo (Li et al. 2005). Despite promising in vitro and in vivo 
studies, these systems have never entered clinical trials due to poor efficacy. The 
TMPRSS2 promoter has never before been investigated as a prostate specific 
promoter; I therefore initially wanted to compare transgene expression levels from 
the TMPRSS2 promoter sequences in L-VISA and W-VISA to the previously 
validated PSA promoter, by replacing the TMPRSS2 promoter in L-VISA with the 
PSA promoter region and the stronger chimeric PSA promoter/enhancer region. L-
VISA and W-VISA drove higher levels of transgene expression in 22RV1 in 
comparison to P-VISA, suggesting that the TMPRSS2 promoter is superior to PSA 
in this construct. Additionally, despite previous in vitro studies with Ad5-TV-CU 
(containing the L-ARE), that demonstrated AR-positive cell line specific transgene 
expression after transfection and infection, I wanted to go back to basics in order 
to establish the promoter activity of the two plasmids without the interference of 
the PSA enhancer and cloned both the L-ARE and W-ARE into the PGL3-B 
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vector, as well as the PSA promoter alone or in combination with the enhancer 
(producing L-PGL3, W-PGL3, P-PGL3 and PWE-PGL3). 
I concluded that both L-VISA and W-VISA drove higher levels of luciferase 
transgene expression in 22RV1 cells than the P-VISA. Additionally, comparison of 
the new PGL3-B vectors containing the L and W-AREs confirmed higher activity 
from the TMPRSS2 promoter elements than the PSA promoter alone or in 
combination with its enhancer. Interestingly, similar levels of luciferase transgene 
expression were detected in 22RV1 AR-positive and Panc1 AR-negative cell lines 
after transfection with both L-PGL3 and W-PGL3, rendering the promoter 
unspecific. This lack of prostate specific expression could be due to the lack of 
other transcription factors required in addition to AR, which are responsible for the 
transcriptional activation of the TMPRSS2 promoter. Alternatively, Panc1 cells 
may express AR, or transcriptional regulators of TMPRSS2 that are as of yet 
unknown, as low level expression of TMPRSS2 RNA has previously been 
described in the pancreas (Lin et al. 1999). I also detected very low level 
luciferase expression in the normal human embryonic kidney cell line (HEK293) 
and  TMPRSS2 RNA expression has also been detected in the kidney at low 
levels (Lin et al. 1999), further confirming the possible unspecific nature of the 
TMPRRS2 regulatory regions.  
I later found that the VISA expression cassette contained 660 bp of the PSA 
enhancer DNA that I was previously unaware of. This enhancer sequence, 
consisting of 4/6 of the previously published AREs of the PSA enhancer, was 
clearly able to drive some low level transgene expression alone, demonstrated by 
the high background luciferase expression in 22RV1 cells transfected with E-VISA 
(promoter-less empty-VISA). Surprisingly, luciferase expression from P-VISA did 
not seem to be restricted to AR-positive cell lines, this is possibly due to the 
interaction between the 660 bp enhancer present in VISA and the PSA promoter. 
The promoter may require all 6 AREs of the PSA enhancer, allowing for a more 
complete set of transcription factors implicated in endogenous gene regulation to 
drive prostate specific expression from the PSA promoter. Consequently, the 
presence of 600 bp of the PSA enhancer may affect transgene expression from 
this plasmid. A similar pattern was seen in the PGL3 plasmids that did not contain 
the VISA sequence. The PSA promoter alone did not drive specific expression in 
AR-positive cell lines, however a combination with the PSA enhancer resulted in 
decreased expression in both 22RV1 and Panc1 cells, with an overall effect of 
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increasing specific expression in 22RV1 cells in comparison to Panc1 (Figure 
79A). 
Firstly, whilst both the L and W AREs have failed to demonstrate clear prostate 
specific expression in the 22RV1 cell line, the L-ARE, present in L-VISA is capable 
of driving high levels of prostate specific transgene expression in Ad5-TV-CU. This 
lead to questions as to what contribution the PSA enhancer, that was already 
present in VISA was giving towards the activity and tissue specificity in L-VISA 
and as a consequence Ad5-TV-CU and whether this could be replicated using 
TMPRSS2 enhancer regions. To investigate this further, I aimed to increase 
prostate specific transgene expression by a combining the TMPRSS2 enhancer 
(WE) with either L-PGL3 or W-PGL3. Unfortunately this combination did not 
enhance the promoter activity of these plasmids. There could be two potential 
reasons for the poor enhancer activity of the combination with the TMPRSS2 
enhancer: 1) The TMPRSS2 enhancer requires long-distance interaction with a 
promoter though chromatin looping in order to drive transcription of TMPRSS2, as 
previously described (Wang et al. 2007) and therefore when cloned in direct 
sequence, loses its interaction with TMPRSS2 promoter regions. 2) The previously 
identified TMPRSS2 enhancer does not in fact have enhancer activity, contrary to 
previous reports suggesting it interacts with the TMPRSS2 promoter to drive 
higher levels of prostate specific expression (Wang, Carroll, and Brown 2005). 
After failing to increase transgene expression by combining the previously 
published TMPRSS2 upstream enhancer, I cloned, in sequence, the L-ARE that 
drives prostate specific expression in VISA, with W-ARE, that drives high levels of 
unspecific luciferase transgene expression in all cell lines, resulting in increased 
prostate specific transgene expression after LW-PGL3 transfection. Evidence 
suggests that the L-ARE and W-ARE work in combination to drive high levels of 
prostate specific expression. This is similar to the previous studies with the PSA 
promoter and enhancer elements, which have demonstrated that chimeric 
promoters, comprised of a tissue specific promoter in combination with an 
enhancer, drive high levels of tissue specific expression in prostate cells (Pang et 
al. 1997, Latham et al. 2000). In fact, the DNA sequence upstream of the PSA 
gene promoter was found to perform not only as an enhancer but also as a 
promoter (Pang et al. 1997). We therefore propose a model, whereby the L-ARE 
acts as the promoter of TMPRSS2 and through interaction with the W-ARE, 
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functioning as both a promoter and enhancer, drives high levels of prostate 
specific transgene expression.  
Despite the higher levels of transgene expression in 22RV1 AR-positive cell lines 
in comparison to AR-negative cell lines transfected with LW-PGL3, there is still 
some expression of LW-PGL3 in Panc1 cells. Previous studies with the PSA 
promoter have shown that promoter activation does not solely depend on 
activation by AR, but is also dependent on other promoter-DNA-binding proteins 
produced exclusively in prostate cells (Pang et al. 1995). The full repertoire of 
prostate specific transcription factors has not yet been fully elucidated, and could 
vary from promoter to promoter. It is possible that the LW TMPRSS2 promoter is 
activated by a number of transcription factors exclusive to the prostate, or that 
these factors are also expressed in cell lines where TMPRSS2 expression has 
been previously detected, for example the pancreas  (Lin et al. 1999), explaining 
activity of LW-PGL3 in Panc1 cells. Further investigation into this is necessary, 
through screening a larger number of AR-positive and negative cell lines.  
After establishing that a combination of the L and W regions of TMPRSS2 drove 
the highest levels of transgene expression, I wanted to compare the activity of this 
new optimal promoter with the constitutively active SV40 and CMV promoters. 
SV40-PGL3 expression was 4-fold and 10-fold lower in 22RV1 and LNCaP-104S 
cells respectively, in comparison to Panc1, suggesting that SV40 does not function 
well as a constitutive promoter in LNCaP-104-S and 22RV1 cells. In fact, other 
labs have experienced similar difficulties in establishing high levels of luciferase 
expression from the SV40 promoter in combination with its enhancer in LNCaP 
cells, where they found that the addition of the SV40 promoter did not increase 
luciferase transgene expression. Contrarily in PC-3 cells there was a huge 
increase in reporter activity when the SV40 promoter was combined with its 
enhancer, suggesting that SV40 promoter activity is potentially repressed in some 
prostate cell lines (Chung, Isaacs, and Simons 2007). SV40 has also been shown 
to drive 3-fold lower levels of expression in LNCaP and MDA PCa 2b cells in 
comparison to HeLa and NMU cells (Logg et al. 2002). This lead to investigating 
whether a second constitutively active promoter, CMV, would behave differently in 
22RV1 cells. Luciferase expression from the CMV promoter was ~214-fold higher 
than the LW promoter in 22RV1 cells and considerably higher than the previous 
SV40 promoter. Although the LW promoter alone cannot drive similar levels of 
luciferase expression to the constitutively active CMV promoter, nor the L-VISA 
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TSTA system that is currently in Ad5-TV-CU. Inclusion of the LW promoter in the 
VISA expression cassette will potentially drive levels of luciferase expression that 
are equal to, or greater than the CMV promoter. LW-PGL3 is able to drive 8.9-fold 
and 1.5-fold higher expression than both the L-PGL3 and W-PGL3 promoters 
respectively (section 6.2.2.2). These promoters are currently present in L-VISA 
and W-VISA and already drive similar levels of luciferase expression to the CMV 
promoter. Thus, increasing both the prostate specificity and activity by 
incorporation of the LW promoter into the VISA TSTA could increase the 
therapeutic efficacy of a new adenovirus construct. 
After discovering promising results in 22RV1 AR-positive cells with the new LW-
PGL3 chimeric promoter, I wanted to establish whether the same activity could be 
achieved in MM453 and MCF7 AR-positive BCa cell lines. LW-PGL3 is active in 
MM453 cells, but luciferase transgene expression levels do not increase in this 
cell line in comparison to W-PGL3 alone, contradictory to what we see in 22RV1 
cells. The difference in enhancer effect of LW-PGL3 between MM453 cells and 
22RV1 cells is possibly due to: 1) lower levels of AR expression in MM453 
compared to 22RV1 or 2) absence of prostate specific transcription factors 
required to further activate the LW chimeric TMPRSS2 promoter. Luciferase 
transgene expression from LW-PGL3 in MCF7 cells is 1.3-fold higher than L-PGL3 
and 1.6-fold lower than W-PGL3. This low level transgene expression after 
transfection in MCF7 cells is most probably due to very low levels of AR 
expression in this cell line in comparison to 22RV1 and MM453 (Cochrane et al. 
2014). Thus, luciferase transgene expression levels in MM453 cells transfected 
with LW-PGL3 suggests that the new virus with the optimal LW promoter could be 
effective against some AR-positive BCas that currently have very limited 
therapeutic interventions.    
It was also important to establish the androgen responsiveness of the L and W 
AREs both alone and in combination, I therefore employed luciferase assays plus 
and minus mibolerone or Bicalutamide in combination with the different plasmids 
in 22RV1 cells. Furthermore, previous studies have suggested that the TMPRSS2 
promoter is under the transcriptional control of ER (Setlur et al. 2008, Bonkhoff 
and Berges 2009). I therefore also employed the ER-α agonist, Estradiol, to see if 
it would stimulate expression from the TMPRSS2 promoter plasmids. I saw a 10-
fold increase in luciferase transgene expression when MMTV-Luc was treated with 
both Mibolerone and Estradiol, demonstrating the activity of both drugs. The 
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MMTV-Luc plasmid is a control for AR activity and should be stimulated by 
mibolerone, a synthetic AR agonist, however the increase in luciferase expression 
from MMTV-Luc treated with Estradiol highlights the cross-reactivity between the 
ER and AR pathways. I also saw a small increase in luciferase expression when 
LW-PGL3 was treated with Estradiol, however this was not anywhere near the 10-
fold induction of MMTV-Luc. 
It is most probable that we do not see a difference in expression levels after 
treatment in androgen-independent 22RV1 cells due to the mutated AR in this cell 
line (previously discussed in section 4.3). The same experiments would need to be 
repeated in androgen-dependent cell lines LNCaP-104-S, LNCaP-CDXR3 or 
LNCaP-104R1 to truly establish the AR-responsiveness of these plasmids. 
Preliminary studies in LNCaP-CDXR3 cells have demonstrated much lower levels 
of luciferase expression from all plasmids, most probably due to the poor 
transfectability of these cell lines (discussed earlier). Future work would need to 
include transfection by electroporation in this cell line to increase transfection 
efficiencies. 
In conclusion, the combination of L and W AREs restore prostate specificity of the 
W promoter, by simultaneously increasing transgene expression in 22RV1 cells, 
whilst decreasing expression in Panc1. LW is therefore a more superior promoter 
to L, which is currently in Ad5-TV-CU, and could be used to drive higher and more 
specific transgene expression for adenoviral gene therapy in PCa, with potential 
clinical applications for the treatment of AR-positive BCa. If incorporated into the 
VISA vector, the LW promoter is capable of driving similar or potentially even 
higher levels of luciferase expression than the constitutively active CMV promoter. 
However, despite demonstrating prostate specificity, there is no increase in 
luciferase expression from any of the plasmids when treated with mibolerone, and 
only a slight increase when treated with Estradiol. Further investigation into what 
causes prostate specific activation of these promoter elements may help to fully 
elucidate the role of TMPRRSS2 in PCa progression and provide potential targets 
for future therapies. 
I also wanted to investigate the effect of the PSA enhancer in VISA on activity of 
non-prostate specific promoters. N-VISA contains the promoter element of the 
gene NKAIN2, this gene is not prostate specific, however 2-fold higher luciferase 
expression was detected in 22RV1 AR-positive cells after transfection with N-VISA 
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in comparison to any other cell line. A previous study has shown that the PSA 
enhancer can work together with other prostate specific and non-prostate specific 
promoters to drive high levels of prostate specific expression (Lee et al. 2002, 
Chapel-Fernandes et al. 2006), where fusion of the PSA enhancer to the 
constitutively active PGK promoter increased transgene expression specifically in 
LNCaP cells. Furthermore, C-VISA was used as a control for luciferase expression 
in Panc1 cells. However, this plasmid showed no activity in Panc1 cells, and was 
in fact more active in 22RV1 cells,  despite previous publications showing this 
promoter was capable of driving high levels of transgene expression in Panc1 (Xie 
et al. 2007). The PSA enhancer present could possibly be responsible for this high 
expression in 22RV1, increasing transgene expression from a non-prostate 
promoter. Finally, C-VISA that Xie et al gifted us may be different to the one used 
in previous studies, possibly explaining the lack of activity from this promoter in 
Panc1. 
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7.1 Implications of the findings 
The rationale behind this research was as a proof of concept to create a non-
replicating adenovirus that was capable of infecting and killing PCa cells 
specifically, by taking advantage of the androgen regulated expression of the 
CD/UPRT suicide gene, due to the TMPRSS2 promoter. Once proven, the 
ultimate goal was to engineer an oncolytic virus that is replication selective and 
expresses CD/UPRT from the optimal TMPRSS2 chimeric promoter. This will be 
produced by replacing the E1B or E3 genes with the optimal construct, resulting in 
the death of cancer cells, both through viral gene replication, and through tissue 
specific expression of the CD/UPRT transgene. 
Watchful waiting is employed as the current mainstay treatment for localised 
prostate cancer; however as it progresses to locally advanced cancer, depending 
on the age and stage of the patient, hormonal therapies or more aggressive 
treatment may be given. Aggressive treatments usually incur lifelong unwanted 
side effects and prolonged treatment with hormonal therapies such as the 
antiandrogen Bicalutamide can lead to castration resistant PCa; therefore it is 
necessary to find a less invasive, yet effective treatment for PCa. Enzyme prodrug 
therapy has been widely investigated for the treatment of many cancers, including 
prostate cancer. Most often expression of the enzyme is controlled by a tissue 
specific promoter, restricting expression to the cell type of choice, and therefore 
limiting off-target toxicity. Previous studies utilizing tissue specific promoters for 
this purpose have not yet made phase III clinical trials. In this study we aimed to 
produce a highly efficacious and targeted adenovirus for prostate cancer, which 
would have potentially massive clinical implications for the treatment of early and 
late stage PCa. 
The data presented in this thesis demonstrated that a non-replicating adenovirus, 
with CD/UPRT gene expression controlled by androgen responsive elements of 
the TMPRSS2 gene, enhances cell death in combination with 5-FC in AR-positive 
prostate cancer cell lines, 22RV1, LNCaP-104-S, LNCaP-CDXR3 and LNCaP-
104R1 in vitro, while having no significant toxicity in AR-negative cell lines, 
including normal immortalized prostate cells (PNT1A), primary prostate epithelial 
cells (PrEC) and the metastatic prostate cancer cell line PC3. 
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Since fusion of the regulatory region of TMPRSS2 to the ERG oncogene is 
prevalent in >50% of prostate cancers, we believed the TMRPSS2 promoter 
region would drive high levels of prostate specific expression. I demonstrated the 
increased activity of the TMPRSS2 promoter regions in comparison to the 
chimeric PSA promoter and enhancer. I also generated a new chimeric TMPRSS2 
promoter composed of a combination of one TMPRSS2 region upstream of Exon1 
with another TMPRSS2 region upstream of Exon2. This new chimeric promoter 
(LW) can drive 8.9-fold higher levels of transgene expression that the L promoter 
alone, which is currently in Ad5-TV-CU. Replacement of the L promoter in Ad5-
TV-CU with LW is likely to result in the generation of a new Ad5-TV-CU that is 
able to express higher levels of CD/UPRT, leading to more prostate cancer cell 
death, however due to time constraints I was unable to complete this part of the 
project. 
Previous studies that have utilised prostate tissue specific promoters to drive 
transgene expression have ultimately failed due to poor efficacy in preclinical 
studies. Many of these studies have focussed around utilising specific regulatory 
regions of the PSA promoter, for example the PSA promoter region alone, Lu et al 
constructed a virus whereby E1 gene expression was under the control of the PSA 
promoter (Lu et al. 2013). They found that the virus inhibited PCa cell growth in 
vitro, detected transgene expression in xenograft tissues after infection and 
demonstrated inhibition of PCa tumour growth in vivo. Despite this the PSA 
promoter alone is not strong enough to induce cell death in a clinical setting, 
therefore studies with chimeric promoters (a fusion of the PSA promoter and 
enhancer), have also been investigated. Latham et al placed nitroreductase 
expression under the control of an optimal PSA promoter/enhancer and 
demonstrated sensitisation to the CB1954 prodrug following infection of LNCaP 
cells in vitro (Latham et al. 2000). More recently, chimeric promoters that are 
formed from regulatory regions of the PSA and PSMA genes have been used to 
restrict viral replication to prostate cells, but have limitations, in that they are only 
active in PSA/PSMA positive, androgen independent cells (Lee et al. 2004, Cheng 
et al. 2004). All have ultimately failed. From the data produced in this project, 
including the superior promoter activity of TMPRSS2 in comparison to the 
previously validated PSA and PSA promoter/enhancer and enhanced cell killing 
with the combination of Ad5-TV-CU and 5-FC, I propose that Ad5-TV-CU could 
have greater cell killing potential than any of the previously published 
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adenoviruses, whereby suicide transgene expression is under the control of a 
prostate specific promoter. This could be further adapted by incorporation of the 
optimal LW promoter into the expression cassette to drive even higher levels of 
transgene expression for prostate cancer specific cell death. Ad5-TV-CU may also 
be effective in the apocrine ER- AR+ subtype of BCa. Apocrine BCas do not 
benefit from endocrine or Her2 targeted therapies, necessitating novel treatments 
that take advantage of AR expression. 
7.1.1 Ad5-TV-CU enhances cell killing in vitro in combination 
with 5-FC in AR-positive PCa cell lines 
Significant increased cell killing was observed in 22RV1, LNCaP-104-S, LNCaP-
CDXR3 and LNCaP-104R1 cells when treated with a combination of Ad5-TV-CU 
and 5-FC prodrug. To demonstrate the target cell specificity of Ad5-TV-CU, 5-FC 
prodrug sensitization assays were also performed in a panel of AR-negative cell 
lines, including normal primary prostate epithelial cells (PrEC), Immortalized 
normal prostate cells (PNT1A) and the metastatic prostate cell line PC3. No 
increased cell killing was observed in the AR-negative cells. In fact the highest 
viral dose (105ppc) killed only ~20% of cells. This was believed to be due to the 
lack of CD/UPRT protein expression, which is intrinsically cytotoxic to the AR-
positive cell lines in which it was translated. Additionally PC3 cells are extremely 
insensitive to most cytotoxic agents, including adenovirus (Oberg et al. 2010). 
Despite proven efficacy of Ad5-TV-CU in 4/6 AR-positive PCa cell lines tested 
(22RV1, LNCaP-CDXR3, LNCaP-104R1 and LNCaP-104-S), these results could 
not be replicated in AR-positive LNCaP in our lab (ATCC) or VCaP cells. 
CD/UPRT protein was expressed in VCaP cells in a dose dependent manner 
following Ad5-TV-CU infection. However, no increased cytotoxicity was observed 
in prodrug sensitization assays. Treatment of VCaP with either 5-FC or 5-FU alone 
demonstrated poor sensitivity to the drugs, with no cell death induced at the 
highest concentration of 5-FC and only 75% cell death at the highest 
concentration of 5-FU (1 mg/ml), suggesting VCaP cells are resistant to 5-FU and 
therefore Ad5-TV-CU may have been ineffective. Resistance of VCaP cells to 5-
FU was proposed to be due to the slow doubling time of this cell line (5-6 days), 
requiring a 6 day incubation with 5-FU for therapeutic efficacy. On one occasion, a 
prolonged 6 day treatment of VCaP cells with 5-FU induced a higher percentage 
of cell killing, suggesting that prolonged treatment of this cell line with Ad5-TV-CU 
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in combination with 5-FC could potentially increase 5-FC dose-dependent 
cytotoxicity. Furthermore, VCaP cells have a homozygous p53 mutation (A248W), 
that may modulate resistance to 5-FU. In fact, previous studies have described 
resistance to 5-FU in HCT116p53-/- colorectal cancer cells (Bunz et al. 1999). 
Therefore, a combination of the slow doubling time of the cells, coupled with the 
mutational background, may affect their propensity to undergo cell death.  
Interestingly, LNCaP cells in our lab (ATCC) did not express CD/UPRT after Ad5-
TV-CU infection, despite proven AR protein expression (section 4.2.1.1). Very low 
levels of dose dependent expression could be observed in one experimental 
repeat out of 3, and no increased cytotoxicity was observed in prodrug 
sensitization assays. The levels of AR expression in this cell line are lower than 
LNCaP-CDXR3 and LNCaP-104R1, but similar to the parental LNCaP-104-S cells. 
CD/UPRT expression was clearly observed in the LNCaP Chicago sublines with 
doses of Ad5-TV-CU as low as 2000 ppc. However, neither similar nor increasing 
doses of Ad5-TV-CU could induce clear CD/UPRT expression in LNCaP in our 
lab. This lead to STR profiling of all four LNCaP sublines, that revealed differences 
of the 8 core STR markers between the cell lines. There were mutational 
differences in 3/8 markers between LNCaP-104-S and LNCaP (ATCC). This might 
be sufficient to induce a differential responses to Ad5-TV-CU infection, as LNCaP 
(ATCC) could be missing additional transcription factors that are essential for the 
transcriptional activation of TMPRSS2 AREs, for example CHD8 (Menon, Yates, 
and Bochar 2010) or GATA2 (Perez-Stable, Pozas, and Roos 2000) (Figure 84).  
 
Figure 84 AR co-regulators necessary for activation of AR dependent genes 
In order for AR-dependent transcription to take place a full repertoire of coactivators are 
required for activation, for example CHD8. Not only can these coactivators be specific for 
AR dependent activation, but they can also be specific to a cell line. 
Previous studies have highlighted the upregulation of androgen responsive genes, 
including PSA and TMPRSS2, upon treatment with the synthetic androgen 
mibolerone in LNCaP cells (Lin et al. 1999). Efforts to demonstrate the androgen 
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responsiveness of the TMPRSS2 promoter in Ad5-TV-CU have been 
unsuccessful. No increase or decrease in CD/UPRT transgene expression could 
be detected upon addition of either mibolerone or Bicalutamide, leading to 
questions surrounding the androgen responsiveness of Ad5-TV-CU. However, I 
performed these studies solely in 22RV1 cells, with a constitutively active AR. This 
constitutive activation renders AR insensitive to activation by additional androgens 
and unresponsive to antagonists, therefore the AREs in the TMPRSS2 promoter 
sequence present in Ad5-TV-CU are unresponsive to the androgen bound 
receptor, or androgens do not bind to the receptor in 22RV1 cells. Further studies 
in androgen-dependent cell lines, for example AR transfected CHO cells, in 
combination with utilising more sensitive methods for detecting changes in 
expression levels, for example a luciferase reporter assay, would confirm whether 
this was the case. In addition these experiments would demonstrate the androgen 
responsiveness of the TMPRSS2 promoter elements present in Ad5-TV-CU. 
7.1.2 Combination of L and W AREs from TMPRSS2 drive high 
specific expression in AR-positive cell lines  
Both the L and W promoters are incapable of driving high levels of prostate 
specific transgene expression alone. The increased specificity of the L-promoter in 
Ad5-TV-CU, that contains four out of six AREs located in the PSA enhancer, lead 
to questions surrounding whether transgene expression from the TMPRSS2 
promoter regions could be increased through a combination of multiple androgen 
responsive regions. Therefore, I combined the L and W-AREs and found that this 
combination increased both luciferase transgene expression and specificity 
(section 6.2.2.2). Furthermore, previous studies have demonstrated that 
combining multiple androgen responsive regions increases transgene expression 
(Latham et al. 2000). Li et al demonstrated that expression of viral E1A and E4 
genes could be tightly controlled by the PSES chimeric enhancer, containing 
enhancer elements from PSA and (Li et al. 2005). The efficacy of this virus was 
tested in vivo, and showed that the growth of CWR22rv xenografts was greatly 
inhibited compared to tumours treated with a control virus. However, this is only 
effective in PSA/PSMA-positive androgen-independent cell lines, as PSMA is 
inhibited by androgens, and viral replication slowed after several days. Similarly, 
Ahn et al used the PSA/PSMA chimeric promoter to restrict a replicating 
adenovirus armed with the herpex simplex virus thymidine kinase, called AdIU1, to 
treat CWR22rv tumour xenografts and found a stronger therapeutic effect with the 
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combination Of AdIU1 and GCV, compared to AdIU1 alone (Li et al. 2005, Ahn et 
al. 2009). These cases provided further evidence for the hypothesis that 
combining multiple androgen responsive regions, including promoters and 
enhancers could increase transgene expression. 
Three models have been suggested that could explain the interaction between a 
proximal promoter and a distal enhancer, including the tracking model, the linking 
model and the looping model. The tracking model suggests that signals are 
recruited by enhancers through the DNA to promoters and the linking model 
suggests that the looped enhancer-promoter interaction is due to propagation of 
nucleoprotein structures along the intervening DNA.  The looping model suggests 
that proteins that are directly bound to either enhancers or promoters interact with 
each other (Bulger and Groudine 1999). In fact, Wang et al demonstrated, using 
ChIP-3C methodology, that recruitment of AR and its essential coactivators to the 
W region and the upstream W enhancer resulted in the formation of chromatin 
looping that allowed RNA polymerase II to track from the enhancer to the promoter 
(Wang, Carroll, and Brown 2005). Consequently, I initially combined both the L 
and W AREs with the previously published TMPRSS2 enhancer (WE), located -
13.5 kb upstream from the TMPRSS2 promoter (Wang et al. 2007). However, 
combining these sequences did not increase transgene expression in my hands; 
in fact it had very little effect on expression levels from the vector, possibly due to 
the close proximity of the sequences. A further combination of the L-ARE 
(upstream of Exon1) and W-ARE (upstream of Exon2), creating the LW chimeric 
promoter, not only drove higher levels of expression than the W-ARE alone, but 
restored prostate specificity to the vector, resulting in higher levels of prostate 
specific transgene expression and a new optimal promoter. I therefore 
hypothesise that the L and the W regions interact, through chromatin looping, in a 
similar fashion to that identified by Wang et al, in order to drive higher levels of 
prostate specific expression (Figure 85). 
It will be important to establish the AR dependency of both the L and W regions for 
future studies, simple experiments to demonstrate this could include comparison 
of luciferase expression in LW-PGL3 transfected PC3 and DU145 (AR negative) 
cell lines co-transfected with an AR expressing plasmid vs without, as well as 
transfection of 22RV1 cells with LW-PGL3 ± AR siRNA to demonstrate the effect 
of inhibiting AR expression on the activation of LW-PGL3 using traditional 
luciferase promoter assays. 
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Figure 85 Proposed model for the interaction of L and W regions through chromatin 
looping 
Transcription factors bind to both the L and W regions of the TMPRSS2 gene, these 
regions then interact with each other through chromatin looping to initiate transcription. 
7.1.3 Ad5-TV-CU failed to prevent xenograft growth due to poor 
animal models in vivo. 
A number of different animal models and cell types were utilised to investigate the 
efficacy of Ad5-TV-CU in vivo ( 
Table 31).  Whilst all three studies testing Ad5-TV-CU in vivo showed a trend 
towards decreased tumour growth after treatment, there was no clear 
differentiation between the control group treated in combination with PBS, and the 
target group treated in combination with 5-FC. The main reason for this in the 
LNCaP-CDXR3 cells and LNCaP-104-S studies was poor tumour growth. Some 
causes for the poor tumour growth include; testosterone levels in the animals, 
immune infiltration and physical manipulation of the tumours. Attempts to develop 
a better model by eliminating the addition of testosterone and using animals with 
more complete immunodeficiency (NOD/SCID) also failed to generate a suitable in 
vivo model. Tumours did not develop in NOD/SCID mice bearing 1.25 mg 
subcutaneous testosterone pellets and grew both slowly and erratically in the 
animals without testosterone pellets, suggesting a more complex affect of 
testosterone on the development of LNCaP-104-S tumours than previously 
thought. The final model, CD-1 mice bearing 22RV1 xenografts developed much 
faster than both the LNCaP-CDXR3 and LNCaP-104-S (within two weeks 
compared to 5-6 weeks for LNCaP-CDXR3 and 4 weeks for LNCaP-104-S). All 
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untreated control animals with 22RV1 xenografts had to be culled 2 weeks later as 
a result of tumour burden due to the accelerated growth of these tumours 
compared to the LNCaP sublines. However, tumours treated with Ad5-TV-CU in 
combination with either PBS or 5-FC in the remaining animals progressed much 
slower. Unfortunately there was no significant difference in tumour growth 
between the two groups treated in combination with either 5-FC or PBS, 
suggesting that Ad5-TV-CU alone, or potentially physical manipulation of the 
tumour is responsible for inhibited tumour growth. Therefore, a more appropriate 
animal and tumour model would need to be established to truly determine the in 
vivo efficacy of Ad5-TV-CU in combination with 5-FC. 
7.1.4 Realistic summary of the findings 
There were a number of points throughout this study where careful consideration 
should have been taken over decisions in order to avoid larger problems 
accumulating further down the line, most noticeably the discovery of the PSA 
enhancer in the VISA system. When we received the VISA vector we were given a 
plain plasmid map with very little annotation. We were aware that the system had 
been used to control luciferase expression through the CCKAR promoter and were 
given the positions of the restriction enzymes needed to cut out both CCKAR and 
luciferase, but were unaware of what else remained in the plasmid. Once 
received, the entire plasmid should have been immediately sequenced and run 
through UCSC genome browser in order to confirm exactly what the plasmid 
contained. Alternatively we should have questioned professor Hung when we 
realised that there was ~700 bp of sequence unaccounted for in order to learn 
more about the history of the plasmid. After further investigation later on in my 
study I identified that the plasmid was obtained from Zhang and they had 
previously been working with PSA enhancer constructs in the VISA vector. The 
discovery of the PSA enhancer led to many questions over the contribution it gave 
to transgene expression levels and questions surrounding the entire foundation of 
the project, as it was already present in Ad5-TV-CU. Although the potential effects 
of the PSA enhancer and TMPRSS2 promoters were investigated at a later stage 
of my study, if the PSA enhancer had been discovered earlier, the investigations 
into the TMPRSS2 promoter regions would have started at an earlier stage in my 
project. This would have resulted in the best combination of the promoter 
elements, (LW) being used for the in vitro and in vivo investigation of therapeutic 
efficacy. Had this been the case, the replicating virus containing the LW promoter 
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could have been made along with a number of controls to properly assess the 
transgene expression.  
Despite the identification of the PSA enhancer in VISA it also would have been 
beneficial to produce a control virus that did not contain the VISA expression 
cassette, whereby CD/UPRT expression was simply controlled by the TMPRSS2 
promoter in order to see the true amplification affect of VISA. Xie et al. 
demonstrated that the VISA system dramatically amplified the CCKAR promoter 
activity in AsPC-1, PANC-1 and Panc02 cells by 826-, 256- and 353-fold 
respectively (Xie et al. 2007). However, it would have been difficult to directly 
compare expression levels of the two viruses due to interference from the existing 
PSA enhancer, therefore inactivation of this region from the VISA vector via site 
directed mutagenesis or deletion would be beneficial for future studies. 
Alternatively, an identical control virus whereby CD/UPRT expression is under the 
control of either a CMV or PSA promoter would also be beneficial in determining 
the true specificity and strength of the TMPRSS2 promoter.  
Furthermore, Ad5-TV-CU, containing the L-ARE alone, has cell killing abilities in 
vitro in combination with 5-FC in 22RV1 and LNCaP-104S, as well as in the 
castration resistant cell lines, LNCaP-CDXR3 and LNCaP-104R1. However, this 
efficacy was not comparable to that which has been seen using similar GDEPT 
systems in replicating viruses at much lower multiplicity of infection (MOI). Dias et 
al induced  40 and 90% cell killing in UT-SCC and UT-SCC-29 cells respectively in 
combination with 500 µg/ml 5-FC at an MOI of 1 (Dias et al. 2010). In contrast 
4000 ppc of Ad5-TV-CU in combination with 500 µg/ml was required to kill 95% of 
22RV1 cells in my hands. It could be argued that this may be due to the 
replication-deficient nature of Ad5-TV-CU. However Erbs et al. induced 80, 95 and 
80% cell killing in SW480, SK-BR-3 and Panc-1 human tumour cells respectively, 
with a non-replicating adenovirus expressing CD/UPRT at MOI of 5 in combination 
with 500 µg/ml 5-FC (Erbs et al. 2000), further demonstrating that Ad5-TV-CU is 
not as effective at cell killing in combination with 5-FC as some previously 
validated adenoviral vectors. It is however worth noting that these viruses used the 
constitutively active CMV promoter and are therefore not directly comparable to 
Ad5-TV-CU. It is not expected that a tissue specific promoter would outcompete 
the CMV or SV40 promoters and nor do they drive tissue specific expression, 
rendering them inadequate for clinical use in this instance. Therefore, the LW 
promoter shows promise as it demonstrated both increased expression and high 
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selectivity, warranting further investigation of this sequence and continuation of the 
project in the future.  
Finally, in vivo studies failed to demonstrate tumour growth inhibition in 
combination with 5-FC, due to a number of technical difficulties including poor 
animal models, inefficient controls (Ad5-GFP induced too much toxicity alone in 
the initial pilot studies), the replication-deficient nature of the virus preventing 
intratumoural spread, and other factors resulting in poor or no efficacy. In its 
current format non-replicating Ad5-TV-CU is not efficacious enough to be 
translated into the clinic. However, the ultimate goal of my work presented in this 
thesis, in combination with future findings guided by this study, is to more fully 
understand the AR transcriptional control of the TMPRSS2 promoter. Once this is 
understood I hope these regions could be utilised to drive prostate specific 
expression in a replicating virus, which will be translated into the clinic to treat 
patients with both primary PCa, and castration resistant forms of the disease.  
In conclusion, I have identified an optimal TMPRSS2 chimeric promoter (LW), 
which specifically drives luciferase expression in AR-positive 22RV1 cells, whilst 
remaining inactive or driving minimal expression in AR-negative cell lines. The LW 
promoter induced 8.9-fold higher expression levels than the L-ARE alone (already 
present in Ad5-TV-CU). Incorporation of this optimal promoter into future targeted 
therapies may aid further developments in the treatment of PCa, with potential 
applications in forms of aggressive AR-positive BCa. 
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7.2 Future directions 
Once cloned into the VISA vector, the LW promoter should be capable of driving 
similar expression levels to the constitutively active CMV promoter. Cloning of this 
new optimal expression cassette into a replication-competent adenovirus will 
dramatically increase efficacy of the virus and is more likely to induce cytotoxicity 
in xenografts in vivo in combination with 5-FC. This is due to the increased cell 
killing potential of replicating viruses and has been demonstrated in numerous 
clinical trials that have utilised replicating viruses, over replication deficient viruses 
to target PCa (Freytag et al. 2003, DeWeese et al. 2001).  
Whilst modifications to the virus are essential for producing an efficacious gene 
therapy system, careful selection of a model in which to test the virus in vivo is 
also imperative. It is possible that future in vivo studies, including novel AR 
expressing cell lines, patient ex vivo specimens or alternative model systems for 
example zebrafish will allow a more clear idea of the full potential for Ad5-TV-CU 
as a treatment for PCa. Combinatorial therapies with other cytotoxic drugs may 
also enhance the activity of this virus in vivo and present a more effective 
treatment with potentially groundbreaking results for the treatment of both 
localised and metastatic PCa in the clinic. 
Therefore, future studies must focus on utilising the optimal LW promoter in a 
replication-competent virus. These studies should initially involve inserting the LW-
promoter into the E1A region of the adenovirus so that viral replication is under the 
control of the TMPRSS2 promoter. This will demonstrate the prostate specificity of 
viral replication without interference from the rest of the expression cassette. Once 
prostate specificity has been established the CD/UPRT transgene can be inserted 
downstream to evaluate enhanced cell killing of the virus in combination with 5-FC 
prodrug. Previous studies have shown that 5-FU and 5-FUMP interfere with viral 
replication (McCart et al. 2000, Nakamura et al. 2001, Dias et al, 2010). However, 
Dias et al showed that although the addition of 5-FC reduced adenoviral 
replication 9.2-fold, the combined oncolytic efficacy was greater with the addition 
of 5-FC than without, with a 27% increase in cell killing in combination. Therefore 
careful consideration needs to be taken in deciding whether to use this CD/UPRT 
GDEPT approach in the new replicating adenoviral construct, or whether the 
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oncolytic virus driven specifically by the TMPRSS2 promoter elements will be 
enough to significantly increase cell killing compared to the non-replicating virus. 
This can be achieved as follows: 
 Identifying the minimal regions of the LW promoter that retains potency and 
selectivity.  
 Inserting the optimal promoter into the E1A region of the adenovirus to 
control viral replication and evaluate specificity and efficacy of the 
TMPRSS2 promoter alone. 
 Inserting CD or CD/UPRT downstream of the TMPRSS2 promoter in the 
replicating virus (Ad5-TV-CUrep) to evaluate the efficacy of the two 
prodrug systems in combination with 5-FC. This would include experiments 
to evaluate whether the timing of 5-FC addition affects the cell killing 
potential of the virus/ viral replication. 
 Testing the new Ad5-TV-CUrep again in all cell lines, including our LNCaP 
(ATCC) cells to see if efficacy can be generated with the new virus. 
 Testing Ad5-TV-CU in vivo in combination with 5-FC and other cytotoxic 
drugs to enhance cell killing. 
 Identifying a suitable in vivo model in which to test the tumour inhibition 
capabilities of Ad5-TV-CU in combination with 5-FC and cytotoxic drugs 
that have demonstrated synergistic effects on cell killing in vitro. 
Additionally, it will be important to explore in depth, the AR-dependency of the 
various TMPRSS2 promoter/enhancer constructs and how they interact. The 
TMPRSS:ERG fusion gene is the most common fusion gene in PCa, occurring 
in 50% of PCas. It is not yet clear whether the fusion gene contributes to the 
progression of aggressive forms of PCa, and arguments exist for and against 
(Rajput et al. 2007, Eguchi et al. 2014). Therefore, investigating and 
determining the contribution of AR-dependent regions of the TMPRSS2 
promoters identified in this project, may reveal the true nature and role of the 
TMPRSS2:ERG fusion. Findings from this future work may guide the 
development of more effective therapies for late stage PCa that harbour the 
gene fusion.  
This could be achieved by the following: 
  270 
 
 Comparison of luciferase expression levels in LW-PGL3 transfected 
PC3 and DU145 (AR negative) cell lines co-transfected with an AR 
expressing plasmid vs without.  
 Transfecting 22RV1 cells with LW-PGL3 ± AR siRNA. 
 Demonstrating the interaction between the L and W regions via 
chromatin looping through ChIP-3C assays. 
 Co-transfecting AR negative cells with a plasmid expressing AR as well 
as the various TMRPSS2 promoter/enhancer constructs and 
measuring luciferase expression as a result. 
 Infecting cells that harbour wildtype AR with the new Ad5-TV-CUrep 
virus, in combination with a repertoire of AR agonists and antagonists 
to establish the effect on CD/UPRT or luciferase expression. 
 Demonstrating AR binding to the putative AR binding sites in both the L 
and W regions through ChIP assays. 
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8.1 Sequencing 
L-PGL3  
ref             ATGTTTTTGGCGTCTTCCATGGTGGCTTTACCAACAGTACCGGAATGCCAAGCTTCAGAA  
seq             ----------------------------------CAGTACCGGAATGCCAAGCTTCAGAA  
                                                  ************************** 
ref             GGGACAAGGGAACAAAGAAAAGGCCAGGAAGGTAATAATTAACCACTTACTGAGTTCAAA  
seq             GGGACAAGGGAACAAAGAAAAGGCCAGGAAGGTAATAATTAACCACTTACTGAGTTCAAA  
                ************************************************************ 
ref             GCCATCTTGCTGTTATCAACAGCATCGAGTAATGATAGGTATCTGGAATGTTCAATATGA  
seq             GCCATCTTGCTGTTATCAACAGCATCGAGTAATGATAGGTATCTGGAATGTTCAATATGA  
                ************************************************************ 
ref             CCTAGAAGAAAGAATTACAGGACTGTAATATTTCCATACCAGTTAGTTTTTAGAAGATAA  
seq             CCTAGAAGAAAGAATTACAGGACTGTAATATTTCCATACCAGTTAGTTTTTAGAAGATAA  
                ************************************************************ 
ref             ATCTGGAAAGAACTAGAAGAATCTCTAGATGAAGGTTACCTACAACAAAGACCAGTGTTG  
seq             ATCTGGAAAGAACTAGAAGAATCTCTAGATGAAGGTTACCTACAACAAAGACCAGTGTTG  
                ************************************************************ 
ref             CCTGCTGACCTTTGGCCTGCATCTTCACCACTGCTTCCCCACATCCCTCCATATTTAAGG  
seq             CCTGCTGACCTTTGGCCTGCATCTTCACCACTGCTTCCCCACATCCCTCCATATTTAAGG  
                ************************************************************ 
ref             ACTTTGGGACCCACTTGTGCCTTAGAGGTTACAGCAGAAGCACTCTCCTCTGGGATCAGA  
seq             ACTTTGGGACCCACTTGTGCCTTAGAGGTTACAGCAGAAGCACTCTCCTCTGGGATCAGA  
                ************************************************************ 
ref             GTGGGTAGGAGGATGGGGTGCAATTGTAAGTGCAGCGGCCAGGACAGCCTGACCAGAAAG  
seq             GTGGGTAGGAGGATGGGGTGCAATTGTAAGTGCAGCGGCCAGGACAGCCTGACCAGAAAG  
                ************************************************************ 
ref             AAGAAGGAACACACTCAGTGACTCAAACATCCATCGGGAAGGGCTCTCAGGGGACTGCCT  
seq             AAGAAGGAACACACTCAGTGACTCAAACATCCATCGGGAAGGGCTCTCAGGGGACTGCCT  
                ************************************************************ 
ref             GGGGCTCAAGGCCACCCACAACTCCAGTGCCACTAAGCCCAGGCATCCTGCTGGACTTAA  
seq             GGGGCTCAAGGCCACCCACAACTCCAGTGCCACTAAGCCCAGGCATCCTGCTGGACTTAA  
                ************************************************************ 
ref             CCCAGTTCTCACCAGGAAGCTGTGATATCCCCTATACAGAACATCTACTCAAGGGAGACT  
seq             CCCAGTTCTCACCAGGAAGCTGTGATATCCCCTATACAGAACATCTACTCAAGGGAGACT  
                ************************************************************ 
ref             GTATGGCATAAAACACTGAAGAAACACGACAAGGTAACTAAACCCATCAATGTCAGCAGA  
seq             GTATGGCATAAAACACTGAAGAAACACGACAAGGTAACTAAACCCATCAATGTCAGCAGA  
                ************************************************************ 
ref             GATTAAGGACAAGATGGGCCCAGGAGGGAAAGACCTGGGCCAGTTCCTGGCAACACAGCT  
seq             GATTAAGGACAAGATGGGCCCAGGAGGGAAAGGCCTGGGCCAGTTCCTGGCAACACAGCT  
                ******************************** *************************** 
ref             CCCTGGAAGTGTCGATGTGTGAGTTACTGAACCTTGTTGAAATCTCAGGGTCCTCATGGG  
seq             CCCTGGAAGTGTCGATGTGTGAGTTACTGAACCTTGTTGAAATCTCAGGGTCCTCATGGG  
                ************************************************************ 
ref             AAAACGGACAAAGCAATCACCACAGTTGTGTTAAGCTGAGGGTTGTGGGAGAGTGGGGAA  
seq             AAAACGGACAAAGCAATCACCACAGTTGTGTTAAGCTGAGGGTTGTGGGAGAGTGGGGAA  
                ************************************************************ 
ref             AGAGTGCCTCACAGTACTAGGAACTGAGGAAGAGCAGGTGCAATCAGACCGTCTTTCCCC  
seq             AGAGTGCCTCACAGTACTAGGAACTGAGGAAGAGCAGGTGCAATCAGACCGTCTTTCCCC  
                ************************************************************ 
ref             GAGAACGTCCACAGGCACTGCCAGTAGCCACCCACTGCCCAGCGGGTGGTTCAGGGCTCA  
seq             GAGAACGTCCACAGGCACTGCCAGTAGCCACCCACTGCCCAGCGGGTGGTTCAGGGCTCA  
                *********************************************************** 
ref             GCACCAAATACAGCTCACAGTTGACTTTTTAAAGCAGGCCATGTGGGCCCTCTCAATTTT  
seq             GCACCAAATACAGCTCACAGTTGACTTTTTAAAGCAGACCATGTGGGCCCTCTCAATTTT  
                ************************************* ********************** 
ref             TAATAGATACATACGCTTAAAATAATCCATAAAACATGTCCACAGTCACTCCATTTACTA  
seq             TAATAGATACATACGCTTAAAATAATCCATAAAACATGTCCACAGTCACTCCATTTACTA  
                ************************************************************ 
ref             CCCCAAACCCAAAAAAGAAAGAAATTCAGAGCCAACCATTTTGACCACTGCTAAGATTAG  
seq             CCCCAAACCCAAAAAAGAAAGAAATTCAGAGCCAACCATTTTGACCACTGCTAAGGTTAG  
                ******************************************************* **** 
ref             CAGTAATGAAAAGAAAGCTGTGGGCCATTTTGCTTGTTGTCCTGGTACCTATCGATAGAG  
seq             CAGTAATGAAAAGAAAGCTGTGGGCCATTTTGCTTGTTGTCCTGGTACCTATCGATAGAG  
                ************************************************************ 
WE-PGL3  
ref             CTAGCAAAATAGGCTGTCCCCAG-TGCAAG-TGCAGG-TGCCAGAACATTTCTCTATCGA 57 
Seq             ----------AGGCTGTCCCCAAGTGCAAAGTGCAGGGTRCCAGAACATTTCTYTATYGA 50 
                          ************. *****. ****** * ************* *** ** 
ref             TAGGTACCGCCTTGTGACACTTCACCCATCTTTGACATATACAGCCTTTCATTCAAAATG 117 
Seq             TAGGTACCGCCTTGTGACACTTCACCCATCTTTGACATATACAGCCTTTCATTCAAAATG 110 
                ************************************************************ 
ref             GTGCTTTTTCAAAAAGCCCAGGATGTGAGCTTGAAATGTAATTCTGGAAGCTGACCTTTA 177 
Seq             GTGCTTTTTCAAAAAGCCCAGGATGTGAGCTTGAAATGTAATTCTGGAAGCTGACCTTTA 170 
                ************************************************************ 
ref             ATGAAGTTTGTTTAATCATAAACTCTTATTGTTGGAGCTAGTGCTGCATGTCTTAAAAGC 237 
Seq             ATGAAGTTTGTTTAATCATAAACTCTTATTGTTGGAGCTAGTGCTGCATGTCTTAAAAGC 230 
                ************************************************************ 
ref             TTTAAAGGGTACGGCAGGTACTCATATCTGATTAGCATCTGCACTTCACCAGGTGGCCAT 297 
Seq             TTTAAAGGGTACGGCAGGTACTCATATCTGATTAGCATCTGCACTTCACCAGGTGGCCAT 290 
                ************************************************************ 
ref             TTGTTGTCTAAAAATGTTGACATTCAACAATGTAATGAAAATGTTGGTCCTGGATGATAA 357 
Seq             TTGTTGTCTAAAAATGTTGACATTCAACAATGTAATGAAAATGTTGGTCCTGGATGATAA 350 
                ************************************************************ 
ref             AAAAAGTTTTTCACACAGCAAGGCAGAGGACAGTGCACTCTGTTGTGGGGCGTATGTCTC 417 
Seq             AAAAAGTTTTTCACACAGCAAGGCAGAGGACAGTGCACTCTGTTGTGGGGCGTATGTCTC 410 
                ************************************************************ 
ref             CCTGCACCACTAACTAGGGCAGGGGTGAGGAAGTGGTGGGCCACACCTCTGCCTGGAAGA 477 
Seq             CCTGCACCACTAACTAGGGCAGGGGTGAGGAAGTGGTGGGCCACACCTCTGCCTGGAAGA 470 
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                ************************************************************ 
ref             CGTGGTTTTTCCCAGGTACTTCAGAGGCTCTTTTCAATGTTTGCAATTGTAGGGGGCTCA 537 
Seq             CGTGGTTTTTCCCAGGTACTTCAGAGGCTCTTTTCAATGTTTGCAATTGTAGGGGGCTCA 530 
                ************************************************************ 
ref             GAATTCGCCAGGATTTAACAGGACTGGAGGAGGCCAAATTCACTAGGATTTAATAGGACT 597 
Seq             GAATTCGCCAGGATTTAACAGGACTGGAGGAGGCCAAATTCACTAGGATTTAATAGGACT 590 
                ************************************************************ 
ref             GGAGGAGACCAGAATGGGCTCCCCAGAGGCCTCAAACCCCCATTCCTTTCTGTCACCCAG 657 
Seq             GGAGGAGACCAGAATGGGCTCCCCAGAGGCCTCAAACCCCCATTCCTTTCTGTCACCCAG 650 
                ************************************************************ 
ref             AGTGACATATAAGCCTCCTCCCCACCTTTTTCACGGGGGAAGTTCTTATTGCAATGAGAT 717 
Seq             AGTGACATATAAGCCTCCTCCCCACCTTTTTCACGGGGGAAGTTCTTATTGCAATGAGAT 710 
                ************************************************************ 
ref             CTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGAAGACGCC 777 
Seq             CTGCGATCTAAGTAAGCT-GGCAT-CCGGTACKTGAG-------CACCTG---------- 751 
                ****************** ***** *******.  :*       ****:            
 
** 
 
W-PGL3  
ref             GTGCAGGTGCCAGAACATTTCTCTATCGATAGGTACCTGCCGTGTGAGGCAGATAAAAGT 1740 
seq             GTGCAG--------ACATTTCTCTATCGATAGGTACCTGCCGTGTGAGGCAGATAAAAGT 58 
                ******        ********************************************** 
ref             TTCCCAGGTGATAAAAGTTGTCCGGGAACAGCTCTCTTCCTGGTACAGATCTGCTGACTA 1800 
seq             TTCCCAGGTGATAAAAGTTGTCCGGGAACAGCTCTCTTCCTGGTACAGATCTGCTGACTA 118 
                ************************************************************ 
ref             ACAAACATTTCCTTTATAGGTGCAAATTTCCTTTACAAAAGGGCATTTTCTCAGAGGTAC 1860 
seq             ACAAACATTTCCTTTATAGGTGCAAATTTCCTTTACAAAAGGGCATTTTCTCAGAGGTAC 178 
                ************************************************************ 
ref             TCTGGTGTCTGCAGTTCCTCAACATAACCAGTTCCAAATCATCAATGTGCCAAAGAGGAC 1920 
seq             TCTGGTGTCTGCAGTTCCTCAACATAGCCAGTTCCAAATCATCAATGTGCCAAAGAGGAC 238 
                **************************.********************************* 
ref             TATGTTGGGGTAGCAGATTCTGGTCTCCTCCAGTCCTACTTGGGGTGATGAATTCTGGTC 1980 
seq             TATGTTGGGGTAGCAGATTCTGGTCTCCTCCAGTCCTACTTGGGGTGATGAATTCTGGTC 298 
                ************************************************************ 
ref             TACGGTCCTATTAAATTCTGGTGAATTCTGAGCCCCCACAATTGCAAACATTAGAAAGAA 2040 
seq             TACGGTCCTATTAAATTCTGGTGAATTCTGAGCCCCCACAATTGCAAACATTAGAAAGAA 358 
                ************************************************************ 
ref             CCTCTCAAGTGCCCGGGAACAGCCACGTCTTCCTGGCTGAGGTGTGTCCCACCACTTCCT 2100 
seq             CCTCTCAAGTGCCCGGGAACAGCCACGTCTTCCTGGCTGAGGTGTGTCCCACCACTTCCT 418 
                ************************************************************ 
ref             CACTCCCGCCCTGGCCGGTGGTGCCGAGAGACCTGGGACCATCCGGGGGAGCACTTTCCA 2160 
seq             CACTCCCGCCCTGGCCGGTGGTGCCGAGAGACCTGGGACCATCCGGGGGAGCCCTTTCCA 478 
                ****************************************************.******* 
ref             CCGGACGCTGGTGGGGGCCAAGAAATGCCAGCCTAGGCGGACTGGGGAGGGTCTTGGGCG 2220 
seq             CCGGACGCTGGTGGGGGCCAAGAAATGCCAGCCTAGGCGGACTGGGGAGGGTCTTGGGCG 538 
                ************************************************************ 
ref             TCCGGCGCTGTGTCCCCGCCACTCGTGCTTGGGCCAGCAGTCCCCAAGGCCTAC-CCTGG 2279 
seq             TCCGGCGCTGTGTCCCCGCCACTCGTGCTTGGGCCAGCAGTCCCCAAGGCCTACTCCTGG 598 
                ****************************************************** ***** 
ref             GTCCTTGCCCAGAGGCTACAGTGGGTTCCCCGGAGGCCAAGACGGGGCCGGCCGCCTACA 2339 
seq             GTCCTTGCCCAGAGGCCGCAGTGGGTTCCCCGGAGGCCAAGACGGGGCCGGCCGCCTACA 658 
                **************** .****************************************** 
ref             GGAGCTCGTGAGGTAGCAGCTCCGGGGGCTCACCCAGGACTCCAGGAGCGCTCCCCAGAA 2399 
seq             GGAGCTCGTGAGGTAGCAGCTCCGGGGGCTCACCCAGGACTCCAGGAGCGCTCCCCAGAA 718 
                ************************************************************ 
ref             TCCCCTTCCTTAACCCAAACTCGAGCCCTCGGGCAGCGCTGCGCCGCGGACCGGAGAGGG 2459 
seq             TCCCCTTCCTTAACCCAAACTCGAGCCCTCGG----------GCAGCGGACCGGAGAGGG 768 
                ********************************          **.*************** 
ref             GCAGGTTGGCCGCTGTGGCCGGGCCCGGGAAGCGCCCCAGAGTCCCTTATGGGTCCCTCC 2519 
seq             GCAGGCTGGCCGCTGGGGCCGGGCCCGGGAAGCGCCCCAGAGTCCCTTATGGGTCCCTCC 828 
                ***** ********* ******************************************** 
ref             GCAGCCGGGGTTGAGCCAGGCAGGGAACCCGTCCCGGACTTCCCTTGGGAAACGCCTCCT 2579 
seq             GCAGCCGGGGTTGAGCCAGGCAGGGAACCCGTCCCGGACTTCCCTTGGGAAACGCCTCCT 888 
                ************************************************************ 
ref             CCCGCCGCCCCCGCCCCCGCCCGCCCAGGGTGACCCGCGACCCGCTTGGGGGTGTCGCCC 2639 
seq             CCCGCCGCCCCCGCCCCG--CCGCCCAGGGTGACCG-CGACCG-CTTGGGGGTGTCRCCT 944 
                *****************   ***************  *****  ************ **  
ref             TGGACCCTGGGACACCGCCTCCTGAGATTAAAGCGAGAGCCAGGGCGGGCCGGGCCGAGT 2699 
seq             GG--ACCTGG-ACAYCG-CTCCTGAGATTAAAGC-AGAGCMAGG-CGG--CGG--CGR-T 993 
                 *  .***** *** ** **************** ***** *** ***  ***  **  * 
ref             AGGCGCGAGCTAAGCAGGAGGCGGAGGCAAGCTTGGCATTCCGGTACTGTTGGTAAAGCC 2759 
seq             AG--CCSARCTAAGCAGAGCGAGGAAGCTTGCAT-------CGGTACWG-TGGTAAG--- 
P-PGL3 
ref             ------------------------------------GGTACCTAGTACATTGTTTGCTGC 24 
seq             GTCCMMSKTMAGTKCCAGACATTTCTCTATCGATAGGTACCCTAGTACATTGTTTGCTGC 60 
                                                    * :.******************** 
ref             ACGTTGGATTTTGAAATGCTAGGGAACTTTGGGAGACTCATATTTCTGGGCTAGAGGATC 84 
seq             ACGTTGGATTTTGAAATGCTAGGGAACTTTGGGAGACTCATATTTCTGGGCTAGAGGATC 120 
                ************************************************************ 
ref             TGTGGACCACAAGATCTTTTTATGATGACAGTAGCAATGTATCTGTGGAGCTGGATTCTG 144 
seq             TGTGGACCACAAGATCTTTTTATGATGACAGTAGCAATGTATCTGTGGAGCTGGATTCTG 180 
                ************************************************************ 
ref             GGTTGGGAGTGCAAGGAAAAGAATGTACTAAATGCCAAGACATCTATTTCAGGAGCATGA 204 
seq             GGTTGGGAGTGCAAGGAAAAGAATGTACTAAATGCCAAGACATCTATTTCAGGAGCATGA 240 
                ************************************************************ 
 
ref             GGAATAAAAGTTCTAGTTTCTGGTCTCAGAGTGGTGCAGGGATCAGGGAGTCTCACAATC 264 
seq             GGAATAAAAGTTCTAGTTTCTGGTCTCAGAGTGGTGCAGGGATCAGGGAGTCTCACAATC 300 
                ************************************************************ 
ref             TCCTGAGTGCTGGTGTCTTAGGGCACACTGGGTCTTGGAGTGCAAAGGATCTAGGCACGT 324 
seq             TCCTGAGTGCTGGTGTCTTAGGGCACACTGGGTCTTGGAGTGCAAAGGATCTAGGCACGT 360 
                ************************************************************ 
ref             GAGGCTTTGTATGAAGAATCGGGGATCGTACCCACCCCCTGTTTCTGTTTCATCCTGGGC 384 
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seq             GAGGCTTTGTATGAAGAATCGGGGATCGTACCCACCCCCTGTTTCTGTTTCATCCTGGGC 420 
                ************************************************************ 
ref             GTGTCTCCTCTGCCTTTGTCCCCTAGATGAAGTCTCCATGAGCTACAGGGCCTGGTGCAT 444 
seq             GTGTCTCCTCTGCCTTTGTCCCCTAGATGAAGTCTCCATGAGCTACAGGGCCTGGTGCAT 480 
                ************************************************************ 
ref             CCAGGGTGATCTAGTAATTGCAGAACAGCAAGTGCTAGCTCTCCCTCCCCTTCCACAGCT 504 
seq             CCAGGGTGATCTAGTAATTGCAGAACAGCAAGTGCTAGCTCTCCCTCCCCTTCCACAGCT 540 
                ************************************************************ 
ref             CTGGGTGTGGGAGGGGGTTGTCCAGCCTCCAGCAGCATGGGGAGGGCCTTGGTCAGCCTC 564 
seq             CTGGGTGTGGGAGGGGGTTGTCCAGCCTCCAGCAGCATGGGGAGGGCCTTGGTCAGCCTC 600 
                ************************************************************ 
ref             TGGGTGCCAGCAGGGCAGGGGCGGAGTCCTGGGGAATGAAGGTTTTATAGGGCTCCTGGG 624 
seq             TGGGTGCCAGCAGGGCAGGGGCGGAGTCCTGGGGAATGAAGGTTTTATAGGGCTCCTGGG 660 
                ************************************************************ 
ref             GGAGGCTCCCCAGCCCCAAGCTTACCACCTGCACCCGGAGAGCTGTGTCAC-TCGAGAT 682 
seq             GGAGGCTCCCCAGCCCCAAGCTTACCACCTGCACCCGGAGAGCTGTGTCACCTCSARAT 720 
                *************************************************** **.* ** 
ref             CTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGAAGACGCC 742 
seq             CTGCS------------------------------------------------------- 725 
                ****.                                                        
 
PSA promoter/enhancer-PGL3 
 
 
ref             -----------------------------------------GGTACCCTGCAGGCCTCTA 19 
seq             TTTWKSMCCAYMYMGGTKCCAGACATTTTCTCTATCGATAGGTACCCCTGCAGGCCTCTA 60 
                                                         * :.*************** 
ref             GAAATCTAGCTGATATAGTGTGGCTCAAAACCTTCAGCACAAATCACACCGTTAGACTAT 79 
seq             GAAATCTAGCTGATATAGTGTGGCTCAAAACCTTCAGCACAAATCACACCGTTAGACTAT 120 
                ************************************************************ 
ref             CTGGTGTGGCCCAAACCTTCAGGTGAACAAAGGCACTCTAATCTGGCAGGATATTCCAAA 139 
seq             CTGGTGTGGCCCAAACCTTCAGGTGAACAAAGGCACTCTAATCTGGCAGGATATTCCAAA 180 
                ************************************************************ 
ref             GCATTAGAGATGACCTCTTGCAAAGAAAAAGAAATGGAAAAGAAAAAGAAAGAAAGGAAA 199 
seq             GCATTAGAGATGACCTCTTGCAAAGAAAAAGAAATGGAAAAGAAAAAGAAAGAAAGGAAA 240 
                ************************************************************ 
ref             AAAAAAAAAAAAAAGAGATGACCTCTCAGGCTCTGAGGGGAAACGCCTGAGGTCTTTGAG 259 
seq             AAAAAAAAAAAAAAGAGATGACCTCTCAGGCTCTGAGGGGAAACGCCTGAGGTCTTTGAG 300 
                ************************************************************ 
ref             CAAGGTCAGTCCTCTGTTGCACAGTCTCCCTCACAGGGTCATTGTGACGATCAAATGTGG 319 
seq             CAAGGTCAGTCCTCTGTTGCACAGTCTCCCTCACAGGGTCATTGTGACGATCAAATGTGG 360 
                ************************************************************ 
ref             TCACGTGTATGAGGCACCAGCACATGCCTGGCTCTGGGGAGTGCCGTGTAAGTGTATGCT 379 
seq             TCACGTGTATGAGGCACCAGCACATGCCTGGCTCTGGGGAGTGCCGTGTAAGTGTATGCT 420 
                ************************************************************ 
ref             TGCACTGCTGAATGGCTGGGATGTGTCAGGGATTATCTTCAGCACTTACAGATGCTCAT 438 
seq             TGCACTGCTGAATGGCTGGGATGTGTCAGGGATTATCTTCAGCACTTACAGATGCTCAT 480 
                *********************************************************** 
ref             CTCATCCTCACAGCATCACTATGGGATGGGTATTACTGGCCT 480 
seq             CTCATCCTCACAGCATCACTATGGGATGGGTATTACTGGCCT 65 
                ****************************************** 
ref             CATTTGATGGAGAAAGTGGCTGTGGCTCAGAAAGGGGGGACCACTAGACCAGGGACACTC 540 
seq             CATTTGATGGAGAAAGTGGCTGTGGCTCAGAAAGGGGGGACCACTAGACCAGGGACACTC 125 
                ************************************************************ 
ref             TGGATGCTGGGGACTCCAGAGACCATGACCACTCACCAACTGCAGAGAAATTAATTGTGG 600 
seq             TGGATGCTGGGGACTCCAGAGACCATGACCACTCACCAACTGCAGAGAAATTAATTGTGG 185 
                ************************************************************ 
ref             CCTGATGTCCCTGTCCTGGAGAGGGTGGAGGTGGACCTTCACTAACCTCCTACCTTGACC 660 
seq             CCTGATGTCCCTGTCCTGGAGAGGGTGGAGGTGGACCTTCACTAACCTCCTACCTTGACC 245 
                ************************************************************ 
ref             CTCTCTTTTAGGGCTCTTTCTGACCTCCACCATGATACTAGGACCCCATTGTATTCTGTA 720 
seq             CTCTCTTTTAGGGCTCTTTCTGACCTCCACCATGATACTAGGACCCCATTGTATTCTGTA 305 
                ************************************************************ 
ref             CCCTCTTGACTCTATGACCCCCACTGCCCACTGCATCCAGCTGGGTCCCCTCCTATCTCT 780 
seq             CCCTCTTGACTCTATGACCCCCACTGCCCACTGCATCCAGCTGGGTCCCCTCCTATCTCT 365 
                ************************************************************ 
ref             ATTCCCAGCTGGCCAGTGCAGTCTCAGTGCCCACCTGTTTGTCAGTAACTCTGAAGGGGC 840 
seq             ATTCCCAGCTGGCCAGTGCAGTCTCAGTGCCCACCTGTTTGTCAGTAACTCTGAAGGGGC 425 
                ************************************************************ 
ref             TGACATTTTACTGACTTGCAAACAAATAAGCTAACTTTCCAGAGTTTTGTGAATGCTGGC 900 
seq             TGACATTTTACTGACTTGCAAACAAATAAGCTAACTTTCCAGAGTTTTGTGAATGCTGGC 485 
                ************************************************************ 
ref             AGAGTCCATGAGACTCCTGAGTCAGAGGCAAAGGCTTTTACTGCTCACAGCTTAGCAGAC 960 
seq             AGAGTCCATGAGACTCCTGAGTCAGAGGCAAAGGCTTTTACTGCTCACAGCTTAGCAGAC 545 
                ************************************************************ 
ref             AGCATGAGGTTCATGTTCACATTAGTACACCTTGCCCCCCCCCAAATCTTGTAGGGTGAC 1020 
seq             AGCATGAGGTTCATGTTCACATTAGTACACCTTGCCCCCCCCCAAATCTTGTAGGGTGAC 605 
                ************************************************************ 
ref             CAGAGCAGTCTAGGTGGATGCTGTGCACACGGGGTTTGTGCCACTGGTGAGAAACCTGAG 1080 
seq             CAGAGCAGTCTAGGTGGATGCTGTGCACACGGGGTTTGTGCCACTGGTGAGAAACCTGAG 665 
                ************************************************************ 
ref             ATTAGGAATCCTCAATCTTATACTGGGACAACTTGCAAACCTGCTCAGCCTTTGTCTCTG 1140 
seq             ATTAGGAATCCTCAATCTTATACTGGGACAACTTGCAAACCTGCTCAGCCTTTGTCTCTG 725 
                ************************************************************ 
ref             ATGAAGATATTATCTTCATGATCTTGGATTGAAAACAGACCTACTCTGGAGGAACATATT 1200 
seq             ATGAAGATATTATCTTCATGATCTTGGATTGAAAACAGACCTACTCTGGAGGAACATATT 785 
                ************************************************************ 
ref             GTATCGATTGTCCTTGACAGTAAACAAATCTGTTGTAAGAGACATTATCTTTATTATCTA 1260 
seq             GTATCGATTGTCCTTGACAGTAAACAAATCTGTTGTAAGAGACATTATCTTTATTATCTA 845 
                ************************************************************ 
ref             GGACAGTAAGCAAGCCTGGATCTGAGAGAGATATCATCTTGCAAGGATGCCTGCTTTACA 1320 
seq             GGACAGTAAGCAAGCCTGGATCTGAGAGAGATATCATCTTGCAAGGATGCCTGCTTTACA 537 
                ************************************************************ 
ref             AACATCCTTGAAACAACAATCCAGAAAAAAAAAGGTGTTGCTGTCTTTGCTCAGAAGACA 1380 
seq             AACATCCTTGAAACAACAATCCAGAAAAAAAAAGGTGTTGCTGTCTTTGCTCAGAAGACA 597 
                ************************************************************ 
ref             CACAGATACGTGACAGAACCATGGAGAATTGCCTCCCAACGCTGTTCAGCCAGAGCCTTC 1440 
seq             CACAGATACGTGACAGAACCATGGAGAATTGCCTCCCAACGCTGTTCAGCCAGAGCCTTC 657 
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                ************************************************************ 
ref             CACCCTTGTCTGCAGGACAGTCTCAACGTTCCACCATTAAATACTTCTTCTATCACATCC 1500 
seq             CACCCTTGTCTGCAGGACAGTCTCAACGTTCCACCATTAAATACTTCTTCTATCACATCC 717 
                ************************************************************ 
ref             TGCTTCTTTATGCCTAACCAAGGTTCTAGGTCCCGATCGACTGTGTCTGGCAGCACTCCA 1560 
seq             TGCTTCTTTATGCCTAACCAAGGTTCTAGGTCCCGATCGACTGTGTCTGGCAGCACTCCA 377 
                ************************************************************ 
 
ref             CTGCCAAACCCAGAATAAGGCAGCGCTCAGGATCCCGACTAGTACATTGTTTGCTGCACG 1620 
seq             CTGCCAAACCCAGAATAAGGCAGCGCTCAGGATCCCGACTAGTACATTGTTTGCTGCACG 437 
                ************************************************************ 
ref             TTGGATTTTGAAATGCTAGGGAACTTTGGGAGACTCATATTTCTGGGCTAGAGGATCTGT 1680 
seq             TTGGATTTTGAAATGCTAGGGAACTTTGGGAGACTCATATTTCTGGGCTAGAGGATCTGT 497 
                ************************************************************ 
ref             GGACCACAAGATCTTTTTATGATGACAGTAGCAATGTATCTGTGGAGCTGGATTCTGGGT 1740 
seq             GGACCACAAGATCTTTTTATGATGACAGTAGCAATGTATCTGTGGAGCTGGATTCTGGGT 557 
                ************************************************************ 
ref             TGGGAGTGCAAGGAAAAGAATGTACTAAATGCCAAGACATCTATTTCAGGAGCATGAGGA 1800 
seq             TGGGAGTGCAAGGAAAAGAATGTACTAAATGCCAAGACATCTATTTCAGGAGCATGAGGA 617 
                ************************************************************ 
ref             ATAAAAGTTCTAGTTTCTGGTCTCAGAGTGGTGCAGGGATCAGGGAGTCTCACAATCTCC 1860 
seq             ATAAAAGTTCTAGTTTCTGGTCTCAGAGTGGTGCAGGGATCAGGGAGTCTCACAATCTCC 677 
                ************************************************************ 
ref             TGAGTGCTGGTGTCTTAGGGCACACTGGGTCTTGGAGTGCAAAGGATCTAGGCACGTGAG 1920 
seq             TGAGTGCTGGTGTCTTAGGGCACACTGGGTCTTGGAGTGCAAAGGATCTAGGCACGTGAG 737 
                ************************************************************ 
ref             GCTTTGTATGAAGAATCGGGGATCGTACCCACCCCCTGTTTCTGTTTCATCCTGGGCGTG 1980 
seq             GCTTTGTATGAAGAATCGGGGATCGTACCCACCCCCTGTTTCTGTTTCATCCTGGGCGTG 432 
                ************************************************************ 
ref             TCTCCTCTGCCTTTGTCCCCTAGATGAAGTCTCCATGAGCTACAGGGCCTGGTGCATCCA 2040 
seq             TCTCCTCTGCCTTTGTCCCCTAGATGAAGTCTCCATGAGCTACAGGGCCTGGTGCATCCA 492 
                ************************************************************ 
ref             GGGTGATCTAGTAATTGCAGAACAGCAAGTGCTAGCTCTCCCTCCCCTTCCACAGCTCTG 2100 
seq             GGGTGATCTAGTAATTGCAGAACAGCAAGTGCTAGCTCTCCCTCCCCTTCCACAGCTCTG 552 
                ************************************************************ 
ref             GGTGTGGGAGGGGGTTGTCCAGCCTCCAGCAGCATGGGGAGGGCCTTGGTCAGCCTCTGG 2160 
seq             GGTGTGGGAGGGGGTTGTCCAGCCTCCAGCAGCATGGGGAGGGCCTTGGTCAGCCTCTGG 612 
                ************************************************************ 
ref             GTGCCAGCAGGGCAGGGGCGGAGTCCTGGGGAATGAAGGTTTTATAGGGCTCCTGGGGGA 2220 
seq             GTGCCAGCAGGGCAGGGGCGGAGTCCTGGGGAATGAAGGTTTTATAGGGCTCCTGGGGGA 672 
                ************************************************************ 
ref             GGCTCCCCAGCCCCAAGCTTACCACCTGCACCCGGAGAGCTGTGTCAC-TCGAGATCTGC 2279 
seq             GGCTCCCCAGCCCCAAGCTTACCACCTGCACCCGGAGAGCTGTGTCACCTCGAGATCTGC 341 
                ************************************************ *********** 
 
PW-PGL3 
ref             GTGCAGGTGCCAGAACATTTCTCTATCGATAGGTACCCCTGCAGGCCTCTAGAAATCTAG 1740 
seq             --KCAG--------ACATTTCTCTATCGATAGGTACCCCTGCAGGCCTCTAGAAATCTAG 60 
                   ***        ********************************************** 
ref             CTGATATAGTGTGGCTCAAAACCTTCAGCACAAATCACACCGTTAGACTATCTGGTGTGG 1800 
seq             CTGATATAGTGTGGCTCAAAACCTTCAGCACAAATCACACCGTTAGACTATCTGGTGTGG 120 
                ************************************************************ 
ref             CCCAAACCTTCAGGTGAACAAAGGCACTCTAATCTGGCAGGATATTCCAAAGCATTAGAG 1860 
seq             CCCAAACCTTCAGGTGAACAAAGGCACTCTAATCTGGCAGGATATTCCAAAGCATTAGAG 180 
                ************************************************************ 
ref             ATGACCTCTTGCAAAGAAAAAGAAATGGAAAAGAAAAAGAAAGAAAGGAAAAAAAAAAAA 1920 
seq             ATGACCTCTTGCAAAGAAAAAGAAATGGAAAAGAAAAAGAAAGAAAGG-AAAAAAAAAAA 239 
                ************************************************ *********** 
ref             AAAAAGAGATGACCTCTCAGGCTCTGAGGGGAAACGCCTGAGGTCTTTGAGCAAGGTCAG 1980 
seq             AAAAAGARATGACCTCTCAGGCTCTGAGGGGAAACGCCTGAGGTCTTTGAGCAAGGTCAG 299 
                ******* **************************************************** 
ref             TCCTCTGTTGCACAGTCTCCCTCACAGGGTCATTGTGACGATCAAATGTGGTCACGTGTA 2040 
seq             TCCTCTGTTGCACAGTCTCCCTCACAGGGTCATTGTGACGATCAAATGTGGTCACGTGTA 359 
                ************************************************************ 
ref             TGAGGCACCAGCACATGCCTGGCTCTGGGGAGTGCCGTGTAAGTGTATGCTTGCACTGCT 2100 
seq             TGAGGCACCAGCACATGCCTGGCTCTGGGGAGTGCCGTGTAAGTGTATGCTTGCACTGCT 419 
                ************************************************************ 
ref             GAATGGCTGGGATGTGTCAGGGATTATCTTCAGCACTTACAGATGCTCATCTCATCCTCA 2160 
seq             GAATGGCTGGGATGTGTCAGGGATTATCTTCAGCACTTACAGATGCTCATCTCATCCTCA 479 
                ************************************************************ 
ref             CAGCATCACTATGGGATGGGTATTACTGGCCTCATTTGATGGAGAAAGTGGCTGTGGCTC 2220 
seq             CAGCATCACTATGGGATGGGTATTACTGGCCTCATTTGATGGAGAAAGTGGCTGTGGCTC 92 
                ************************************************************ 
ref             AGAAAGGGGGGACCACTAGACCAGGGACACTCTGGATGCTGGGGACTCCAGAGACCATGA 2280 
seq             AGAAAGGGGGGACCACTAGACCAGGGACACTCTGGATGCTGGGGACTCCAGAGACCATGA 152 
                ************************************************************ 
ref             CCACTCACCAACTGCAGAGAAATTAATTGTGGCCTGATGTCCCTGTCCTGGAGAGGGTGG 2340 
seq             CCACTCACCAACTGCAGAGAAATTAATTGTGGCCTGATGTCCCTGTCCTGGAGAGGGTGG 212 
                ************************************************************ 
ref             AGGTGGACCTTCACTAACCTCCTACCTTGACCCTCTCTTTTAGGGCTCTTTCTGACCTCC 2400 
seq             AGGTGGACCTTCACTAACCTCCTACCTTGACCCTCTCTTTTAGGGCTCTTTCTGACCTCC 272 
                ************************************************************ 
ref             ACCATGATACTAGGACCCCATTGTATTCTGTACCCTCTTGACTCTATGACCCCCACTGCC 2460 
seq             ACCATGATACTAGGACCCCATTGTATTCTGTACCCTCTTGACTCTATGACCCCCACTGCC 332 
                ************************************************************ 
ref             CACTGCATCCAGCTGGGTCCCCTCCTATCTCTATTCCCAGCTGGCCAGTGCAGTCTCAGT 2520 
seq             CACTGCATCCAGCTGGGTCCCCTCCTATCTCTATTCCCAGCTGGCCAGTGCAGTCTCAGT 392 
                ************************************************************ 
ref             GCCCACCTGTTTGTCAGTAACTCTGAAGGGGCTGACATTTTACTGACTTGCAAACAAATA 2580 
seq             GCCCACCTGTTTGTCAGTAACTCTGAAGGGGCTGACATTTTACTGACTTGCAAACAAATA 452 
                ************************************************************ 
ref             AGCTAACTTTCCAGAGTTTTGTGAATGCTGGCAGAGTCCATGAGACTCCTGAGTCAGAGG 2640 
seq             AGCTAACTTTCCAGAGTTTTGTGAATGCTGGCAGAGTCCATGAGACTCCTGAGTCAGAGG 512 
                ************************************************************ 
ref             CAAAGGCTTTTACTGCTCACAGCTTAGCAGACAGCATGAGGTTCATGTTCACATTAGTAC 2700 
seq             CAAAGGCTTTTACTGCTCACAGCTTAGCAGACAGCATGAGGTTCATGTTCACATTAGTAC 572 
                ************************************************************ 
ref             ACCTTGCCCCCCCCCAAATCTTGTAGGGTGACCAGAGCAGTCTAGGTGGATGCTGTGCAC 2760 
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seq             ACCTTGCCCCCCCCCAAATCTTGTAGGGTGACCAGAGCAGTCTAGGTGGATGCTGTGCAC 632 
                ************************************************************ 
ref             ACGGGGTTTGTGCCACTGGTGAGAAACCTGAGATTAGGAATCCTCAATCTTATACTGGGA 2820 
seq             ACGGGGTTTGTGCCACTGGTGAGAAACCTGAGATTAGGAATCCTCAATCTTATACTGGGA 321 
                ************************************************************ 
ref             CAACTTGCAAACCTGCTCAGCCTTTGTCTCTGATGAAGATATTATCTTCATGATCTTGGA 2880 
seq             CAACTTGCAAACCTGCTCAGCCTTTGTCTCTGATGAAGATATTATCTTCATGATCTTGGA 381 
                ************************************************************ 
ref             TTGAAAACAGACCTACTCTGGAGGAACATATTGTATCGATTGTCCTTGACAGTAAACAAA 2940 
seq             TTGAAAACAGACCTACTCTGGAGGAACATATTGTATCGATTGTCCTTGACAGTAAACAAA 441 
                ************************************************************ 
ref             TCTGTTGTAAGAGACATTATCTTTATTATCTAGGACAGTAAGCAAGCCTGGATCTGAGAG 3000 
seq             TCTGTTGTAAGAGACATTATCTTTATTATCTAGGACAGTAAGCAAGCCTGGATCTGAGAG 501 
                ************************************************************ 
ref             AGATATCATCTTGCAAGGATGCCTGCTTTACAAACATCCTTGAAACAACAATCCAGAAAA 3060 
seq             AGATATCATCTTGCAAGGATGCCTGCTTTACAAACATCCTTGAAACAACAATCCAGAAAA 561 
                ************************************************************ 
ref             AAAAAGGTGTTGCTGTCTTTGCTCAGAAGACACACAGATACGTGACAGAACCATGGAGAA 3120 
seq             AAAAAGGTGTTGCTGTCTTTGCTCAGAAGACACACAGATACGTGACAGAACCATGGAGAA 621 
                ************************************************************ 
ref             TTGCCTCCCAACGCTGTTCAGCCAGAGCCTTCCACCCTTGTCTGCAGGACAGTCTCAACG 3180 
seq             TTGCCTCCCAACGCTGTTCAGCCAGAGCCTTCCACCCTTGTCTGCAGGACAGTCTCAACG 681 
                ************************************************************ 
 
ref             TTCCACCATTAAATACTTCTTCTATCACATCCTGCTTCTTTATGCCTAACCAAGGTTCTA 3240 
seq             TTCCACCATTAAATACTTCTTCTATCACATCCTGCTTCTTTATGCCTAACCAAGGTTCTA 741 
                ************************************************************ 
ref             GGTCCCGATCGACTGTGTCTGGCAGCACTCCACTGCCAAACCCAGAATAAGGCAGCGCT 3299 
seq             GGTCCCGATCGACTGTGTCTGGCAGCACTCCACTGCCAAACCCAGAATAAGGCAGCGCT 406 
                ************************************************************ 
ref             CAGGATCCCGAGGTACCTGCCGTGTGAGGCAGATAAAAGTTTCCCAGGTGATAAAAGTTG 3359 
seq             CAGGATCCCGAGGTACCTGCCGTGTGAGGCAGATAAAAGTTTCCCAGGTGATAAAAGTTG 466 
                ************************************************************ 
ref             TCCGGGAACAGCTCTCTTCCTGGTACAGATCTGCTGACTAACAAACATTTCCTTTATAGGT 3419 
seq             TCCGGGAACAGCTCTCTTCCTGGTACAGATCTGCTGACTAACAAACATTTCCTTTATAGGT 526 
                *************************************************************         
ref             GCAAATTTCCTTTACAAAAGGGCATTTTCTCAGAGGTACTCTGGTGTCTGCAGTTCCTCA 3480 
seq             GCAAATTTCCTTTACAAAAGGGCATTTTCTCAGAGGTACTCTGGTGTCTGCAGTTCCTCA 217 
                ************************************************************ 
ref             ACATAACCAGTTCCAAATCATCAATGTGCCAAAGAGGACTATGTTGGGGTAGCAGATTCT 3540 
seq             ACATAGCCAGTTCCAAATCATCAATGTGCCAAAGAGGACTATGTTGGGGTAGCAGATTCT 277 
                *****.****************************************************** 
ref             GGTCTCCTCCAGTCCTACTTGGGGTGATGAATTCTGGTCTACGGTCCTATTAAATTCTGG 3600 
seq             GGTCTCCTCCAGTCCTACTTGGGGTGATGAATTCTGGTCTACGGTCCTATTAAATTCTGG 337 
                ************************************************************ 
ref             TGAATTCTGAGCCCCCACAATTGCAAACATTAGAAAGAACCTCTCAAGTGCCCGGGAACA 3660 
seq             TGAATTCTGAGCCCCCACAATTGCAAACATTAGAAAGAACCTCTCAAGTGCCCGGGAACA 397 
                ************************************************************ 
ref             GCCACGTCTTCCTGGCTGAGGTGTGTCCCACCACTTCCTCACTCCCGCCCTGGCCGGTGG 3720 
seq             GCCACGTCTTCCTGGCTGAGGTGTGTCCCACCACTTCCTCACTCCCGCCCTGGCCGGTGG 457 
                ************************************************************ 
ref             TGCCGAGAGACCTGGGACCATCCGGGGGAGCACTTTCCACCGGACGCTGGTGGGGGCCAA 3780 
seq             TGCCGAGAGACCTGGGACCATCCGGGGGAGCCCTTTCCACCGGACGCTGGTGGGGGCCAA 517 
                *******************************.**************************** 
ref             GAAATGCCAGCCTAGGCGGACTGGGGAGGGTCTTGGGCGTCCGGCGCTGTGTCCCCGCCA 3840 
seq             GAAATGCCAGCCTAGGCGGACTGGGGAGGGTCTTGGGCGTCCGGCGCTGTGTCCCCGCCA 577 
                ************************************************************ 
ref             CTCGTGCTTGGGCCAGCAGTCCCCAAGGCCTAC-CCTGGGTCCTTGCCCAGAGGCTACAG 3899 
seq             CTCGTGCTTGGGCCAGCAGTCCCCAAGGCCTACTCCTGGGTCCTTGCCCAGAGGCCGCAG 637 
                ********************************* ********************* .*** 
ref             TGGGTTCCCCGGAGGCCAAGACGGGGCCGGCCGCCTACAGGAGCTCGTGAGGTAGCAGCT 3959 
seq             TGGGTTCCCCGGAGGCCAAGACGRGGCCGGCCGCCTACAGGAGCTCGTGAGGTAGCAGCT 129 
                *********************** ************************************ 
ref             CCGGGGGCTCACCCAGGACTCCAGGAGCGCTCCCCAGAATCCCCTTCCTTAACCCAAACT 4019 
seq             CCGGGGGCTCACCCAGGACTCCAGGAGCGCTCCCCAGAATCCCCTTCCTTAACCCAAACT 189 
                ************************************************************ 
ref             CGAGCCCTCGGGCAGCGCTGCGCCGCGGACCGGAGAGGGGCAGGTTGGCCGCTGTGGCCG 4079 
seq             CGAGCCCTCGG----------GCAGCGGACCGGAGAGGGGCAGGCTGGCCGCTGGGGCCG 239 
                ***********          **.******************** ********* ***** 
ref             GGCCCGGGAAGCGCCCCAGAGTCCCTTATGGGTCCCTCCGCAGCCGGGGTTGAGCCAGGC 4139 
seq             GGCCCGGGAAGCGCCCCAGAGTCCCTTATGGGTCCCTCCGCAGCCGGGGTTGAGCCAGGC 299 
                ************************************************************ 
ref             AGGGAACCCGTCCCGGACTTCCCTTGGGAAACGCCTCCTCCCGCCGCCCCCGCCCCCGCC 4199 
seq             AGGGAACCCGTCCCGGACTTCCCTTGGGAAACGCCTCCTCCCGCCGCCCCCGCCCCCGCC 359 
                ************************************************************ 
ref             CGCCCAGGGTGACCCGCGACCCGCTTGGGGGTGTCGCCCTGGACCCTGGGACACCGCCTC 4259 
seq             CGCCCAGGGTGACCCGCGACCCGCTTGGGGGTGTCGCCCTGGACCCTGGGACACCGCCTC 419 
                ************************************************************ 
ref             CTGAGATTAAAGCGAGAGCCAGGGCGGGCCGGGCCGAGTAGGCGCGAGCTAAGCAGGAGG 4319 
seq             CTGAGATTAAAGCGAGAGCCAGGGCGGGCCGGGCCGAGTAGGCGCGAGCTAAGCAGGAGG 479 
                ************************************************************ 
 
ref             CGGAGGCAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGAAGACGCCAAAAAC 4379 
seq             CGGAGGGAAGCT-GGCAT-CCG-TACK--TG----AGCCACCY-----GAC--------- 516 
                ****** ***** ***** *** ***.  **    *******      ***          
W-prom enhancer-PGL3 
ref             CATATAAGCCTCCTCCCCACCTTTTTCACGGGGGAAGTTCTTATTGCAATGAGAACCGCC 660 
seq             -TTATCTGCCTCA-------------CACGG----------------------CAGCGCC 161 
                 :***.:*****.             *****                      .* **** 
ref             TTGTGACACTTCACCCATCTTTGACATATACAGCCTTTCATTCAAAATGGTGCTTTTTCA 720 
seq             TTGTGACACTTCACCCATCTTTGACATATACAGCCTTTCATTCAAAATGGTGCTTTTTCA 221 
                ************************************************************ 
ref             AAAAGCCCAGGATGTGAGCTTGAAATGTAATTCTGGAAGCTGACCTTTAATGAAGTTTGT 780 
seq             AAAAGCCCAGGATGTGAGCTTGAAATGTAATTCTGGAAGCTGACCTTTAATGAAGTTTGT 281 
                ************************************************************ 
ref             TTAATCATAAACTCTTATTGTTGGAGCTAGTGCTGCATGTCTTAAAAGCTTTAAAGGGTA 840 
seq             TTAATCATAAACTCTTATTGTTGGAGCTAGTGCTGCATGTCTTAAAAGCTTTAAAGGGTA 341 
                ************************************************************ 
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ref             CGGCAGGTACTCATATCTGATTAGCATCTGCACTTCACCAGGTGGCCATTTGTTGTCTAA 900 
seq             CGGCAGGTACTCATATCTGATTAGCATCTGCACTTCACCAGGTGGCCATTTGTTGTCTAA 401 
                ************************************************************ 
ref             AAATGTTGACATTCAACAATGTAATGAAAATGTTGGTCCTGGATGATAAAAAAAGTTTTT 960 
seq             AAATGTTGACATTCAACAATGTAATGAAAATGTTGGTCCTGGATGATAAAAAAAGTTTTT 461 
                ************************************************************ 
ref             CACACAGCAAGGCAGAGGACAGTGCACTCTGTTGTGGGGCGTATGTCTCCCTGCACCACT 1020 
seq             CACACAGCAAGGCAGAGGACAGTGCACTCTGTTGTGGGGCGTATGTCTCCCTGCACCACT 521 
                ************************************************************ 
ref             AACTAGGGCAGGGGTGAGGAAGTGGTGGGCCACACCTCTGCCTGGAAGACGTGGTTTTTC 1080 
seq             AACTAGGGCAGGGGTGAGGAAGTGGTGGGCCACACCTCTGCCTGGAAGACGTGGTTTTTC 581 
                ************************************************************ 
ref             CCAGGTACTTCAGAGGCTCTTTTCAATGTTTGCAATTGTAGGGGGCTCAGAATTCGCCAG 1140 
seq             CCAGGTACTTCAGAGGCTCTTTTCAATGTTTGCAATTGTAGGGGGCTCAGAATTCGCCAG 641 
                ************************************************************ 
ref             GATTTAACAGGACTGGAGGAGGCCAAATTCACTAGGATTTAATAGGACTGGAGGAGACCA 1200 
seq             GATTTAACAGGACTGGAGGAGGCCAAATTCACTAGGATTTAATAGGACTGGAGGAGACCA 701 
                ************************************************************ 
ref             GAATGGGCTCCCCAGAGGCCTCAAACCCCCATTCCTTTCTGTCACCCAGAGTGACATATA 1260 
seq             GAATGGGCTCCCCAGAGGCCTCAAACCCCCATTCCTTTCTGTCACCCAGAGTGACATATA 761 
                ************************************************************ 
ref             AGCCTCCTCCCCACCTTTTTCACGGGGGAAGTTCTTATTGCAATGAGATCTGCGATCTAA 1320 
seq             AGCCTCCTCCCCACCTTTTTCACGGGGGAAGTTCTTATTGCAATGAGATC---------- 811 
                **************************************************           
EL-PGL3 sequencing 
ref             GTGCAGGTGCCAGAACATTTCTCTATCGATAGGTACCGCCTTGTGACACTTCACCCATCT 1740 
seq             ------------------------------------CGCCTTGTGACACTTCACCCATCT 326 
                                                    ************************ 
ref             TTGACATATACAGCCTTTCATTCAAAATGGTGCTTTTTCAAAAAGCCCAGGATGTGAGCT 1800 
seq             TTGACATATACAGCCTTTCATTCAAAATGGTGCTTTTTCAAAAAGCCCAGGATGTGAGCT 386 
                ************************************************************ 
ref             TGAAATGTAATTCTGGAAGCTGACCTTTAATGAAGTTTGTTTAATCATAAACTCTTATTG 1860 
seq             TGAAATGTAATTCTGGAAGCTGACCTTTAATGAAGTTTGTTTAATCATAAACTCTTATTG 446 
                ************************************************************ 
ref             TTGGAGCTAGTGCTGCATGTCTTAAAAGCTTTAAAGGGTACGGCAGGTACTCATATCTGA 1920 
seq             TTGGAGCTAGTGCTGCATGTCTTAAAAGCTTTAAAGGGTACGGCAGGTACTCATATCTGA 506 
                ************************************************************ 
ref             TTAGCATCTGCACTTCACCAGGTGGCCATTTGTTGTCTAAAAATGTTGACATTCAACAAT 1980 
seq             TTAGCATCTGCACTTCACCAGGTGGCCATTTGTTGTCTAAAAATGTTGACATTCAACAAT 566 
                ************************************************************ 
ref             GTAATGAAAATGTTGGTCCTGGATGATAAAAAAAGTTTTTCACACAGCAAGGCAGAGGAC 2040 
seq             GTAATGAAAATGTTGGTCCTGGATGATAAAAAAAGTTTTTCACACAGCAAGGCAGAGGAC 626 
                ************************************************************ 
ref             AGTGCACTCTGTTGTGGGGCGTATGTCTCCCTGCACCACTAACTAGGGCAGGGGTGAGGA 2100 
seq             AGTGCACTCTGTTGTGGGGCGTATGTCTCCCTGCACCACTAACTAGGGCAGGGGTGAGGA 686 
                ************************************************************ 
ref             AGTGGTGGGCCACACCTCTGCCTGGAAGACGTGGTTTTTCCCAGGTACTTCAGAGGCTCT 2160 
seq             AGTGGTGGGCCACACCTCTGCCTGGAAGACGTGGTTTTTCCCAGGTACTTCAGAGGCTCT 746 
                ************************************************************ 
ref             TTTCAATGTTTGCAATTGTAGGGGGCTCAGAATTCGCCAGGATTTAACAGGACTGGAGGA 2220 
seq             TTTCAATGTTTGCAATTGTAGGGGGCTCAGAATTCGCCAGGATTTAACAGGACTGGAGGA 806 
                ************************************************************ 
ref             GGCCAAATTCACTAGGATTTAATAGGACTGGAGGAGACCAGAATGGGCTCCCCAGAGGCC 2280 
seq             GGCCAAATTCACTAGGATTTAATAGGACTGGAGGAGACCAGAATGGGCTCCCCAGAGGCC 866 
                ************************************************************ 
ref             TCAAACCCCCATTCCTTTCTGTCACCCAGAGTGACATATAAGCCTCCTCCCCACCTTTTT 2340 
seq             TCAAACCCCCATTCCTTTCTGTCACCCAGAGTGACATATAAGCCTCCTCCCCACCTTTTT 926 
                ************************************************************ 
ref             CACGGGGGAAGTTCTTATTGCAATGAGAACCAGGACAACAAGCAAAATGGCCCACAGCTT  
seq             CACGGGGGAAGTTCTTATTGCAATGAGATCCAGGACAACAAGCAAAATGGCCCACAGCTT 973 
                ****************************:******************************* 
REF             TCTTTTCATTACTGCTAATCTTAGCAGTGGTCAAAATGGTTGGCTCTGAATTTCTTTCTT 2460 
SEQ             TCTTTTCATTACTGCTAACCTTAGCAGTGGTCAAAATGGTTGGCTCTGAATTTCTTTCTT 634 
                ****************** ***************************************** 
REF             TTTTGGGTTTGGGGTAGTAAATGGAGTGACTGTGGACATGTTTTATGGATTATTTTAAGC 2520 
SEQ             TTTTGGGTTTGGGGTAGTAAATGGAGTGACTGTGGACATGTTTTATGGATTATTTTAAGC 694 
                ************************************************************ 
REF             GTATGTATCTATTAAAAATTGAGAGGGCCCACATGGCCTGCTTTAAAAAGTCAACTGTGA 2580 
SEQ             GTATGTATCTATTAAAAATTGAGAGGGCCCACATGGTCTGCTTTAAAAAGTCAACTGTGA 754 
                ************************************ *********************** 
REF             GCTGTATTTGGTGCTGAGCCCTGAACCACCCGCTGGGCAGTGGGTGGCTACTGGCAGTGC 2640 
SEQ             GCTGTATTTGGTGCTGAGCCCTGAACCACCCGCTGGGCAGTGGGTGGCTACTGGCAGTGC 814 
                ************************************************************ 
REF             CTGTGGACGTTCTCGGGGAAAGACGGTCTGATTGCACCTGCTCTTCCTCAGTTCCTAGTA 2700 
SEQ             CTGTGGACGTTCTCGGGGAAAGACGGTCTGATTGCACCTGCTCTTCCTCAGTTCCTAGTA 874 
                ************************************************************ 
REF             CTGTGAGGCACTCTTTCCCCACTCTCCCACAACCCTCAGCTTAACACAACTGTGGTGATT 2760 
SEQ             CTGTGAGGCACTCTTTCCCCACTCTCCCACAACCCTCAGCTTAACACAACTGTGGTGATT 934 
                ************************************************************ 
REF             GCTTTGTCCGTTTTCCCATGAGGACCCTGAGATTTCAACAAGGTTCAGTAACTCACACAT  
SEQ             GCTTTGTCCG-TTTCCCATGAGGACCCTGAGATTTCAACAAGGTTCAGTAACTCACACAT 
                ********** ************************************************* 
ref             CGACACTTCCAGGGAGCTGTGTTGCCAGGAACTGGCCCAGGTCTTTCCCTCCTGGGCCCA 2880 
seq             CGACACTTCCAGGGAGCTGTGTTGCCAGGAACTGGCCCAGGCCTTTCCCTCCTGGGCCCA 102 
                ***************************************** ****************** 
ref             TCTTGTCCTTAATCTCTGCTGACATTGATGGGTTTAGTTACCTTGTCGTGTTTCTTCAGT 2940 
seq             TCTTGTCCTTAATCTCTGCTGACATTGATGGGTTTAGTTACCTTGTCGTGTTTCTTCAGT 162 
                ************************************************************ 
ref             GTTTTATGCCATACAGTCTCCCTTGAGTAGATGTTCTGTATAGGGGATATCACAGCTTCC 3000 
seq             GTTTTATGCCATACAGTCTCCCTTGAGTAGATGTTCTGTATAGGGGATATCACAGCTTCC 222 
                ************************************************************ 
ref             TGGTGAGAACTGGGTTAAGTCCAGCAGGATGCCTGGGCTTAGTGGCACTGGAGTTGTGGG 3060 
seq             TGGTGAGAACTGGGTTAAGTCCAGCAGGATGCCTGGGCTTAGTGGCACTGGAGTTGTGGG 282 
                ************************************************************ 
ref             TGGCCTTGAGCCCCAGGCAGTCCCCTGAGAGCCCTTCCCGATGGATGTTTGAGTCACTGA 3120 
seq             TGGCCTTGAGCCCCAGGCAGTCCCCTGAGAGCCCTTCCCGATGGATGTTTGAGTCACTGA 342 
                ************************************************************ 
ref             GTGTGTTCCTTCTTCTTTCTGGTCAGGCTGTCCTGGCCGCTGCACTTACAATTGCACCCC 3180 
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seq             GTGTGTTCCTTCTTCTTTCTGGTCAGGCTGTCCTGGCCGCTGCACTTACAATTGCACCCC 402 
                ************************************************************ 
ref             ATCCTCCTACCCACTCTGATCCCAGAGGAGAGTGCTTCTGCTGTAACCTCTAAGGCACAA 3240 
seq             ATCCTCCTACCCACTCTGATCCCAGAGGAGAGTGCTTCTGCTGTAACCTCTAAGGCACAA 462 
                ************************************************************ 
ref             GTGGGTCCCAAAGTCCTTAAATATGGAGGGATGTGGGGAAGCAGTGGTGAAGATGCAGGC 3300 
seq             GTGGGTCCCAAAGTCCTTAAATATGGAGGGATGTGGGGAAGCAGTGGTGAAGATGCAGGC 522 
                ************************************************************ 
ref             CAAAGGTCAGCAGGCAACACTGGTCTTTGTTGTAGGTAACCTTCATCTAGAGATTCTTCT 3360 
seq             CAAAGGTCAGCAGGCAACACTGGTCTTTGTTGTAGGTAACCTTCATCTAGAGATTCTTCT 582 
                ************************************************************ 
ref             AGTTCTTTCCAGATTTATCTTCTAAAAACTAACTGGTATGGAAATATTACAGTCCTGTAA 3420 
seq             AGTTCTTTCCAGATTTATCTTCTAAAAACTAACTGGTATGGAAATATTACAGTCCTGTAA 642 
                ************************************************************ 
ref             TTCTTTCTTCTAGGTCATATTGAACATTCCAGATACCTATCATTACTCGATGCTGTTGAT 3480 
seq             TTCTTTCTTCTAGGTCATATTGAACATTCCAGATACCTATCATTACTCGATGCTGTTGAT 702 
                ************************************************************ 
ref             AACAGCAAGATGGCTTTGAACTCAGTAAGTGGTTAATTATTACCTTCCTGGCCTTTTCTT 3540 
seq             AACAGCAAGATGGCTTTGAACTCAGTAAGTGGTTAATTATTACCTTCCTGGCCTTTTCTT 762 
                ************************************************************ 
ref             TGTTCCCTTGTCCCTTCTGAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGAA 3600 
seq             TGTTCCCTTGTCCCTTCTGAAGCTTGGCATTCCGGTACTG-------------------- 802 
                ****************************************                     
LW-PGL3 sequencing 
GGKCAG--------ACATTTCTCTATCGATAG----CAGGACAACAAGCAAAATGGCCCA 54 ref             
GTGCAGGTGCCAGAACATTTCTCTATCGATAGGTACCAGGACAACAAGCAAAATGGC*  ***        
******************************************  seq             
CAGCTTTCTTTTCATTACTGCTAACCTTAGCAGTGGTCAAAATGGTTGGCTCTGAATTTC 114 ref             
CAGCTTTCTTTTCATTACTGCTAATCTTAGCAGTGGTCAAAATGGTTGGCTCTGAATTTC 1800                 
***********************************************************  seq             
TTTCTTTTTTGGGTTTGGGGTAGTAAATGGAGTGACTGTGGACATGTTTTATGGATTATT 174 ref             
TTTCTTTTTTGGGTTTGGGGTAGTAAATGGAGTGACTGTGGACATGTTTTATGGATTATT 1860                 
************************************************************  seq             
TTAAGCGTATGTATCTATTAAAAATTGAGAGGGCCCACATGGTCTGCTTTAAAAAGTCAA 234 ref             
TTAAGCGTATGTATCTATTAAAAATTGAGAGGGCCCACATGGCCTGCTTTAAAAAGTCAA 1920                 
***********************************************************  seq             
CTGTGAGCTGTATTTGGTGCTGAGCCCTGAACCACCCGCTGGGCAGTGGGTGGCTACTGG 294 ref             
CTGTGAGCTGTATTTGGTGCTGAGCCCTGAACCACCCGCTGGGCAGTGGGTGGCTACTGG 1980                 
************************************************************  seq             
CAGTGCCTGTGGACGTTCTCGGGGAAAGACGGTCTGATTGCACCTGCTCTTCCTCAGTTC 354 ref             
CAGTGCCTGTGGACGTTCTCGGGGAAAGACGGTCTGATTGCACCTGCTCTTCCTCAGTTC 2040                 
************************************************************  seq             
CTAGTACTGTGAGGCACTCTTTCCCCACTCTCCCACAACCCTCAGCTTAACACAACTGTG 414 ref             
CTAGTACTGTGAGGCACTCTTTCCCCACTCTCCCACAACCCTCAGCTTAACACAACTGTG 2100                 
************************************************************  seq             
GTGATTGCTTTGTCCGTTTTCCCATGAGGACCCTGAGATTTCAACAAGGTTCAGTAACTC 474 ref             
GTGATTGCTTTGTCCGTTTTCCCATGAGGACCCTGAGATTTCAACAAGGTTCAGTAACTC 2160                 
************************************************************  seq             
ACACATCGACACTTCCAGGGAGCTGTGTTGCCAGGAACTGGCCCAGGCCTTTCCCTCCTG 534 ref             
ACACATCGACACTTCCAGGGAGCTGTGTTGCCAGGAACTGGCCCAGGTCTTTCCCTCCTG 2220                 
***********************************************************  seq             
GGCCCATCTTGTCCTTAATCTCTGCTGACATTGATGGGTTTAGTTACCTTGTCGTGTTTC 594 ref             
GGCCCATCTTGTCCTTAATCTCTGCTGACATTGATGGGTTTAGTTACCTTGTCGTGTTTC 2280                 
************************************************************  seq             
TTCAGTGTTTTATGCCATACARTCTCCCTTGAGTAGATGTTCTGTATAGGGGATATCACA 654 ref             
TTCAGTGTTTTATGCCATACAGTCTCCCTTGAGTAGATGTTCTGTATAGGGGATATCACA 2340                  
********************* **************************************  seq              
GCTTTCCTGGYGAGAACTGGGGTTAA---------------------------------- 680 ref              
GCTT-CCTGGTGAGAACTGGGTTAAGTCCAGCAGGATGCCTGGGCTTAGTGGCACTGGAG 2399                  
*** ***** ********** *:*.                                   
ref             GGTGATAAAAGTTGTCCGGGAACAGCTCTCTTCCTGGTACAGATCTGCTGACTAACAAAC 3000 
seq             ---------------------------------CTGMTACA-----------------AC 17 
                                                 *** ****                 ** 
ref             ATTTCCTTTATAGGTGCAAATTTCCTTTACAAAAGGGCATTTTCTCAGAGGTACTCTGGT 3060 
seq             ATTTCCTTTATAGGTGCAAATTTCCTTTACAAAAGGGCATTTTCTCAGAGGTACTCTGGT 77 
                ************************************************************ 
ref             GTCTGCAGTTCCTCAACATAACCAGTTCCAAATCATCAATGTGCCAAAGAGGACTATGTT 3120 
seq             GTCTGCAGTTCCTCAACATAGCCAGTTCCAAATCATCAATGTGCCAAAGAGGACTATGTT 137 
                ********************.*************************************** 
ref             GGGGTAGCAGATTCTGGTCTCCTCCAGTCCTACTTGGGGTGATGAATTCTGGTCTACGGT 3180 
seq             GGGGTAGCAGATTCTGGTCTCCTCCAGTCCTACTTGGGGTGATGAATTCTGGTCTACGGT 197 
                ************************************************************ 
ref             CCTATTAAATTCTGGTGAATTCTGAGCCCCCACAATTGCAAACATTAGAAAGAACCTCTC 3240 
seq             CCTATTAAATTCTGGTGAATTCTGAGCCCCCACAATTGCAAACATTAGAAAGAACCTCTC 257 
                ************************************************************ 
ref             AAGTGCCCGGGAACAGCCACGTCTTCCTGGCTGAGGTGTGTCCCACCACTTCCTCACTCC 3300 
seq             AAGTGCCCGGGAACAGCCACGTCTTCCTGGCTGAGGTGTGTCCCACCACTTCCTCACTCC 317 
                ************************************************************ 
ref             CGCCCTGGCCGGTGGTGCCGAGAGACCTGGGACCATCCGGGGGAGCACTTTCCACCGGAC 3360 
seq             CGCCCTGGCCGGTGGTGCCGAGAGACCTGGGACCATCCGGGGGAGCCCTTTCCACCGGAC 377 
                **********************************************.************* 
ref             GCTGGTGGGGGCCAAGAAATGCCAGCCTAGGCGGACTGGGGAGGGTCTTGGGCGTCCGGC 3420 
seq             GCTGGTGGGGGCCAAGAAATGCCAGCCTAGGCGGACTGGGGAGGGTCTTGGGCGTCCGGC 437 
                ************************************************************ 
GCTGTGTCCCCGCCACTCGTGCTTGGGCCAGCAGTCCCCAAGGCCTACTCCTGGGTCCTT              
GCTGTGTCCCCGCCACTCGTGCTTGGGCCAGCAGTCCCCAAGGCCTAC-CCTGGGTCCTT                 
************************************************************               
GCCCAGAGGCCGCAGTGGGTTCCCCGGAGGCCAAGACGGGGCCGGCCGCCTACAGGAGCT              
GCCCAGAGGCTACAGTGGGTTCCCCGGAGGCCAAGACGGGGCCGGCCGCCTACAGGAGCT                  
**********.*************************************************              
CGTGAGGTAGCAGCTCCGGGGGCTCACCCAGGACTCCAGGAGCGCTCCCCAGAATCCCCT              
CGTGAGGTAGCAGCTCCGGGGGCTCACCCAGGACTCCAGGAGCGCTCCCCAGAATCCCCT                  
************************************************************               
TCCTTAACCCAAACTCGAGCCCTCGG----------GCAGCGGACCGGAGAGGGGCAGGC              
TCCTTAACCCAAACTCGAGCCCTCGGGCAGCGCTGCGCCGCGGACCGGAGAGGGGCAGGT  
****************************   .********************                
TGGCCGCTGGGGCCGGGCCCGGGAAGCGCCCCAGAGTCCCTTATGGGTCCCTCCGCAGCC              
TGGCCGCTGTGGCCGGGCCCGGGAAGCGCCCCAGAGTCCCTTATGGGTCCCTCCGCAGCC                   
  279 
 
************************************************************              
GGGGTTGAGCCAGGCAGGGAACCCGTCCCGGACTTCCCTTGGGAAACGCCTCCTCCCGCC              
GGGGTTGAGCCAGGCAGGGAACCCGTCCCGGACTTCCCTTGGGAAACGCCTCCTCCCGCC                  
************************************************************              
GCCCCCGCCCCCGCCCGCCCAGGGTGACCCGCGACCCGCTTGGGGGTGTCGCCCTGGACC               
GCCCCCGCCCCCGCCCGCCCAGGGTGACCCGCGACCCGCTTGGGGGTGTCGCCCTGGACC                  
************************************************************               
CTGGGACACCGCCTCCTGAGATTAAAGCGAGAGCCAGGGCGGGCCGGGCCGAGTAGGCGC               
CTGGGACACCGCCTCCTGAGATTAAAGCGAGAGCCAGGGCGGGCCGGGCCGAGTAGGCGC                  
************************************************************               
GAGCTAAGCAGGAGGCGGAGGGAAGCT-GGCAT-CCG-TACK------------------             
GAGCTAAGCAGGAGGCGGAGGCAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATG                   
********************* ***** ***** *** ***.                    
 
Sequences of the L-VISA and W-VISA promoter regions present in the plasmids. underlined regions show AREs: 
L-VISA 
>chr21:42869985-42871184 1200bp  
CCACAGCTTTCTTTTCATTACTGCTAATCTTAGCAGTGGTCAAAATGGTTGGCTCTGAATTTCTTTCTTTTTTG
GGTTTGGGGTAGTAAATGGAGTGACTGTGGACATGTTTTATGGATTATTTTAAGCGTATGTATCTATTAAAAAT
TGAGAGGGCCCACATGGCCTGCTTTAAAAAGTCAACTGTGAGCTGTATTTGGTGCTGAGCCCTGAACCACCC
GCTGGGCAGTGGGTGGCTACTGGCAGTGCCTGTGGACGTTCTCGGGGAAAGACGGTCTGATTGCACCTGC
TCTTCCTCAGTTCCTAGTACTGTGAGGCACTCTTTCCCCACTCTCCCACAACCCTCAGCTTAACACAACTGTG
GTGATTGCTTTGTCCGTTTTCCCATGAGGACCCTGAGATTTCAACAAGGTTCAGTAACTCACACATCGACACT
TCCAGGGAGCTGTGTTGCCAGGAACTGGCCCAGGTCTTTCCCTCCTGGGCCCATCTTGTCCTTAATCTCTGC
TGACATTGATGGGTTTAGTTACCTTGTCGTGTTTCTTCAGTGTTTTATGCCATACAGTCTCCCTTGAGTAGATG
TTCTGTATAGGGGATATCACAGCTTCCTGGTGAGAACTGGGTTAAGTCCAGCAGGATGCCTGGGCTTAGTG
GCACTGGAGTTGTGGGTGGCCTTGAGCCCCAGGCAGTCCCCTGAGAGCCCTTCCCGATGGATGTTTGAGTC
ACTGAGTGTGTTCCTTCTTCTTTCTGGTCAGGCTGTCCTGGCCGCTGCACTTACAATTGCACCCCATCCTCCT
ACCCACTCTGATCCCAGAGGAGAGTGCTTCTGCTGTAACCTCTAAGGCACAAGTGGGTCCCAAAGTCCTTAA
ATATGGAGGGATGTGGGGAAGCAGTGGTGAAGATGCAGGCCAAAGGTCAGCAGGCAACACTGGTCTTTGTT
GTAGGTAACCTTCATCTAGAGATTCTTCTAGTTCTTTCCAGATTTATCTTCTAAAAACTAACTGGTATGGAAAT
ATTACAGTCCTGTAATTCTTTCTTCTAGGTCATATTGAACATTCCAGATACCTATCATTACTCGATGCTGTTGA
TAACAGCAAGATGGCTTTGAACTCAGTAAGTGGTTAATTATTACCTTCCTGGCCTTTTCT 
W-VISA 
>chr21:42880049-42881071 1023bp  
ACGCAGGTTGCCGTGTGAGGCAGATAAAAGTTTCCCAGGTGATAAAAGTTGTCCGGGAACAGCTCTCTTCCT
GGTACAGATCTGCTGACTAACAAACATTTCCTTTATAGGTGCAAATTTCCTTTACAAAAGGGCATTTTCTCAGA
GGTACTCTGGTGTCTGCAGTTCCTCAACATAACCAGTTCCAAATCATCAATGTGCCAAAGAGGACTATGTTG
GGGTAGCAGATTCTGGTCTCCTCCAGTCCTACTTGGGGTGATGAATTCTGGTCTACGGTCCTATTAAATTCT
GGTGAATTCTGAGCCCCCACAATTGCAAACATTAGAAAGAACCTCTCAAGTGCCCGGGAACAGCCACGTCTT
CCTGGCTGAGGTGTGTCCCACCACTTCCTCACTCCCGCCCTGGCCGGTGGTGCCGAGAGACCTGGGACCA
TCCGGGGGAGCACTTTCCACCGGACGCTGGTGGGGGCCAAGAAATGCCAGCCTAGGCGGACTGGGGAGG
GTCTTGGGCGTCCGGCGCTGTGTCCCCGCCACTCGTGCTTGGGCCAGCAGTCCCCAAGGCCTACCCTGGG
TCCTTGCCCAGAGGCTACAGTGGGTTCCCCGGAGGCCAAGACGGGGCCGGCCGCCTACAGGAGCTCGTGA
GGTAGCAGCTCCGGGGGCTCACCCAGGACTCCAGGAGCGCTCCCCAGAATCCCCTTCCTTAACCCAAACTC
GAGCCCTCGGGCAGCGCTGCGCCGCGGACCGGAGAGGGGCAGGTTGGCCGCTGTGGCCGGGCCCGGGA
AGCGCCCCAGAGTCCCTTATGGGTCCCTCCGCAGCCGGGGTTGAGCCAGGCAGGGAACCCGTCCCGGACT
TCCCTTGGGAAACGCCTCCTCCCGCCGCCCCCGCCCCCGCCCGCCCAGGGTGACCCGCGACCCGCTTGG
GGGTGTCGCCCTGGACCCTGGGACACCGCCTCCTGAGATTAAAGCGAGAGCCAGGGCGGGCCGGGCCGA
GTAGGCGCGAGCTAAGCAGGAGGCGGAGGCGGAGG 
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Lin Paper, identification of putative ARE and promoter of TMPRSS2 
 
gtccgaagcccagagcctcctccaggttcttgttccctcattgggaacatggtcttgtgg        
       acggataatcttgaaccccgtttcttaaaatattctttggtcatttaaagccaagcggga        
       aggggtggaaaaaagccctttatttgctcaggaaggtgcatgttaaagaaaaaaaaatcg        
       tccaatgagacttgttaaaatggtgaagcgaactttattcaggaccacggaggcaggtac        
       agggaccacagccagcagattttgcagtgggaagaagagactgggatccgcttgagtaca        
       gtatgggcaagtgggagttaatttataaccaaggatcagggtggggttggtgggtggaaa        
       aatcacaaagagaaaacatcaagggtaagggggattctggctaaaccaaccaaacaggat        
       tcttgctgaagacaggctgggtgatcagacatcacctgtggcacggtggaggctgaggaa        
       cccgatcagatatccagagtgatcagataccgagggtgggaggttctggctaaactgact        
       gagcaaggttttttgctaaaactggattttacaaggaaatgcacagatggcctagaaggt        
       tcaggagcttgatataagtttgatcaagcgaagaatctttgtccatggagagtgatgtca        
       gaatgcggctttactatacagcatttcgtgttgacggcatctctagctattattgttaac        
       tgttcacaaaggacaacaagcaaaatggcccacagctttcttttcattactgctaatctt        
       agcagtggtcaaaatggttggctctgaatttctttcttttttgggtttggggtagtaaat        
       ggagtgactgtggacatgttttatggattattttaagcgtatgtatctattaaaaattga        
       gagggcccacatggcctgctttaaaaagtcaactgtgagctgtatttggtgctgagccct        
       gaaccacccgctgggcagtgggtggctactggcagtgcctgtggacgttctcggggaaag        
       acggtctgattgcacctgctcttcctcagttcctagtactgtgaggcactctttccccac        
       tctcccacaaccctcagcttaacacaactgtggtgattgctttgtccgttttcccatgag        
       gaccctgagatttcaacaaggttcagtaactcacacatcgacacttccagggagctgtgt        
       tgccaggaactggcccaggtctttccctcctgggcccatcttgtccttaatctctgctga        
       cattgatgggtttagttaccttgtcgtgtttcttcagtgttttatgccatacagtctccc        
       ttgagtagatgttctgtataggggatatcacagcttcctggtgagaactgggttaagtcc        
       agcaggatgcctgggcttagtggcactggagttgtgggtggccttgagccccaggcagtc        
       ccctgagagcccttcccgatggatgtttgagtcactgagtgtgttccttcttctttctgg        
       tcaggctgtcctggccgctgcacttacaattgcaccccatcctcctacccactctgatcc        
       cagaggagagtgcttctgctgtaacctctaaggcaca agtgggtcccaaagtccttaaat        
       atggagggatgtggggaagcagtggtgaagatgcaggccaaaggtcagcaggcaacactg        
       gtctttgttgtaggtaaccttcatctagagattcttctagttctttccagatttatcttc        
       taaaaactaactggtatggaaatattacagtcctgtaattctttcttctag  
GTCATATTGAACATTCCAGATACCTATCATTACTCGATGCTGTTGATAACAGCAAGATGG        
       CTTTGAACTCA 
 gtaagtggttaattattaccttcctggccttttctttgttcccttgtcccttctgttatt        
       cccaacattgtttggggtcagcaattgcaagggctatttgtagggaacgccgggccacgc        
       tgatgctgttcaaggcaccctctagaaagagtgagtcaggtgcgcagccacacagctgcc        
       caggtgagtcgcaagagccatggctgttgggtacacgtgggtgatatgcattctcacctt        
       gacctcatcccttcctgctttgcagggcagggggcagggacaaggagtggggacagatga        
       ggcaggatggcgataacaggggtatgttccagggaagagacccacgtgggatcccatcga        
       tgcccaactgaaggactaggaaaagtcataactgcatgaggcatgggcgggccttccctc        
       tccctggagc 
 
 
 
Putative ARE 
Putative 
promoter   
TATA box 
EXON 2  and 
translational 
start site 
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8.2 In vivo 
 
Figure_ Apx1 Graphs showing LNCaP-CDXR3 tumours in individual animals (on the 
left and right flanks) 
Male BALB/c castrated mice were injected subcutaneously with 1 x10
6
 hormone 
independent LNCaP-CDXR3 cells in 50% matrigel. After allowing tumours to grow for 5 
weeks to 100 mm
3 
mice were separated into groups treated with Ad5-TV-CU in 
combination with 5-FC or Ad5-TV-CU in combination with PBS and the day designated day 
1. Graphs show LNCaP-CDXR3 tumours on the left and right flanks of individual mice. A, 
B and C show mice treated with 5-FC in combination with Ad5-TV-CU (red lines) or Ad5-
GFP (green lines). D, E and F show all animals treated with PBS in combination with Ad5-
TV-CU (yellow lines) or Ad5-GFP (blue lines). One mouse developed a second tumour 30 
days post treatment initiation, which was left untreated (purple line). Tumours were 
measured relative to the starting tumour volume on day 1 of treatment, 
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Figure_Apx2 Graphs showing LNCaP-104-S tumours in individual animals (on the 
left and right flanks) 
Male BALB/c mice were injected subcutaneously with 1 x10
6
 hormone dependent LNCaP-
104-S cells in 50% matrigel in combination with a 1.25 mg testosterone pellet. After 
allowing tumours to grow for 5 weeks to 100 mm
3 
mice were separated into groups treated 
with Ad5-TV-CU in combination with 5-FC or Ad5-TV-CU in combination with PBS and the 
day designated day 1. Intratumoural injections of Ad5-TV-CU were administered on days 
1, 3 and 6 and intraperitoneal injections of either 5-FC or PBS given on days 2, 5, 8 and 
15.Graphs show LNCaP-104-S tumours on the left and right flanks of individual mice. A 
and B show mice treated with Ad5-TV-CU in combination with 5-FC (red lines) or 
untreated tumours (purple lines) that developed 22 days post treatment initiation. C and D 
show all animals treated with Ad5-TV-CU in combination with PBS (yellow lines) or 
untreated tumours (purple lines), that developed a number of days after treatment 
initiation. Tumours were measured relative to the starting tumour volume on day 1 of 
treatment, 
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Figure_Apx3.  Tumour growth was inhibited in 22RV1 tumour xenografts treated 
with Ad5-TV-CU in combination with 5-FC and PBS 
Male CD-1 athymic mice were injected subcutaneously with 1 x10
6
 hormone independent 
22RV1 cells in 50% matrigel. After allowing the tumours to grow for 2 weeks to ~100 mm
3
 
mice were separated into the control groups, Untreated (purple lines), Ad5-TV-CU plus 
PBS (yellow lines), or target group, Ad5-TV-CU plus 5-FC (red lines)  The first tumour 
measurement was designated day 0. Intratumoural injections of Ad5-TV-CU were 
administered on days 1, 3 and 6 and intraperitoneal injections of either 5-FC or PBS given 
on days 2, 5, 8 and 15. A. Data shows the tumour volume in mm
3 
up to day 32, when the 
study was terminated. B. Data shows relative tumour volume post treatment initiation. 
Tumour volume was normalised relative to the individual starting tumour volume 
determined on day 0 to illustrate the effect of treatment on tumour volume. n= number of 
tumours per group. n=4 (Ad5-TV-CU+5-FC, Ad5-TV-CU+PBS, UN).  
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